PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33877810-5	2021	Several lipases from different sources and PEX11, FOX1, FOX2, and FOX3, the key genes of the fatty acid beta-oxidation pathway, were overexpressed during the production of (2S)-naringenin in yeast.	naringenin	172-187	Pex11p	Saccharomyces cerevisiae S288C	43-48
11540853-7	1985	Other flavonoids such as epicatechin, quercetin and naringenin also inhibited calmodulin-promoted phosphodiesterase activity.	naringenin	52-62	calmodulin1	Zea mays	78-88
33691213-0	2021	Effect of enzymatic cross-linking of naringenin-loaded beta-casein micelles on their release properties and fate in in vitro digestion.	naringenin	37-47	casein beta	Homo sapiens	55-66
33691213-1	2021	The microbial transglutaminase (mTG) was used to improve the stability of the naringenin-loaded beta-casein micelles (CNMs).	naringenin	78-88	protease, serine 3	Mus musculus	32-35
33691213-1	2021	The microbial transglutaminase (mTG) was used to improve the stability of the naringenin-loaded beta-casein micelles (CNMs).	naringenin	78-88	casein beta	Homo sapiens	96-107
33691213-7	2021	We conclude that crosslinking with mTG is a suitable method to modulate naringenin release kinetics from beta-CN micelles and improves the potential of these micelles as delivery systems targeted to the small intestine.	naringenin	72-82	protease, serine 3	Mus musculus	35-38
7407100-5	1980	Results (phloretin, 9 +/- 1 muM; naringenin, 21 +/- 4 muM) agree with the dissociation constants obtained using absorption titration performed in the absence of fluorescent probes.	naringenin	33-43	latexin	Homo sapiens	54-57
33877810-6	2021	The level of acetyl-CoA was 0.205 nmol higher than that in the original strain and the production of (2S)-naringenin increased to 286.62 mg/g dry cell weight when PEX11 was overexpressed in S. cerevisiae strain L07.	naringenin	101-116	Pex11p	Saccharomyces cerevisiae S288C	163-168
33877810-5	2021	Several lipases from different sources and PEX11, FOX1, FOX2, and FOX3, the key genes of the fatty acid beta-oxidation pathway, were overexpressed during the production of (2S)-naringenin in yeast.	naringenin	172-187	acyl-CoA oxidase	Saccharomyces cerevisiae S288C	50-54
33877810-5	2021	Several lipases from different sources and PEX11, FOX1, FOX2, and FOX3, the key genes of the fatty acid beta-oxidation pathway, were overexpressed during the production of (2S)-naringenin in yeast.	naringenin	172-187	bifunctional hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase FOX2	Saccharomyces cerevisiae S288C	56-60
33877810-5	2021	Several lipases from different sources and PEX11, FOX1, FOX2, and FOX3, the key genes of the fatty acid beta-oxidation pathway, were overexpressed during the production of (2S)-naringenin in yeast.	naringenin	172-187	acetyl-CoA C-acyltransferase	Saccharomyces cerevisiae S288C	66-70
33599956-0	2021	Naringenin Ameliorates Chronic Sleep Deprivation-Induced Pain via Sirtuin1 Inhibition.	naringenin	0-10	sirtuin 1	Mus musculus	66-74
33890787-6	2021	Hesperidin upregulates ABCA1 by 1.8-fold to enhance cholesterol reverse transport, while the aglycones naringenin and hesperetin inhibited cholesterol synthesis via downregulating HMGCR by 2.4- and 2.3-fold, respectively.	naringenin	103-113	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	180-185
33968984-9	2021	Molecular docking results suggest that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) is capable to bind with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5.	naringenin	95-105	signal transducer and activator of transcription 3	Homo sapiens	147-152
33968984-9	2021	Molecular docking results suggest that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) is capable to bind with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5.	naringenin	95-105	prostaglandin-endoperoxide synthase 2	Homo sapiens	154-159
33968984-9	2021	Molecular docking results suggest that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) is capable to bind with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5.	naringenin	95-105	vascular endothelial growth factor A	Homo sapiens	166-171
33968984-9	2021	Molecular docking results suggest that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) is capable to bind with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5.	naringenin	95-105	epidermal growth factor receptor	Homo sapiens	173-177
33968984-9	2021	Molecular docking results suggest that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) is capable to bind with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5.	naringenin	95-105	arachidonate 5-lipoxygenase	Homo sapiens	183-188
33370589-0	2021	Naringenin improves depressive- and anxiety-like behaviors in mice exposed to repeated hypoxic stress through inhibition of oxido-inflammatory mediators and NF-kB/BDNF expressions.	naringenin	0-10	brain derived neurotrophic factor	Mus musculus	163-167
33912040-12	2021	In vitro experiments suggested that the mechanism may involve hesperidin and naringenin acting on CASP3, BAX, and BCL2 to affect the apoptosis pathway, attenuating liver fibrosis.	naringenin	77-87	caspase 3	Homo sapiens	98-103
33912040-12	2021	In vitro experiments suggested that the mechanism may involve hesperidin and naringenin acting on CASP3, BAX, and BCL2 to affect the apoptosis pathway, attenuating liver fibrosis.	naringenin	77-87	BCL2 associated X, apoptosis regulator	Homo sapiens	105-108
33912040-12	2021	In vitro experiments suggested that the mechanism may involve hesperidin and naringenin acting on CASP3, BAX, and BCL2 to affect the apoptosis pathway, attenuating liver fibrosis.	naringenin	77-87	BCL2 apoptosis regulator	Homo sapiens	114-118
33912040-13	2021	Naringenin significantly inhibited AKT1 phosphorylation, which in turn mediated activation of the phosphoinositide 3-kinase-Akt signaling pathways against LI.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	35-39
33912040-13	2021	Naringenin significantly inhibited AKT1 phosphorylation, which in turn mediated activation of the phosphoinositide 3-kinase-Akt signaling pathways against LI.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	124-127
33898820-0	2021	Binding mechanism of naringenin with monoamine oxidase - B enzyme: QM/MM and molecular dynamics perspective.	naringenin	21-31	monoamine oxidase B	Homo sapiens	37-58
33898820-3	2021	Reports outline that the naringenin molecule acts as an inhibitor of MAO-B enzyme and it potentially prevents the development of PD.	naringenin	25-35	monoamine oxidase B	Homo sapiens	69-74
33898820-4	2021	To elucidate the binding mechanism of naringenin with MAO-B, we performed the molecular docking, QM/MM and molecular dynamics (MD) simulations.	naringenin	38-48	monoamine oxidase B	Homo sapiens	54-59
33898820-5	2021	The molecular docking results confirm that the naringenin strongly binds with the substrate binding site of MAO-B enzyme (-12.0 kcal/mol).	naringenin	47-57	monoamine oxidase B	Homo sapiens	108-113
33898820-6	2021	The low values of RMSD, RMSF and Rg indicate that the naringenin - MAO-B complex is stable over the entire period of MD simulation.	naringenin	54-64	monoamine oxidase B	Homo sapiens	67-72
33898820-9	2021	The QM/MM study coupled with the charge density analysis reveals the charge density distribution and the strength of intermolecular interactions of naringenin-MAO-B complex.	naringenin	148-158	monoamine oxidase B	Homo sapiens	159-164
33856270-13	2021	Naringenin also increased the MAO activity and 5-HT levels in the striatum.	naringenin	0-10	monoamine oxidase A	Rattus norvegicus	30-33
33856270-14	2021	Moreover, co-treatment with naringenin reduced the expression of GFAP protein in the striatal part and significantly attenuated the neuronal cell death.	naringenin	28-38	glial fibrillary acidic protein	Rattus norvegicus	65-69
33370589-10	2021	The increased brain contents of malondialdehyde, TNF-alpha, interleukin-1beta, and decreased antioxidant (GSH and SOD) status were attenuated by Naringenin.	naringenin	145-155	tumor necrosis factor	Mus musculus	49-58
33370589-10	2021	The increased brain contents of malondialdehyde, TNF-alpha, interleukin-1beta, and decreased antioxidant (GSH and SOD) status were attenuated by Naringenin.	naringenin	145-155	interleukin 1 beta	Mus musculus	60-77
33370589-11	2021	Naringenin (10 mg/kg) increases BDNF expression but did not significantly (p < 0.05) alter corticosterone and catalase contents.	naringenin	0-10	brain derived neurotrophic factor	Mus musculus	32-36
33370589-12	2021	The increased expressions of iNOS and NF-kB as well as loss of amygdala neuronal cells were reduced by naringenin (10 mg/kg).	naringenin	103-113	nitric oxide synthase 2, inducible	Mus musculus	29-33
33370589-13	2021	Overall, these findings suggest that naringenin improves depressive- and anxiety-like behaviors in mice exposed to hypoxic stress by modulating oxido-inflammatory insults and NF-kB/BDNF expressions.	naringenin	37-47	brain derived neurotrophic factor	Mus musculus	181-185
33389723-9	2021	Pregnenolone sulphate (TRPM3 agonist) alone induced a dose-related mechanical hypersensitivity that was prevented by ononetin, isosakuranetin and naringenin.	naringenin	146-156	transient receptor potential cation channel, subfamily M, member 3	Rattus norvegicus	23-28
33624733-11	2021	After they were treated with different doses of NAR, the LC3B and beclin 1 levels were improved while the p62 protein level was decreased.	naringenin	48-51	beclin 1, autophagy related	Mus musculus	66-74
33842467-15	2021	Conclusions: VIM positively regulated by NR5A2 affected EMT signaling pathways in metastatic CESC, and naringenin was the inhibitor for the treatment of metastatic CESC via suppressing cancer stemness.	naringenin	103-113	vimentin	Homo sapiens	13-16
33667286-0	2021	Naringenin prevents TNF-alpha-induced gut-vascular barrier disruption associated with inhibiting the NF-kappaB-mediated MLCK/p-MLC and NLRP3 pathways.	naringenin	0-10	tumor necrosis factor	Rattus norvegicus	20-29
33667286-0	2021	Naringenin prevents TNF-alpha-induced gut-vascular barrier disruption associated with inhibiting the NF-kappaB-mediated MLCK/p-MLC and NLRP3 pathways.	naringenin	0-10	myosin light chain kinase 3	Rattus norvegicus	120-124
33667286-0	2021	Naringenin prevents TNF-alpha-induced gut-vascular barrier disruption associated with inhibiting the NF-kappaB-mediated MLCK/p-MLC and NLRP3 pathways.	naringenin	0-10	NLR family, pyrin domain containing 3	Rattus norvegicus	135-140
33667286-8	2021	The results show that naringenin (100 muM) inhibits TNF-alpha-induced interleukin (IL)-6 hypersecretion, alleviates GVB disruption and mitigates the change in the tight junction protein expression pattern.	naringenin	22-32	tumor necrosis factor	Rattus norvegicus	52-61
33667286-8	2021	The results show that naringenin (100 muM) inhibits TNF-alpha-induced interleukin (IL)-6 hypersecretion, alleviates GVB disruption and mitigates the change in the tight junction protein expression pattern.	naringenin	22-32	interleukin 6	Rattus norvegicus	70-88
33667286-9	2021	Naringenin inhibits the GVB-disruption-associated activation of the MLCK/p-MLC system and TLR4/NF-kappaB/NLRP3 pathways.	naringenin	0-10	myosin light chain kinase 3	Rattus norvegicus	68-72
33667286-9	2021	Naringenin inhibits the GVB-disruption-associated activation of the MLCK/p-MLC system and TLR4/NF-kappaB/NLRP3 pathways.	naringenin	0-10	toll-like receptor 4	Rattus norvegicus	90-94
33667286-9	2021	Naringenin inhibits the GVB-disruption-associated activation of the MLCK/p-MLC system and TLR4/NF-kappaB/NLRP3 pathways.	naringenin	0-10	NLR family, pyrin domain containing 3	Rattus norvegicus	105-110
33667286-10	2021	Furthermore, naringenin shows a similar effect to that of NF-kappaB inhibitor Bay 11-7082 in reducing the TNF-alpha-induced activation of NLRP3, p-MLC and secondary GVB disruption.	naringenin	13-23	tumor necrosis factor	Rattus norvegicus	106-115
33667286-10	2021	Furthermore, naringenin shows a similar effect to that of NF-kappaB inhibitor Bay 11-7082 in reducing the TNF-alpha-induced activation of NLRP3, p-MLC and secondary GVB disruption.	naringenin	13-23	NLR family, pyrin domain containing 3	Rattus norvegicus	138-143
33667286-11	2021	The results suggest that naringenin evidently alleviates TNF-alpha-induced in vitro GVB disruption via the maintenance of a tight junction protein pattern, partly with the inhibition of the NF-kappaB-mediated MLCK/p-MLC and NLRP3 pathway activation.	naringenin	25-35	tumor necrosis factor	Rattus norvegicus	57-66
33667286-11	2021	The results suggest that naringenin evidently alleviates TNF-alpha-induced in vitro GVB disruption via the maintenance of a tight junction protein pattern, partly with the inhibition of the NF-kappaB-mediated MLCK/p-MLC and NLRP3 pathway activation.	naringenin	25-35	myosin light chain kinase 3	Rattus norvegicus	209-213
33667286-11	2021	The results suggest that naringenin evidently alleviates TNF-alpha-induced in vitro GVB disruption via the maintenance of a tight junction protein pattern, partly with the inhibition of the NF-kappaB-mediated MLCK/p-MLC and NLRP3 pathway activation.	naringenin	25-35	NLR family, pyrin domain containing 3	Rattus norvegicus	224-229
33249188-6	2021	Naringenin decreased the accumulation and maturation of conventional dendritic cells (cDCs), CCL19, and CCR7 in the CNS.	naringenin	0-10	chemokine (C-C motif) ligand 19	Mus musculus	93-98
33249188-6	2021	Naringenin decreased the accumulation and maturation of conventional dendritic cells (cDCs), CCL19, and CCR7 in the CNS.	naringenin	0-10	chemokine (C-C motif) receptor 7	Mus musculus	104-108
33249188-7	2021	Also, naringenin blocked the chemotaxis and antigen-presenting function of cDCs that resulted in reducing T-cell secreting cytokines (IFN-gamma, IL-17, and IL-6) in the spleen.	naringenin	6-16	interferon gamma	Mus musculus	134-143
33249188-7	2021	Also, naringenin blocked the chemotaxis and antigen-presenting function of cDCs that resulted in reducing T-cell secreting cytokines (IFN-gamma, IL-17, and IL-6) in the spleen.	naringenin	6-16	interleukin 17A	Mus musculus	145-150
33249188-7	2021	Also, naringenin blocked the chemotaxis and antigen-presenting function of cDCs that resulted in reducing T-cell secreting cytokines (IFN-gamma, IL-17, and IL-6) in the spleen.	naringenin	6-16	interleukin 6	Mus musculus	156-160
33618628-3	2021	After the initial virtual screening of a number of bioactive flavonoids, the binding affinity of three compounds - Naringin, Naringenin and Amentoflavone - at the active site of Mpro was investigated through MD Simulations, MM-PBSA and DFT Binding Energy calculations.	naringenin	125-135	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	178-182
33624733-0	2021	Naringenin promotes cell autophagy to improve high-fat-diet-induced atherosclerosis in ApoE-/- mice.	naringenin	0-10	apolipoprotein E	Mus musculus	87-91
33624733-2	2021	This study aims to investigate the mechanism of NAR in high-fat-diet (HFD)-induced atherosclerosis (AS) in apolipoprotein E-knockout (ApoE-/-) mice.	naringenin	48-51	apolipoprotein E	Mus musculus	107-123
33624733-11	2021	After they were treated with different doses of NAR, the LC3B and beclin 1 levels were improved while the p62 protein level was decreased.	naringenin	48-51	microtubule-associated protein 1 light chain 3 beta	Mus musculus	57-61
33624733-11	2021	After they were treated with different doses of NAR, the LC3B and beclin 1 levels were improved while the p62 protein level was decreased.	naringenin	48-51	nucleoporin 62	Mus musculus	106-109
33157041-8	2021	The beneficial effects of using both the naringenin and metformin along with the lower dose of doxorubicin were evident from the reduced dose-related body weight loss and increase in cytokines (TNF-alpha and IL-1beta) compared to a large dose of doxorubicin alone.	naringenin	41-51	tumor necrosis factor	Mus musculus	194-203
33527250-1	2021	Poorly water-soluble naringenin (NAR) was selected as a model drug and loaded into the porous MOFs for the construction of NAR@ZIF-8 inclusion complex.	naringenin	21-31	cleavage and polyadenylation specific factor 4	Homo sapiens	123-132
33552925-7	2021	Molecular docking of hGS with detected phytochemicals in TT (aridanin, naringenin, ferulic acid, and scopoletin) was performed and the number of interactions with the lead compounds, aridanin, analyzed.	naringenin	71-81	hepatocyte growth factor-regulated tyrosine kinase substrate	Homo sapiens	21-24
33552925-11	2021	Aridanin, naringenin, ferulic acid, and scopoletin demonstrated good binding affinities with hGS indicating that Tetrapleura tetraptera is a potential source of new plant-based bioactives relevant in the therapy of neurodegenerative diseases.	naringenin	10-20	hepatocyte growth factor-regulated tyrosine kinase substrate	Homo sapiens	93-96
33523599-11	2021	Naringenin increased d the expression of caspase-3 and reduced the expression of MMP-2 and MMP-9.	naringenin	0-10	caspase 3	Homo sapiens	41-50
33523599-11	2021	Naringenin increased d the expression of caspase-3 and reduced the expression of MMP-2 and MMP-9.	naringenin	0-10	matrix metallopeptidase 9	Homo sapiens	91-96
33614911-0	2021	Inhibition of tumor invasion and metastasis by targeting TGF-beta-Smad-MMP2 pathway with Asiatic acid and Naringenin.	naringenin	106-116	transforming growth factor alpha	Mus musculus	57-65
33614911-0	2021	Inhibition of tumor invasion and metastasis by targeting TGF-beta-Smad-MMP2 pathway with Asiatic acid and Naringenin.	naringenin	106-116	SMAD family member 7	Mus musculus	66-70
33614911-0	2021	Inhibition of tumor invasion and metastasis by targeting TGF-beta-Smad-MMP2 pathway with Asiatic acid and Naringenin.	naringenin	106-116	matrix metallopeptidase 2	Mus musculus	71-75
33614911-2	2021	In the present study, we found that combined therapy with Asiatic acid (AA), a Smad7 agonist, and Naringenin (NG), a Smad3 inhibitor, effectively retrieved the balance between Smad3 and Smad7 signaling in the TGF-beta-rich tumor microenvironment and thus significantly suppressed tumor invasion and metastasis in mouse models of melanoma and lung carcinoma.	naringenin	98-108	SMAD family member 3	Mus musculus	117-122
33614911-2	2021	In the present study, we found that combined therapy with Asiatic acid (AA), a Smad7 agonist, and Naringenin (NG), a Smad3 inhibitor, effectively retrieved the balance between Smad3 and Smad7 signaling in the TGF-beta-rich tumor microenvironment and thus significantly suppressed tumor invasion and metastasis in mouse models of melanoma and lung carcinoma.	naringenin	98-108	SMAD family member 3	Mus musculus	176-181
33614911-2	2021	In the present study, we found that combined therapy with Asiatic acid (AA), a Smad7 agonist, and Naringenin (NG), a Smad3 inhibitor, effectively retrieved the balance between Smad3 and Smad7 signaling in the TGF-beta-rich tumor microenvironment and thus significantly suppressed tumor invasion and metastasis in mouse models of melanoma and lung carcinoma.	naringenin	98-108	SMAD family member 7	Mus musculus	186-191
33614911-2	2021	In the present study, we found that combined therapy with Asiatic acid (AA), a Smad7 agonist, and Naringenin (NG), a Smad3 inhibitor, effectively retrieved the balance between Smad3 and Smad7 signaling in the TGF-beta-rich tumor microenvironment and thus significantly suppressed tumor invasion and metastasis in mouse models of melanoma and lung carcinoma.	naringenin	110-112	SMAD family member 3	Mus musculus	117-122
33614911-2	2021	In the present study, we found that combined therapy with Asiatic acid (AA), a Smad7 agonist, and Naringenin (NG), a Smad3 inhibitor, effectively retrieved the balance between Smad3 and Smad7 signaling in the TGF-beta-rich tumor microenvironment and thus significantly suppressed tumor invasion and metastasis in mouse models of melanoma and lung carcinoma.	naringenin	110-112	SMAD family member 3	Mus musculus	176-181
33614911-2	2021	In the present study, we found that combined therapy with Asiatic acid (AA), a Smad7 agonist, and Naringenin (NG), a Smad3 inhibitor, effectively retrieved the balance between Smad3 and Smad7 signaling in the TGF-beta-rich tumor microenvironment and thus significantly suppressed tumor invasion and metastasis in mouse models of melanoma and lung carcinoma.	naringenin	110-112	SMAD family member 7	Mus musculus	186-191
33157041-8	2021	The beneficial effects of using both the naringenin and metformin along with the lower dose of doxorubicin were evident from the reduced dose-related body weight loss and increase in cytokines (TNF-alpha and IL-1beta) compared to a large dose of doxorubicin alone.	naringenin	41-51	interleukin 1 alpha	Mus musculus	208-216
33006902-13	2021	In addition, chronic morphine-induced GFAP and COX-2 overexpression was significantly reversed by 50 mg/kg naringenin (p < .05 and p < .01, respectively).	naringenin	107-117	glial fibrillary acidic protein	Rattus norvegicus	38-42
33438556-10	2021	Furthermore expression level of Bax and Bcl2 mRNAs altered significantly in all samples treated with 50 (mug/ml) of naringenin, resveratrol, or simultaneously with both.	naringenin	116-126	BCL2 associated X, apoptosis regulator	Homo sapiens	32-35
33438556-10	2021	Furthermore expression level of Bax and Bcl2 mRNAs altered significantly in all samples treated with 50 (mug/ml) of naringenin, resveratrol, or simultaneously with both.	naringenin	116-126	BCL2 apoptosis regulator	Homo sapiens	40-44
33006902-13	2021	In addition, chronic morphine-induced GFAP and COX-2 overexpression was significantly reversed by 50 mg/kg naringenin (p < .05 and p < .01, respectively).	naringenin	107-117	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	47-52
33398525-0	2021	Reduction of oxidative stress and ornithine decarboxylase expression in a human prostate cancer cell line PC-3 by a combined treatment with alpha-tocopherol and naringenin.	naringenin	161-171	ornithine decarboxylase 1	Homo sapiens	34-57
33398525-7	2021	In addition, a significant reduction of both ornithine decarboxylase (ODC) expression and intracellular levels of polyamines, both well-known positive regulators of cell proliferation, accompanied the reduction of oxidative stress observed in the combined alpha-TOC and NG treatment.	naringenin	270-272	ornithine decarboxylase 1	Homo sapiens	45-68
32819237-0	2021	The Natural Flavonoid Naringenin Inhibits the Cell Growth of WilmsTumorinChildren by Suppressing TLR4/NF-kappaB Signaling.	naringenin	22-32	toll like receptor 4	Homo sapiens	97-101
32819237-0	2021	The Natural Flavonoid Naringenin Inhibits the Cell Growth of WilmsTumorinChildren by Suppressing TLR4/NF-kappaB Signaling.	naringenin	22-32	nuclear factor kappa B subunit 1	Homo sapiens	102-111
32819237-7	2021	RESULTS: Naringenin displayed significant inhibitory effect on NF-kappaB activation in SK-NEP-1 cells.	naringenin	9-19	nuclear factor kappa B subunit 1	Homo sapiens	63-72
32819237-8	2021	In SK-NEP-1 and G-401 cells, naringenin inhibited p65 phosphorylation.	naringenin	29-39	RELA proto-oncogene, NF-kB subunit	Homo sapiens	50-53
32819237-9	2021	Moreover, naringenin suppressed TNF-alpha-induced p65 phosphorylation in WT cells.	naringenin	10-20	tumor necrosis factor	Homo sapiens	32-41
32819237-9	2021	Moreover, naringenin suppressed TNF-alpha-induced p65 phosphorylation in WT cells.	naringenin	10-20	RELA proto-oncogene, NF-kB subunit	Homo sapiens	50-53
32819237-10	2021	Naringenin inhibited TLR4 expression at both mRNA and protein levels in WT cells.	naringenin	0-10	toll like receptor 4	Homo sapiens	21-25
32819237-13	2021	Western blot found that naringenin inhibited TLR4 expression and p65 phosphorylation in WT xenograft tumors.	naringenin	24-34	toll like receptor 4	Homo sapiens	45-49
32819237-13	2021	Western blot found that naringenin inhibited TLR4 expression and p65 phosphorylation in WT xenograft tumors.	naringenin	24-34	RELA proto-oncogene, NF-kB subunit	Homo sapiens	65-68
32819237-14	2021	CONCLUSION: Naringenin inhibits WT development viasuppressing TLR4/NF-kappaB signaling.	naringenin	12-22	toll like receptor 4	Homo sapiens	62-66
32819237-14	2021	CONCLUSION: Naringenin inhibits WT development viasuppressing TLR4/NF-kappaB signaling.	naringenin	12-22	nuclear factor kappa B subunit 1	Homo sapiens	67-76
33459225-7	2021	Of the compounds addressed in this review, 7 phenolic compounds, including quercetin, curcumin, naringenin, luteolin, hesperidin, mangiferin, and gallic acid showed binding affinity with molecular ACE-2 target in silico, and 1, esculetin, decreased ACE-2 expression in vivo.	naringenin	96-106	angiotensin converting enzyme 2	Homo sapiens	197-202
32949818-5	2021	Naringenin reduced 6-OHDA induced oxidative stress biomarker levels such as CAT, GSH, SOD, and ROS.	naringenin	0-10	catalase	Danio rerio	76-79
32949818-8	2021	Naringenin was also found to downregulate the expression of some Parkinsonian genes such as casp9, lrrk2, and polg and upregulate pink1.	naringenin	0-10	caspase 9, apoptosis-related cysteine peptidase	Danio rerio	92-97
32949818-8	2021	Naringenin was also found to downregulate the expression of some Parkinsonian genes such as casp9, lrrk2, and polg and upregulate pink1.	naringenin	0-10	leucine-rich repeat kinase 2	Danio rerio	99-104
32949818-8	2021	Naringenin was also found to downregulate the expression of some Parkinsonian genes such as casp9, lrrk2, and polg and upregulate pink1.	naringenin	0-10	polymerase (DNA directed), gamma	Danio rerio	110-114
32949818-8	2021	Naringenin was also found to downregulate the expression of some Parkinsonian genes such as casp9, lrrk2, and polg and upregulate pink1.	naringenin	0-10	PTEN induced kinase 1	Danio rerio	130-135
33459225-7	2021	Of the compounds addressed in this review, 7 phenolic compounds, including quercetin, curcumin, naringenin, luteolin, hesperidin, mangiferin, and gallic acid showed binding affinity with molecular ACE-2 target in silico, and 1, esculetin, decreased ACE-2 expression in vivo.	naringenin	96-106	angiotensin converting enzyme 2	Homo sapiens	249-254
33221601-13	2021	Simultaneous supplementation of Nar and Cd markedly restored the decreased levels of GnRH, FSH, LH, testosterone, GSH, and T-AOC and the activities of SOD, CAT, and GPx caused by Cd treatment.	naringenin	32-35	gonadotropin releasing hormone 1	Rattus norvegicus	85-89
33704767-0	2021	Naringenin promotes SDF-1/CXCR4 signaling pathway in BMSCs osteogenic differentiation.	naringenin	0-10	C-X-C motif chemokine ligand 12	Rattus norvegicus	20-25
33704767-0	2021	Naringenin promotes SDF-1/CXCR4 signaling pathway in BMSCs osteogenic differentiation.	naringenin	0-10	C-X-C motif chemokine receptor 4	Rattus norvegicus	26-31
33704767-3	2021	The aim of this study was to investigate the effect of naringenin on the osteogenic differentiation and its roles in the C-X-C chemokine receptor type 4/stromal cell-derived factor 1 (SDF-1/CXCR4) signal pathway of bone marrow-derived mesenchymal stem cells (BMSCs).	naringenin	55-65	C-X-C motif chemokine ligand 12	Rattus norvegicus	184-189
33704767-3	2021	The aim of this study was to investigate the effect of naringenin on the osteogenic differentiation and its roles in the C-X-C chemokine receptor type 4/stromal cell-derived factor 1 (SDF-1/CXCR4) signal pathway of bone marrow-derived mesenchymal stem cells (BMSCs).	naringenin	55-65	C-X-C motif chemokine receptor 4	Rattus norvegicus	190-195
33704767-13	2021	The expression of ALP, Runt-related transcription factor 2, CXCR4 and SDF-1alpha at the gene and protein levels in naringenin-treated cells were significantly higher than those in the control cells.	naringenin	115-125	RUNX family transcription factor 2	Rattus norvegicus	23-58
33704767-13	2021	The expression of ALP, Runt-related transcription factor 2, CXCR4 and SDF-1alpha at the gene and protein levels in naringenin-treated cells were significantly higher than those in the control cells.	naringenin	115-125	C-X-C motif chemokine receptor 4	Rattus norvegicus	60-65
33704767-16	2021	Naringenin promotes the expression of the SDF-1alpha gene and protein via the SDF-1/CXCR4 signaling pathway.	naringenin	0-10	C-X-C motif chemokine ligand 12	Rattus norvegicus	42-47
33704767-16	2021	Naringenin promotes the expression of the SDF-1alpha gene and protein via the SDF-1/CXCR4 signaling pathway.	naringenin	0-10	C-X-C motif chemokine receptor 4	Rattus norvegicus	84-89
33249629-8	2021	In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1beta, IL-6, TNF-alpha, and IL-8.	naringenin	13-23	interleukin 1 alpha	Homo sapiens	104-112
33249629-8	2021	In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1beta, IL-6, TNF-alpha, and IL-8.	naringenin	13-23	interleukin 6	Homo sapiens	114-118
33249629-8	2021	In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1beta, IL-6, TNF-alpha, and IL-8.	naringenin	13-23	tumor necrosis factor	Homo sapiens	120-129
33249629-8	2021	In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1beta, IL-6, TNF-alpha, and IL-8.	naringenin	13-23	C-X-C motif chemokine ligand 8	Homo sapiens	135-139
33221601-13	2021	Simultaneous supplementation of Nar and Cd markedly restored the decreased levels of GnRH, FSH, LH, testosterone, GSH, and T-AOC and the activities of SOD, CAT, and GPx caused by Cd treatment.	naringenin	32-35	catalase	Rattus norvegicus	156-159
33221601-14	2021	Nar further suppressed MDA and H2O2 production and protected the testes from Cd-induced autophagy by downregulating P62 and LC3 II expression.	naringenin	0-3	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	116-130
33096452-0	2021	Naringenin protects RPE cells from NaIO3-induced oxidative damage in vivo and in vitro through up-regulation of SIRT1.	naringenin	0-10	sirtuin 1	Homo sapiens	112-117
33096452-4	2021	PURPOSE: We tested the hypothesis that anti-oxidation mediated by Sirtuin 1 (SIRT1) was important to the protective effect of NAR on dAMD.	naringenin	126-129	sirtuin 1	Homo sapiens	66-75
33096452-4	2021	PURPOSE: We tested the hypothesis that anti-oxidation mediated by Sirtuin 1 (SIRT1) was important to the protective effect of NAR on dAMD.	naringenin	126-129	sirtuin 1	Homo sapiens	77-82
33096452-11	2021	NAR up-regulated SIRT1 protein expression, and decreased levels of ROS and carbonyl protein.	naringenin	0-3	sirtuin 1	Homo sapiens	17-22
33096452-12	2021	Moreover, EX527, a selective inhibitor of SIRT1, abolished the effects of NAR on the cell viability and ROS.	naringenin	74-77	sirtuin 1	Homo sapiens	42-47
33234364-0	2021	Naringenin alleviates nonalcoholic steatohepatitis in middle-aged Apoe-/-mice: role of SIRT1.	naringenin	0-10	apolipoprotein E	Mus musculus	66-70
33234364-3	2021	PURPOSE: The present study is aimed to investigate the effect of naringenin on NASH in 12-mo-old male ApoE-/- mice and its possible underlying mechanism.	naringenin	65-75	apolipoprotein E	Mus musculus	102-106
33250176-6	2021	NAR also promoted the mRNA expression of SDF-1 in a concentration dependent manner in PDLSCs.	naringenin	0-3	C-X-C motif chemokine ligand 12	Homo sapiens	41-46
33234364-4	2021	METHODS: In vivo, 12-mo-old male ApoE-/- mice were administrated with naringenin by intragastric gavage for 12 weeks.	naringenin	70-80	apolipoprotein E	Mus musculus	33-37
33234364-12	2021	RESULTS: Naringenin administration improved metabolic parameters, suppressed hepatic steatosis, regulated expression of genes involved in lipid metabolism (FASN, SCD1, PPARalpha and CPT1alpha), reduced hepatic fibrosis and cell senescence, inhibited hepatic inflammation as evidenced by the decreased macrophage recruitment and content of TNF-alpha and IL-6, and reduced hepatic oxidative stress by suppressing ROS generation and normalizing activities of antioxidant enzymes.	naringenin	9-19	fatty acid synthase	Mus musculus	156-160
33250176-7	2021	After adding the selective CXCR4 antagonist AMD3100, the osteogenic effect of NAR on PDLSCs is slightly enhanced, while the endothelial differentiation effect of NAR on hPDLSCs is attenuated.	naringenin	78-81	C-X-C motif chemokine receptor 4	Homo sapiens	27-32
30900959-0	2021	Naringenin, a dietary flavanone, enhances insulin-like growth factor 1 receptor-mediated antioxidant defense and attenuates methylglyoxal-induced neurite damage and apoptotic death.	naringenin	0-10	insulin-like growth factor I receptor	Mus musculus	42-79
30900959-13	2021	However, AG1024, an IGF-1R antagonist, attenuated the anti-oxidative and anti-apoptotic effects of NGEN in MG-treated cells.	naringenin	99-103	insulin-like growth factor I receptor	Mus musculus	20-26
33234364-12	2021	RESULTS: Naringenin administration improved metabolic parameters, suppressed hepatic steatosis, regulated expression of genes involved in lipid metabolism (FASN, SCD1, PPARalpha and CPT1alpha), reduced hepatic fibrosis and cell senescence, inhibited hepatic inflammation as evidenced by the decreased macrophage recruitment and content of TNF-alpha and IL-6, and reduced hepatic oxidative stress by suppressing ROS generation and normalizing activities of antioxidant enzymes.	naringenin	9-19	stearoyl-Coenzyme A desaturase 1	Mus musculus	162-166
33234364-12	2021	RESULTS: Naringenin administration improved metabolic parameters, suppressed hepatic steatosis, regulated expression of genes involved in lipid metabolism (FASN, SCD1, PPARalpha and CPT1alpha), reduced hepatic fibrosis and cell senescence, inhibited hepatic inflammation as evidenced by the decreased macrophage recruitment and content of TNF-alpha and IL-6, and reduced hepatic oxidative stress by suppressing ROS generation and normalizing activities of antioxidant enzymes.	naringenin	9-19	peroxisome proliferator activated receptor alpha	Mus musculus	168-177
33234364-12	2021	RESULTS: Naringenin administration improved metabolic parameters, suppressed hepatic steatosis, regulated expression of genes involved in lipid metabolism (FASN, SCD1, PPARalpha and CPT1alpha), reduced hepatic fibrosis and cell senescence, inhibited hepatic inflammation as evidenced by the decreased macrophage recruitment and content of TNF-alpha and IL-6, and reduced hepatic oxidative stress by suppressing ROS generation and normalizing activities of antioxidant enzymes.	naringenin	9-19	carnitine palmitoyltransferase 1a, liver	Mus musculus	182-191
33234364-13	2021	Notably, naringenin administration increased hepatic SIRT1 protein expression and activity along with the increased deacetylation of liver kinase B1 (LKB1), PGC1alpha and NF-kappaB.	naringenin	9-19	sirtuin 1	Mus musculus	53-58
33234364-12	2021	RESULTS: Naringenin administration improved metabolic parameters, suppressed hepatic steatosis, regulated expression of genes involved in lipid metabolism (FASN, SCD1, PPARalpha and CPT1alpha), reduced hepatic fibrosis and cell senescence, inhibited hepatic inflammation as evidenced by the decreased macrophage recruitment and content of TNF-alpha and IL-6, and reduced hepatic oxidative stress by suppressing ROS generation and normalizing activities of antioxidant enzymes.	naringenin	9-19	tumor necrosis factor	Mus musculus	339-348
33234364-12	2021	RESULTS: Naringenin administration improved metabolic parameters, suppressed hepatic steatosis, regulated expression of genes involved in lipid metabolism (FASN, SCD1, PPARalpha and CPT1alpha), reduced hepatic fibrosis and cell senescence, inhibited hepatic inflammation as evidenced by the decreased macrophage recruitment and content of TNF-alpha and IL-6, and reduced hepatic oxidative stress by suppressing ROS generation and normalizing activities of antioxidant enzymes.	naringenin	9-19	interleukin 6	Mus musculus	353-357
33603536-11	2021	The mRNA of tumor suppressors P53 and ERalpha were downregulated in the mammosphere, but were significantly upregulated upon naringenin treatment.	naringenin	125-135	tumor protein p53	Homo sapiens	30-33
33234364-13	2021	Notably, naringenin administration increased hepatic SIRT1 protein expression and activity along with the increased deacetylation of liver kinase B1 (LKB1), PGC1alpha and NF-kappaB.	naringenin	9-19	serine/threonine kinase 11	Mus musculus	133-148
33234364-13	2021	Notably, naringenin administration increased hepatic SIRT1 protein expression and activity along with the increased deacetylation of liver kinase B1 (LKB1), PGC1alpha and NF-kappaB.	naringenin	9-19	serine/threonine kinase 11	Mus musculus	150-154
33234364-13	2021	Notably, naringenin administration increased hepatic SIRT1 protein expression and activity along with the increased deacetylation of liver kinase B1 (LKB1), PGC1alpha and NF-kappaB.	naringenin	9-19	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	157-166
33234364-13	2021	Notably, naringenin administration increased hepatic SIRT1 protein expression and activity along with the increased deacetylation of liver kinase B1 (LKB1), PGC1alpha and NF-kappaB.	naringenin	9-19	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	171-180
33234364-14	2021	In vitro study, the benefits of naringenin on lipid accumulation, oxidative stress and inflammation were diminished by SIRT1 siRNA transfection.	naringenin	32-42	sirtuin 1	Mus musculus	119-124
33234364-15	2021	CONCLUSIONS: These results indicate that naringenin administration may be a potential curative therapy for NASH treatment and the activation of hepatic SIRT1-mediated signaling cascades is involved in its beneficial effects.	naringenin	41-51	sirtuin 1	Mus musculus	152-157
33603536-11	2021	The mRNA of tumor suppressors P53 and ERalpha were downregulated in the mammosphere, but were significantly upregulated upon naringenin treatment.	naringenin	125-135	estrogen receptor 1	Homo sapiens	38-45
33603536-12	2021	By modulating the P53 and ERalpha mRNA, naringenin has the potential of inhibiting BCSCs.	naringenin	40-50	tumor protein p53	Homo sapiens	18-21
33603536-12	2021	By modulating the P53 and ERalpha mRNA, naringenin has the potential of inhibiting BCSCs.	naringenin	40-50	estrogen receptor 1	Homo sapiens	26-33
33140889-12	2020	Six active compounds of LQC can enter the active pocket of Akt1, namely beta-carotene, kaempferol, luteolin, naringenin, quercetin and wogonin, thereby exerting potential therapeutic effects in COVID-19.	naringenin	109-119	AKT serine/threonine kinase 1	Homo sapiens	59-63
33663922-0	2021	Inhibition of histone acetyltransferase by naringenin and hesperetin suppresses Txnip expression and protects pancreatic beta cells in diabetic mice.	naringenin	43-53	thioredoxin interacting protein	Mus musculus	80-85
33663922-10	2021	The further study found that the inhibition of thioredoxin-interacting protein (Txnip) expression regulated by histone acetylation was critical for the protective role of naringenin and hesperetin.	naringenin	171-181	thioredoxin interacting protein	Mus musculus	47-78
33663922-10	2021	The further study found that the inhibition of thioredoxin-interacting protein (Txnip) expression regulated by histone acetylation was critical for the protective role of naringenin and hesperetin.	naringenin	171-181	thioredoxin interacting protein	Mus musculus	80-85
33663922-11	2021	Mechanistically, the histone acetylation inhibition by naringenin and hesperetin was achieved through regulating AMPK-mediated p300 inactivation.	naringenin	55-65	E1A binding protein p300	Mus musculus	127-131
32667124-0	2020	Cytotoxicity of naringenin induces Bax-mediated mitochondrial apoptosis in human lung adenocarcinoma A549 cells.	naringenin	16-26	BCL2 associated X, apoptosis regulator	Homo sapiens	35-38
32667124-6	2020	Knockdown of the Bax expression by the shRNA method dramatically protected A549 cells against NGEN-induced apoptosis.	naringenin	94-98	BCL2 associated X, apoptosis regulator	Homo sapiens	17-20
32667124-7	2020	Treatment with the inhibitors of caspase-3, -8, or -9 significantly reduced NGEN-induced apoptotic deaths.	naringenin	76-80	caspase 3	Homo sapiens	33-53
32667124-8	2020	Taken together, our results demonstrate that NGEN-induced apoptosis may occur via a Bax-activated mitochondrial pathway in lung adenocarcinoma A549 cells.	naringenin	45-49	BCL2 associated X, apoptosis regulator	Homo sapiens	84-87
33334792-0	2020	Mechanism of Naringenin Blocking the Protection of LTB4/BLT1 Receptor Against Septic Cardiac Dysfunction.	naringenin	13-23	leukotriene B4 receptor 1	Mus musculus	56-60
32767162-6	2020	After NG treatment, glioma cells resumed the sensitivity to APO2L and cell apoptosis was induced via the activation of caspases, elevation of decoy receptors 4 and 5 (DR4 and DR5) and induction of p53.	naringenin	6-8	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	60-65
32767162-6	2020	After NG treatment, glioma cells resumed the sensitivity to APO2L and cell apoptosis was induced via the activation of caspases, elevation of decoy receptors 4 and 5 (DR4 and DR5) and induction of p53.	naringenin	6-8	tumor necrosis factor receptor superfamily, member 10b	Mus musculus	175-178
32767162-6	2020	After NG treatment, glioma cells resumed the sensitivity to APO2L and cell apoptosis was induced via the activation of caspases, elevation of decoy receptors 4 and 5 (DR4 and DR5) and induction of p53.	naringenin	6-8	transformation related protein 53, pseudogene	Mus musculus	197-200
32767162-9	2020	The present study provides a novel therapeutic strategy for glioma by potentiating APO2L-induced apoptosis via the combination with NG in glioma tumor cells.	naringenin	132-134	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	83-88
33007396-0	2020	Differential inhibition of naringenin on human and rat cytochrome P450 2E1 activity.	naringenin	27-37	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	55-74
33210911-6	2020	Other flavanone derivatives from grapefruit juice also inhibited OATP1A2/OATP2B1-mediated transport (order of inhibitory potency: naringenin > narirutin > naringin).	naringenin	130-140	solute carrier organic anion transporter family member 1A2	Homo sapiens	65-72
33210911-6	2020	Other flavanone derivatives from grapefruit juice also inhibited OATP1A2/OATP2B1-mediated transport (order of inhibitory potency: naringenin > narirutin > naringin).	naringenin	130-140	solute carrier organic anion transporter family member 2B1	Homo sapiens	73-80
33182380-0	2020	Evaluation of VCAM-1 Targeted Naringenin/Indocyanine Green-Loaded Lipid Nanoemulsions as Theranostic Nanoplatforms in Inflammation.	naringenin	30-40	vascular cell adhesion molecule 1	Mus musculus	14-20
33182380-2	2020	To overcome these limitations, naringenin was loaded into lipid nanoemulsions directed towards vascular cell adhesion molecule (VCAM)-1, exposed by activated endothelium, and delivered intravenously in a murine model of lipopolysaccharide (LPS)-induced inflammation.	naringenin	31-41	vascular cell adhesion molecule 1	Mus musculus	95-135
33334792-9	2020	RESULTS: The expressions of TNF-alpha, IL-6, pNF-kappaB and IkappaB-alpha have changed after Naringenin treatment.	naringenin	93-103	tumor necrosis factor	Mus musculus	28-37
33334792-9	2020	RESULTS: The expressions of TNF-alpha, IL-6, pNF-kappaB and IkappaB-alpha have changed after Naringenin treatment.	naringenin	93-103	interleukin 6	Mus musculus	39-43
33334792-9	2020	RESULTS: The expressions of TNF-alpha, IL-6, pNF-kappaB and IkappaB-alpha have changed after Naringenin treatment.	naringenin	93-103	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	60-73
33334792-11	2020	Naringenin has significantly inhibited AMPK and ACC phosphorylation, and decreased PGC1alpha expression.	naringenin	0-10	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	83-92
33334792-12	2020	Moreover, Naringenin reversed the increased expressions of PGC1alpha and phosphorylation of AMPK and ACC by U75302 treatment, and decreased the expressions of complex I, complex II and OPA1.	naringenin	10-20	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	59-68
33334792-12	2020	Moreover, Naringenin reversed the increased expressions of PGC1alpha and phosphorylation of AMPK and ACC by U75302 treatment, and decreased the expressions of complex I, complex II and OPA1.	naringenin	10-20	OPA1, mitochondrial dynamin like GTPase	Mus musculus	185-189
33334792-13	2020	CONCLUSION: Naringenin inhibits LTB4/BLT1 receptors to attenuate cardiomyocyte inflammation and apoptosis, which may mediate the protective effect of anti-septic cardiac dysfunction by activating AMPK signaling pathway and inhibiting NF-kappaB signaling and mitochondrial damage.	naringenin	12-22	leukotriene B4 receptor 1	Mus musculus	37-41
33050575-4	2020	Luteolin, apigenin, quercetin, myricetin, rutin, naringenin, epicatechin, and genistein activate the Nrf2/ARE pathway in both normal and cancer cells.	naringenin	49-59	NFE2 like bZIP transcription factor 2	Homo sapiens	101-105
32814161-0	2020	Defective insulin receptor signaling in patients with gestational diabetes is related to dysregulated miR-140 which can be improved by naringenin.	naringenin	135-145	insulin receptor	Homo sapiens	10-26
32814161-0	2020	Defective insulin receptor signaling in patients with gestational diabetes is related to dysregulated miR-140 which can be improved by naringenin.	naringenin	135-145	microRNA 140	Homo sapiens	102-109
32814161-9	2020	Meanwhile, IR-alpha and IGF1R expression was upregulated by naringenin, and the glucose uptake was increased in naringenin treated trophoblasts and endothelial cells.	naringenin	60-70	insulin like growth factor 1 receptor	Homo sapiens	24-29
32125927-6	2020	In our study, we investigated the effects of naringenin (NRG), a flavanon abundant in citrus fruits, on ER stress and autophagy in CCl4-injured rat liver.	naringenin	45-55	C-C motif chemokine ligand 4	Rattus norvegicus	131-135
33173425-4	2020	Moreover, we assessed the effects of naringenin treatment on angiogenesis of HUVECs and ex vivo sprouting of microvessels.Naringenin inhibited tumor cell proliferation and migration in a dose-dependent manner in B16F10 and SK-MEL-28 cells, which is supported by the results that phosphorylation of ERK1/2 and JNK MAPK decreased.	naringenin	122-132	mitogen-activated protein kinase 3	Homo sapiens	298-304
33173425-6	2020	Western blot analysisshowed naringenin treatment significantly upregulated the protein expression of activated cas3 and PARP in B16F10 and SK-MEL-28 cells.	naringenin	28-38	poly (ADP-ribose) polymerase family, member 1	Mus musculus	120-124
33173425-8	2020	RT-PCR analysis showed that naringenin treatment significantly reduced the mRNA expression of Tie2, but did not inhibit the expression of Ang2.	naringenin	28-38	TEK receptor tyrosine kinase	Homo sapiens	94-98
33119667-11	2020	In conclusion, crocin at 1 mM and naringenin at 100 muM seem to improve the post-thawing rooster semen quality, fertility and could protect the sperm by reducing the pro-apoptotic (CASPASE 3) and increasing anti-apoptotic (Bcl-2) genes.	naringenin	34-44	caspase 3	Homo sapiens	181-190
33119667-11	2020	In conclusion, crocin at 1 mM and naringenin at 100 muM seem to improve the post-thawing rooster semen quality, fertility and could protect the sperm by reducing the pro-apoptotic (CASPASE 3) and increasing anti-apoptotic (Bcl-2) genes.	naringenin	34-44	BCL2 apoptosis regulator	Homo sapiens	223-228
33192517-3	2020	Treatment with flavonoids (naringenin, quercetin, and naringin) plus Balsamin for 48 h reduced HepG2 and MCF-7 cell viability, increased the activation of caspase-3 and -8, and induced apoptosis through up-regulation of pro-apoptotic genes and down-regulation of anti-apoptotic genes.	naringenin	27-37	caspase 3	Homo sapiens	155-171
32628779-0	2020	By reducing oxidative stress, naringenin mitigates hyperglycaemia-induced upregulation of hepatic nuclear factor erythroid 2-related factor 2 protein.	naringenin	30-40	NFE2 like bZIP transcription factor 2	Rattus norvegicus	98-141
33066647-5	2020	System bioinformatic analysis indicated that naringenin exhibits protective effects on lung through the inhibition of inflammation and suppression of oxidative stress based on a multi-pathways network, mainly including oxidative stress pathway, Nrf2 pathway, Lung fibrosis pathway, IL-3 signaling pathway, and Aryl hydrocarbon receptor pathway.	naringenin	45-55	NFE2 like bZIP transcription factor 2	Homo sapiens	245-249
33066647-5	2020	System bioinformatic analysis indicated that naringenin exhibits protective effects on lung through the inhibition of inflammation and suppression of oxidative stress based on a multi-pathways network, mainly including oxidative stress pathway, Nrf2 pathway, Lung fibrosis pathway, IL-3 signaling pathway, and Aryl hydrocarbon receptor pathway.	naringenin	45-55	interleukin 3	Homo sapiens	282-286
33066647-5	2020	System bioinformatic analysis indicated that naringenin exhibits protective effects on lung through the inhibition of inflammation and suppression of oxidative stress based on a multi-pathways network, mainly including oxidative stress pathway, Nrf2 pathway, Lung fibrosis pathway, IL-3 signaling pathway, and Aryl hydrocarbon receptor pathway.	naringenin	45-55	aryl hydrocarbon receptor	Homo sapiens	310-335
33066647-6	2020	The in vitro results showed that naringenin significantly attenuated CSE-induced up-regulation of IL-8 and TNF-alpha.	naringenin	33-43	C-X-C motif chemokine ligand 8	Homo sapiens	98-102
33066647-6	2020	The in vitro results showed that naringenin significantly attenuated CSE-induced up-regulation of IL-8 and TNF-alpha.	naringenin	33-43	tumor necrosis factor	Homo sapiens	107-116
33066647-8	2020	Naringenin can balance the antioxidant system by regulating Nrf2 and its downstream genes, preliminarily validating that Nrf2 pathway is involved in the protection offered by naringenin against cigarette smoke-induced damage to the lung.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	60-64
33066647-8	2020	Naringenin can balance the antioxidant system by regulating Nrf2 and its downstream genes, preliminarily validating that Nrf2 pathway is involved in the protection offered by naringenin against cigarette smoke-induced damage to the lung.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	121-125
33066647-8	2020	Naringenin can balance the antioxidant system by regulating Nrf2 and its downstream genes, preliminarily validating that Nrf2 pathway is involved in the protection offered by naringenin against cigarette smoke-induced damage to the lung.	naringenin	175-185	NFE2 like bZIP transcription factor 2	Homo sapiens	60-64
33066647-8	2020	Naringenin can balance the antioxidant system by regulating Nrf2 and its downstream genes, preliminarily validating that Nrf2 pathway is involved in the protection offered by naringenin against cigarette smoke-induced damage to the lung.	naringenin	175-185	NFE2 like bZIP transcription factor 2	Homo sapiens	121-125
32999809-7	2020	Naringenin mediated altered alpha-amylase activity improved the mungbean seed germination rate.	naringenin	0-10	alpha-amylase	Vigna radiata	28-41
32628779-7	2020	Naringenin further significantly reduced hepatic oxidative stress and nuclear factor erythroid 2-related factor 2 (Nrf2) protein expression and liver : body weight ratios in diabetic compared to controls rats.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	70-113
32628779-7	2020	Naringenin further significantly reduced hepatic oxidative stress and nuclear factor erythroid 2-related factor 2 (Nrf2) protein expression and liver : body weight ratios in diabetic compared to controls rats.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	115-119
32628779-8	2020	CONCLUSIONS: Naringenin confers hepatoprotective antioxidant effects by initially preventing upregulation of Nrf2 protein expression and its downstream antioxidant enzymes.	naringenin	13-23	NFE2 like bZIP transcription factor 2	Rattus norvegicus	109-113
32180335-2	2020	The purpose of this study was to evaluate the role of naringenin on hepatic expression of organic cation transporter 1 (OCT 1) protein and its associated effects on metformin-associated hyperlactataemia in diabetes.	naringenin	54-64	solute carrier family 22 member 1	Rattus norvegicus	90-118
32437808-0	2020	Mechanistic inhibition of non-enzymatic glycation and aldose reductase activity by naringenin: Binding, enzyme kinetics and molecular docking analysis.	naringenin	83-93	aldo-keto reductase family 1 member B	Homo sapiens	54-70
32437808-2	2020	In this study, we describe the binding and enzyme kinetics of AR by naringenin, a bioflavonoid present in many dietary sources.	naringenin	68-78	aldo-keto reductase family 1 member B	Homo sapiens	62-64
32437808-3	2020	Naringenin showed an inhibitory effect on the activity of AR with an IC50 value of 2.6 muM in an uncompetitive manner.	naringenin	0-10	aldo-keto reductase family 1 member B	Homo sapiens	58-60
32437808-9	2020	Furthermore, molecular docking of naringenin with AR revealed that naringenin formed two hydrogen bonds (Asn160 and Ile260), and three Pi-Pi interactions (two with Trp20 and one with His110).	naringenin	67-77	aldo-keto reductase family 1 member B	Homo sapiens	50-52
32437808-10	2020	This study provides molecular insight of naringenin-AR interaction and mechanism of antiglycation which may be useful in the development of inhibitors for AGEs formation.	naringenin	41-51	aldo-keto reductase family 1 member B	Homo sapiens	52-54
32920547-10	2020	These findings suggest that R. meyeri anthocyanins increase NSC proliferation and improve neurogenesis with aging via Nar-induced reductions in TNF-alpha protein levels in vivo.	naringenin	118-121	tumor necrosis factor	Mus musculus	144-153
32955605-10	2020	Nanoformulation enhances the bioavailability of Naringenin and liver specific delivery of the same, which up-regulates MMP-2 hepatic proteins resulting in reduced liver fibrosis.	naringenin	48-58	matrix metallopeptidase 2	Rattus norvegicus	119-124
32180335-2	2020	The purpose of this study was to evaluate the role of naringenin on hepatic expression of organic cation transporter 1 (OCT 1) protein and its associated effects on metformin-associated hyperlactataemia in diabetes.	naringenin	54-64	solute carrier family 22 member 1	Rattus norvegicus	120-125
32180335-11	2020	Furthermore, naringenin with or without metformin but not metformin only significantly increased hepatic OCT1 expression in diabetic compared to non-treated diabetic rats.	naringenin	13-23	solute carrier family 22 member 1	Rattus norvegicus	105-109
32180335-15	2020	These results suggest that naringenin ameliorated hyperglycaemia-induced reduction in hepatic OCT 1 expression leading to metformin accumulation and increased lactic acid production.	naringenin	27-37	solute carrier family 22 member 1	Rattus norvegicus	94-99
32864429-8	2020	Naringenin, resveratrol, but not quercetin inhibited survival of TICs in vitro and in vivo in a DAXX-dependent manner.	naringenin	0-10	death domain associated protein	Homo sapiens	96-100
32677738-7	2020	Further mechanism research indicated that naringenin reduced Abeta production, tau-hyperphosphorylation, oxidative stress, and neuroinflammation in the brain.	naringenin	42-52	amyloid beta (A4) precursor protein	Mus musculus	61-66
32864429-9	2020	Naringenin-induced DAXX protein expression and inhibition of TICs seemed to be more selective towards ERbeta while resveratrol was more selective through ERalpha.	naringenin	0-10	death domain associated protein	Homo sapiens	19-23
32864429-9	2020	Naringenin-induced DAXX protein expression and inhibition of TICs seemed to be more selective towards ERbeta while resveratrol was more selective through ERalpha.	naringenin	0-10	estrogen receptor 1	Homo sapiens	102-108
32864429-9	2020	Naringenin-induced DAXX protein expression and inhibition of TICs seemed to be more selective towards ERbeta while resveratrol was more selective through ERalpha.	naringenin	0-10	estrogen receptor 1	Homo sapiens	154-161
32864429-10	2020	Naringenin or resveratrol inhibited the rate of tumor initiation and rate of tumor growth in a DAXX-dependent manner.	naringenin	0-10	death domain associated protein	Homo sapiens	95-99
32630135-10	2020	Naringenin protected cells against damage induced by tumor necrosis factor (TNF-) in combination with cycloheximide.	naringenin	0-10	tumor necrosis factor	Homo sapiens	53-74
32657124-4	2020	Naringenin and hesperetin increased the Sirt1 mRNA level by 91 and 71% (p < 0.05), which was followed by increased Sirt1 expression by 20 and 15% (p < 0.05), respectively.	naringenin	0-10	sirtuin 1	Rattus norvegicus	40-45
32657124-4	2020	Naringenin and hesperetin increased the Sirt1 mRNA level by 91 and 71% (p < 0.05), which was followed by increased Sirt1 expression by 20 and 15% (p < 0.05), respectively.	naringenin	0-10	sirtuin 1	Rattus norvegicus	115-120
32657124-7	2020	Naringenin lowered mRNA levels of Tpo, Sod1, Sod2, Cat, and Nrf2 by 50, 32, 45, 35, and 42% (p < 0.05), respectively, and increased Gpx by 54% (p < 0.05), while hesperetin decreased Sod1 and Sod2 mRNA levels by 46 and 55% (p < 0.05), respectively.	naringenin	0-10	thyroid peroxidase	Rattus norvegicus	34-37
32657124-7	2020	Naringenin lowered mRNA levels of Tpo, Sod1, Sod2, Cat, and Nrf2 by 50, 32, 45, 35, and 42% (p < 0.05), respectively, and increased Gpx by 54% (p < 0.05), while hesperetin decreased Sod1 and Sod2 mRNA levels by 46 and 55% (p < 0.05), respectively.	naringenin	0-10	superoxide dismutase 1	Rattus norvegicus	39-43
32657124-7	2020	Naringenin lowered mRNA levels of Tpo, Sod1, Sod2, Cat, and Nrf2 by 50, 32, 45, 35, and 42% (p < 0.05), respectively, and increased Gpx by 54% (p < 0.05), while hesperetin decreased Sod1 and Sod2 mRNA levels by 46 and 55% (p < 0.05), respectively.	naringenin	0-10	superoxide dismutase 2	Rattus norvegicus	45-49
32657124-7	2020	Naringenin lowered mRNA levels of Tpo, Sod1, Sod2, Cat, and Nrf2 by 50, 32, 45, 35, and 42% (p < 0.05), respectively, and increased Gpx by 54% (p < 0.05), while hesperetin decreased Sod1 and Sod2 mRNA levels by 46 and 55% (p < 0.05), respectively.	naringenin	0-10	catalase	Rattus norvegicus	51-54
32657124-7	2020	Naringenin lowered mRNA levels of Tpo, Sod1, Sod2, Cat, and Nrf2 by 50, 32, 45, 35, and 42% (p < 0.05), respectively, and increased Gpx by 54% (p < 0.05), while hesperetin decreased Sod1 and Sod2 mRNA levels by 46 and 55% (p < 0.05), respectively.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	60-64
32657124-7	2020	Naringenin lowered mRNA levels of Tpo, Sod1, Sod2, Cat, and Nrf2 by 50, 32, 45, 35, and 42% (p < 0.05), respectively, and increased Gpx by 54% (p < 0.05), while hesperetin decreased Sod1 and Sod2 mRNA levels by 46 and 55% (p < 0.05), respectively.	naringenin	0-10	superoxide dismutase 1	Rattus norvegicus	182-186
32657124-7	2020	Naringenin lowered mRNA levels of Tpo, Sod1, Sod2, Cat, and Nrf2 by 50, 32, 45, 35, and 42% (p < 0.05), respectively, and increased Gpx by 54% (p < 0.05), while hesperetin decreased Sod1 and Sod2 mRNA levels by 46 and 55% (p < 0.05), respectively.	naringenin	0-10	superoxide dismutase 2	Rattus norvegicus	191-195
32657124-8	2020	Naringenin increased the protein expressions of Nrf2 and SOD2 by 58 and 50% (p < 0.05), respectively, and decreased SOD1 expression by 48% (p < 0.05), while hesperetin protein decreased expressions of SOD1 and Nrf2 by 63 and 32% (p < 0.05), respectively.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	48-52
32657124-8	2020	Naringenin increased the protein expressions of Nrf2 and SOD2 by 58 and 50% (p < 0.05), respectively, and decreased SOD1 expression by 48% (p < 0.05), while hesperetin protein decreased expressions of SOD1 and Nrf2 by 63 and 32% (p < 0.05), respectively.	naringenin	0-10	superoxide dismutase 2	Rattus norvegicus	57-61
32657124-8	2020	Naringenin increased the protein expressions of Nrf2 and SOD2 by 58 and 50% (p < 0.05), respectively, and decreased SOD1 expression by 48% (p < 0.05), while hesperetin protein decreased expressions of SOD1 and Nrf2 by 63 and 32% (p < 0.05), respectively.	naringenin	0-10	superoxide dismutase 1	Rattus norvegicus	116-120
32657124-8	2020	Naringenin increased the protein expressions of Nrf2 and SOD2 by 58 and 50% (p < 0.05), respectively, and decreased SOD1 expression by 48% (p < 0.05), while hesperetin protein decreased expressions of SOD1 and Nrf2 by 63 and 32% (p < 0.05), respectively.	naringenin	0-10	superoxide dismutase 1	Rattus norvegicus	201-205
32657124-8	2020	Naringenin increased the protein expressions of Nrf2 and SOD2 by 58 and 50% (p < 0.05), respectively, and decreased SOD1 expression by 48% (p < 0.05), while hesperetin protein decreased expressions of SOD1 and Nrf2 by 63 and 32% (p < 0.05), respectively.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	210-214
33680016-10	2020	Moreover, Naringenin up-regulated the expression of BAX while decreased the expression of Bcl-2.	naringenin	10-20	BCL2 associated X, apoptosis regulator	Homo sapiens	52-55
33680016-10	2020	Moreover, Naringenin up-regulated the expression of BAX while decreased the expression of Bcl-2.	naringenin	10-20	BCL2 apoptosis regulator	Homo sapiens	90-95
33680016-11	2020	Caspases 3 and 9 were activated by Naringenin, an influence, which was augmented via cyclophosphamide.	naringenin	35-45	caspase 3	Homo sapiens	0-16
33680016-12	2020	Docking studies revealed an interaction between Naringenin and STAT3 that was confirmed via attenuation of STAT3 phosphorylation subsequent to treating the cells with Naringenin.	naringenin	48-58	signal transducer and activator of transcription 3	Homo sapiens	63-68
33680016-12	2020	Docking studies revealed an interaction between Naringenin and STAT3 that was confirmed via attenuation of STAT3 phosphorylation subsequent to treating the cells with Naringenin.	naringenin	48-58	signal transducer and activator of transcription 3	Homo sapiens	107-112
33680016-12	2020	Docking studies revealed an interaction between Naringenin and STAT3 that was confirmed via attenuation of STAT3 phosphorylation subsequent to treating the cells with Naringenin.	naringenin	167-177	signal transducer and activator of transcription 3	Homo sapiens	63-68
33680016-13	2020	Furthermore, Naringenin exhibited the capacity to suppress the function of IL-6 in modulating apoptosis-associated genes expression.	naringenin	13-23	interleukin 6	Homo sapiens	75-79
32422184-0	2020	Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/ angiotensin converting enzyme (ACE)/ kidney injury molecule (Kim-1) signaling pathway.	naringenin	26-36	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	68-94
32422184-0	2020	Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/ angiotensin converting enzyme (ACE)/ kidney injury molecule (Kim-1) signaling pathway.	naringenin	26-36	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	96-99
32422184-0	2020	Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/ angiotensin converting enzyme (ACE)/ kidney injury molecule (Kim-1) signaling pathway.	naringenin	26-36	angiotensin I converting enzyme	Rattus norvegicus	102-131
32422184-0	2020	Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/ angiotensin converting enzyme (ACE)/ kidney injury molecule (Kim-1) signaling pathway.	naringenin	26-36	angiotensin I converting enzyme	Rattus norvegicus	133-136
32422184-0	2020	Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/ angiotensin converting enzyme (ACE)/ kidney injury molecule (Kim-1) signaling pathway.	naringenin	26-36	hepatitis A virus cellular receptor 1	Rattus norvegicus	163-168
32422184-11	2020	However, co-treatment with either Naringenin or Lisinopril mitigated both renal and neuronal oxidative stress, normalized blood pressure and lowered the expressions of kidney injury molecule 1, mineralocorticoid receptor and angiotensin converting enzyme.	naringenin	34-44	hepatitis A virus cellular receptor 1	Rattus norvegicus	168-192
32422184-11	2020	However, co-treatment with either Naringenin or Lisinopril mitigated both renal and neuronal oxidative stress, normalized blood pressure and lowered the expressions of kidney injury molecule 1, mineralocorticoid receptor and angiotensin converting enzyme.	naringenin	34-44	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	194-220
32422184-11	2020	However, co-treatment with either Naringenin or Lisinopril mitigated both renal and neuronal oxidative stress, normalized blood pressure and lowered the expressions of kidney injury molecule 1, mineralocorticoid receptor and angiotensin converting enzyme.	naringenin	34-44	angiotensin I converting enzyme	Rattus norvegicus	225-254
32422184-12	2020	Collectively, Naringenin offered a novel antihypertensive and neuroprotective effect through down regulation of kidney injury molecule 1, mineralocorticoid receptor and angiotensin converting enzyme.	naringenin	14-24	hepatitis A virus cellular receptor 1	Rattus norvegicus	112-136
32542594-6	2020	Naringenin can induce autophagy promoting proteins such as ULK1, Beclin1, ATG5, and ATG7 in Neuro2a cells and primary mouse neurons as well.	naringenin	0-10	unc-51 like kinase 1	Mus musculus	59-63
32542594-6	2020	Naringenin can induce autophagy promoting proteins such as ULK1, Beclin1, ATG5, and ATG7 in Neuro2a cells and primary mouse neurons as well.	naringenin	0-10	beclin 1, autophagy related	Mus musculus	65-72
32542594-6	2020	Naringenin can induce autophagy promoting proteins such as ULK1, Beclin1, ATG5, and ATG7 in Neuro2a cells and primary mouse neurons as well.	naringenin	0-10	autophagy related 5	Mus musculus	74-78
32542594-6	2020	Naringenin can induce autophagy promoting proteins such as ULK1, Beclin1, ATG5, and ATG7 in Neuro2a cells and primary mouse neurons as well.	naringenin	0-10	autophagy related 7	Mus musculus	84-88
32542594-8	2020	Further, naringenin can reduce the levels of Abeta at a nontoxic concentration from neuronal cells.	naringenin	9-19	amyloid beta (A4) precursor protein	Mus musculus	45-50
32751373-4	2020	In this work, we have used mass-spectrometry-based lipidomics to characterize the changes in the phospholipidome of proinflammatory human-macrophage-like cells (THP-1-derived and LPS+IFN-gamma-stimulated) incubated with non-cytotoxic concentrations of three flavonoids: quercetin, naringin and naringenin.	naringenin	294-304	GLI family zinc finger 2	Homo sapiens	161-166
33680016-0	2020	Naringenin Enhances the Anti-Cancer Effect of Cyclophosphamide against MDA-MB-231 Breast Cancer Cells Via Targeting the STAT3 Signaling Pathway.	naringenin	0-10	signal transducer and activator of transcription 3	Homo sapiens	120-125
32630135-10	2020	Naringenin protected cells against damage induced by tumor necrosis factor (TNF-) in combination with cycloheximide.	naringenin	0-10	tumor necrosis factor	Homo sapiens	76-79
32536965-14	2020	Second, the molecular docking results showed that there was a certain affinity between the core compounds (kaempferol, quercetin, 7-Methoxy-2-methyl isoflavone, naringenin, formononetin) and core target genes (IL6, IL1B, CCL2).	naringenin	161-171	interleukin 6	Homo sapiens	210-213
32598178-0	2020	Naringenin Inhibits Cell Migration, Invasion, and Tumor Growth by Regulating circFOXM1/miR-3619-5p/SPAG5 Axis in Lung Cancer.	naringenin	0-10	sperm associated antigen 5	Mus musculus	99-104
32598178-8	2020	In addition, naringenin could decrease the expression levels of circFOXM1 and SPAG5, which were highly expressed in lung cancer and increase the level of miR-3619-5p with low expression in lung cancer in a dose-dependent manner.	naringenin	13-23	sperm associated antigen 5	Mus musculus	78-83
32598178-9	2020	miR-3619-5p has an interactive relationship with circFOXM1 or SPAG5, and circFOXM1 could enhance SPAG5 expression by sponging miR-3619-5p in naringenin-treated lung cancer cells.	naringenin	141-151	sperm associated antigen 5	Mus musculus	62-67
32598178-9	2020	miR-3619-5p has an interactive relationship with circFOXM1 or SPAG5, and circFOXM1 could enhance SPAG5 expression by sponging miR-3619-5p in naringenin-treated lung cancer cells.	naringenin	141-151	sperm associated antigen 5	Mus musculus	97-102
32598178-10	2020	Moreover, naringenin inhibited cell migration, invasion, and tumor growth by regulating circFOXM1/miR-3619-5p/SPAG5 axis in lung cancer.	naringenin	10-20	sperm associated antigen 5	Mus musculus	110-115
32598178-11	2020	Conclusion: Naringenin hindered cell metastasis in vitro and tumor growth in vivo by reducing circFOXM1 and SPAG5 expression and inducing the expression of miR-3619-5p in lung cancer.	naringenin	12-22	sperm associated antigen 5	Mus musculus	108-113
32536965-14	2020	Second, the molecular docking results showed that there was a certain affinity between the core compounds (kaempferol, quercetin, 7-Methoxy-2-methyl isoflavone, naringenin, formononetin) and core target genes (IL6, IL1B, CCL2).	naringenin	161-171	interleukin 1 beta	Homo sapiens	215-219
32536965-14	2020	Second, the molecular docking results showed that there was a certain affinity between the core compounds (kaempferol, quercetin, 7-Methoxy-2-methyl isoflavone, naringenin, formononetin) and core target genes (IL6, IL1B, CCL2).	naringenin	161-171	C-C motif chemokine ligand 2	Homo sapiens	221-225
32400767-0	2020	Naringenin ameliorates diabetic neuropathic pain by modulation of oxidative-nitrosative stress, cytokines and MMP-9 levels.	naringenin	0-10	matrix metallopeptidase 9	Rattus norvegicus	110-115
32656311-11	2020	However, few other natural products like resveratrol, quercetin, luteolin, naringenin, zingiberene, and gallic acid has the significant binding affinity towards ACE2 receptor only and therefore may be used for ACE2-mediated attachment inhibition of SARS-CoV-2.	naringenin	75-85	angiotensin converting enzyme 2	Homo sapiens	161-165
32656311-11	2020	However, few other natural products like resveratrol, quercetin, luteolin, naringenin, zingiberene, and gallic acid has the significant binding affinity towards ACE2 receptor only and therefore may be used for ACE2-mediated attachment inhibition of SARS-CoV-2.	naringenin	75-85	angiotensin converting enzyme 2	Homo sapiens	210-214
32220586-11	2020	Naringenin, a flavanone analog with three hydroxyl moieties, could suppress IL-6 overexpression to baseline control.	naringenin	0-10	interleukin 6	Mus musculus	76-80
32077406-10	2020	Naringenin supplementation during pregnancy significantly inhibited IDH, alpha-KGDH, and MDH activities in offspring"s cerebellum.	naringenin	0-10	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	68-71
32077406-10	2020	Naringenin supplementation during pregnancy significantly inhibited IDH, alpha-KGDH, and MDH activities in offspring"s cerebellum.	naringenin	0-10	oxoglutarate dehydrogenase	Homo sapiens	73-83
32077406-10	2020	Naringenin supplementation during pregnancy significantly inhibited IDH, alpha-KGDH, and MDH activities in offspring"s cerebellum.	naringenin	0-10	malic enzyme 1	Homo sapiens	89-92
32077406-11	2020	A similar reduction was observed in vitro, using purified alpha-KGDH and MDH, subjected to pre-incubation with naringenin.	naringenin	111-121	oxoglutarate dehydrogenase	Homo sapiens	58-68
32077406-11	2020	A similar reduction was observed in vitro, using purified alpha-KGDH and MDH, subjected to pre-incubation with naringenin.	naringenin	111-121	malic enzyme 1	Homo sapiens	73-76
32421738-5	2020	Furthermore, a reduction in serum concentration of TNF-alpha, IFN-gamma and IL-6 was observed in the mice provided with Naringenin.	naringenin	120-130	tumor necrosis factor	Mus musculus	51-60
32421738-5	2020	Furthermore, a reduction in serum concentration of TNF-alpha, IFN-gamma and IL-6 was observed in the mice provided with Naringenin.	naringenin	120-130	interferon gamma	Mus musculus	62-71
32421738-5	2020	Furthermore, a reduction in serum concentration of TNF-alpha, IFN-gamma and IL-6 was observed in the mice provided with Naringenin.	naringenin	120-130	interleukin 6	Mus musculus	76-80
32400767-11	2020	Modulation of MMP-9 by a natural flavonoid like naringenin seems to be a novel approach to target diabetic neuropathic pain.	naringenin	48-58	matrix metallopeptidase 9	Rattus norvegicus	14-19
32344607-7	2020	Naringenin-attenuated ROS production, ROS-induced lipid peroxidation, and replenished reduced antioxidant armory, namely, catalase (CAT), glutathione reductase (GR), superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione (GSH).	naringenin	0-10	catalase	Rattus norvegicus	122-130
32425923-0	2020	Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?	naringenin	89-99	mannosidase endo-alpha	Homo sapiens	24-28
32344607-7	2020	Naringenin-attenuated ROS production, ROS-induced lipid peroxidation, and replenished reduced antioxidant armory, namely, catalase (CAT), glutathione reductase (GR), superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione (GSH).	naringenin	0-10	catalase	Rattus norvegicus	132-135
32344607-7	2020	Naringenin-attenuated ROS production, ROS-induced lipid peroxidation, and replenished reduced antioxidant armory, namely, catalase (CAT), glutathione reductase (GR), superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione (GSH).	naringenin	0-10	glutathione-disulfide reductase	Rattus norvegicus	138-159
32344607-7	2020	Naringenin-attenuated ROS production, ROS-induced lipid peroxidation, and replenished reduced antioxidant armory, namely, catalase (CAT), glutathione reductase (GR), superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione (GSH).	naringenin	0-10	glutathione-disulfide reductase	Rattus norvegicus	161-163
32344607-8	2020	Naringenin similarly diminished expression of Cox-2 and levels of NF-kappaB and other inflammatory molecules induced by the Dox treatment.	naringenin	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	46-51
31758699-0	2020	Naringenin attenuates nonalocholic fatty liver disease by downregulating NLRP3/NF-kappaB pathway in mice.	naringenin	0-10	NLR family, pyrin domain containing 3	Mus musculus	73-78
32290154-0	2020	Improving Anticancer Therapy with Naringenin-Loaded Silk Fibroin Nanoparticles.	naringenin	34-44	fibroin light chain	Bombyx mori	57-64
32290154-5	2020	The aim of this work is to synthesize naringenin-loaded silk fibroin nanoparticles (NAR-SFNs) by dissolving the SF in the ionic liquid 1-ethyl-3-methylimidazolium acetate, using high-power ultrasounds and rapid desolvation in methanol followed by the adsorption of NAR.	naringenin	38-48	fibroin light chain	Bombyx mori	61-68
31758699-0	2020	Naringenin attenuates nonalocholic fatty liver disease by downregulating NLRP3/NF-kappaB pathway in mice.	naringenin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	79-88
31758699-7	2020	Treating the HepG2 cells with NGN or NLRP3 inhibitor MCC950 reduced lipid accumulation, and NGN inhibited activation of NLRP3/NF-kappaB pathway stimulated by OA together with LPS.	naringenin	92-95	NLR family pyrin domain containing 3	Homo sapiens	120-125
31758699-7	2020	Treating the HepG2 cells with NGN or NLRP3 inhibitor MCC950 reduced lipid accumulation, and NGN inhibited activation of NLRP3/NF-kappaB pathway stimulated by OA together with LPS.	naringenin	92-95	nuclear factor kappa B subunit 1	Homo sapiens	126-135
31758699-8	2020	In KCs isolated from WT mice, NGN could inhibit NLRP3 expression.	naringenin	30-33	NLR family, pyrin domain containing 3	Mus musculus	48-53
31758699-9	2020	Besides, NGN also inhibited lipid deposition, NLRP3 and IL-1beta expression in WT hepatocytes, but lost efficacy in NLRP3-/- hepatocytes.	naringenin	9-12	NLR family, pyrin domain containing 3	Mus musculus	46-51
31758699-9	2020	Besides, NGN also inhibited lipid deposition, NLRP3 and IL-1beta expression in WT hepatocytes, but lost efficacy in NLRP3-/- hepatocytes.	naringenin	9-12	interleukin 1 beta	Mus musculus	56-64
31758699-10	2020	After re-expressing NLRP3 in NLRP3-/- hepatocytes by adenovirus, the anti-lipid deposition effect of NGN was restored.	naringenin	101-104	NLR family, pyrin domain containing 3	Mus musculus	20-25
31758699-10	2020	After re-expressing NLRP3 in NLRP3-/- hepatocytes by adenovirus, the anti-lipid deposition effect of NGN was restored.	naringenin	101-104	NLR family, pyrin domain containing 3	Mus musculus	29-34
31758699-11	2020	CONCLUSION AND IMPLICATIONS: Our results elucidated that NGN prevented NAFLD via downregulating NLRP3/NF-kappaB signaling pathway both in KCs and hepatocytes, thus attenuating inflammation in the mice livers.	naringenin	57-60	NLR family, pyrin domain containing 3	Mus musculus	96-101
31758699-11	2020	CONCLUSION AND IMPLICATIONS: Our results elucidated that NGN prevented NAFLD via downregulating NLRP3/NF-kappaB signaling pathway both in KCs and hepatocytes, thus attenuating inflammation in the mice livers.	naringenin	57-60	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	102-111
31888829-6	2020	In vitro and in vivo performance attested the potent anti-inflammatory and antinociceptive profile of NAR with significant suppression of TNF-alpha production.	naringenin	102-105	tumor necrosis factor	Homo sapiens	138-147
31922618-10	2020	The cytoprotective effect of NAR, but not CAF, involved alteration of Bax/Bcl-2 mRNA ratio or MMP disruption, but not CHOP transcription.	naringenin	29-32	BCL2 associated X, apoptosis regulator	Homo sapiens	70-73
31922618-10	2020	The cytoprotective effect of NAR, but not CAF, involved alteration of Bax/Bcl-2 mRNA ratio or MMP disruption, but not CHOP transcription.	naringenin	29-32	BCL2 apoptosis regulator	Homo sapiens	74-79
31670603-0	2020	Naringenin Increases Insulin Sensitivity and Metabolic Rate: A Case Study.	naringenin	0-10	insulin	Homo sapiens	21-28
32515177-3	2020	In this experiment, we explored whether naringenin can increase the expression of superoxide dismutase 1(SOD1), reduce the oxidative stress of PC12 cells induced by homocysteine (Hcy), and decrease the apoptosis of PC12 cells induced by Hcy by inhibiting the expression of mir-224-3p.	naringenin	40-50	superoxide dismutase 1	Rattus norvegicus	105-109
32515177-13	2020	The treatment of Hcy-induced PC12 cells with different concentrations of naringenin for 24 h decreased the expression of miR-224-3p in a dose-dependent manner and increased the expressions of SOD1 mRNA and protein.	naringenin	73-83	superoxide dismutase 1	Rattus norvegicus	192-196
32515177-15	2020	The mechanism may be related to naringenin decreasing the expression of miR-224-3p in PC12 cells induced by Hcy and increasing the expressions of SOD1 mRNA and protein.	naringenin	32-42	microRNA 224	Rattus norvegicus	72-79
32515177-15	2020	The mechanism may be related to naringenin decreasing the expression of miR-224-3p in PC12 cells induced by Hcy and increasing the expressions of SOD1 mRNA and protein.	naringenin	32-42	superoxide dismutase 1	Rattus norvegicus	146-150
31670603-1	2020	Our studies in primary human adipocytes show that naringenin, a citrus flavonoid, increases oxygen consumption rate and gene expression of uncoupling protein 1 (UCP1), glucose transporter type 4, and carnitine palmitoyltransferase 1beta (CPT1beta).	naringenin	50-60	uncoupling protein 1	Homo sapiens	139-159
31670603-1	2020	Our studies in primary human adipocytes show that naringenin, a citrus flavonoid, increases oxygen consumption rate and gene expression of uncoupling protein 1 (UCP1), glucose transporter type 4, and carnitine palmitoyltransferase 1beta (CPT1beta).	naringenin	50-60	uncoupling protein 1	Homo sapiens	161-165
31670603-1	2020	Our studies in primary human adipocytes show that naringenin, a citrus flavonoid, increases oxygen consumption rate and gene expression of uncoupling protein 1 (UCP1), glucose transporter type 4, and carnitine palmitoyltransferase 1beta (CPT1beta).	naringenin	50-60	carnitine palmitoyltransferase 1A	Homo sapiens	200-236
31670603-1	2020	Our studies in primary human adipocytes show that naringenin, a citrus flavonoid, increases oxygen consumption rate and gene expression of uncoupling protein 1 (UCP1), glucose transporter type 4, and carnitine palmitoyltransferase 1beta (CPT1beta).	naringenin	50-60	carnitine palmitoyltransferase 1A	Homo sapiens	238-246
31670603-12	2020	We conclude that naringenin supplementation is safe in humans, reduces body weight and insulin resistance, and increases metabolic rate by PPARalpha and PPARgamma activation.	naringenin	17-27	insulin	Homo sapiens	87-94
31670603-12	2020	We conclude that naringenin supplementation is safe in humans, reduces body weight and insulin resistance, and increases metabolic rate by PPARalpha and PPARgamma activation.	naringenin	17-27	peroxisome proliferator activated receptor alpha	Homo sapiens	139-148
31670603-12	2020	We conclude that naringenin supplementation is safe in humans, reduces body weight and insulin resistance, and increases metabolic rate by PPARalpha and PPARgamma activation.	naringenin	17-27	peroxisome proliferator activated receptor gamma	Homo sapiens	153-162
32047858-3	2020	We found that naringenin and nobiletin strongly inhibited URAT1, and may therefore serve as an anti-hyperuricemic food ingredient that can reduce the risk of urate-related diseases.	naringenin	14-24	solute carrier family 22 member 12	Homo sapiens	58-63
31961679-0	2020	Correction to 6-C-(E-Phenylethenyl)Naringenin Attenuates the Stemness of Hepatocellular Carcinoma Cells by Suppressing Wnt/beta-Catenin Signaling.	naringenin	14-45	catenin beta 1	Homo sapiens	123-135
31830578-2	2020	In this study, we reported the preparation and evaluation of naringenin (Nar) -loaded albumin self-modified liposomes (NaAlLs), which delivered Nar, a specific Smad3 inhibitor that blocked the TGF-beta/Smad3 signaling pathway and played an anti-fibrosis role.	naringenin	61-71	SMAD family member 3	Homo sapiens	160-165
31871020-4	2020	Moreover, in a murine colon adenocarcinoma model, naringenin induced more CD103+ DCs infiltration into tumor and facilitated the activation of CD8+ T cells and strengthened the performance of therapeutic E7 vaccine against TC-1 murine lung cancer.	naringenin	50-60	integrin alpha E, epithelial-associated	Mus musculus	74-79
31830578-2	2020	In this study, we reported the preparation and evaluation of naringenin (Nar) -loaded albumin self-modified liposomes (NaAlLs), which delivered Nar, a specific Smad3 inhibitor that blocked the TGF-beta/Smad3 signaling pathway and played an anti-fibrosis role.	naringenin	61-71	transforming growth factor alpha	Homo sapiens	193-201
31830578-2	2020	In this study, we reported the preparation and evaluation of naringenin (Nar) -loaded albumin self-modified liposomes (NaAlLs), which delivered Nar, a specific Smad3 inhibitor that blocked the TGF-beta/Smad3 signaling pathway and played an anti-fibrosis role.	naringenin	61-71	SMAD family member 3	Homo sapiens	202-207
31830578-2	2020	In this study, we reported the preparation and evaluation of naringenin (Nar) -loaded albumin self-modified liposomes (NaAlLs), which delivered Nar, a specific Smad3 inhibitor that blocked the TGF-beta/Smad3 signaling pathway and played an anti-fibrosis role.	naringenin	73-76	SMAD family member 3	Homo sapiens	160-165
31830578-2	2020	In this study, we reported the preparation and evaluation of naringenin (Nar) -loaded albumin self-modified liposomes (NaAlLs), which delivered Nar, a specific Smad3 inhibitor that blocked the TGF-beta/Smad3 signaling pathway and played an anti-fibrosis role.	naringenin	73-76	transforming growth factor alpha	Homo sapiens	193-201
31830578-2	2020	In this study, we reported the preparation and evaluation of naringenin (Nar) -loaded albumin self-modified liposomes (NaAlLs), which delivered Nar, a specific Smad3 inhibitor that blocked the TGF-beta/Smad3 signaling pathway and played an anti-fibrosis role.	naringenin	73-76	SMAD family member 3	Homo sapiens	202-207
31830578-2	2020	In this study, we reported the preparation and evaluation of naringenin (Nar) -loaded albumin self-modified liposomes (NaAlLs), which delivered Nar, a specific Smad3 inhibitor that blocked the TGF-beta/Smad3 signaling pathway and played an anti-fibrosis role.	naringenin	144-147	SMAD family member 3	Homo sapiens	160-165
31830578-2	2020	In this study, we reported the preparation and evaluation of naringenin (Nar) -loaded albumin self-modified liposomes (NaAlLs), which delivered Nar, a specific Smad3 inhibitor that blocked the TGF-beta/Smad3 signaling pathway and played an anti-fibrosis role.	naringenin	144-147	transforming growth factor alpha	Homo sapiens	193-201
31622021-4	2019	Naringenin enhances the viability of the PA-treated HUVECs and, additionally, effectively decreases oxidative stress by scavenging ROS, and increasing the SOD2 level and GPx activity.	naringenin	0-10	superoxide dismutase 2	Homo sapiens	155-159
31790691-0	2020	Naringenin complexed with hydroxypropyl-beta-cyclodextrin improves the sciatic nerve regeneration through inhibition of p75NTR and JNK pathway.	naringenin	0-10	nerve growth factor receptor (TNFR superfamily, member 16)	Mus musculus	120-126
31790691-0	2020	Naringenin complexed with hydroxypropyl-beta-cyclodextrin improves the sciatic nerve regeneration through inhibition of p75NTR and JNK pathway.	naringenin	0-10	mitogen-activated protein kinase 8	Mus musculus	131-134
32021351-11	2020	Upon treatment with NGN, the levels of peroxisome proliferator-activated receptor alpha were significantly increased, while the activity of enzymes involved in the oxidative metabolism of fatty acids was significantly decreased.	naringenin	20-23	peroxisome proliferator activated receptor alpha	Rattus norvegicus	39-87
31697467-0	2019	The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels.	naringenin	22-32	sodium channel, voltage-gated, type X, alpha	Mus musculus	73-79
31697467-8	2019	Instead, naringenin inhibited NaV1.8-dependent and tetrodotoxin (TTX)-resistant while sparing tetrodotoxin sensitive (TTX-S) voltage-gated Na+ channels as evidenced by the lack of further inhibition by the NaV1.8 blocker A-803467.	naringenin	9-19	sodium channel, voltage-gated, type X, alpha	Mus musculus	30-36
31697467-8	2019	Instead, naringenin inhibited NaV1.8-dependent and tetrodotoxin (TTX)-resistant while sparing tetrodotoxin sensitive (TTX-S) voltage-gated Na+ channels as evidenced by the lack of further inhibition by the NaV1.8 blocker A-803467.	naringenin	9-19	sodium channel, voltage-gated, type X, alpha	Mus musculus	206-212
31618621-3	2019	Therefore, the objective of this work was to investigate whether naringenin could reverse carbon tetrachloride (CCl4)-induced fibrosis in rats and, if so, to search for the mechanisms involved.	naringenin	65-75	C-C motif chemokine ligand 4	Rattus norvegicus	112-116
31618621-12	2019	Naringenin reversed liver damage, biochemical and oxidative stress marker elevation, and fibrosis and restored normal MMP-9 and MMP-2 activity.	naringenin	0-10	matrix metallopeptidase 9	Rattus norvegicus	118-123
31618621-12	2019	Naringenin reversed liver damage, biochemical and oxidative stress marker elevation, and fibrosis and restored normal MMP-9 and MMP-2 activity.	naringenin	0-10	matrix metallopeptidase 2	Rattus norvegicus	128-133
31618621-14	2019	Moreover, naringenin decreased JNK activation and Smad3 phosphorylation in the linker region.	naringenin	10-20	SMAD family member 3	Rattus norvegicus	50-55
31618621-15	2019	Finally, alpha-SMA and Smad3 protein and mRNA levels were reduced by naringenin administration.	naringenin	69-79	SMAD family member 3	Rattus norvegicus	23-28
31618621-16	2019	The results of this study demonstrate that naringenin blocks oxidative stress, inflammation and the TGF-beta-Smad3 and JNK-Smad3 pathways, thereby carrying out its antifibrotic effects and making it a good candidate to treat human fibrosis, as previously demonstrated in toxicological and clinical studies.	naringenin	43-53	SMAD family member 3	Rattus norvegicus	109-114
31618621-16	2019	The results of this study demonstrate that naringenin blocks oxidative stress, inflammation and the TGF-beta-Smad3 and JNK-Smad3 pathways, thereby carrying out its antifibrotic effects and making it a good candidate to treat human fibrosis, as previously demonstrated in toxicological and clinical studies.	naringenin	43-53	SMAD family member 3	Rattus norvegicus	123-128
30612217-0	2019	The citrus flavanone naringenin attenuates zymosan-induced mouse joint inflammation: induction of Nrf2 expression in recruited CD45+ hematopoietic cells.	naringenin	21-31	nuclear factor, erythroid derived 2, like 2	Mus musculus	98-102
30612217-0	2019	The citrus flavanone naringenin attenuates zymosan-induced mouse joint inflammation: induction of Nrf2 expression in recruited CD45+ hematopoietic cells.	naringenin	21-31	protein tyrosine phosphatase, receptor type, C	Mus musculus	127-131
30612217-8	2019	Naringenin also inhibited inflammasome upregulation (reduced Nlrp3, ASC, caspase-1, and pro-IL-1beta mRNA expression) and oxidative stress (reduced gp91phox mRNA expression and superoxide anion production, increased GSH levels, induced Nrf2 protein in CD45+ hematopoietic recruited cells, and induced Nrf2 and HO-1 mRNA expression).	naringenin	0-10	NLR family, pyrin domain containing 3	Mus musculus	61-66
30612217-8	2019	Naringenin also inhibited inflammasome upregulation (reduced Nlrp3, ASC, caspase-1, and pro-IL-1beta mRNA expression) and oxidative stress (reduced gp91phox mRNA expression and superoxide anion production, increased GSH levels, induced Nrf2 protein in CD45+ hematopoietic recruited cells, and induced Nrf2 and HO-1 mRNA expression).	naringenin	0-10	steroid sulfatase	Mus musculus	68-71
30612217-8	2019	Naringenin also inhibited inflammasome upregulation (reduced Nlrp3, ASC, caspase-1, and pro-IL-1beta mRNA expression) and oxidative stress (reduced gp91phox mRNA expression and superoxide anion production, increased GSH levels, induced Nrf2 protein in CD45+ hematopoietic recruited cells, and induced Nrf2 and HO-1 mRNA expression).	naringenin	0-10	caspase 1	Mus musculus	73-82
30612217-8	2019	Naringenin also inhibited inflammasome upregulation (reduced Nlrp3, ASC, caspase-1, and pro-IL-1beta mRNA expression) and oxidative stress (reduced gp91phox mRNA expression and superoxide anion production, increased GSH levels, induced Nrf2 protein in CD45+ hematopoietic recruited cells, and induced Nrf2 and HO-1 mRNA expression).	naringenin	0-10	interleukin 1 beta	Mus musculus	92-100
30612217-8	2019	Naringenin also inhibited inflammasome upregulation (reduced Nlrp3, ASC, caspase-1, and pro-IL-1beta mRNA expression) and oxidative stress (reduced gp91phox mRNA expression and superoxide anion production, increased GSH levels, induced Nrf2 protein in CD45+ hematopoietic recruited cells, and induced Nrf2 and HO-1 mRNA expression).	naringenin	0-10	cytochrome b-245, beta polypeptide	Mus musculus	148-156
30612217-8	2019	Naringenin also inhibited inflammasome upregulation (reduced Nlrp3, ASC, caspase-1, and pro-IL-1beta mRNA expression) and oxidative stress (reduced gp91phox mRNA expression and superoxide anion production, increased GSH levels, induced Nrf2 protein in CD45+ hematopoietic recruited cells, and induced Nrf2 and HO-1 mRNA expression).	naringenin	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	236-240
30612217-8	2019	Naringenin also inhibited inflammasome upregulation (reduced Nlrp3, ASC, caspase-1, and pro-IL-1beta mRNA expression) and oxidative stress (reduced gp91phox mRNA expression and superoxide anion production, increased GSH levels, induced Nrf2 protein in CD45+ hematopoietic recruited cells, and induced Nrf2 and HO-1 mRNA expression).	naringenin	0-10	protein tyrosine phosphatase, receptor type, C	Mus musculus	252-256
30612217-8	2019	Naringenin also inhibited inflammasome upregulation (reduced Nlrp3, ASC, caspase-1, and pro-IL-1beta mRNA expression) and oxidative stress (reduced gp91phox mRNA expression and superoxide anion production, increased GSH levels, induced Nrf2 protein in CD45+ hematopoietic recruited cells, and induced Nrf2 and HO-1 mRNA expression).	naringenin	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	301-305
30612217-8	2019	Naringenin also inhibited inflammasome upregulation (reduced Nlrp3, ASC, caspase-1, and pro-IL-1beta mRNA expression) and oxidative stress (reduced gp91phox mRNA expression and superoxide anion production, increased GSH levels, induced Nrf2 protein in CD45+ hematopoietic recruited cells, and induced Nrf2 and HO-1 mRNA expression).	naringenin	0-10	heme oxygenase 1	Mus musculus	310-314
32047577-0	2020	The Citrus Flavonoid Naringenin Protects the Myocardium from Ageing-Dependent Dysfunction: Potential Role of SIRT1.	naringenin	21-31	sirtuin 1	Mus musculus	109-114
32047577-4	2020	The Citrus flavonoid naringenin (NAR) presents structural similarity with the natural SIRT1 activator resveratrol.	naringenin	21-31	sirtuin 1	Mus musculus	86-91
32047577-4	2020	The Citrus flavonoid naringenin (NAR) presents structural similarity with the natural SIRT1 activator resveratrol.	naringenin	33-36	sirtuin 1	Mus musculus	86-91
32047577-5	2020	In this study, we demonstrate through in vitro assays that NAR significantly activates SIRT1 enzyme and shows antisenescence effects.	naringenin	59-62	sirtuin 1	Mus musculus	87-92
32047577-6	2020	The binding mode of NAR into SIRT1 was detailed investigated through in silico studies.	naringenin	20-23	sirtuin 1	Mus musculus	29-34
32047577-7	2020	Moreover, chronic administration (for six months) of NAR (100 mg/kg/day) to 6-month-old mice leads to an enhancement of SIRT1 expression and a marked reduction of reactive oxygen species production in myocardial tissue.	naringenin	53-56	sirtuin 1	Mus musculus	120-125
32047577-8	2020	Furthermore, at the end of the treatment, the plasma levels of two well-known markers of cardiovascular inflammation, TNF-alpha and IL6, are significantly reduced in 12-month-old mice treated with NAR, as well as the cardiovascular risk (total cholesterol/HDL ratio) compared to control mice.	naringenin	197-200	tumor necrosis factor	Mus musculus	118-127
32047577-8	2020	Furthermore, at the end of the treatment, the plasma levels of two well-known markers of cardiovascular inflammation, TNF-alpha and IL6, are significantly reduced in 12-month-old mice treated with NAR, as well as the cardiovascular risk (total cholesterol/HDL ratio) compared to control mice.	naringenin	197-200	interleukin 6	Mus musculus	132-135
31945778-0	2020	Naringenin protects AlCl3/D-galactose induced neurotoxicity in rat model of AD via attenuation of acetylcholinesterase levels and inhibition of oxidative stress.	naringenin	0-10	acetylcholinesterase	Rattus norvegicus	98-118
31218550-3	2020	We previously showed that naringenin, a citrus flavonoid, suppressed macrophage infiltration into adipose tissue by inhibiting monocyte chemoattractant protein-1 (MCP-1) expression in the progression phase to high-fat diet (HFD)-induced obesity.	naringenin	26-36	chemokine (C-C motif) ligand 2	Mus musculus	127-161
31218550-3	2020	We previously showed that naringenin, a citrus flavonoid, suppressed macrophage infiltration into adipose tissue by inhibiting monocyte chemoattractant protein-1 (MCP-1) expression in the progression phase to high-fat diet (HFD)-induced obesity.	naringenin	26-36	chemokine (C-C motif) ligand 2	Mus musculus	163-168
31218550-6	2020	Naringenin tended to inhibit the HFD-induced expression of several chemokines, including MCP-1 and MCP-3, in adipose tissue.	naringenin	0-10	chemokine (C-C motif) ligand 2	Mus musculus	89-94
31218550-6	2020	Naringenin tended to inhibit the HFD-induced expression of several chemokines, including MCP-1 and MCP-3, in adipose tissue.	naringenin	0-10	mast cell protease 3	Mus musculus	99-104
31218550-7	2020	Naringenin also inhibited MCP-3 expression in 3T3-L1 adipocytes and a co-culture of 3T3-L1 adipocytes and RAW264 macrophages.	naringenin	0-10	mast cell protease 3	Mus musculus	26-31
31218550-9	2020	Our results suggest that naringenin suppresses neutrophil infiltration into adipose tissue via the regulation of MCP-3 expression and macrophage infiltration.	naringenin	25-35	mast cell protease 3	Mus musculus	113-118
31746415-8	2020	FEX and fentanyl uptake experiments were also performed with naringenin, an inhibitor of OATP1A2.	naringenin	61-71	solute carrier organic anion transporter family member 1A2	Homo sapiens	89-96
31797960-7	2019	The PLS-DA, OPLS-DA and VIP analysis demonstrate guttiferone E, guttiferone B, liquiritigenin, naringenin are considered important substances responsible by anti-staphylococcal activity in red propolis composition during the rainy season and drought period, but a synergistic effect with other flavonoids and isoflavonoids are not ruled out.	naringenin	95-105	vasoactive intestinal peptide	Homo sapiens	24-27
31622021-5	2019	Autophagy flux is protected by naringenin, as evidenced by the decreases in the ratio of LC3B-II/I, expression level of p62 and number of autophagosomes, and the increase in the number of autolysosomes in the PA-induced HUVECs.	naringenin	31-41	nucleoporin 62	Homo sapiens	120-123
31622021-7	2019	The molecular data indicate that the protective effects of naringenin on autophagy flux may also be regulated via the JNK pathway, as verified via the application of JNK inhibitor SP600125.	naringenin	59-69	mitogen-activated protein kinase 8	Homo sapiens	118-121
31622021-7	2019	The molecular data indicate that the protective effects of naringenin on autophagy flux may also be regulated via the JNK pathway, as verified via the application of JNK inhibitor SP600125.	naringenin	59-69	mitogen-activated protein kinase 8	Homo sapiens	166-169
31076999-0	2019	Naringenin Inhibit the Hydrogen Peroxide-Induced SH-SY5Y Cells Injury Through Nrf2/HO-1 Pathway.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	78-82
31814878-0	2019	The Nrf2/HO-1 Axis as Targets for Flavanones: Neuroprotection by Pinocembrin, Naringenin, and Eriodictyol.	naringenin	78-88	NFE2 like bZIP transcription factor 2	Homo sapiens	4-8
31426023-2	2019	By acting on human TPC2, naringenin, was able to dampen intracellular calcium responses to VEGF in cultured human endothelial cells and to impair angiogenic activity in VEGF-containing matrigel plugs implanted in mice.	naringenin	25-35	two pore segment channel 2	Homo sapiens	19-23
31426023-2	2019	By acting on human TPC2, naringenin, was able to dampen intracellular calcium responses to VEGF in cultured human endothelial cells and to impair angiogenic activity in VEGF-containing matrigel plugs implanted in mice.	naringenin	25-35	vascular endothelial growth factor A	Homo sapiens	91-95
31426023-2	2019	By acting on human TPC2, naringenin, was able to dampen intracellular calcium responses to VEGF in cultured human endothelial cells and to impair angiogenic activity in VEGF-containing matrigel plugs implanted in mice.	naringenin	25-35	vascular endothelial growth factor A	Homo sapiens	169-173
31076999-0	2019	Naringenin Inhibit the Hydrogen Peroxide-Induced SH-SY5Y Cells Injury Through Nrf2/HO-1 Pathway.	naringenin	0-10	heme oxygenase 1	Homo sapiens	83-87
31076999-9	2019	The HO-1 inhibitor ZnPP abolished the neuroprotective effect of NGN against H2O2-induced neurotoxicity.	naringenin	64-67	heme oxygenase 1	Homo sapiens	4-8
31591391-8	2019	It was further found that naringenin inhibited TNF-alpha-induced ROS production, enhanced GLUT4 membrane translocation, and glucose uptake, which were abolished by inhibition of AMP-activated protein kinase (AMPK).	naringenin	26-36	tumor necrosis factor	Mus musculus	47-56
31665932-6	2022	The treatment of DEN/2AAF-administered rats with quercetin and naringenin significantly prevented the elevations in serum levels of liver function indicators (ALT, AST, ALP, gamma-GT, total bilirubin and albumin) and liver tumor biomarkers including AFP, CEA and CA19.9.	naringenin	63-73	alpha-fetoprotein	Rattus norvegicus	250-253
31665932-6	2022	The treatment of DEN/2AAF-administered rats with quercetin and naringenin significantly prevented the elevations in serum levels of liver function indicators (ALT, AST, ALP, gamma-GT, total bilirubin and albumin) and liver tumor biomarkers including AFP, CEA and CA19.9.	naringenin	63-73	carcinoembryonic antigen gene family 4	Rattus norvegicus	255-258
31665932-9	2022	Furthermore, the lowered mRNA expression of liver IL-4, P53 and Bcl-2 in of DEN/2AAF-administered rats were significantly counteracted by treatment with quercetin and naringenin.	naringenin	167-177	interleukin 4	Rattus norvegicus	50-54
31665932-9	2022	Furthermore, the lowered mRNA expression of liver IL-4, P53 and Bcl-2 in of DEN/2AAF-administered rats were significantly counteracted by treatment with quercetin and naringenin.	naringenin	167-177	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	56-59
31665932-9	2022	Furthermore, the lowered mRNA expression of liver IL-4, P53 and Bcl-2 in of DEN/2AAF-administered rats were significantly counteracted by treatment with quercetin and naringenin.	naringenin	167-177	BCL2, apoptosis regulator	Rattus norvegicus	64-69
31591391-8	2019	It was further found that naringenin inhibited TNF-alpha-induced ROS production, enhanced GLUT4 membrane translocation, and glucose uptake, which were abolished by inhibition of AMP-activated protein kinase (AMPK).	naringenin	26-36	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	90-95
31176760-0	2019	Enhanced cellular cholesterol efflux by naringenin is mediated through inhibiting endoplasmic reticulum stress - ATF6 activity in macrophages.	naringenin	40-50	activating transcription factor 6	Mus musculus	113-117
31176760-7	2019	Naringenin-induced cholesterol efflux was modulated by treatment with ER stress inhibitor 4-phenylbutyric acid, inducer tunicamycin and ATF6 overexpression in RAW264.7 and/or THP-1 cells, which suggested the naringenin functions were mediated through inhibiting ER stress-ATF6 pathway.	naringenin	0-10	activating transcription factor 6	Homo sapiens	272-276
31407037-4	2019	In the first system, YjiC, a UGT from Bacillus licheniformis DSM 13, was used for transferring glucose from UDP-alpha-D-glucose to naringenin, in which AtSUS1 from Arabidopsis thaliana was used to synthesize UDP-alpha-D-glucose and fructose as a by-product from sucrose.	naringenin	131-141	sucrose synthase 1	Arabidopsis thaliana	152-158
31176760-5	2019	Results showed that naringenin increased cholesterol efflux to both apoA-I and HDL and gene expressions in ABCA1, ABCG1 and LXRalpha in RAW264.7 macrophages.	naringenin	20-30	apolipoprotein A-I	Mus musculus	68-74
31176760-7	2019	Naringenin-induced cholesterol efflux was modulated by treatment with ER stress inhibitor 4-phenylbutyric acid, inducer tunicamycin and ATF6 overexpression in RAW264.7 and/or THP-1 cells, which suggested the naringenin functions were mediated through inhibiting ER stress-ATF6 pathway.	naringenin	208-218	activating transcription factor 6	Mus musculus	136-140
31176760-8	2019	Next, we found high-fat diet (HFD) supplemented with naringenin increased by >1.2-fold in cholesterol efflux capacity in primary peritoneal macrophage in apoE-/- mice compared to only HFD-fed mice.	naringenin	53-63	apolipoprotein E	Mus musculus	154-158
31176760-10	2019	Naringenin decreased GRP78, XBP-1 and nuclear ATF6 levels in peritoneal macrophage and aorta and reduced atherosclerotic lesion at aortic root, but reversed by tunicamycin.	naringenin	0-10	heat shock protein 5	Mus musculus	21-26
31176760-5	2019	Results showed that naringenin increased cholesterol efflux to both apoA-I and HDL and gene expressions in ABCA1, ABCG1 and LXRalpha in RAW264.7 macrophages.	naringenin	20-30	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	107-112
31176760-10	2019	Naringenin decreased GRP78, XBP-1 and nuclear ATF6 levels in peritoneal macrophage and aorta and reduced atherosclerotic lesion at aortic root, but reversed by tunicamycin.	naringenin	0-10	X-box binding protein 1	Mus musculus	28-33
31176760-10	2019	Naringenin decreased GRP78, XBP-1 and nuclear ATF6 levels in peritoneal macrophage and aorta and reduced atherosclerotic lesion at aortic root, but reversed by tunicamycin.	naringenin	0-10	activating transcription factor 6	Mus musculus	46-50
31176760-11	2019	These confirmed participation of ER stress-ATF6 in naringenin efficacy.	naringenin	51-61	activating transcription factor 6	Mus musculus	43-47
31176760-5	2019	Results showed that naringenin increased cholesterol efflux to both apoA-I and HDL and gene expressions in ABCA1, ABCG1 and LXRalpha in RAW264.7 macrophages.	naringenin	20-30	ATP binding cassette subfamily G member 1	Mus musculus	114-119
31176760-5	2019	Results showed that naringenin increased cholesterol efflux to both apoA-I and HDL and gene expressions in ABCA1, ABCG1 and LXRalpha in RAW264.7 macrophages.	naringenin	20-30	nuclear receptor subfamily 1, group H, member 3	Mus musculus	124-132
31176760-6	2019	Naringenin inhibited the cleaved ATF6 nuclear translocation and its target GRP78 and XBP-1 expressions.	naringenin	0-10	activating transcription factor 6	Mus musculus	33-37
31176760-6	2019	Naringenin inhibited the cleaved ATF6 nuclear translocation and its target GRP78 and XBP-1 expressions.	naringenin	0-10	heat shock protein 5	Mus musculus	75-80
31176760-6	2019	Naringenin inhibited the cleaved ATF6 nuclear translocation and its target GRP78 and XBP-1 expressions.	naringenin	0-10	X-box binding protein 1	Mus musculus	85-90
31176760-12	2019	Finally, we found naringenin promoted AKT phosphorylation; PI3K inhibitor LY294002 treatment increased nuclear ATF6 and reduced naringenin-enhanced ABCA1 expression and cholesterol efflux.	naringenin	18-28	thymoma viral proto-oncogene 1	Mus musculus	38-41
31176760-7	2019	Naringenin-induced cholesterol efflux was modulated by treatment with ER stress inhibitor 4-phenylbutyric acid, inducer tunicamycin and ATF6 overexpression in RAW264.7 and/or THP-1 cells, which suggested the naringenin functions were mediated through inhibiting ER stress-ATF6 pathway.	naringenin	0-10	activating transcription factor 6	Mus musculus	136-140
31176760-12	2019	Finally, we found naringenin promoted AKT phosphorylation; PI3K inhibitor LY294002 treatment increased nuclear ATF6 and reduced naringenin-enhanced ABCA1 expression and cholesterol efflux.	naringenin	128-138	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	148-153
31343820-9	2019	Daily intraperitoneal injections of GDM mice with naringenin from gestational day 10-17 significantly improve glucose tolerance, reduces IL1A mRNA expression, and increases antioxidant mRNA expression in placenta, VAT, and subcutaneous adipose tissue.	naringenin	50-60	interleukin 1 alpha	Mus musculus	137-141
31176760-13	2019	We concluded naringenin as a regulator for cholesterol efflux, and the regulation was mediated by ATF6 branch of ER stress and PI3K/AKT pathway.	naringenin	13-23	activating transcription factor 6	Mus musculus	98-102
31176760-13	2019	We concluded naringenin as a regulator for cholesterol efflux, and the regulation was mediated by ATF6 branch of ER stress and PI3K/AKT pathway.	naringenin	13-23	thymoma viral proto-oncogene 1	Mus musculus	132-135
31351365-0	2019	Naringenin-induced HO-1 ameliorates high glucose or free fatty acids-associated apoptosis via PI3K and JNK/Nrf2 pathways in human umbilical vein endothelial cells.	naringenin	0-10	mitogen-activated protein kinase 8	Homo sapiens	103-106
31351365-0	2019	Naringenin-induced HO-1 ameliorates high glucose or free fatty acids-associated apoptosis via PI3K and JNK/Nrf2 pathways in human umbilical vein endothelial cells.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	107-111
31351365-1	2019	Naringenin (NG), a flavanone extracted from various plants, has potent vasoprotective effects likely related to the induction of heme oxygenase-1 (HO-1).	naringenin	0-10	heme oxygenase 1	Homo sapiens	129-145
31351365-1	2019	Naringenin (NG), a flavanone extracted from various plants, has potent vasoprotective effects likely related to the induction of heme oxygenase-1 (HO-1).	naringenin	0-10	heme oxygenase 1	Homo sapiens	147-151
31351365-1	2019	Naringenin (NG), a flavanone extracted from various plants, has potent vasoprotective effects likely related to the induction of heme oxygenase-1 (HO-1).	naringenin	12-14	heme oxygenase 1	Homo sapiens	129-145
31351365-1	2019	Naringenin (NG), a flavanone extracted from various plants, has potent vasoprotective effects likely related to the induction of heme oxygenase-1 (HO-1).	naringenin	12-14	heme oxygenase 1	Homo sapiens	147-151
31351365-2	2019	In the current study, we investigated mechanisms underlying the effect of NG on HO-1 expression and high glucose (HG)- or free fatty acids (FFA)-induced apoptosis in human umbilical vein endothelial cells (HUVECs).	naringenin	74-76	heme oxygenase 1	Homo sapiens	80-84
31351365-3	2019	First, we found that HUVECs exposed to NG exhibited enhanced HO-1 expression in a concentration- and time-dependent manner.	naringenin	39-41	heme oxygenase 1	Homo sapiens	61-65
31351365-4	2019	Moreover, HUVECs treated with NG exhibited activation of phosphoinositide 3 kinase (PI3K)/Akt, extracellular-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	naringenin	30-32	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	57-82
31351365-4	2019	Moreover, HUVECs treated with NG exhibited activation of phosphoinositide 3 kinase (PI3K)/Akt, extracellular-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	naringenin	30-32	AKT serine/threonine kinase 1	Homo sapiens	90-93
31351365-4	2019	Moreover, HUVECs treated with NG exhibited activation of phosphoinositide 3 kinase (PI3K)/Akt, extracellular-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	naringenin	30-32	mitogen-activated protein kinase 1	Homo sapiens	95-125
31351365-4	2019	Moreover, HUVECs treated with NG exhibited activation of phosphoinositide 3 kinase (PI3K)/Akt, extracellular-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	naringenin	30-32	mitogen-activated protein kinase 1	Homo sapiens	127-130
31351365-4	2019	Moreover, HUVECs treated with NG exhibited activation of phosphoinositide 3 kinase (PI3K)/Akt, extracellular-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	naringenin	30-32	mitogen-activated protein kinase 8	Homo sapiens	137-160
31351365-4	2019	Moreover, HUVECs treated with NG exhibited activation of phosphoinositide 3 kinase (PI3K)/Akt, extracellular-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	naringenin	30-32	mitogen-activated protein kinase 8	Homo sapiens	162-165
31343820-10	2019	CONCLUSION: Naringenin is shown to improve insulin sensitivity, inflammation, and oxidative stress associated with GDM and shows promise as a novel preventive therapeutic.	naringenin	12-22	insulin	Homo sapiens	43-50
31132359-10	2019	It indicated that flavanones such as hesperetin, naringenin, liquiritigenin were efficient to repress COX-2 mRNA and they were potential anti-inflammatory natural products.	naringenin	49-59	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	102-107
31254498-0	2019	Promotion of mitochondrial protection by naringenin in methylglyoxal-treated SH-SY5Y cells: Involvement of the Nrf2/GSH axis.	naringenin	41-51	NFE2 like bZIP transcription factor 2	Homo sapiens	111-115
31254498-10	2019	Therefore, NGN caused mitochondrial protection by an Nrf2/GSH-dependent manner in SH-SY5Y cells exposed to MG.	naringenin	11-14	NFE2 like bZIP transcription factor 2	Homo sapiens	53-57
31259654-0	2019	Naringin and Naringenin Relax Rat Tracheal Smooth by Regulating BKCa Activation.	naringenin	13-23	neurogenin 3	Rattus norvegicus	24-29
31259654-0	2019	Naringin and Naringenin Relax Rat Tracheal Smooth by Regulating BKCa Activation.	naringenin	13-23	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	64-68
31259654-5	2019	In rat tracheal rings, addition of both naringin and naringenin could concentration dependently relax carbachol (CCh)-evoked tonic contraction.	naringenin	53-63	neurogenin 3	Rattus norvegicus	96-101
31037465-0	2019	Antidepressant and Neuroprotective Effects of Naringenin via Sonic Hedgehog-GLI1 Cell Signaling Pathway in a Rat Model of Chronic Unpredictable Mild Stress.	naringenin	46-56	sonic hedgehog signaling molecule	Rattus norvegicus	61-75
31037465-0	2019	Antidepressant and Neuroprotective Effects of Naringenin via Sonic Hedgehog-GLI1 Cell Signaling Pathway in a Rat Model of Chronic Unpredictable Mild Stress.	naringenin	46-56	GLI family zinc finger 1	Rattus norvegicus	76-80
31401645-11	2019	Admistration of naringenin at the dosage of 10 and 20 mg/kg to sepsis rats caused significant reduction in the sepsis-induced apoptosis of kidney cells, accompanied by decrease in Bax and increase in Bcl-2 expression.	naringenin	16-26	BCL2 associated X, apoptosis regulator	Rattus norvegicus	180-183
31401645-11	2019	Admistration of naringenin at the dosage of 10 and 20 mg/kg to sepsis rats caused significant reduction in the sepsis-induced apoptosis of kidney cells, accompanied by decrease in Bax and increase in Bcl-2 expression.	naringenin	16-26	BCL2, apoptosis regulator	Rattus norvegicus	200-205
31401645-12	2019	Moreover, naringenin also decreased the ROS levels in septic rats and downregulated the expression of SOD, CAT, and APX.	naringenin	10-20	catalase	Rattus norvegicus	107-110
31194956-3	2019	In the present study, we investigated the anti-AD potential of four flavonoids, naringenin, didymin, prunin, and poncirin, by evaluating their ability to inhibit acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).	naringenin	80-90	acetylcholinesterase	Rattus norvegicus	184-188
31252288-0	2019	Naringenin ameliorates progression of endometriosis by modulating Nrf2/Keap1/HO1 axis and inducing apoptosis in rats.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	66-70
31382634-2	2019	We aimed to overcome these limitations and encapsulated naringenin and hesperetin into lipid nanoemulsions (LNs), targeted to vascular cell adhesion molecule-1 (VCAM-1), which is expressed on activated endothelial cells (ECs).	naringenin	56-66	vascular cell adhesion molecule 1	Homo sapiens	126-159
31382634-2	2019	We aimed to overcome these limitations and encapsulated naringenin and hesperetin into lipid nanoemulsions (LNs), targeted to vascular cell adhesion molecule-1 (VCAM-1), which is expressed on activated endothelial cells (ECs).	naringenin	56-66	vascular cell adhesion molecule 1	Homo sapiens	161-167
31252288-0	2019	Naringenin ameliorates progression of endometriosis by modulating Nrf2/Keap1/HO1 axis and inducing apoptosis in rats.	naringenin	0-10	Kelch-like ECH-associated protein 1	Rattus norvegicus	71-76
31252288-0	2019	Naringenin ameliorates progression of endometriosis by modulating Nrf2/Keap1/HO1 axis and inducing apoptosis in rats.	naringenin	0-10	heme oxygenase 1	Rattus norvegicus	77-80
31252288-5	2019	The endometrial lesion volumes, weight, serum TNF-alpha level and the histopathologic scores were significantly reduced in the naringenin- treated group as compared to the endometriotic control group.	naringenin	127-137	tumor necrosis factor	Rattus norvegicus	46-55
31252288-6	2019	Naringenin ameliorated the expression of prognostic markers (TAK1, PAK1, VEGF and PCNA) involved in development and progression of endometriotic cells.	naringenin	0-10	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	61-65
31252288-6	2019	Naringenin ameliorated the expression of prognostic markers (TAK1, PAK1, VEGF and PCNA) involved in development and progression of endometriotic cells.	naringenin	0-10	p21 (RAC1) activated kinase 1	Rattus norvegicus	67-71
31252288-6	2019	Naringenin ameliorated the expression of prognostic markers (TAK1, PAK1, VEGF and PCNA) involved in development and progression of endometriotic cells.	naringenin	0-10	vascular endothelial growth factor A	Rattus norvegicus	73-77
31252288-6	2019	Naringenin ameliorated the expression of prognostic markers (TAK1, PAK1, VEGF and PCNA) involved in development and progression of endometriotic cells.	naringenin	0-10	proliferating cell nuclear antigen	Rattus norvegicus	82-86
31252288-9	2019	Naringenin significantly modulated the expression of Nrf2 and its effector molecules downstream.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	53-57
30543828-0	2019	Molecular binding response of naringin and naringenin to H46R mutant SOD1 protein in combating protein aggregation using density functional theory and discrete molecular dynamics.	naringenin	43-53	superoxide dismutase 1	Homo sapiens	69-73
30543828-6	2019	Further, we described the interaction of two naturally occurring polyphenol compounds, naringin and naringenin with mutant SOD1 that is regarded to hinder the protein aggregation.	naringenin	100-110	superoxide dismutase 1	Homo sapiens	123-127
31102954-0	2019	Naringenin enhances the regression of atherosclerosis induced by a chow diet in Ldlr-/- mice.	naringenin	0-10	low density lipoprotein receptor	Mus musculus	80-84
31075238-0	2019	Naringenin attenuates carotid restenosis in rats after balloon injury through its anti-inflammation and anti-oxidative effects via the RIP1-RIP3-MLKL signaling pathway.	naringenin	0-10	receptor-interacting serine-threonine kinase 3	Rattus norvegicus	140-144
31075238-0	2019	Naringenin attenuates carotid restenosis in rats after balloon injury through its anti-inflammation and anti-oxidative effects via the RIP1-RIP3-MLKL signaling pathway.	naringenin	0-10	mixed lineage kinase domain like pseudokinase	Rattus norvegicus	145-149
31075238-9	2019	Immunohistochemistry revealed that naringenin decreased the expression of proliferating cell nuclear antigen (PCNA) and the cluster of differentiation 163 (CD163).	naringenin	35-45	proliferating cell nuclear antigen	Rattus norvegicus	74-108
31075238-9	2019	Immunohistochemistry revealed that naringenin decreased the expression of proliferating cell nuclear antigen (PCNA) and the cluster of differentiation 163 (CD163).	naringenin	35-45	proliferating cell nuclear antigen	Rattus norvegicus	110-114
31075238-10	2019	ELISA indicated naringenin significantly reduced the overproduction of IL-1beta and TNF-alpha.	naringenin	16-26	interleukin 1 alpha	Rattus norvegicus	71-79
31075238-10	2019	ELISA indicated naringenin significantly reduced the overproduction of IL-1beta and TNF-alpha.	naringenin	16-26	tumor necrosis factor	Rattus norvegicus	84-93
31075238-12	2019	Additionally, RT-qPCR demonstrated that receptor-interacting protein 1 (RIP1), RIP3 and mixed lineage kinase domain-like (MLKL) mRNA expression were further down-regulated by naringenin treatment.	naringenin	175-185	receptor-interacting serine-threonine kinase 3	Rattus norvegicus	79-83
31075238-12	2019	Additionally, RT-qPCR demonstrated that receptor-interacting protein 1 (RIP1), RIP3 and mixed lineage kinase domain-like (MLKL) mRNA expression were further down-regulated by naringenin treatment.	naringenin	175-185	mixed lineage kinase domain like pseudokinase	Rattus norvegicus	88-120
31075238-12	2019	Additionally, RT-qPCR demonstrated that receptor-interacting protein 1 (RIP1), RIP3 and mixed lineage kinase domain-like (MLKL) mRNA expression were further down-regulated by naringenin treatment.	naringenin	175-185	mixed lineage kinase domain like pseudokinase	Rattus norvegicus	122-126
31075238-13	2019	These results suggested that naringenin can suppress BI-induced vascular neointimal hyperplasia through anti-inflammation and anti-oxidative stress, which may be related to the regulation of RIP1-RIP3-MLKL signaling pathway.	naringenin	29-39	receptor-interacting serine-threonine kinase 3	Rattus norvegicus	196-200
31075238-13	2019	These results suggested that naringenin can suppress BI-induced vascular neointimal hyperplasia through anti-inflammation and anti-oxidative stress, which may be related to the regulation of RIP1-RIP3-MLKL signaling pathway.	naringenin	29-39	mixed lineage kinase domain like pseudokinase	Rattus norvegicus	201-205
31102954-1	2019	BACKGROUND AND AIMS: Naringenin is a citrus-derived flavonoid with lipid-lowering and insulin-sensitizing effects leading to athero-protection in Ldlr-/- mice fed a high-fat diet.	naringenin	21-31	low density lipoprotein receptor	Mus musculus	146-150
31102954-3	2019	In the present study, we assessed the capacity of naringenin to enhance regression in Ldlr-/- mice with diet-induced intermediate atherosclerosis intervened with a chow diet.	naringenin	50-60	low density lipoprotein receptor	Mus musculus	86-90
31102954-13	2019	CONCLUSIONS: Naringenin supplementation to chow enhances atherosclerosis regression in male Ldlr-/- mice.	naringenin	13-23	low density lipoprotein receptor	Mus musculus	92-96
31039496-0	2019	Naringenin ameliorates insulin resistance by modulating endoplasmic reticulum stress in hepatitis C virus-infected liver.	naringenin	0-10	insulin	Homo sapiens	23-30
30776180-9	2019	The addition of naringenin significantly and dose-dependently increased the respiratory rate from 5.8 +- 0.2 to 14.0 +- 0.6 nmol O2  x min-1  x mg protein-1 .	naringenin	16-26	CD59 molecule (CD59 blood group)	Homo sapiens	135-140
31039496-2	2019	In our previous study, naringenin (NGEN) had an insulin sensitization effect on the HCV core protein (HCVCP) infected mouse livers.	naringenin	23-33	insulin	Homo sapiens	48-55
31039496-2	2019	In our previous study, naringenin (NGEN) had an insulin sensitization effect on the HCV core protein (HCVCP) infected mouse livers.	naringenin	35-39	insulin	Homo sapiens	48-55
30843661-0	2019	The effect of naringenin on the role of nuclear factor (erythroid-derived 2)-like2 (Nrf2) and haem oxygenase 1 (HO-1) in reducing the risk of oxidative stress-related radiotoxicity in the spleen of rats.	naringenin	14-24	NFE2 like bZIP transcription factor 2	Rattus norvegicus	84-88
31041965-0	2019	Naringenin improves mitochondrial function and reduces cardiac damage following ischemia-reperfusion injury: the role of the AMPK-SIRT3 signaling pathway.	naringenin	0-10	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	125-129
31041965-0	2019	Naringenin improves mitochondrial function and reduces cardiac damage following ischemia-reperfusion injury: the role of the AMPK-SIRT3 signaling pathway.	naringenin	0-10	sirtuin 3	Rattus norvegicus	130-135
31041965-4	2019	This study was designed to elucidate naringenin"s mitochondrial protective actions during MI/R with a focus on AMPK-SIRT3 signaling.	naringenin	37-47	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	111-115
31041965-4	2019	This study was designed to elucidate naringenin"s mitochondrial protective actions during MI/R with a focus on AMPK-SIRT3 signaling.	naringenin	37-47	sirtuin 3	Rattus norvegicus	116-121
31041965-8	2019	Naringenin improved post-reperfusion left ventricular systolic pressure and the instantaneous first derivative of left ventricular pressure, and reduced the infarction size and myocardial apoptosis index by suppressing mitochondrial oxidative stress damage (as evidenced by decreased mitochondrial cytochrome c release and oxidative markers) and enhancing mitochondrial biogenesis [as evidenced by increased NRF1, TFAM and oxidative phosphorylation subunit complexes (II, III and IV)].	naringenin	0-10	nuclear respiratory factor 1	Rattus norvegicus	408-412
31041965-8	2019	Naringenin improved post-reperfusion left ventricular systolic pressure and the instantaneous first derivative of left ventricular pressure, and reduced the infarction size and myocardial apoptosis index by suppressing mitochondrial oxidative stress damage (as evidenced by decreased mitochondrial cytochrome c release and oxidative markers) and enhancing mitochondrial biogenesis [as evidenced by increased NRF1, TFAM and oxidative phosphorylation subunit complexes (II, III and IV)].	naringenin	0-10	transcription factor A, mitochondrial	Rattus norvegicus	414-418
30433834-7	2019	RESULTS: Pretreatment of NGN significantly reversed the toxic effects of MPTP by reducing LPO levels and increasing the activities of glutathione reductase and catalase along with improved behavioural performance.	naringenin	25-28	lactoperoxidase	Mus musculus	90-93
30433834-7	2019	RESULTS: Pretreatment of NGN significantly reversed the toxic effects of MPTP by reducing LPO levels and increasing the activities of glutathione reductase and catalase along with improved behavioural performance.	naringenin	25-28	glutathione reductase	Mus musculus	134-155
30433834-7	2019	RESULTS: Pretreatment of NGN significantly reversed the toxic effects of MPTP by reducing LPO levels and increasing the activities of glutathione reductase and catalase along with improved behavioural performance.	naringenin	25-28	catalase	Mus musculus	160-168
30433834-8	2019	Interestingly, pre-treatment with NGN down-regulated iNOS expression level in MPTP intoxicated mice brain.	naringenin	34-37	nitric oxide synthase 2, inducible	Mus musculus	53-57
31217731-0	2019	Naringenin Ameliorates Renovascular Hypertensive Renal Damage by Normalizing the Balance of Renin-Angiotensin System Components in Rats.	naringenin	0-10	renin	Rattus norvegicus	92-97
31217731-2	2019	We previously demonstrated that naringenin played a protective role in hypertensive myocardial hypertrophy by decreasing angiotensin-converting enzyme (ACE) expression.	naringenin	32-42	angiotensin I converting enzyme	Rattus norvegicus	121-150
31217731-2	2019	We previously demonstrated that naringenin played a protective role in hypertensive myocardial hypertrophy by decreasing angiotensin-converting enzyme (ACE) expression.	naringenin	32-42	angiotensin I converting enzyme	Rattus norvegicus	152-155
31217731-10	2019	Naringenin significantly ameliorated hypertensive nephropathy and retarded the rise of Ang II levels in peripheral blood but had no effect on blood pressure.	naringenin	0-10	angiotensinogen	Rattus norvegicus	87-93
31217731-11	2019	2K1C rats exhibited increases in the ACE/ACE2 protein ratio and AT1R/AT2R protein ratio in the nonclipped kidney compared with sham rats, and these increases were significantly suppressed by naringenin treatment.	naringenin	191-201	angiotensin I converting enzyme	Rattus norvegicus	37-40
31217731-11	2019	2K1C rats exhibited increases in the ACE/ACE2 protein ratio and AT1R/AT2R protein ratio in the nonclipped kidney compared with sham rats, and these increases were significantly suppressed by naringenin treatment.	naringenin	191-201	angiotensin I converting enzyme 2	Rattus norvegicus	41-45
31217731-11	2019	2K1C rats exhibited increases in the ACE/ACE2 protein ratio and AT1R/AT2R protein ratio in the nonclipped kidney compared with sham rats, and these increases were significantly suppressed by naringenin treatment.	naringenin	191-201	angiotensin II receptor, type 1a	Rattus norvegicus	64-68
31217731-11	2019	2K1C rats exhibited increases in the ACE/ACE2 protein ratio and AT1R/AT2R protein ratio in the nonclipped kidney compared with sham rats, and these increases were significantly suppressed by naringenin treatment.	naringenin	191-201	angiotensin II receptor, type 2	Rattus norvegicus	69-73
31217731-12	2019	Conclusions: Naringenin attenuated renal damage in a rat model of renovascular hypertension by normalizing the imbalance of renin-angiotensin system activation.	naringenin	13-23	renin	Rattus norvegicus	124-129
31118933-0	2019	Naringenin Produces Neuroprotection Against LPS-Induced Dopamine Neurotoxicity via the Inhibition of Microglial NLRP3 Inflammasome Activation.	naringenin	0-10	NLR family, pyrin domain containing 3	Mus musculus	112-117
31118933-11	2019	In addition, NAR-mediated DA neuroprotection was dependent on the inhibition of microglial NLRP3 inflammasome activation, as evidenced by the observations that NAR-reduced pro-inflammatory factors production and further NAR-exerted DA neuroprotection against LPS-induced neuronal damage was not discerned after microglial NLRP3 siRNA treatment.	naringenin	13-16	NLR family, pyrin domain containing 3	Mus musculus	91-96
31118933-11	2019	In addition, NAR-mediated DA neuroprotection was dependent on the inhibition of microglial NLRP3 inflammasome activation, as evidenced by the observations that NAR-reduced pro-inflammatory factors production and further NAR-exerted DA neuroprotection against LPS-induced neuronal damage was not discerned after microglial NLRP3 siRNA treatment.	naringenin	13-16	NLR family, pyrin domain containing 3	Mus musculus	322-327
31118933-11	2019	In addition, NAR-mediated DA neuroprotection was dependent on the inhibition of microglial NLRP3 inflammasome activation, as evidenced by the observations that NAR-reduced pro-inflammatory factors production and further NAR-exerted DA neuroprotection against LPS-induced neuronal damage was not discerned after microglial NLRP3 siRNA treatment.	naringenin	160-163	NLR family, pyrin domain containing 3	Mus musculus	91-96
31118933-11	2019	In addition, NAR-mediated DA neuroprotection was dependent on the inhibition of microglial NLRP3 inflammasome activation, as evidenced by the observations that NAR-reduced pro-inflammatory factors production and further NAR-exerted DA neuroprotection against LPS-induced neuronal damage was not discerned after microglial NLRP3 siRNA treatment.	naringenin	160-163	NLR family, pyrin domain containing 3	Mus musculus	322-327
31118933-11	2019	In addition, NAR-mediated DA neuroprotection was dependent on the inhibition of microglial NLRP3 inflammasome activation, as evidenced by the observations that NAR-reduced pro-inflammatory factors production and further NAR-exerted DA neuroprotection against LPS-induced neuronal damage was not discerned after microglial NLRP3 siRNA treatment.	naringenin	160-163	NLR family, pyrin domain containing 3	Mus musculus	91-96
31118933-11	2019	In addition, NAR-mediated DA neuroprotection was dependent on the inhibition of microglial NLRP3 inflammasome activation, as evidenced by the observations that NAR-reduced pro-inflammatory factors production and further NAR-exerted DA neuroprotection against LPS-induced neuronal damage was not discerned after microglial NLRP3 siRNA treatment.	naringenin	160-163	NLR family, pyrin domain containing 3	Mus musculus	322-327
30827104-4	2019	However, the addition of naringenin (Nar, 25 muM) and naringin (Nar-G, 25 muM) standards significantly reduced the incorporation efficiency of Bc by 23.8 and 26.4%, respectively ( p &lt; 0.05).	naringenin	25-35	latexin	Homo sapiens	45-48
31061913-6	2019	Whereas, 50 mg/kg quercetin, and 50 mg/kg Naringenin decreased the oxidative stress (increased SOD, CAT, GSH, and reduced MDA) induced by cART (reduced SOD, CAT, GSH, and increased MDA).	naringenin	42-52	catalase	Rattus norvegicus	100-103
31061913-6	2019	Whereas, 50 mg/kg quercetin, and 50 mg/kg Naringenin decreased the oxidative stress (increased SOD, CAT, GSH, and reduced MDA) induced by cART (reduced SOD, CAT, GSH, and increased MDA).	naringenin	42-52	catalase	Rattus norvegicus	157-160
31061913-8	2019	Furthermore, immunohistochemical studies revealed that quercetin and naringenin attenuates cART-induced upregulation of monoamine oxidase-B (MAO-B) expression.	naringenin	69-79	monoamine oxidase B	Rattus norvegicus	120-139
31061913-8	2019	Furthermore, immunohistochemical studies revealed that quercetin and naringenin attenuates cART-induced upregulation of monoamine oxidase-B (MAO-B) expression.	naringenin	69-79	monoamine oxidase B	Rattus norvegicus	141-146
30768735-0	2019	Naringenin promotes microglial M2 polarization and Abeta degradation enzyme expression.	naringenin	0-10	amyloid beta (A4) precursor protein	Mus musculus	51-56
30768735-11	2019	After naringenin treatment, these Abeta degradation enzymes were downregulated in M1 microglia and upregulated in M2 microglia.	naringenin	6-16	amyloid beta (A4) precursor protein	Mus musculus	34-39
30768735-12	2019	Taken together, our results showed that naringenin increased Abeta degradation enzymes in M2 microglia, probably leading to Abeta plaque reduction.	naringenin	40-50	amyloid beta (A4) precursor protein	Mus musculus	61-66
30768735-12	2019	Taken together, our results showed that naringenin increased Abeta degradation enzymes in M2 microglia, probably leading to Abeta plaque reduction.	naringenin	40-50	amyloid beta (A4) precursor protein	Mus musculus	124-129
31005717-0	2019	Combined administration of naringenin and hesperetin with optimal ratio maximizes the anti-cancer effect in human pancreatic cancer via down regulation of FAK and p38 signaling pathway.	naringenin	27-37	protein tyrosine kinase 2	Homo sapiens	155-158
31005717-0	2019	Combined administration of naringenin and hesperetin with optimal ratio maximizes the anti-cancer effect in human pancreatic cancer via down regulation of FAK and p38 signaling pathway.	naringenin	27-37	mitogen-activated protein kinase 14	Homo sapiens	163-166
31005717-5	2019	RESULTS: Combined treatment with naringenin and hesperetin inhibited the growth of human pancreatic cancer cells (epsilonCUP mimic condition, p &lt; 0.001 for Miapaca-2 cells) through induction of caspase-3 cleavage compared to separate treatment with naringenin or hesperetin.	naringenin	33-43	caspase 3	Homo sapiens	197-206
31005717-8	2019	In addition, epsilonCUP mimic condition inhibited the phosphorylation of focal adhesion kinase (FAK) and p38 signaling compared with separate treatment with naringenin or hesperetin.	naringenin	157-167	mitogen-activated protein kinase 14	Homo sapiens	105-108
30802726-0	2019	Naringenin promotes recovery from colonic damage through suppression of epithelial tumor necrosis factor-alpha production and induction of M2-type macrophages in colitic mice.	naringenin	0-10	tumor necrosis factor	Mus musculus	83-110
30802726-3	2019	When mice were fed diets lacking or containing naringenin (0.3%, w/w) for 11 days after colitis induction through DSS administration, the supplemental naringenin was found to promote a reversal of body weight loss and suppress tumor necrosis factor (TNF)-alpha mRNA expression in the DSS-administered mice.	naringenin	151-161	tumor necrosis factor	Mus musculus	227-260
30802726-4	2019	Moreover, protein expression of two tight junction proteins, claudin-3 and junctional adhesion molecule-A, was higher in DSS-administered mice that were fed naringenin than in the mice that did not receive naringenin.	naringenin	157-167	claudin 3	Mus musculus	61-105
30802726-4	2019	Moreover, protein expression of two tight junction proteins, claudin-3 and junctional adhesion molecule-A, was higher in DSS-administered mice that were fed naringenin than in the mice that did not receive naringenin.	naringenin	206-216	claudin 3	Mus musculus	61-105
30802726-6	2019	Flow cytometry results further demonstrated that naringenin reduced TNF-alpha-positive epithelial cells, but not macrophages, and promoted the polarization of M2-type macrophages in the colonic tissues.	naringenin	49-59	tumor necrosis factor	Mus musculus	68-77
30771018-10	2019	Accordingly, the naringenin-betaine cocrystals showed improved anti-hyperlipidemia effects on the C57 BL/6J PNPLA3 I148M transgenic mouse hyperlipidemia model.	naringenin	17-27	patatin-like phospholipase domain containing 3	Mus musculus	108-114
31049130-11	2019	The treatments of APAP-administered rats with the peel extract, naringin, and naringenin produced a significant decrease in the elevated serum AST, ALT, ALP, LDH, and GGT activities as well as total bilirubin and TNF-alpha levels while they induced a significant increase in the lowered serum albumin and IL-4 levels.	naringenin	78-88	PDZ and LIM domain 3	Rattus norvegicus	153-156
31049130-11	2019	The treatments of APAP-administered rats with the peel extract, naringin, and naringenin produced a significant decrease in the elevated serum AST, ALT, ALP, LDH, and GGT activities as well as total bilirubin and TNF-alpha levels while they induced a significant increase in the lowered serum albumin and IL-4 levels.	naringenin	78-88	tumor necrosis factor	Rattus norvegicus	213-222
31049130-11	2019	The treatments of APAP-administered rats with the peel extract, naringin, and naringenin produced a significant decrease in the elevated serum AST, ALT, ALP, LDH, and GGT activities as well as total bilirubin and TNF-alpha levels while they induced a significant increase in the lowered serum albumin and IL-4 levels.	naringenin	78-88	interleukin 4	Rattus norvegicus	305-309
30578663-0	2019	Naringenin Supplementation to a Chow Diet Enhances Energy Expenditure and Fatty Acid Oxidation, and Reduces Adiposity in Lean, Pair-Fed Ldlr-/- Mice.	naringenin	0-10	low density lipoprotein receptor	Mus musculus	136-140
30578663-3	2019	Therefore, in the present study, the effect of naringenin supplementation in lean, chow-fed Ldlr-/- mice is investigated.	naringenin	47-57	low density lipoprotein receptor	Mus musculus	92-96
30578663-4	2019	METHODS AND RESULTS: In Ldlr-/- mice with isocaloric food consumption, treatment with naringenin for 8 weeks reduces body weight and adiposity compared to littermate controls pair-fed the chow diet alone.	naringenin	86-96	low density lipoprotein receptor	Mus musculus	24-28
30431227-4	2019	Naringenin inhibits the migration of bladder and lung cancer via modulation of MMP-2 and/or MMP-9 activities, Naringenin inhibits migration and trigger apoptosis in gastric cancer cells through downregulation of AKT pathway.	naringenin	0-10	matrix metallopeptidase 2	Homo sapiens	79-84
30431227-4	2019	Naringenin inhibits the migration of bladder and lung cancer via modulation of MMP-2 and/or MMP-9 activities, Naringenin inhibits migration and trigger apoptosis in gastric cancer cells through downregulation of AKT pathway.	naringenin	0-10	matrix metallopeptidase 9	Homo sapiens	92-97
30431227-4	2019	Naringenin inhibits the migration of bladder and lung cancer via modulation of MMP-2 and/or MMP-9 activities, Naringenin inhibits migration and trigger apoptosis in gastric cancer cells through downregulation of AKT pathway.	naringenin	110-120	AKT serine/threonine kinase 1	Homo sapiens	212-215
30431227-10	2019	Zymography analysis also revealed that the activities of MMP-2 and MMP-9 of GBM cells were significantly inhibited in response to 100, 200, or 300 muM naringenin treatment.	naringenin	151-161	matrix metallopeptidase 2	Homo sapiens	57-62
30431227-10	2019	Zymography analysis also revealed that the activities of MMP-2 and MMP-9 of GBM cells were significantly inhibited in response to 100, 200, or 300 muM naringenin treatment.	naringenin	151-161	matrix metallopeptidase 9	Homo sapiens	67-72
30431227-11	2019	Proteins of MMP-2 and MMP-9 were downregulated in naringenin treated GBM cells.	naringenin	50-60	matrix metallopeptidase 2	Homo sapiens	12-17
30431227-11	2019	Proteins of MMP-2 and MMP-9 were downregulated in naringenin treated GBM cells.	naringenin	50-60	matrix metallopeptidase 9	Homo sapiens	22-27
30431227-12	2019	In addition, naringenin also attenuated the activities of ERK and p38.	naringenin	13-23	mitogen-activated protein kinase 1	Homo sapiens	58-61
30431227-12	2019	In addition, naringenin also attenuated the activities of ERK and p38.	naringenin	13-23	mitogen-activated protein kinase 14	Homo sapiens	66-69
30431227-13	2019	Naringenin decreased mesenchymal markers (snail and slug) expression as revealed by Western blot analysis.	naringenin	0-10	snail family transcriptional repressor 2	Homo sapiens	52-56
30431227-14	2019	Taken together, our findings indicated that naringenin eliminated the migration and invasion of GBM cells through multiple mechanisms including inhibition of MMPs, ERK, and p38 activities and modulation of EMT markers.	naringenin	44-54	matrix metallopeptidase 2	Homo sapiens	158-162
30431227-14	2019	Taken together, our findings indicated that naringenin eliminated the migration and invasion of GBM cells through multiple mechanisms including inhibition of MMPs, ERK, and p38 activities and modulation of EMT markers.	naringenin	44-54	mitogen-activated protein kinase 1	Homo sapiens	164-167
30431227-14	2019	Taken together, our findings indicated that naringenin eliminated the migration and invasion of GBM cells through multiple mechanisms including inhibition of MMPs, ERK, and p38 activities and modulation of EMT markers.	naringenin	44-54	mitogen-activated protein kinase 14	Homo sapiens	173-176
30431227-14	2019	Taken together, our findings indicated that naringenin eliminated the migration and invasion of GBM cells through multiple mechanisms including inhibition of MMPs, ERK, and p38 activities and modulation of EMT markers.	naringenin	44-54	IL2 inducible T cell kinase	Homo sapiens	206-209
30467676-5	2019	Sakuranetin and (-)-naringenin, which were present in an ethyl acetate-soluble fraction of the bark extract, significantly inhibited NO induction and inducible nitric oxide synthase (iNOS) expression.	naringenin	16-30	nitric oxide synthase 2	Homo sapiens	150-181
30467676-5	2019	Sakuranetin and (-)-naringenin, which were present in an ethyl acetate-soluble fraction of the bark extract, significantly inhibited NO induction and inducible nitric oxide synthase (iNOS) expression.	naringenin	16-30	nitric oxide synthase 2	Homo sapiens	183-187
30636259-8	2019	RESULTS Naringenin treatment in a rat model of PCOS significantly increased the levels of the reactive oxygen species (ROS) scavenging enzymes CAT, SOD, and GPX (p&lt;0.05), and prevented weight increase.	naringenin	8-18	catalase	Rattus norvegicus	143-146
30745874-0	2018	Treatment With Naringenin Elevates the Activity of Transcription Factor Nrf2 to Protect Pancreatic beta-Cells From Streptozotocin-Induced Diabetes in vitro and in vivo.	naringenin	15-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	72-76
30745874-3	2018	Naringenin is one such activator of Nrf2.	naringenin	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	36-40
30745874-5	2018	Hence, the potential of naringenin to activate Nrf2 and protect pancreatic beta-cells from STZ-induced damage in MIN6 cells is studied.	naringenin	24-34	nuclear factor, erythroid derived 2, like 2	Mus musculus	47-51
30745874-6	2018	In MIN6 cells, naringenin could activate Nrf2 and its target genes GST and NQO1, thereby inhibit cellular apoptosis.	naringenin	15-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	41-45
30745874-6	2018	In MIN6 cells, naringenin could activate Nrf2 and its target genes GST and NQO1, thereby inhibit cellular apoptosis.	naringenin	15-25	NAD(P)H dehydrogenase, quinone 1	Mus musculus	75-79
30745874-10	2018	In conclusion, naringenin could be a good anti-diabetic agent, which works by promoting Nrf2 levels and by decreasing cellular oxidative stress.	naringenin	15-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	88-92
30728891-10	2019	Furthermore, pretreatment with naringenin suppressed MI/R-induced oxidative stress as well as ER stress as evidenced by decreased superoxide generation, myocardial MDA level, gp91 phox expression, and phosphorylation of PERK, IRE1alpha, and EIF2alpha as well as reduced ATF6 and CHOP.	naringenin	31-41	eukaryotic translation initiation factor 2A	Rattus norvegicus	241-250
31956555-10	2020	Assessment of TNF-alpha indicated therapeutic efficacy of naringenin at molecular level.	naringenin	58-68	tumor necrosis factor	Rattus norvegicus	14-23
30728891-10	2019	Furthermore, pretreatment with naringenin suppressed MI/R-induced oxidative stress as well as ER stress as evidenced by decreased superoxide generation, myocardial MDA level, gp91 phox expression, and phosphorylation of PERK, IRE1alpha, and EIF2alpha as well as reduced ATF6 and CHOP.	naringenin	31-41	activating transcription factor 6	Rattus norvegicus	270-274
30728891-10	2019	Furthermore, pretreatment with naringenin suppressed MI/R-induced oxidative stress as well as ER stress as evidenced by decreased superoxide generation, myocardial MDA level, gp91 phox expression, and phosphorylation of PERK, IRE1alpha, and EIF2alpha as well as reduced ATF6 and CHOP.	naringenin	31-41	DNA-damage inducible transcript 3	Rattus norvegicus	279-283
30527894-0	2019	Naringenin targets on astroglial Nrf2 to support dopaminergic neurons.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	33-37
30462381-0	2019	Antidiabetic-Like Effects of Naringenin-7-O-glucoside from Edible Chrysanthemum "Kotobuki" and Naringenin by Activation of the PI3K/Akt Pathway and PPARgamma.	naringenin	29-39	thymoma viral proto-oncogene 1	Mus musculus	132-135
30462381-0	2019	Antidiabetic-Like Effects of Naringenin-7-O-glucoside from Edible Chrysanthemum "Kotobuki" and Naringenin by Activation of the PI3K/Akt Pathway and PPARgamma.	naringenin	29-39	peroxisome proliferator activated receptor gamma	Mus musculus	148-157
30462381-6	2019	Among the isolated compounds and their aglycones, naringenin (NA) and naringenin-7-O-glucoside (NAG) up-regulated the intracellular accumulation of lipid and adiponectin-secretion and down-regulated the diameter of 3T3-L1 cells during adipocyte differentiation.	naringenin	50-60	adiponectin, C1Q and collagen domain containing	Mus musculus	158-169
30506905-7	2019	RESULTS: In hADSC, naringenin increased expression of the genes associated with thermogenesis and fat oxidation, including uncoupling protein 1 and adipose triglyceride lipase, and key factors associated with insulin sensitivity, including glucose transporter type 4, adiponectin, and carbohydrate-responsive element-binding protein (P &lt; 0.01).	naringenin	19-29	uncoupling protein 1	Homo sapiens	123-143
30655887-0	2019	Naringenin has a chemoprotective effect in MDA-MB-231 breast cancer cells via inhibition of caspase-3 and -9 activities.	naringenin	0-10	caspase 3	Homo sapiens	92-108
30655887-8	2019	Naringenin treatment also resulted in a significant increase in caspase-3 and caspase-9 activity (P&lt;0.001).	naringenin	0-10	caspase 3	Homo sapiens	64-73
30655887-8	2019	Naringenin treatment also resulted in a significant increase in caspase-3 and caspase-9 activity (P&lt;0.001).	naringenin	0-10	caspase 9	Homo sapiens	78-87
30655887-9	2019	Taken together, the results of the present study suggested that naringenin caused an inhibitory effect on MDA-MB-231 cells via induction of apoptosis and inhibition of caspase-3 and -9 activity.	naringenin	64-74	caspase 3	Homo sapiens	168-184
30551401-7	2019	RESULTS: Naringenin (0.1, 1, 10 mumol/L) inhibited cardiomyocyte hypertrophy in a concentration-dependent manner (P &lt; 0.05), up-regulated the expressions of PPARalpha, PPARbeta, PPARgamma and CYP2J3 (P &lt; 0.05), and increased the level of 14,15-EET (P &lt; 0.05).	naringenin	9-19	peroxisome proliferator activated receptor alpha	Rattus norvegicus	160-169
30551401-7	2019	RESULTS: Naringenin (0.1, 1, 10 mumol/L) inhibited cardiomyocyte hypertrophy in a concentration-dependent manner (P &lt; 0.05), up-regulated the expressions of PPARalpha, PPARbeta, PPARgamma and CYP2J3 (P &lt; 0.05), and increased the level of 14,15-EET (P &lt; 0.05).	naringenin	9-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	171-179
30551401-7	2019	RESULTS: Naringenin (0.1, 1, 10 mumol/L) inhibited cardiomyocyte hypertrophy in a concentration-dependent manner (P &lt; 0.05), up-regulated the expressions of PPARalpha, PPARbeta, PPARgamma and CYP2J3 (P &lt; 0.05), and increased the level of 14,15-EET (P &lt; 0.05).	naringenin	9-19	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	181-190
30551401-7	2019	RESULTS: Naringenin (0.1, 1, 10 mumol/L) inhibited cardiomyocyte hypertrophy in a concentration-dependent manner (P &lt; 0.05), up-regulated the expressions of PPARalpha, PPARbeta, PPARgamma and CYP2J3 (P &lt; 0.05), and increased the level of 14,15-EET (P &lt; 0.05).	naringenin	9-19	cytochrome P450, family 2, subfamily j, polypeptide 3	Rattus norvegicus	195-201
30551401-8	2019	PPOH, a CYP2J3 inhibitor, blocked the naringenin-mediated improvement of myocardial hypertrophy (P &lt; 0.01), and abolished the up-regulation of PPARs expressions (P &lt; 0.01).	naringenin	38-48	cytochrome P450, family 2, subfamily j, polypeptide 3	Rattus norvegicus	8-14
30551401-9	2019	Meanwhile, MK886, a PPARalpha antagonist, GSK0660, a PPARbeta antagonist, and GW9662, a PPARgamma antagonist, reversed the protection of naringenin on cardiomyocytes (P &lt; 0.05), and abrogated the up-regulation of CYP2J3-EET produced by naringenin (P &lt; 0.05).	naringenin	137-147	peroxisome proliferator-activated receptor delta	Rattus norvegicus	53-61
30551401-9	2019	Meanwhile, MK886, a PPARalpha antagonist, GSK0660, a PPARbeta antagonist, and GW9662, a PPARgamma antagonist, reversed the protection of naringenin on cardiomyocytes (P &lt; 0.05), and abrogated the up-regulation of CYP2J3-EET produced by naringenin (P &lt; 0.05).	naringenin	137-147	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	88-97
30551401-9	2019	Meanwhile, MK886, a PPARalpha antagonist, GSK0660, a PPARbeta antagonist, and GW9662, a PPARgamma antagonist, reversed the protection of naringenin on cardiomyocytes (P &lt; 0.05), and abrogated the up-regulation of CYP2J3-EET produced by naringenin (P &lt; 0.05).	naringenin	137-147	cytochrome P450, family 2, subfamily j, polypeptide 3	Rattus norvegicus	216-222
29968480-8	2018	NARNS treatment significantly increased intracellular ROS level, mitochondrial membrane potential, caspase-3 activity, lipid peroxidation status (TBARS) and decreased GSH levels when compared to free NAR treatment in MCF-7 cells.	naringenin	0-3	caspase 3	Homo sapiens	99-108
30609878-0	2018	Naringenin attenuates inflammation in chronic obstructive pulmonary disease in cigarette smoke induced mouse model and involves suppression of NF-kappaB.	naringenin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	143-152
30609878-9	2018	Naringenin was found to significantly improve the pulmonary function, decreased inflammatory cells, and inhibited the production of pro-inflammatory cytokines such as IL-8, TNF-alpha, and MMP9 in the BALF and serum of CS animal group.	naringenin	0-10	chemokine (C-X-C motif) ligand 15	Mus musculus	167-171
30609878-9	2018	Naringenin was found to significantly improve the pulmonary function, decreased inflammatory cells, and inhibited the production of pro-inflammatory cytokines such as IL-8, TNF-alpha, and MMP9 in the BALF and serum of CS animal group.	naringenin	0-10	tumor necrosis factor	Mus musculus	173-182
30609878-9	2018	Naringenin was found to significantly improve the pulmonary function, decreased inflammatory cells, and inhibited the production of pro-inflammatory cytokines such as IL-8, TNF-alpha, and MMP9 in the BALF and serum of CS animal group.	naringenin	0-10	matrix metallopeptidase 9	Mus musculus	188-192
30609878-10	2018	Naringenin also appeared to inhibit the NF-kappaB pathway as revealed by reduced phosphorylation of NF-kappaB and IkappaB in western blot test.	naringenin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	40-49
30609878-10	2018	Naringenin also appeared to inhibit the NF-kappaB pathway as revealed by reduced phosphorylation of NF-kappaB and IkappaB in western blot test.	naringenin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	100-109
30609878-11	2018	Moreover, the levels GR mRNA and protein were also significantly increased upon treatment with naringenin to CS-exposed animals and cell culture.	naringenin	95-105	nuclear receptor subfamily 3, group C, member 1	Mus musculus	21-23
30290062-0	2018	Exploring the C-Terminal Tail Dynamics: Structural and Molecular Perspectives into the Therapeutic Activities of Novel CRMP-2 Inhibitors, Naringenin and Naringenin-7-O-glucuronide, in the Treatment of Alzheimer"s Disease.	naringenin	138-148	dihydropyrimidinase like 2	Homo sapiens	119-125
30290062-3	2018	The abilities of naringenin (NAR) and naringenin-7-O-glucuronide (NAR-7-O-G) to selectively bind CRMP-2 and reduce its phosphorylation have been previously demonstrated; the molecular interplay between these events remains unresolved.	naringenin	17-27	dihydropyrimidinase like 2	Homo sapiens	97-103
30290062-3	2018	The abilities of naringenin (NAR) and naringenin-7-O-glucuronide (NAR-7-O-G) to selectively bind CRMP-2 and reduce its phosphorylation have been previously demonstrated; the molecular interplay between these events remains unresolved.	naringenin	29-32	dihydropyrimidinase like 2	Homo sapiens	97-103
30360615-9	2018	The proinflammatory cytokines TNF-alpha and IL-6 were alleviated by quercetin, genistein, and naringenin.	naringenin	94-104	tumor necrosis factor	Rattus norvegicus	30-39
30360615-9	2018	The proinflammatory cytokines TNF-alpha and IL-6 were alleviated by quercetin, genistein, and naringenin.	naringenin	94-104	interleukin 6	Rattus norvegicus	44-48
30466984-0	2018	Naringenin suppresses growth of human placental choriocarcinoma via reactive oxygen species-mediated P38 and JNK MAPK pathways.	naringenin	0-10	mitogen-activated protein kinase 1	Homo sapiens	101-104
30466984-0	2018	Naringenin suppresses growth of human placental choriocarcinoma via reactive oxygen species-mediated P38 and JNK MAPK pathways.	naringenin	0-10	mitogen-activated protein kinase 8	Homo sapiens	109-112
30466984-0	2018	Naringenin suppresses growth of human placental choriocarcinoma via reactive oxygen species-mediated P38 and JNK MAPK pathways.	naringenin	0-10	mitogen-activated protein kinase 3	Homo sapiens	113-117
30466984-9	2018	We also determined naringenin activated phosphorylation of ERK1/2, P38, JNK and P70S6K in JAR and JEG3 cells in a dose-response manner.	naringenin	19-29	mitogen-activated protein kinase 3	Homo sapiens	59-65
30466984-9	2018	We also determined naringenin activated phosphorylation of ERK1/2, P38, JNK and P70S6K in JAR and JEG3 cells in a dose-response manner.	naringenin	19-29	mitogen-activated protein kinase 8	Homo sapiens	72-75
30466984-11	2018	In addition, we confirmed the mechanism of naringenin-induced cell signaling by using a combination of naringenin and pharmacological inhibitors of the PI3K and MAPK pathways, as well as a ROS inhibitor in JAR and JEG3 cell lines.	naringenin	43-53	mitogen-activated protein kinase 3	Homo sapiens	161-165
30466984-12	2018	CONCLUSIONS: Collectively, results of this study indicate that naringenin is a potential therapeutic molecule with anti-cancer effects on choriocarcinoma cells by inducing generation of ROS and activation of the MAPK pathways.	naringenin	63-73	mitogen-activated protein kinase 3	Homo sapiens	212-216
30504386-0	2018	Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial-to-Mesenchymal Transition and Inhibited uPA Activity.	naringenin	0-10	plasminogen activator, urokinase	Homo sapiens	114-117
30504386-6	2018	RESULTS: Transwell assay and zymography revealed that naringenin suppressed the migration and invasion of PC-3 cells and uPA activity in proportion to the concentration of naringenin.	naringenin	172-182	plasminogen activator, urokinase	Homo sapiens	121-124
30504386-7	2018	Western blot analysis indicated that naringenin up-regulated E-cadherin expression, but down-regulated the expression of vimentin, SNAIL family zinc finger 1 (SNAI1), SNAIL family zinc finger 2 (SNAI2), and TWIST family bHLH transcription factor 1 (TWIST1).	naringenin	37-47	cadherin 1	Homo sapiens	61-71
30504386-7	2018	Western blot analysis indicated that naringenin up-regulated E-cadherin expression, but down-regulated the expression of vimentin, SNAIL family zinc finger 1 (SNAI1), SNAIL family zinc finger 2 (SNAI2), and TWIST family bHLH transcription factor 1 (TWIST1).	naringenin	37-47	vimentin	Homo sapiens	121-129
30504386-7	2018	Western blot analysis indicated that naringenin up-regulated E-cadherin expression, but down-regulated the expression of vimentin, SNAIL family zinc finger 1 (SNAI1), SNAIL family zinc finger 2 (SNAI2), and TWIST family bHLH transcription factor 1 (TWIST1).	naringenin	37-47	snail family transcriptional repressor 1	Homo sapiens	159-164
30504386-7	2018	Western blot analysis indicated that naringenin up-regulated E-cadherin expression, but down-regulated the expression of vimentin, SNAIL family zinc finger 1 (SNAI1), SNAIL family zinc finger 2 (SNAI2), and TWIST family bHLH transcription factor 1 (TWIST1).	naringenin	37-47	snail family transcriptional repressor 2	Homo sapiens	195-200
30504386-7	2018	Western blot analysis indicated that naringenin up-regulated E-cadherin expression, but down-regulated the expression of vimentin, SNAIL family zinc finger 1 (SNAI1), SNAIL family zinc finger 2 (SNAI2), and TWIST family bHLH transcription factor 1 (TWIST1).	naringenin	37-47	twist family bHLH transcription factor 1	Homo sapiens	249-255
30504386-8	2018	CONCLUSION: Naringenin inhibited the migration and invasion of PC-3 cells by reversing expression of proteins involved in epithelial-to-mesenchymal transition and down-regulation of uPA activity.	naringenin	12-22	plasminogen activator, urokinase	Homo sapiens	182-185
30232036-10	2018	In the cerebellum, reducing the litter size decreased the activity of thioredoxin reductase, which was prevented by maternal supplementation with naringenin.	naringenin	146-156	peroxiredoxin 5	Rattus norvegicus	70-91
30153467-5	2018	Results from a wound healing assay indicated that the combined treatment of tamoxifen and naringenin markedly suppressed cell migration compared with the single exposure by downregulating the expression of MMP-9 and MMP-2.	naringenin	90-100	matrix metallopeptidase 9	Homo sapiens	206-211
30153467-5	2018	Results from a wound healing assay indicated that the combined treatment of tamoxifen and naringenin markedly suppressed cell migration compared with the single exposure by downregulating the expression of MMP-9 and MMP-2.	naringenin	90-100	matrix metallopeptidase 2	Homo sapiens	216-221
30153467-8	2018	Real-time quantitative polymerase chain reaction (RT-qPCR) and western blotting (WB) analysis results further demonstrated that the two nuclear estrogen receptors-ERalpha66 and ERbeta, as well as the two membrane estrogen receptors-ERalpha36 and GPR30 were downregulated when cells were exposed to single tamoxifen, whereas naringenin treatment group not only downregulated the expression of ERalpha66 and GPR30 but also upregulated ERbeta and ERalpha36.	naringenin	324-334	estrogen receptor 2	Homo sapiens	153-183
30501090-5	2018	Naringenin, a parent structure of naringin with the excellent binding score of -9.3 kcal/mol, was completely in conjunction with the active site of D2R, indicating that it is critical for the treatment of gastrointestinal dysfunction.	naringenin	0-10	dopamine receptor D2	Homo sapiens	148-151
30001606-0	2018	In vitro neuroprotective effects of naringenin nanoemulsion against beta-amyloid toxicity through the regulation of amyloidogenesis and tau phosphorylation.	naringenin	36-46	microtubule associated protein tau	Homo sapiens	136-139
30001606-10	2018	The naringenin loaded nanoemulsion significantly alleviated the direct neurotoxic effects of Abeta on SH-SY5Y cells; this was associated with a down-regulation of APP and BACE expression, indicating reduced amyloidogenesis.	naringenin	4-14	beta-secretase 1	Homo sapiens	171-175
30017880-0	2018	Combination of Asiatic Acid and Naringenin Modulates NK Cell Anti-cancer Immunity by Rebalancing Smad3/Smad7 Signaling.	naringenin	32-42	SMAD family member 3	Mus musculus	97-102
30327657-6	2018	Naringenin mainly inhibited CD4+ T cell proliferation and differentiation to Th1 and Th17, but did not affect Th2 cells.	naringenin	0-10	negative elongation factor complex member C/D, Th1l	Mus musculus	77-80
29990870-6	2018	Moreover, 10 muM naringenin displayed inhibitory effects on cell movement by reducing the expression of the SCN9A gene at the mRNA level.	naringenin	17-27	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	108-113
29990870-7	2018	In conclusion, naringenin was found to have direct or indirect blocking activity on voltage-gated sodium channels encoded by the SCN9A gene.	naringenin	15-25	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	129-134
30327657-7	2018	Impeded Th1 polarization was associated with inhibition of its specific regulator proteins T-bet, p-STAT1, and p-STAT4 by naringenin.	naringenin	122-132	negative elongation factor complex member C/D, Th1l	Mus musculus	8-11
30327657-7	2018	Impeded Th1 polarization was associated with inhibition of its specific regulator proteins T-bet, p-STAT1, and p-STAT4 by naringenin.	naringenin	122-132	signal transducer and activator of transcription 1	Mus musculus	100-105
30327657-7	2018	Impeded Th1 polarization was associated with inhibition of its specific regulator proteins T-bet, p-STAT1, and p-STAT4 by naringenin.	naringenin	122-132	signal transducer and activator of transcription 4	Mus musculus	113-118
30327657-8	2018	Likewise, Th17 regulator proteins RORgammat, p-STAT3, and Ac-STAT3 were also inhibited by naringenin.	naringenin	90-100	signal transducer and activator of transcription 3	Mus musculus	47-52
30327657-8	2018	Likewise, Th17 regulator proteins RORgammat, p-STAT3, and Ac-STAT3 were also inhibited by naringenin.	naringenin	90-100	signal transducer and activator of transcription 3	Mus musculus	61-66
30327657-9	2018	In addition, naringenin promoted Treg polarization and also prevented IL-6-induced suppression of Treg development via down-regulation of p-Smad2/3 as well as inhibition of IL-6 signaling, and the latter was further supported by the in vivo results showing lower soluble IL-6R but higher soluble gp130 levels in plasma of naringenin-fed compared to the control EAE mice.	naringenin	13-23	interleukin 6	Mus musculus	70-74
30327657-9	2018	In addition, naringenin promoted Treg polarization and also prevented IL-6-induced suppression of Treg development via down-regulation of p-Smad2/3 as well as inhibition of IL-6 signaling, and the latter was further supported by the in vivo results showing lower soluble IL-6R but higher soluble gp130 levels in plasma of naringenin-fed compared to the control EAE mice.	naringenin	13-23	interleukin 6	Mus musculus	173-177
30327657-9	2018	In addition, naringenin promoted Treg polarization and also prevented IL-6-induced suppression of Treg development via down-regulation of p-Smad2/3 as well as inhibition of IL-6 signaling, and the latter was further supported by the in vivo results showing lower soluble IL-6R but higher soluble gp130 levels in plasma of naringenin-fed compared to the control EAE mice.	naringenin	13-23	interleukin 6 receptor, alpha	Mus musculus	271-276
30327657-9	2018	In addition, naringenin promoted Treg polarization and also prevented IL-6-induced suppression of Treg development via down-regulation of p-Smad2/3 as well as inhibition of IL-6 signaling, and the latter was further supported by the in vivo results showing lower soluble IL-6R but higher soluble gp130 levels in plasma of naringenin-fed compared to the control EAE mice.	naringenin	13-23	interleukin 6 signal transducer	Mus musculus	296-301
30327657-9	2018	In addition, naringenin promoted Treg polarization and also prevented IL-6-induced suppression of Treg development via down-regulation of p-Smad2/3 as well as inhibition of IL-6 signaling, and the latter was further supported by the in vivo results showing lower soluble IL-6R but higher soluble gp130 levels in plasma of naringenin-fed compared to the control EAE mice.	naringenin	322-332	interleukin 6	Mus musculus	70-74
30017640-10	2018	Naringenin also significantly decreased elevated pro-inflammatory cytokines like IL-1beta, IL-6, TNF-alpha and NF-kbeta levels.	naringenin	0-10	interleukin 1 beta	Mus musculus	81-89
30017640-10	2018	Naringenin also significantly decreased elevated pro-inflammatory cytokines like IL-1beta, IL-6, TNF-alpha and NF-kbeta levels.	naringenin	0-10	interleukin 6	Mus musculus	91-95
30017640-10	2018	Naringenin also significantly decreased elevated pro-inflammatory cytokines like IL-1beta, IL-6, TNF-alpha and NF-kbeta levels.	naringenin	0-10	tumor necrosis factor	Mus musculus	97-106
30017640-11	2018	Naringenin also significantly increased neurotrophic growth factor like BDNF.	naringenin	0-10	brain derived neurotrophic factor	Mus musculus	72-76
30017880-0	2018	Combination of Asiatic Acid and Naringenin Modulates NK Cell Anti-cancer Immunity by Rebalancing Smad3/Smad7 Signaling.	naringenin	32-42	SMAD family member 7	Mus musculus	103-108
29906750-0	2018	Naringenin attenuates behavioral derangements induced by social defeat stress in mice via inhibition of acetylcholinesterase activity, oxidative stress and release of pro-inflammatory cytokines.	naringenin	0-10	acetylcholinesterase	Mus musculus	104-124
29906750-13	2018	Moreover, 50 mg/Kg of naringenin (38.13 +- 2.38 rhog/mL) attenuated (p &lt; 0.05) increased TNF-alpha level when compared with SDS (49.69 +- 2.81 rhog/mL).	naringenin	22-32	tumor necrosis factor	Mus musculus	92-101
29906750-14	2018	SDS-induced increase in brain level of IL-1beta (236.5 +- 6.92 rhog/mL) was significantly (p &lt; 0.05) reduced by naringenin (219.90 +- 15.25 rhog/mL).	naringenin	115-125	interleukin 1 beta	Mus musculus	39-47
29906750-15	2018	Naringenin also elevated antioxidant enzymes and decreased AChE activity in the brains of mice exposed to SDS (p &lt; 0.05).	naringenin	0-10	acetylcholinesterase	Mus musculus	59-63
29906750-16	2018	These findings suggest that naringenin attenuates SDS-induced neurobehavioral deficits through inhibition of acetylcholinesterase activity, oxidative stress and release of pro-inflammatory cytokines.	naringenin	28-38	acetylcholinesterase	Mus musculus	109-129
29885599-5	2018	We found that naringenin dose-dependently suppressed anti-CD3/CD28 and MOG35-55-induced T cell proliferation, production of T cell cytokines IFN-gamma, IL-17, IL-6 and TNF-alpha.	naringenin	14-24	CD3 antigen, epsilon polypeptide	Mus musculus	58-61
29738867-4	2018	We have identified eight bioactive compounds (Apigenin, Dihydromyricetin, Diosmetin, Hesperidin, Hesperitin, Naringenin, Phlorizi, and Quercetin) as the potential inhibitors of PLK-1.	naringenin	109-119	polo like kinase 1	Homo sapiens	177-182
30112041-10	2018	In conclusion, Ang II and ACE1 expression in cardiac tissue was inhibited by NGN in L-NAME-treated rats, which may contribute to the inhibitory effects of NGN on left ventricular hypertrophy that is induced by pressure overload.	naringenin	77-80	angiotensinogen	Rattus norvegicus	15-21
30112041-10	2018	In conclusion, Ang II and ACE1 expression in cardiac tissue was inhibited by NGN in L-NAME-treated rats, which may contribute to the inhibitory effects of NGN on left ventricular hypertrophy that is induced by pressure overload.	naringenin	155-158	angiotensinogen	Rattus norvegicus	15-21
29885599-5	2018	We found that naringenin dose-dependently suppressed anti-CD3/CD28 and MOG35-55-induced T cell proliferation, production of T cell cytokines IFN-gamma, IL-17, IL-6 and TNF-alpha.	naringenin	14-24	interferon gamma	Mus musculus	141-150
29885599-5	2018	We found that naringenin dose-dependently suppressed anti-CD3/CD28 and MOG35-55-induced T cell proliferation, production of T cell cytokines IFN-gamma, IL-17, IL-6 and TNF-alpha.	naringenin	14-24	interleukin 17A	Mus musculus	152-157
29885599-5	2018	We found that naringenin dose-dependently suppressed anti-CD3/CD28 and MOG35-55-induced T cell proliferation, production of T cell cytokines IFN-gamma, IL-17, IL-6 and TNF-alpha.	naringenin	14-24	interleukin 6	Mus musculus	159-163
30008441-3	2018	Previous prevention studies demonstrated that the citrus flavonoids, naringenin and nobiletin, protect against obesity and metabolic dysfunction in Ldlr-/- mice fed a high-fat cholesterol-containing (HFHC) diet.	naringenin	69-79	low density lipoprotein receptor	Mus musculus	148-152
29885599-5	2018	We found that naringenin dose-dependently suppressed anti-CD3/CD28 and MOG35-55-induced T cell proliferation, production of T cell cytokines IFN-gamma, IL-17, IL-6 and TNF-alpha.	naringenin	14-24	CD28 antigen	Mus musculus	62-66
29885599-5	2018	We found that naringenin dose-dependently suppressed anti-CD3/CD28 and MOG35-55-induced T cell proliferation, production of T cell cytokines IFN-gamma, IL-17, IL-6 and TNF-alpha.	naringenin	14-24	tumor necrosis factor	Mus musculus	168-177
29885599-7	2018	Finally, it was revealed that all these T cell-suppressive effects might be related to naringenin"s interference with IL-2/IL-2R-mediated signaling pathway and STAT5 phosphorylation in activated T cells.	naringenin	87-97	interleukin 2	Mus musculus	118-122
29885599-7	2018	Finally, it was revealed that all these T cell-suppressive effects might be related to naringenin"s interference with IL-2/IL-2R-mediated signaling pathway and STAT5 phosphorylation in activated T cells.	naringenin	87-97	interleukin 2 receptor, alpha chain	Mus musculus	123-128
29885599-8	2018	Our results confirmed T cell-suppressive activity of naringenin previously reported by us and others, but for the first time, it was shown that the working mechanism may involve its ability to modulate cell cycle progression, cell cycle-related proteins and IL-2/IL-2R signaling pathway.	naringenin	53-63	interleukin 2	Mus musculus	258-262
29684853-0	2018	Naringenin improve hepatitis C virus infection induced insulin resistance by increase PTEN expression via p53-dependent manner.	naringenin	0-10	insulin	Homo sapiens	55-62
29885599-8	2018	Our results confirmed T cell-suppressive activity of naringenin previously reported by us and others, but for the first time, it was shown that the working mechanism may involve its ability to modulate cell cycle progression, cell cycle-related proteins and IL-2/IL-2R signaling pathway.	naringenin	53-63	interleukin 2 receptor, alpha chain	Mus musculus	263-268
29860210-0	2018	Across the blood-brain barrier: Neurotherapeutic screening and characterization of naringenin as a novel CRMP-2 inhibitor in the treatment of Alzheimer"s disease using bioinformatics and computational tools.	naringenin	83-93	dihydropyrimidinase like 2	Homo sapiens	105-111
29860210-4	2018	As shown in previous studies, Naringenin (NAR), a small molecule derivative of Drynaria rhizome (DR) extract, specifically binds CRMP-2 and reduces its phosphorylation.	naringenin	30-40	dihydropyrimidinase like 2	Homo sapiens	129-135
29860210-4	2018	As shown in previous studies, Naringenin (NAR), a small molecule derivative of Drynaria rhizome (DR) extract, specifically binds CRMP-2 and reduces its phosphorylation.	naringenin	42-45	dihydropyrimidinase like 2	Homo sapiens	129-135
29860210-10	2018	NAR exhibited favorable binding to CRMP-2 and formed strong bonds with active site residues, which accounts for its stabilization and affinity.	naringenin	0-3	dihydropyrimidinase like 2	Homo sapiens	35-41
29860210-11	2018	Moreover, NAR induced notable conformational changes in CRMP-2, an occurrence that could possibly disrupt kinase-mediated phosphorylation.	naringenin	10-13	dihydropyrimidinase like 2	Homo sapiens	56-62
29866791-0	2018	Naringenin Ameliorates Radiation-Induced Lung Injury by Lowering IL-1beta Level.	naringenin	0-10	interleukin 1 beta	Homo sapiens	65-73
29866791-6	2018	Furthermore, we found that naringenin was able to ameliorate RILI through downregulation of IL-1beta and restoration of the homeostasis of inflammatory factors.	naringenin	27-37	interleukin 1 beta	Homo sapiens	92-100
30150895-0	2018	Corrigendum to "Naringenin Protects against Acute Pancreatitis in Two Experimental Models in Mice by NLRP3 and Nrf2/HO-1 Pathways".	naringenin	16-26	NLR family, pyrin domain containing 3	Mus musculus	101-106
30150895-0	2018	Corrigendum to "Naringenin Protects against Acute Pancreatitis in Two Experimental Models in Mice by NLRP3 and Nrf2/HO-1 Pathways".	naringenin	16-26	nuclear factor, erythroid derived 2, like 2	Mus musculus	111-115
30150895-0	2018	Corrigendum to "Naringenin Protects against Acute Pancreatitis in Two Experimental Models in Mice by NLRP3 and Nrf2/HO-1 Pathways".	naringenin	16-26	heme oxygenase 1	Mus musculus	116-120
29684853-0	2018	Naringenin improve hepatitis C virus infection induced insulin resistance by increase PTEN expression via p53-dependent manner.	naringenin	0-10	phosphatase and tensin homolog	Homo sapiens	86-90
29684853-0	2018	Naringenin improve hepatitis C virus infection induced insulin resistance by increase PTEN expression via p53-dependent manner.	naringenin	0-10	tumor protein p53	Homo sapiens	106-109
29684853-2	2018	Naringenin (NGEN), a flavonoid found in grapefruit, has anti-virus, anti-inflammation and insulin sensitization effects.	naringenin	0-10	insulin	Homo sapiens	90-97
29684853-2	2018	Naringenin (NGEN), a flavonoid found in grapefruit, has anti-virus, anti-inflammation and insulin sensitization effects.	naringenin	12-16	insulin	Homo sapiens	90-97
29215718-7	2018	The proliferation of CFs and increased expressions of fibrotic markers induced by elevated hydrostatic pressure could be reversed by the Smad3 inhibitor naringenin.	naringenin	153-163	SMAD family member 3	Rattus norvegicus	137-142
29626522-7	2018	In subcellular fractions hesperetin and naringenin inhibited the activity of glucose 6-phosphatase and glucokinase and the mitochondrial respiration linked to ADP phosphorylation.	naringenin	40-50	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	77-98
29626522-7	2018	In subcellular fractions hesperetin and naringenin inhibited the activity of glucose 6-phosphatase and glucokinase and the mitochondrial respiration linked to ADP phosphorylation.	naringenin	40-50	glucokinase	Rattus norvegicus	103-114
29861831-9	2018	Genistein, daidzein, phloretin, ellagic acid, ursolic acid, (-)-epigallocatechin-3-gallate, kaempferol, and naringenin exhibited different levels for antagonistic activity against ERalpha.	naringenin	108-118	estrogen receptor 1	Homo sapiens	180-187
29849498-2	2018	The aim of this study was to investigate the therapeutic effect and mechanism of naringenin (NRG) on MPP which was an important component of QTF.	naringenin	81-91	M-phase phosphoprotein 6	Homo sapiens	101-104
29140707-0	2018	Grapefruit Flavonoid Naringenin Regulates the Expression of LXRalpha in THP-1 Macrophages by Modulating AMP-Activated Protein Kinase.	naringenin	21-31	nuclear receptor subfamily 1 group H member 3	Homo sapiens	60-68
29140707-0	2018	Grapefruit Flavonoid Naringenin Regulates the Expression of LXRalpha in THP-1 Macrophages by Modulating AMP-Activated Protein Kinase.	naringenin	21-31	GLI family zinc finger 2	Homo sapiens	72-77
29140707-1	2018	The present work investigates the modulation of grapefruit flavonoid naringenin over liver X receptor alpha (LXRalpha) and its target genes in THP-1 macrophages, focusing on AMP-activated protein kinase (AMPK) implication.	naringenin	69-79	nuclear receptor subfamily 1 group H member 3	Homo sapiens	109-117
29140707-2	2018	Naringenin induced LXRalpha at mRNA and protein levels besides influencing the expression of LXRalpha target genes ABCA1, ABCG1 (ATP-binding cassette A1 and G1), and SREBP1c (sterol response element binding protein 1c) in THP-1 macrophages.	naringenin	0-10	nuclear receptor subfamily 1 group H member 3	Homo sapiens	19-27
29140707-2	2018	Naringenin induced LXRalpha at mRNA and protein levels besides influencing the expression of LXRalpha target genes ABCA1, ABCG1 (ATP-binding cassette A1 and G1), and SREBP1c (sterol response element binding protein 1c) in THP-1 macrophages.	naringenin	0-10	nuclear receptor subfamily 1 group H member 3	Homo sapiens	93-101
29140707-2	2018	Naringenin induced LXRalpha at mRNA and protein levels besides influencing the expression of LXRalpha target genes ABCA1, ABCG1 (ATP-binding cassette A1 and G1), and SREBP1c (sterol response element binding protein 1c) in THP-1 macrophages.	naringenin	0-10	ATP binding cassette subfamily A member 1	Homo sapiens	115-120
29140707-2	2018	Naringenin induced LXRalpha at mRNA and protein levels besides influencing the expression of LXRalpha target genes ABCA1, ABCG1 (ATP-binding cassette A1 and G1), and SREBP1c (sterol response element binding protein 1c) in THP-1 macrophages.	naringenin	0-10	ATP binding cassette subfamily G member 1	Homo sapiens	122-127
29140707-2	2018	Naringenin induced LXRalpha at mRNA and protein levels besides influencing the expression of LXRalpha target genes ABCA1, ABCG1 (ATP-binding cassette A1 and G1), and SREBP1c (sterol response element binding protein 1c) in THP-1 macrophages.	naringenin	0-10	sterol regulatory element binding transcription factor 1	Homo sapiens	166-173
29140707-2	2018	Naringenin induced LXRalpha at mRNA and protein levels besides influencing the expression of LXRalpha target genes ABCA1, ABCG1 (ATP-binding cassette A1 and G1), and SREBP1c (sterol response element binding protein 1c) in THP-1 macrophages.	naringenin	0-10	sterol regulatory element binding transcription factor 1	Homo sapiens	175-217
29140707-2	2018	Naringenin induced LXRalpha at mRNA and protein levels besides influencing the expression of LXRalpha target genes ABCA1, ABCG1 (ATP-binding cassette A1 and G1), and SREBP1c (sterol response element binding protein 1c) in THP-1 macrophages.	naringenin	0-10	GLI family zinc finger 2	Homo sapiens	222-227
29140707-4	2018	Naringenin treatments were also able to promote reverse cholesterol transport in THP-1 cells, which is in line with the increase in the ABCA1 and ABCG1 expression found.	naringenin	0-10	GLI family zinc finger 2	Homo sapiens	81-86
29140707-4	2018	Naringenin treatments were also able to promote reverse cholesterol transport in THP-1 cells, which is in line with the increase in the ABCA1 and ABCG1 expression found.	naringenin	0-10	ATP binding cassette subfamily A member 1	Homo sapiens	136-141
29140707-4	2018	Naringenin treatments were also able to promote reverse cholesterol transport in THP-1 cells, which is in line with the increase in the ABCA1 and ABCG1 expression found.	naringenin	0-10	ATP binding cassette subfamily G member 1	Homo sapiens	146-151
29140707-6	2018	In conclusion, LXRalpha and its target genes are up-regulated by naringenin in an AMPK dependent manner in human macrophages.	naringenin	65-75	nuclear receptor subfamily 1 group H member 3	Homo sapiens	15-23
29140707-6	2018	In conclusion, LXRalpha and its target genes are up-regulated by naringenin in an AMPK dependent manner in human macrophages.	naringenin	65-75	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	82-86
29713125-5	2018	The main protective effects of naringenin in liver diseases are the inhibition of oxidative stress, transforming growth factor (TGF-beta) pathway and the prevention of the transdifferentiation of hepatic stellate cells (HSC), leading to decreased collagen synthesis.	naringenin	31-41	transforming growth factor beta 1	Homo sapiens	128-136
29713125-8	2018	Moreover, naringenin protects from HCC, since it inhibits growth factors such as TGF-beta and vascular endothelial growth factor (VEGF), inducing apoptosis and regulating MAPK pathways.	naringenin	10-20	transforming growth factor beta 1	Homo sapiens	81-89
29713125-8	2018	Moreover, naringenin protects from HCC, since it inhibits growth factors such as TGF-beta and vascular endothelial growth factor (VEGF), inducing apoptosis and regulating MAPK pathways.	naringenin	10-20	vascular endothelial growth factor A	Homo sapiens	94-128
29713125-8	2018	Moreover, naringenin protects from HCC, since it inhibits growth factors such as TGF-beta and vascular endothelial growth factor (VEGF), inducing apoptosis and regulating MAPK pathways.	naringenin	10-20	vascular endothelial growth factor A	Homo sapiens	130-134
29849486-0	2018	Naringenin Protects against Acute Pancreatitis in Two Experimental Models in Mice by NLRP3 and Nrf2/HO-1 Pathways.	naringenin	0-10	NLR family, pyrin domain containing 3	Mus musculus	85-90
29849486-0	2018	Naringenin Protects against Acute Pancreatitis in Two Experimental Models in Mice by NLRP3 and Nrf2/HO-1 Pathways.	naringenin	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	95-99
29849486-0	2018	Naringenin Protects against Acute Pancreatitis in Two Experimental Models in Mice by NLRP3 and Nrf2/HO-1 Pathways.	naringenin	0-10	heme oxygenase 1	Mus musculus	100-104
29518393-8	2018	Furthermore, naringenin lowered hippocampal malondialdehyde (MDA) as an index of lipid peroxidation and improved antioxidant defensive system comprising superoxide dismutase (SOD), catalase, and glutathione (GSH) in addition to decreasing acetylcholinesterase (AChE) activity.	naringenin	13-23	catalase	Rattus norvegicus	181-189
29518393-8	2018	Furthermore, naringenin lowered hippocampal malondialdehyde (MDA) as an index of lipid peroxidation and improved antioxidant defensive system comprising superoxide dismutase (SOD), catalase, and glutathione (GSH) in addition to decreasing acetylcholinesterase (AChE) activity.	naringenin	13-23	acetylcholinesterase	Rattus norvegicus	239-259
29518393-8	2018	Furthermore, naringenin lowered hippocampal malondialdehyde (MDA) as an index of lipid peroxidation and improved antioxidant defensive system comprising superoxide dismutase (SOD), catalase, and glutathione (GSH) in addition to decreasing acetylcholinesterase (AChE) activity.	naringenin	13-23	acetylcholinesterase	Rattus norvegicus	261-265
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	toll-like receptor 4	Rattus norvegicus	90-110
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	toll-like receptor 4	Rattus norvegicus	112-116
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	tumor necrosis factor	Rattus norvegicus	119-146
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	tumor necrosis factor	Rattus norvegicus	148-156
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	159-175
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	177-181
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	nitric oxide synthase 2	Rattus norvegicus	184-215
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	nitric oxide synthase 2	Rattus norvegicus	217-221
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	glial fibrillary acidic protein	Rattus norvegicus	224-255
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	glial fibrillary acidic protein	Rattus norvegicus	257-261
29518393-9	2018	Additionally, naringenin was able to lower hippocampal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP) level and its immunoreactivity, and to elevate nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	naringenin	14-24	NFE2 like bZIP transcription factor 2	Rattus norvegicus	355-359
29518393-10	2018	Taken together, naringenin could alleviate LPS-induced cognitive deficits and neuroinflammation, as was evident from attenuation of oxidative stress and AChE and modulation of Nrf2/NF-kappaB/TNFalpha/COX2/iNOS/TLR4/GFAP.	naringenin	16-26	acetylcholinesterase	Rattus norvegicus	153-157
29518393-10	2018	Taken together, naringenin could alleviate LPS-induced cognitive deficits and neuroinflammation, as was evident from attenuation of oxidative stress and AChE and modulation of Nrf2/NF-kappaB/TNFalpha/COX2/iNOS/TLR4/GFAP.	naringenin	16-26	NFE2 like bZIP transcription factor 2	Rattus norvegicus	176-180
29518393-10	2018	Taken together, naringenin could alleviate LPS-induced cognitive deficits and neuroinflammation, as was evident from attenuation of oxidative stress and AChE and modulation of Nrf2/NF-kappaB/TNFalpha/COX2/iNOS/TLR4/GFAP.	naringenin	16-26	tumor necrosis factor	Rattus norvegicus	191-199
29518393-10	2018	Taken together, naringenin could alleviate LPS-induced cognitive deficits and neuroinflammation, as was evident from attenuation of oxidative stress and AChE and modulation of Nrf2/NF-kappaB/TNFalpha/COX2/iNOS/TLR4/GFAP.	naringenin	16-26	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	200-204
29518393-10	2018	Taken together, naringenin could alleviate LPS-induced cognitive deficits and neuroinflammation, as was evident from attenuation of oxidative stress and AChE and modulation of Nrf2/NF-kappaB/TNFalpha/COX2/iNOS/TLR4/GFAP.	naringenin	16-26	nitric oxide synthase 2	Rattus norvegicus	205-209
29518393-10	2018	Taken together, naringenin could alleviate LPS-induced cognitive deficits and neuroinflammation, as was evident from attenuation of oxidative stress and AChE and modulation of Nrf2/NF-kappaB/TNFalpha/COX2/iNOS/TLR4/GFAP.	naringenin	16-26	toll-like receptor 4	Rattus norvegicus	210-214
29518393-10	2018	Taken together, naringenin could alleviate LPS-induced cognitive deficits and neuroinflammation, as was evident from attenuation of oxidative stress and AChE and modulation of Nrf2/NF-kappaB/TNFalpha/COX2/iNOS/TLR4/GFAP.	naringenin	16-26	glial fibrillary acidic protein	Rattus norvegicus	215-219
29345053-9	2018	Administration of Naringenin ameliorated the development of DMH-induced lipid peroxidation, ROS formation, precancerous lesions (ACF and MDF) and it also reduced the infiltration of mast cells, suppressed the immunostaining of NF-kappaB-p65, COX-2, i-NOS PCNA and Ki 67 Naringenin treatment significantly attenuated the level of TNF-alpha and it also prevented the depletion of the mucous layer.	naringenin	18-28	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	242-247
29345053-9	2018	Administration of Naringenin ameliorated the development of DMH-induced lipid peroxidation, ROS formation, precancerous lesions (ACF and MDF) and it also reduced the infiltration of mast cells, suppressed the immunostaining of NF-kappaB-p65, COX-2, i-NOS PCNA and Ki 67 Naringenin treatment significantly attenuated the level of TNF-alpha and it also prevented the depletion of the mucous layer.	naringenin	18-28	proliferating cell nuclear antigen	Rattus norvegicus	255-259
29345053-9	2018	Administration of Naringenin ameliorated the development of DMH-induced lipid peroxidation, ROS formation, precancerous lesions (ACF and MDF) and it also reduced the infiltration of mast cells, suppressed the immunostaining of NF-kappaB-p65, COX-2, i-NOS PCNA and Ki 67 Naringenin treatment significantly attenuated the level of TNF-alpha and it also prevented the depletion of the mucous layer.	naringenin	18-28	tumor necrosis factor	Rattus norvegicus	329-338
29331869-7	2018	We further showed that pathologic T cell proliferation induced by ex vivo re-stimulation with MOG35-55 and proinflammatory cytokines IL-6 and TNF-alpha were lower in naringenin-fed mice than in the control mice.	naringenin	166-176	interleukin 6	Mus musculus	133-137
29411263-0	2018	Naringenin Exerts Anti-inflammatory Effects in Paraquat-Treated SH-SY5Y Cells Through a Mechanism Associated with the Nrf2/HO-1 Axis.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	118-122
29411263-0	2018	Naringenin Exerts Anti-inflammatory Effects in Paraquat-Treated SH-SY5Y Cells Through a Mechanism Associated with the Nrf2/HO-1 Axis.	naringenin	0-10	heme oxygenase 1	Homo sapiens	123-127
29411263-2	2018	NGN is a potent inducer of the nuclear factor erythroid 2-related factor 2 (Nrf2) and upregulates the expression of heme oxygenase-1 (HO-1), an enzyme exhibiting both antioxidant and anti-inflammatory effects.	naringenin	0-3	NFE2 like bZIP transcription factor 2	Homo sapiens	31-74
29411263-2	2018	NGN is a potent inducer of the nuclear factor erythroid 2-related factor 2 (Nrf2) and upregulates the expression of heme oxygenase-1 (HO-1), an enzyme exhibiting both antioxidant and anti-inflammatory effects.	naringenin	0-3	NFE2 like bZIP transcription factor 2	Homo sapiens	76-80
29411263-2	2018	NGN is a potent inducer of the nuclear factor erythroid 2-related factor 2 (Nrf2) and upregulates the expression of heme oxygenase-1 (HO-1), an enzyme exhibiting both antioxidant and anti-inflammatory effects.	naringenin	0-3	heme oxygenase 1	Homo sapiens	116-132
29411263-2	2018	NGN is a potent inducer of the nuclear factor erythroid 2-related factor 2 (Nrf2) and upregulates the expression of heme oxygenase-1 (HO-1), an enzyme exhibiting both antioxidant and anti-inflammatory effects.	naringenin	0-3	heme oxygenase 1	Homo sapiens	134-138
29411263-6	2018	We found that a pretreatment with NGN at 80 microM for 2 h decreased the levels of pro-inflammatory cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in PQ-treated SH-SY5Y cells.	naringenin	34-37	interleukin 1 beta	Homo sapiens	110-127
29411263-6	2018	We found that a pretreatment with NGN at 80 microM for 2 h decreased the levels of pro-inflammatory cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in PQ-treated SH-SY5Y cells.	naringenin	34-37	interleukin 1 beta	Homo sapiens	129-137
29411263-6	2018	We found that a pretreatment with NGN at 80 microM for 2 h decreased the levels of pro-inflammatory cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in PQ-treated SH-SY5Y cells.	naringenin	34-37	tumor necrosis factor	Homo sapiens	143-170
29411263-6	2018	We found that a pretreatment with NGN at 80 microM for 2 h decreased the levels of pro-inflammatory cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in PQ-treated SH-SY5Y cells.	naringenin	34-37	tumor necrosis factor	Homo sapiens	172-181
29411263-9	2018	The anti-apoptotic and anti-inflammatory effects promoted by NGN were abolished by ZnPP IX (a specific inhibitor of HO-1) or by knockdown of Nrf2 by small interfering RNA (siRNA).	naringenin	61-64	heme oxygenase 1	Homo sapiens	116-120
29411263-9	2018	The anti-apoptotic and anti-inflammatory effects promoted by NGN were abolished by ZnPP IX (a specific inhibitor of HO-1) or by knockdown of Nrf2 by small interfering RNA (siRNA).	naringenin	61-64	NFE2 like bZIP transcription factor 2	Homo sapiens	141-145
29411263-10	2018	Therefore, NGN induced anti-inflammatory effects in PQ-treated SH-SY5Y cells by a mechanism associated with the Nrf2/HO-1 signaling pathway.	naringenin	11-14	NFE2 like bZIP transcription factor 2	Homo sapiens	112-116
29411263-10	2018	Therefore, NGN induced anti-inflammatory effects in PQ-treated SH-SY5Y cells by a mechanism associated with the Nrf2/HO-1 signaling pathway.	naringenin	11-14	heme oxygenase 1	Homo sapiens	117-121
29427283-0	2018	Naringenin Decreases alpha-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson"s Disease Model in Mice.	naringenin	0-10	synuclein, alpha	Mus musculus	21-36
29427283-1	2018	The present study was designed to ascertain the role of naringenin (NGN), a citrus fruit flavanone, against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced alpha-synuclein (SYN) pathology and neuroinflammation in a mouse model.	naringenin	56-66	synuclein, alpha	Mus musculus	168-183
29427283-1	2018	The present study was designed to ascertain the role of naringenin (NGN), a citrus fruit flavanone, against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced alpha-synuclein (SYN) pathology and neuroinflammation in a mouse model.	naringenin	56-66	synemin, intermediate filament protein	Mus musculus	185-188
29427283-1	2018	The present study was designed to ascertain the role of naringenin (NGN), a citrus fruit flavanone, against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced alpha-synuclein (SYN) pathology and neuroinflammation in a mouse model.	naringenin	68-71	synuclein, alpha	Mus musculus	168-183
29427283-1	2018	The present study was designed to ascertain the role of naringenin (NGN), a citrus fruit flavanone, against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced alpha-synuclein (SYN) pathology and neuroinflammation in a mouse model.	naringenin	68-71	synemin, intermediate filament protein	Mus musculus	185-188
29744232-4	2018	In this study, affinity capillary electrophoresis (ACE) and in silico molecular docking methods were developed to study the interaction between thrombin and ten phenolic compounds (p-hydroxybenzoic acid, protocatechuic acid, vanillic acid, gallic acid, catechin, epicatechin, dihydroquercetin, naringenin, apigenin, and baicalein).	naringenin	294-304	coagulation factor II, thrombin	Homo sapiens	144-152
28525714-6	2018	In contrast, naringenin and 5,7-dihydroxy-4(4-hydroxyphenyl)chroman-2-one neither reduced the caffeine-induced proton secretion in HGT-1 cells nor showed an effect on bitter intensity perceived by the sensory panel.	naringenin	13-23	solute carrier family 25 member 16	Homo sapiens	131-136
28699113-0	2018	Protective Role Of Naringenin Against Abeta25-35-Caused Damage via ER and PI3K/Akt-Mediated Pathways.	naringenin	19-29	AKT serine/threonine kinase 1	Rattus norvegicus	79-82
28699113-5	2018	We found that naringenin protected cell against Abeta25-35-caused nerve damage by increasing cell viability, promoting Akt and GSK3beta activation, and inhibiting cell apoptosis and caspase-3 activity.	naringenin	14-24	AKT serine/threonine kinase 1	Rattus norvegicus	119-122
28699113-5	2018	We found that naringenin protected cell against Abeta25-35-caused nerve damage by increasing cell viability, promoting Akt and GSK3beta activation, and inhibiting cell apoptosis and caspase-3 activity.	naringenin	14-24	glycogen synthase kinase 3 beta	Rattus norvegicus	127-135
28699113-5	2018	We found that naringenin protected cell against Abeta25-35-caused nerve damage by increasing cell viability, promoting Akt and GSK3beta activation, and inhibiting cell apoptosis and caspase-3 activity.	naringenin	14-24	caspase 3	Rattus norvegicus	182-191
28699113-6	2018	However, treatment with the estrogen receptor (ER) antagonist ICI182, 780 or phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 suppressed the effects of naringenin.	naringenin	159-169	estrogen receptor 1	Rattus norvegicus	28-45
28699113-6	2018	However, treatment with the estrogen receptor (ER) antagonist ICI182, 780 or phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 suppressed the effects of naringenin.	naringenin	159-169	estrogen receptor 1	Rattus norvegicus	47-49
28699113-6	2018	However, treatment with the estrogen receptor (ER) antagonist ICI182, 780 or phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 suppressed the effects of naringenin.	naringenin	159-169	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	Rattus norvegicus	77-106
28699113-7	2018	Our results suggested that naringenin could effectively suppress Abeta25-35-caused nerve damage in PC12 cells by regulating the ER and PI3K/Akt pathways.	naringenin	27-37	AKT serine/threonine kinase 1	Rattus norvegicus	140-143
28808887-0	2018	Chronic Silymarin, Quercetin and Naringenin Treatments Increase Monoamines Synthesis and Hippocampal Sirt1 Levels Improving Cognition in Aged Rats.	naringenin	33-43	sirtuin 1	Rattus norvegicus	101-106
28834554-0	2018	Naringenin inhibits osteoclastogenesis through modulation of helper T cells-secreted IL-4.	naringenin	0-10	interleukin 4	Homo sapiens	85-89
29223569-0	2018	Isolated mangiferin and naringenin exert antidiabetic effect via PPARgamma/GLUT4 dual agonistic action with strong metabolic regulation.	naringenin	24-34	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	65-74
29223569-0	2018	Isolated mangiferin and naringenin exert antidiabetic effect via PPARgamma/GLUT4 dual agonistic action with strong metabolic regulation.	naringenin	24-34	solute carrier family 2 member 4	Rattus norvegicus	75-80
29198856-1	2018	Naringenin, a flavanone found in citrus fruits, is mainly metabolized into glucuronide(s) by UDP-glucuronosyltransferase (UGT) enzymes in mammals.	naringenin	0-10	UDP glycosyltransferase 2 family, polypeptide B	Rattus norvegicus	93-120
29198856-1	2018	Naringenin, a flavanone found in citrus fruits, is mainly metabolized into glucuronide(s) by UDP-glucuronosyltransferase (UGT) enzymes in mammals.	naringenin	0-10	UDP glycosyltransferase 2 family, polypeptide B	Rattus norvegicus	122-125
29198856-10	2018	These results suggest that the metabolic abilities and regioselectivity of UGT enzymes toward naringenin in the liver and intestines generally differ between primates and rodents.	naringenin	94-104	UDP glycosyltransferase 2 family, polypeptide B	Rattus norvegicus	75-78
29193236-0	2018	Inhibitory effect of naringenin via IL-13 level regulation on thymic stromal lymphopoietin-induced inflammatory reactions.	naringenin	21-31	interleukin 13	Homo sapiens	36-41
29193236-0	2018	Inhibitory effect of naringenin via IL-13 level regulation on thymic stromal lymphopoietin-induced inflammatory reactions.	naringenin	21-31	thymic stromal lymphopoietin	Homo sapiens	62-90
29193236-3	2018	The aim of this study was to investigate the regulatory effect of NG on TSLP-induced mast cell proliferation and inflammatory reactions using human mast cell line (HMC-1) cells.	naringenin	66-68	thymic stromal lymphopoietin	Homo sapiens	72-76
29207043-0	2018	Naringenin induces laxative effects by upregulating the expression levels of c-Kit and SCF, as well as those of aquaporin 3 in mice with loperamide-induced constipation.	naringenin	0-10	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	77-82
29207043-0	2018	Naringenin induces laxative effects by upregulating the expression levels of c-Kit and SCF, as well as those of aquaporin 3 in mice with loperamide-induced constipation.	naringenin	0-10	kit ligand	Mus musculus	87-90
29154867-5	2018	Compound 1 demonstrated preferential inhibition against hMAO-A isoenzyme (IC50 0.62muM, SIA/B 0.02) while S-naringenin (13) and isoliquiritigein (15) demonstrated preferential hMAO-B inhibition (IC50 0.27 and 0.51muM, SIA/B 31.77 and 44.69, respectively).	naringenin	106-118	monoamine oxidase B	Homo sapiens	176-182
29154867-8	2018	It suggested that 1 interacts with Gln215, Ala111, Phe352, and Phe208 amino acid residues which have a role in the orientation and stabilization of the inhibitor binding to hMAO-A, while S-naringenin (13) occupies both entrance and substrate cavities and interacts with Tyr326, a critical residue in inhibitor recognition in hMAO-B.	naringenin	189-199	monoamine oxidase B	Homo sapiens	325-331
29331869-7	2018	We further showed that pathologic T cell proliferation induced by ex vivo re-stimulation with MOG35-55 and proinflammatory cytokines IL-6 and TNF-alpha were lower in naringenin-fed mice than in the control mice.	naringenin	166-176	tumor necrosis factor	Mus musculus	142-151
29331869-8	2018	Additionally, we found that naringenin treatment inhibited mRNA expression of CXCL10 (Th1 recruiting chemokine), vascular cell adhesion molecule-1 (VCAM-1), and VLA-4 (VCAM-1 ligand) in the CNS of EAE mice.	naringenin	28-38	chemokine (C-X-C motif) ligand 10	Mus musculus	78-84
29331869-8	2018	Additionally, we found that naringenin treatment inhibited mRNA expression of CXCL10 (Th1 recruiting chemokine), vascular cell adhesion molecule-1 (VCAM-1), and VLA-4 (VCAM-1 ligand) in the CNS of EAE mice.	naringenin	28-38	negative elongation factor complex member C/D, Th1l	Mus musculus	86-89
29331869-8	2018	Additionally, we found that naringenin treatment inhibited mRNA expression of CXCL10 (Th1 recruiting chemokine), vascular cell adhesion molecule-1 (VCAM-1), and VLA-4 (VCAM-1 ligand) in the CNS of EAE mice.	naringenin	28-38	vascular cell adhesion molecule 1	Mus musculus	113-146
29331869-8	2018	Additionally, we found that naringenin treatment inhibited mRNA expression of CXCL10 (Th1 recruiting chemokine), vascular cell adhesion molecule-1 (VCAM-1), and VLA-4 (VCAM-1 ligand) in the CNS of EAE mice.	naringenin	28-38	vascular cell adhesion molecule 1	Mus musculus	148-154
29331869-8	2018	Additionally, we found that naringenin treatment inhibited mRNA expression of CXCL10 (Th1 recruiting chemokine), vascular cell adhesion molecule-1 (VCAM-1), and VLA-4 (VCAM-1 ligand) in the CNS of EAE mice.	naringenin	28-38	vascular cell adhesion molecule 1	Mus musculus	168-174
32625330-0	2017	Scientific Opinion of Flavouring Group Evaluation 410 (FGE.410): 4",5,7-trihydroxyflavanone from chemical group 25 (phenol derivatives containing ring-alkyl, ring-alkoxy, and side-chains with an oxygenated functional group).	naringenin	65-91	sulfatase modifying factor 1	Homo sapiens	55-58
29121349-11	2017	Furthermore, the induction of apoptosis by naringenin involved activation of MAPK and inactivation of PI3K pathways in VK2/E6E7 and End1/E6E7 cells.	naringenin	43-53	VPS11 core subunit of CORVET and HOPS complexes	Homo sapiens	132-136
29183361-3	2017	METHODS: Nar was administered by oral gavage to HBx-transgenic mice from 4 to 6 weeks of age.	naringenin	9-12	X protein	Hepatitis B virus	48-51
29183361-6	2017	RESULTS: Nar counteracted hepatic lipid accumulation and liver dysfunction in HBx-transgenic mice.	naringenin	9-12	X protein	Hepatitis B virus	78-81
29183361-8	2017	These results indicated that naringenin inhibits HBx-induced expression of hepatic adipogenic and lipogenic genes through suppression of HBx-induced gene expression, including decreases in the transcriptional activity of SREBP1c, LXRalpha, and PPARgamma in HBx-trangenic mice and HBx-transfected HepG2 cells.	naringenin	29-39	X protein	Hepatitis B virus	49-52
29183361-8	2017	These results indicated that naringenin inhibits HBx-induced expression of hepatic adipogenic and lipogenic genes through suppression of HBx-induced gene expression, including decreases in the transcriptional activity of SREBP1c, LXRalpha, and PPARgamma in HBx-trangenic mice and HBx-transfected HepG2 cells.	naringenin	29-39	X protein	Hepatitis B virus	137-140
29183361-8	2017	These results indicated that naringenin inhibits HBx-induced expression of hepatic adipogenic and lipogenic genes through suppression of HBx-induced gene expression, including decreases in the transcriptional activity of SREBP1c, LXRalpha, and PPARgamma in HBx-trangenic mice and HBx-transfected HepG2 cells.	naringenin	29-39	sterol regulatory element binding transcription factor 1	Mus musculus	221-228
29183361-8	2017	These results indicated that naringenin inhibits HBx-induced expression of hepatic adipogenic and lipogenic genes through suppression of HBx-induced gene expression, including decreases in the transcriptional activity of SREBP1c, LXRalpha, and PPARgamma in HBx-trangenic mice and HBx-transfected HepG2 cells.	naringenin	29-39	nuclear receptor subfamily 1, group H, member 3	Mus musculus	230-238
29183361-8	2017	These results indicated that naringenin inhibits HBx-induced expression of hepatic adipogenic and lipogenic genes through suppression of HBx-induced gene expression, including decreases in the transcriptional activity of SREBP1c, LXRalpha, and PPARgamma in HBx-trangenic mice and HBx-transfected HepG2 cells.	naringenin	29-39	peroxisome proliferator activated receptor gamma	Mus musculus	244-253
29183361-8	2017	These results indicated that naringenin inhibits HBx-induced expression of hepatic adipogenic and lipogenic genes through suppression of HBx-induced gene expression, including decreases in the transcriptional activity of SREBP1c, LXRalpha, and PPARgamma in HBx-trangenic mice and HBx-transfected HepG2 cells.	naringenin	29-39	X protein	Hepatitis B virus	137-140
29183361-8	2017	These results indicated that naringenin inhibits HBx-induced expression of hepatic adipogenic and lipogenic genes through suppression of HBx-induced gene expression, including decreases in the transcriptional activity of SREBP1c, LXRalpha, and PPARgamma in HBx-trangenic mice and HBx-transfected HepG2 cells.	naringenin	29-39	X protein	Hepatitis B virus	137-140
29121349-0	2017	Naringenin induces mitochondria-mediated apoptosis and endoplasmic reticulum stress by regulating MAPK and AKT signal transduction pathways in endometriosis cells.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	107-110
29121349-6	2017	Effects of naringenin on VK2/E6E7 and End1/E6E7 cells were assessed in diverse assays in a dose- and time-dependent manner.	naringenin	11-21	VPS11 core subunit of CORVET and HOPS complexes	Homo sapiens	38-42
29121349-8	2017	Signal transduction pathways in VK2/E6E7 and End1/E6E7 cells in response to naringenin were determined by western blot analyses.	naringenin	76-86	VPS11 core subunit of CORVET and HOPS complexes	Homo sapiens	45-49
29121349-9	2017	MAIN RESULTS AND THE ROLE OF CHANCE: In the present study, we demonstrated that naringenin suppressed proliferation and increased apoptosis through depolarization of mitochondrial membrane potential and inducing pro-apoptotic proteins, Bax and Bak, in both endometriosis cell lines.	naringenin	80-90	BCL2 associated X, apoptosis regulator	Homo sapiens	236-239
29121349-10	2017	In addition, naringenin increased ROS, ER stress, through activation of eIF2alpha and IRE1alpha, GADD153 and GRP78 proteins in a dose-dependent manner.	naringenin	13-23	eukaryotic translation initiation factor 2A	Homo sapiens	72-81
29121349-10	2017	In addition, naringenin increased ROS, ER stress, through activation of eIF2alpha and IRE1alpha, GADD153 and GRP78 proteins in a dose-dependent manner.	naringenin	13-23	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	86-95
29121349-10	2017	In addition, naringenin increased ROS, ER stress, through activation of eIF2alpha and IRE1alpha, GADD153 and GRP78 proteins in a dose-dependent manner.	naringenin	13-23	DNA damage inducible transcript 3	Homo sapiens	97-104
29121349-10	2017	In addition, naringenin increased ROS, ER stress, through activation of eIF2alpha and IRE1alpha, GADD153 and GRP78 proteins in a dose-dependent manner.	naringenin	13-23	heat shock protein family A (Hsp70) member 5	Homo sapiens	109-114
32625330-1	2017	The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) of EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 4",5,7-trihydroxyflavanone or naringenin [FL-no: 16.132], in the Flavouring Group Evaluation 410 (FGE.410), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council.	naringenin	203-229	sulfatase modifying factor 1	Homo sapiens	301-304
28949376-0	2017	Naringenin reduces oxidative stress and improves mitochondrial dysfunction via activation of the Nrf2/ARE signaling pathway in neurons.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	97-101
28993518-5	2017	Unexpectedly, naringenin inhibits TNF-alpha and IL-6 secretion in macrophages and T cells without interfering with the TLR signaling cascade, cytokine mRNA stability, or protein translation.	naringenin	14-24	tumor necrosis factor	Homo sapiens	34-43
28993518-5	2017	Unexpectedly, naringenin inhibits TNF-alpha and IL-6 secretion in macrophages and T cells without interfering with the TLR signaling cascade, cytokine mRNA stability, or protein translation.	naringenin	14-24	interleukin 6	Homo sapiens	48-52
28993518-7	2017	Further studies show that naringenin enhances intracellular cytokine degradation through lysosome- and TFEB-dependent mechanisms.	naringenin	26-36	transcription factor EB	Homo sapiens	103-107
29048675-5	2017	Naringenin significantly reduced alcoholic liver morphological phenotypes and the expression of alcohol and lipid metabolism-related genes, including cyp2y3, cyp3a65, hmgcra, hmgcrb, fasn, fabp10alpha, fads2 and echs1, in zebrafish larvae.	naringenin	0-10	cytochrome P450, family 2, subfamily Y, polypeptide 3	Danio rerio	150-156
29117277-5	2017	Results: Naringenin eye drops inhibited alkali burn-induced neutrophil (myeloperoxidase activity and recruitment of Lysm-GFP+ cells) and macrophage (N-acetyl-beta-D glucosaminidase activity) recruitment into the eye, decrease in epithelial thickness, and neovascularization in the cornea.	naringenin	9-19	lysozyme 2	Mus musculus	116-120
29117277-6	2017	Further, naringenin inhibited alkali-induced cytokine (IL-1beta and IL-6) production, Vegf, Pdgf, and Mmp14 mRNA expression, and the reduction of ferric reducing antioxidant power and Azinobis-(3-Ethylbenzothiazoline 6-Sulfonic acid) radical scavenging capacity as well as increased the reduced glutathione and protein-bound sulfhydryl groups levels.	naringenin	9-19	interleukin 1 beta	Mus musculus	55-63
29117277-6	2017	Further, naringenin inhibited alkali-induced cytokine (IL-1beta and IL-6) production, Vegf, Pdgf, and Mmp14 mRNA expression, and the reduction of ferric reducing antioxidant power and Azinobis-(3-Ethylbenzothiazoline 6-Sulfonic acid) radical scavenging capacity as well as increased the reduced glutathione and protein-bound sulfhydryl groups levels.	naringenin	9-19	interleukin 6	Mus musculus	68-72
29117277-6	2017	Further, naringenin inhibited alkali-induced cytokine (IL-1beta and IL-6) production, Vegf, Pdgf, and Mmp14 mRNA expression, and the reduction of ferric reducing antioxidant power and Azinobis-(3-Ethylbenzothiazoline 6-Sulfonic acid) radical scavenging capacity as well as increased the reduced glutathione and protein-bound sulfhydryl groups levels.	naringenin	9-19	vascular endothelial growth factor A	Mus musculus	86-90
29117277-6	2017	Further, naringenin inhibited alkali-induced cytokine (IL-1beta and IL-6) production, Vegf, Pdgf, and Mmp14 mRNA expression, and the reduction of ferric reducing antioxidant power and Azinobis-(3-Ethylbenzothiazoline 6-Sulfonic acid) radical scavenging capacity as well as increased the reduced glutathione and protein-bound sulfhydryl groups levels.	naringenin	9-19	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	102-107
28622086-0	2017	Naringenin Ameliorates Behavioral Dysfunction and Neurological Deficits in a d-Galactose-Induced Aging Mouse Model Through Activation of PI3K/Akt/Nrf2 Pathway.	naringenin	0-10	thymoma viral proto-oncogene 1	Mus musculus	142-145
28622086-0	2017	Naringenin Ameliorates Behavioral Dysfunction and Neurological Deficits in a d-Galactose-Induced Aging Mouse Model Through Activation of PI3K/Akt/Nrf2 Pathway.	naringenin	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	146-150
28622086-4	2017	Furthermore, naringenin markedly activated PI3K/Akt signaling, eventually promoted the nuclear translocation of nuclear factor-erythroid 2-related factor 2, and induced the expression of heme oxygenase 1 and NAD(P)H-quinone oxidoreductase 1.	naringenin	13-23	thymoma viral proto-oncogene 1	Mus musculus	48-51
28622086-4	2017	Furthermore, naringenin markedly activated PI3K/Akt signaling, eventually promoted the nuclear translocation of nuclear factor-erythroid 2-related factor 2, and induced the expression of heme oxygenase 1 and NAD(P)H-quinone oxidoreductase 1.	naringenin	13-23	nuclear factor, erythroid derived 2, like 2	Mus musculus	112-155
28622086-4	2017	Furthermore, naringenin markedly activated PI3K/Akt signaling, eventually promoted the nuclear translocation of nuclear factor-erythroid 2-related factor 2, and induced the expression of heme oxygenase 1 and NAD(P)H-quinone oxidoreductase 1.	naringenin	13-23	heme oxygenase 1	Mus musculus	187-240
29048675-6	2017	Naringenin also attenuated hepatic apoptosis in larvae as detected by TUNEL staining, consistent with the expression of critical biomarkers of endoplasmic reticulum stress and of DNA damage genes (chop, gadd45alphaa and edem1).	naringenin	0-10	DNA-damage-inducible transcript 3	Danio rerio	197-201
29048675-6	2017	Naringenin also attenuated hepatic apoptosis in larvae as detected by TUNEL staining, consistent with the expression of critical biomarkers of endoplasmic reticulum stress and of DNA damage genes (chop, gadd45alphaa and edem1).	naringenin	0-10	ER degradation enhancer, mannosidase alpha-like 1	Danio rerio	220-225
29048675-5	2017	Naringenin significantly reduced alcoholic liver morphological phenotypes and the expression of alcohol and lipid metabolism-related genes, including cyp2y3, cyp3a65, hmgcra, hmgcrb, fasn, fabp10alpha, fads2 and echs1, in zebrafish larvae.	naringenin	0-10	cytochrome P450, family 3, subfamily A, polypeptide 65	Danio rerio	158-165
29048675-5	2017	Naringenin significantly reduced alcoholic liver morphological phenotypes and the expression of alcohol and lipid metabolism-related genes, including cyp2y3, cyp3a65, hmgcra, hmgcrb, fasn, fabp10alpha, fads2 and echs1, in zebrafish larvae.	naringenin	0-10	3-hydroxy-3-methylglutaryl-CoA reductase a	Danio rerio	167-173
29048675-5	2017	Naringenin significantly reduced alcoholic liver morphological phenotypes and the expression of alcohol and lipid metabolism-related genes, including cyp2y3, cyp3a65, hmgcra, hmgcrb, fasn, fabp10alpha, fads2 and echs1, in zebrafish larvae.	naringenin	0-10	3-hydroxy-3-methylglutaryl-CoA reductase b	Danio rerio	175-181
29048675-5	2017	Naringenin significantly reduced alcoholic liver morphological phenotypes and the expression of alcohol and lipid metabolism-related genes, including cyp2y3, cyp3a65, hmgcra, hmgcrb, fasn, fabp10alpha, fads2 and echs1, in zebrafish larvae.	naringenin	0-10	fatty acid synthase	Danio rerio	183-187
29048675-5	2017	Naringenin significantly reduced alcoholic liver morphological phenotypes and the expression of alcohol and lipid metabolism-related genes, including cyp2y3, cyp3a65, hmgcra, hmgcrb, fasn, fabp10alpha, fads2 and echs1, in zebrafish larvae.	naringenin	0-10	fatty acid binding protein 10a, liver basic	Danio rerio	189-200
29048675-5	2017	Naringenin significantly reduced alcoholic liver morphological phenotypes and the expression of alcohol and lipid metabolism-related genes, including cyp2y3, cyp3a65, hmgcra, hmgcrb, fasn, fabp10alpha, fads2 and echs1, in zebrafish larvae.	naringenin	0-10	fatty acid desaturase 2	Danio rerio	202-207
29048675-5	2017	Naringenin significantly reduced alcoholic liver morphological phenotypes and the expression of alcohol and lipid metabolism-related genes, including cyp2y3, cyp3a65, hmgcra, hmgcrb, fasn, fabp10alpha, fads2 and echs1, in zebrafish larvae.	naringenin	0-10	enoyl CoA hydratase, short chain, 1, mitochondrial	Danio rerio	212-217
28783583-4	2017	On the other hand, berberine and naringenin supplementation to diabetic animals improved brain IRS 1 levels and restored GLUT 1 and GLUT 3 expression without significant effect on PI3K and Akt 1 activation and GLUT 4 levels.	naringenin	33-43	insulin receptor substrate 1	Rattus norvegicus	95-100
29064407-8	2017	Moreover, decreased levels of neuroprotective factors (Brain derived neurotrophic factor (BDNF)), tropomyosin related kinase B (TrkB) and synaptophysin in diabetic retina were augmented with naringenin treatments.	naringenin	191-201	brain-derived neurotrophic factor	Rattus norvegicus	55-88
29064407-8	2017	Moreover, decreased levels of neuroprotective factors (Brain derived neurotrophic factor (BDNF)), tropomyosin related kinase B (TrkB) and synaptophysin in diabetic retina were augmented with naringenin treatments.	naringenin	191-201	brain-derived neurotrophic factor	Rattus norvegicus	90-94
29064407-8	2017	Moreover, decreased levels of neuroprotective factors (Brain derived neurotrophic factor (BDNF)), tropomyosin related kinase B (TrkB) and synaptophysin in diabetic retina were augmented with naringenin treatments.	naringenin	191-201	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	98-126
29064407-8	2017	Moreover, decreased levels of neuroprotective factors (Brain derived neurotrophic factor (BDNF)), tropomyosin related kinase B (TrkB) and synaptophysin in diabetic retina were augmented with naringenin treatments.	naringenin	191-201	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	128-132
29064407-8	2017	Moreover, decreased levels of neuroprotective factors (Brain derived neurotrophic factor (BDNF)), tropomyosin related kinase B (TrkB) and synaptophysin in diabetic retina were augmented with naringenin treatments.	naringenin	191-201	synaptophysin	Rattus norvegicus	138-151
29064407-9	2017	In addition, naringenin treatment ameliorated the levels of apoptosis regulatory proteins; B cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein (Bax) and caspase-3 in the diabetic retina.	naringenin	13-23	BCL2, apoptosis regulator	Rattus norvegicus	91-108
29064407-9	2017	In addition, naringenin treatment ameliorated the levels of apoptosis regulatory proteins; B cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein (Bax) and caspase-3 in the diabetic retina.	naringenin	13-23	BCL2, apoptosis regulator	Rattus norvegicus	110-115
29064407-9	2017	In addition, naringenin treatment ameliorated the levels of apoptosis regulatory proteins; B cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein (Bax) and caspase-3 in the diabetic retina.	naringenin	13-23	BCL2, apoptosis regulator	Rattus norvegicus	118-123
29064407-9	2017	In addition, naringenin treatment ameliorated the levels of apoptosis regulatory proteins; B cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein (Bax) and caspase-3 in the diabetic retina.	naringenin	13-23	BCL2 associated X, apoptosis regulator	Rattus norvegicus	146-149
29064407-9	2017	In addition, naringenin treatment ameliorated the levels of apoptosis regulatory proteins; B cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein (Bax) and caspase-3 in the diabetic retina.	naringenin	13-23	caspase 3	Rattus norvegicus	155-164
29029741-4	2017	CSP2 with normal CD orientation affords best separation for isoxazolines while CSP1 with reversed CD orientation better separates naringenin, hesperetin and Troger"s base.	naringenin	130-140	regulator of calcineurin 2	Homo sapiens	0-4
29029741-4	2017	CSP2 with normal CD orientation affords best separation for isoxazolines while CSP1 with reversed CD orientation better separates naringenin, hesperetin and Troger"s base.	naringenin	130-140	regulator of calcineurin 1	Homo sapiens	79-83
29023372-3	2017	We hypothesized that common flavonoids in diet naringenin, hesperetin and their glycosides have a similar structure to quercetin, which might have comparable PARP inhibitory effects, and can induce selective cytotoxicity in BRCA2-deficient cells.	naringenin	47-57	LOW QUALITY PROTEIN: breast cancer type 2 susceptibility protein	Cricetulus griseus	224-229
29023372-5	2017	In vitro analysis revealed that both naringenin and hesperetin present a PARP inhibitory effect.	naringenin	37-47	poly [ADP-ribose] polymerase 1	Cricetulus griseus	73-77
29023372-8	2017	Quercetin and naringenin killed V-C8 cells with lower concentrations, and presented selective cytotoxicity to BRCA2-deficient cells.	naringenin	14-24	LOW QUALITY PROTEIN: breast cancer type 2 susceptibility protein	Cricetulus griseus	110-115
28759757-8	2017	In conclusion, the navel orange peel hydroethanolic extract, naringin and naringenin have potent anti-diabetic effects in NA/STZ-induced type 2 diabetic rats via their insulinotropic effects and insulin improving action which in turn may be mediated through enhancing insulin receptor, GLUT4 and adiponectin expression in adipose tissue.	naringenin	74-84	insulin receptor	Rattus norvegicus	268-284
28759757-8	2017	In conclusion, the navel orange peel hydroethanolic extract, naringin and naringenin have potent anti-diabetic effects in NA/STZ-induced type 2 diabetic rats via their insulinotropic effects and insulin improving action which in turn may be mediated through enhancing insulin receptor, GLUT4 and adiponectin expression in adipose tissue.	naringenin	74-84	solute carrier family 2 member 4	Rattus norvegicus	286-291
28759757-8	2017	In conclusion, the navel orange peel hydroethanolic extract, naringin and naringenin have potent anti-diabetic effects in NA/STZ-induced type 2 diabetic rats via their insulinotropic effects and insulin improving action which in turn may be mediated through enhancing insulin receptor, GLUT4 and adiponectin expression in adipose tissue.	naringenin	74-84	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	296-307
28783583-4	2017	On the other hand, berberine and naringenin supplementation to diabetic animals improved brain IRS 1 levels and restored GLUT 1 and GLUT 3 expression without significant effect on PI3K and Akt 1 activation and GLUT 4 levels.	naringenin	33-43	solute carrier family 2 member 1	Rattus norvegicus	121-127
28783583-4	2017	On the other hand, berberine and naringenin supplementation to diabetic animals improved brain IRS 1 levels and restored GLUT 1 and GLUT 3 expression without significant effect on PI3K and Akt 1 activation and GLUT 4 levels.	naringenin	33-43	solute carrier family 2 member 3	Rattus norvegicus	132-138
28849050-9	2017	In addition, mRNA and protein expression levels of TNF-alpha, IL-1beta, IL-6 and TGF-beta1 were downregulated following naringenin treatment.	naringenin	120-130	tumor necrosis factor	Mus musculus	51-60
28849050-9	2017	In addition, mRNA and protein expression levels of TNF-alpha, IL-1beta, IL-6 and TGF-beta1 were downregulated following naringenin treatment.	naringenin	120-130	interleukin 1 beta	Mus musculus	62-70
28849050-9	2017	In addition, mRNA and protein expression levels of TNF-alpha, IL-1beta, IL-6 and TGF-beta1 were downregulated following naringenin treatment.	naringenin	120-130	interleukin 6	Mus musculus	72-76
28849050-9	2017	In addition, mRNA and protein expression levels of TNF-alpha, IL-1beta, IL-6 and TGF-beta1 were downregulated following naringenin treatment.	naringenin	120-130	transforming growth factor, beta 1	Mus musculus	81-90
28624598-0	2017	Inhibition of LPS induced pro-inflammatory responses in RAW 264.7 macrophage cells by PVP-coated naringenin nanoparticle via down regulation of NF-kappaB/P38MAPK mediated stress signaling.	naringenin	97-107	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	144-153
28624598-0	2017	Inhibition of LPS induced pro-inflammatory responses in RAW 264.7 macrophage cells by PVP-coated naringenin nanoparticle via down regulation of NF-kappaB/P38MAPK mediated stress signaling.	naringenin	97-107	mitogen-activated protein kinase 14	Mus musculus	154-161
28943290-9	2017	Naringenin significantly reduced the level of the inflammatory marker TNF-alpha.	naringenin	0-10	tumor necrosis factor	Rattus norvegicus	70-79
28943290-10	2017	Naringenin increased Nrf-2/HO-1 and reduced NF-kappaB mRNA levels in CFA-treated animal joints.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	21-26
28943290-10	2017	Naringenin increased Nrf-2/HO-1 and reduced NF-kappaB mRNA levels in CFA-treated animal joints.	naringenin	0-10	heme oxygenase 1	Rattus norvegicus	27-31
28943290-11	2017	Additionally, naringenin treatment decreased the expression of extracellular matrix degrading enzymes, such as matrix metalloproteinase (MMP-3 and MMP-9), in CFA-induced arthritic rats.	naringenin	14-24	matrix metallopeptidase 3	Rattus norvegicus	137-142
28943290-11	2017	Additionally, naringenin treatment decreased the expression of extracellular matrix degrading enzymes, such as matrix metalloproteinase (MMP-3 and MMP-9), in CFA-induced arthritic rats.	naringenin	14-24	matrix metallopeptidase 9	Rattus norvegicus	147-152
28943290-12	2017	CONCLUSIONS: We conclude that naringenin exerts anti-arthritic effects by downregulating NF-kappaB and activating the Nrf-2/HO-1 pathway.	naringenin	30-40	NFE2 like bZIP transcription factor 2	Rattus norvegicus	118-123
28943290-12	2017	CONCLUSIONS: We conclude that naringenin exerts anti-arthritic effects by downregulating NF-kappaB and activating the Nrf-2/HO-1 pathway.	naringenin	30-40	heme oxygenase 1	Rattus norvegicus	124-128
28674493-6	2017	To explore the mechanism of action, we combined the drug affinity responsive target stability with immunoprecipitation-liquid chromatography/mass spectrometry analysis, identifying the collapsin response mediator protein 2 protein as a target of naringenin.	naringenin	246-256	dihydropyrimidinase-like 2	Mus musculus	185-222
28962147-0	2017	Naringenin ameliorates LPS-induced acute lung injury through its anti-oxidative and anti-inflammatory activity and by inhibition of the PI3K/AKT pathway.	naringenin	0-10	thymoma viral proto-oncogene 1	Mus musculus	141-144
28962147-7	2017	Moreover, naringenin pre-treatment reduced the total and the phosphorylated protein levels of PI3K and AKT.	naringenin	10-20	thymoma viral proto-oncogene 1	Mus musculus	103-106
28962147-8	2017	The present study suggested that naringenin pre-treatment ameliorated LPS-induced ALI through its anti-oxidative and anti-inflammatory activity and by inhibition of the PI3K/AKT pathway in mice.	naringenin	33-43	thymoma viral proto-oncogene 1	Mus musculus	174-177
28370954-0	2017	Citrus flavonoid naringenin reduces mammary tumor cell viability, adipose mass, and adipose inflammation in obese ovariectomized mice.	naringenin	17-27	WD and tetratricopeptide repeats 1	Mus musculus	66-73
28370954-4	2017	METHODS AND RESULTS: Naringenin inhibited cell growth, increased phosphorylation of AMP-activated protein kinase (AMPK), down-regulated CyclinD1 expression, and induced cell death in E0771 mammary tumor cells.	naringenin	21-31	cyclin D1	Mus musculus	136-144
28370954-9	2017	CONCLUSION: Naringenin reduces adiposity and ameliorates adipose tissue inflammation, with a moderate inhibitory effect on tumor growth in obese ovariectomized mice.	naringenin	12-22	WD and tetratricopeptide repeats 1	Mus musculus	57-64
28682138-7	2017	Denatonium and naringenin also increased vascular endothelial growth factor-A expression via arginase and tumor neovascularization in vivo.	naringenin	15-25	vascular endothelial growth factor A	Mus musculus	41-77
28706418-0	2017	Naringenin prevents experimental liver fibrosis by blocking TGFbeta-Smad3 and JNK-Smad3 pathways.	naringenin	0-10	SMAD family member 3	Rattus norvegicus	68-73
28706418-0	2017	Naringenin prevents experimental liver fibrosis by blocking TGFbeta-Smad3 and JNK-Smad3 pathways.	naringenin	0-10	mitogen-activated protein kinase 8	Rattus norvegicus	78-81
28706418-0	2017	Naringenin prevents experimental liver fibrosis by blocking TGFbeta-Smad3 and JNK-Smad3 pathways.	naringenin	0-10	SMAD family member 3	Rattus norvegicus	82-87
28706418-1	2017	AIM: To study the molecular mechanisms involved in the hepatoprotective effects of naringenin (NAR) on carbon tetrachloride (CCl4)-induced liver fibrosis.	naringenin	83-93	C-C motif chemokine ligand 4	Rattus norvegicus	125-129
28706418-1	2017	AIM: To study the molecular mechanisms involved in the hepatoprotective effects of naringenin (NAR) on carbon tetrachloride (CCl4)-induced liver fibrosis.	naringenin	95-98	C-C motif chemokine ligand 4	Rattus norvegicus	125-129
28706418-15	2017	Although zymography assays showed that CCl4 produced an increase in MMP-9 and MMP-2 gelatinase activity; interestingly, NAR administration was associated with normal MMP-9 and MMP-2 activity (P &lt; 0.05).	naringenin	120-123	matrix metallopeptidase 9	Rattus norvegicus	166-171
28706418-15	2017	Although zymography assays showed that CCl4 produced an increase in MMP-9 and MMP-2 gelatinase activity; interestingly, NAR administration was associated with normal MMP-9 and MMP-2 activity (P &lt; 0.05).	naringenin	120-123	matrix metallopeptidase 2	Rattus norvegicus	176-181
28786049-0	2017	Naringenin Attenuates H2O2-Induced Mitochondrial Dysfunction by an Nrf2-Dependent Mechanism in SH-SY5Y Cells.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	67-71
28786049-5	2017	NGN is a potent activator of Nrf2.	naringenin	0-3	NFE2 like bZIP transcription factor 2	Homo sapiens	29-33
28786049-7	2017	Therefore, we investigate here whether Nrf2 would be involved in the mitochondrial protection elicited by NGN in SH-SY5Y cells exposed to H2O2.	naringenin	106-109	NFE2 like bZIP transcription factor 2	Homo sapiens	39-43
28786049-13	2017	Silencing of Nrf2 abolished the protective effects induced by NGN.	naringenin	62-65	NFE2 like bZIP transcription factor 2	Homo sapiens	13-17
28786049-14	2017	Overall, NGN induced mitochondrial protection by an Nrf2-dependent mechanism in H2O2-treated SH-SY5Y cells.	naringenin	9-12	NFE2 like bZIP transcription factor 2	Homo sapiens	52-56
28591691-0	2017	Naringenin protects keratinocytes from oxidative stress injury via inhibition of the NOD2-mediated NF-kappaB pathway in pemphigus vulgaris.	naringenin	0-10	nucleotide binding oligomerization domain containing 2	Homo sapiens	85-89
28591691-4	2017	Moreover, PV serum increased the expression of bax and caspase-3, and decreased the expression of bcl-2; but naringenin significantly suppressed the expression of bax and caspase-3, induced the expression of bcl-2.	naringenin	109-119	BCL2 associated X, apoptosis regulator	Homo sapiens	163-166
28591691-4	2017	Moreover, PV serum increased the expression of bax and caspase-3, and decreased the expression of bcl-2; but naringenin significantly suppressed the expression of bax and caspase-3, induced the expression of bcl-2.	naringenin	109-119	caspase 3	Homo sapiens	171-180
28591691-4	2017	Moreover, PV serum increased the expression of bax and caspase-3, and decreased the expression of bcl-2; but naringenin significantly suppressed the expression of bax and caspase-3, induced the expression of bcl-2.	naringenin	109-119	BCL2 apoptosis regulator	Homo sapiens	208-213
28591691-6	2017	Naringenin also down-regulated the expression of Dsg1, Dsg3 and E-cadherin compared with the PV group.	naringenin	0-10	desmoglein 1	Homo sapiens	49-53
28591691-6	2017	Naringenin also down-regulated the expression of Dsg1, Dsg3 and E-cadherin compared with the PV group.	naringenin	0-10	desmoglein 3	Homo sapiens	55-59
28591691-6	2017	Naringenin also down-regulated the expression of Dsg1, Dsg3 and E-cadherin compared with the PV group.	naringenin	0-10	cadherin 1	Homo sapiens	64-74
28591691-9	2017	Naringenin also decreased the expression of NOD2, RIPK2 and NF-kappaB p-p65, but this effect could be reversed by muramyl dipeptide (MDP).	naringenin	0-10	nucleotide binding oligomerization domain containing 2	Homo sapiens	44-48
28591691-9	2017	Naringenin also decreased the expression of NOD2, RIPK2 and NF-kappaB p-p65, but this effect could be reversed by muramyl dipeptide (MDP).	naringenin	0-10	receptor interacting serine/threonine kinase 2	Homo sapiens	50-55
28591691-10	2017	In conclusion, these results suggested that naringenin protected keratinocytes from apoptosis and oxidative stress injury through inhibition of the NOD2-mediated NF-kappaB pathway.	naringenin	44-54	nucleotide binding oligomerization domain containing 2	Homo sapiens	148-152
28698624-0	2017	Naringenin Impairs Two-Pore Channel 2 Activity And Inhibits VEGF-Induced Angiogenesis.	naringenin	0-10	two pore segment channel 2	Homo sapiens	19-37
28698624-0	2017	Naringenin Impairs Two-Pore Channel 2 Activity And Inhibits VEGF-Induced Angiogenesis.	naringenin	0-10	vascular endothelial growth factor A	Homo sapiens	60-64
28698624-1	2017	Our research introduces the natural flavonoid naringenin as a novel inhibitor of an emerging class of intracellular channels, Two-Pore Channel 2 (TPC2), as shown by electrophysiological evidence in a heterologous system, i.e. Arabidopsis vacuoles lacking endogenous TPCs.	naringenin	46-56	two pore segment channel 2	Homo sapiens	126-144
28698624-1	2017	Our research introduces the natural flavonoid naringenin as a novel inhibitor of an emerging class of intracellular channels, Two-Pore Channel 2 (TPC2), as shown by electrophysiological evidence in a heterologous system, i.e. Arabidopsis vacuoles lacking endogenous TPCs.	naringenin	46-56	two pore segment channel 2	Homo sapiens	146-150
28698624-2	2017	In view of the control exerted by TPC2 on intracellular calcium signaling, we demonstrated that naringenin dampens intracellular calcium responses of human endothelial cells stimulated with VEGF, histamine or NAADP-AM, but not with ATP or Angiopoietin-1 (negative controls).	naringenin	96-106	two pore segment channel 2	Homo sapiens	34-38
28698624-2	2017	In view of the control exerted by TPC2 on intracellular calcium signaling, we demonstrated that naringenin dampens intracellular calcium responses of human endothelial cells stimulated with VEGF, histamine or NAADP-AM, but not with ATP or Angiopoietin-1 (negative controls).	naringenin	96-106	vascular endothelial growth factor A	Homo sapiens	190-194
28698624-2	2017	In view of the control exerted by TPC2 on intracellular calcium signaling, we demonstrated that naringenin dampens intracellular calcium responses of human endothelial cells stimulated with VEGF, histamine or NAADP-AM, but not with ATP or Angiopoietin-1 (negative controls).	naringenin	96-106	angiopoietin 1	Homo sapiens	239-253
28698624-3	2017	The ability of naringenin to impair TPC2-dependent biological activities was further explored in an established in vivo model, in which VEGF-containing matrigel plugs implanted in mice failed to be vascularized in the presence of naringenin.	naringenin	15-25	two pore segment channel 2	Homo sapiens	36-40
28698624-4	2017	Overall, the present data suggest that naringenin inhibition of TPC2 activity and the observed inhibition of angiogenic response to VEGF are linked by impaired intracellular calcium signaling.	naringenin	39-49	two pore segment channel 2	Homo sapiens	64-68
28698624-6	2017	The identification of naringenin as an inhibitor of TPC2-mediated signaling provides a novel and potentially relevant tool for the advancement of this field of research.	naringenin	22-32	two pore segment channel 2	Homo sapiens	52-56
28395574-6	2017	Naringenin treatment also led to a dose-dependent increase in the mRNA expression of c-jun, c-fos and NF-kappaB.	naringenin	0-10	jun proto-oncogene	Mus musculus	85-90
28395574-6	2017	Naringenin treatment also led to a dose-dependent increase in the mRNA expression of c-jun, c-fos and NF-kappaB.	naringenin	0-10	FBJ osteosarcoma oncogene	Mus musculus	92-97
28395574-6	2017	Naringenin treatment also led to a dose-dependent increase in the mRNA expression of c-jun, c-fos and NF-kappaB.	naringenin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	102-111
28454670-0	2017	Structure-related protein tyrosine phosphatase 1B inhibition by naringenin derivatives.	naringenin	64-74	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	18-49
28454670-2	2017	To unveil the structure-activity relationship of a naturally occurring flavonoid, we investigated the effects of the glycosylation of naringenin on the inhibition of enzyme systems related to diabetes (protein tyrosine phosphatase 1B (PTP1B) and alpha-glycosidase) and on glucose uptake in the insulin-resistant state.	naringenin	134-144	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	202-233
28454670-3	2017	Among the tested naringenin derivatives, prunin, a single-glucose-containing flavanone glycoside, potently inhibited PTP1B with an IC50 value of 17.5+-2.6microM.	naringenin	17-27	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	117-122
28454670-6	2017	Regarding the inhibition of alpha-glucosidase, naringenin exhibited more potent inhibitory activity (IC50: 10.6+-0.49microM) than its glycosylated forms and the reference inhibitor, acarbose (IC50: 178.0+-0.27microM).	naringenin	47-57	sucrase-isomaltase	Homo sapiens	28-45
28058739-1	2017	This study aims to investigate the interaction between 3 flavonoids (quercetin, apigenin, and naringenin) and fat mass and obesity-associated protein by fluorescence, ultraviolet-visible absorption spectroscopy, and molecular modeling.	naringenin	94-104	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	110-149
27785700-0	2017	Naringenin ameliorates hypoxia/reoxygenation-induced endoplasmic reticulum stress-mediated apoptosis in H9c2 myocardial cells: involvement in ATF6, IRE1alpha and PERK signaling activation.	naringenin	0-10	activating transcription factor 6	Rattus norvegicus	142-146
27151135-5	2017	The in vivo studies also revealed an increase in AUC of the naringenin-loaded liposome from 16648.48 to 223754.0 ng mL-1 h as compared with the free naringenin.	naringenin	60-70	2'-5' oligoadenylate synthetase 1B	Mus musculus	116-120
28415935-9	2017	SOD, catalase, GPx and GST activities were markedly inhibited in wounded skin tissues, and were significantly increased in naringenin-treated rats.	naringenin	123-133	catalase	Rattus norvegicus	5-13
28415935-9	2017	SOD, catalase, GPx and GST activities were markedly inhibited in wounded skin tissues, and were significantly increased in naringenin-treated rats.	naringenin	123-133	hematopoietic prostaglandin D synthase	Rattus norvegicus	23-26
28567424-1	2017	The aim of the present study was to evaluate in vitro effects of dietary phytochemicals naringenin, quercetin, and sesamin on the activities of ethoxy- (EROD; CYP1A) and benzyloxy- (BROD; CYP3A) resorufin O-dealkylases after the exposure to the cocktail of persistent organic pollutants (POPs).	naringenin	88-98	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	188-193
28567424-9	2017	We concluded that the interactions of quercetin and naringenin with CYP1A and CYP3A in mice liver were not affected by the levels of POPs exposure.	naringenin	52-62	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	78-83
29179179-0	2017	Naringenin Regulates CFTR Activation and Expression in Airway Epithelial Cells.	naringenin	0-10	CF transmembrane conductance regulator	Homo sapiens	21-25
29179179-2	2017	This study aimed to identify an efficacious expectorant treatment stratagem through evaluating the secretion-promoting activation and cystic fibrosis transmembrane conductance regulator (CFTR) expression of the bioactive herbal monomer naringenin.	naringenin	236-246	CF transmembrane conductance regulator	Homo sapiens	134-185
29179179-2	2017	This study aimed to identify an efficacious expectorant treatment stratagem through evaluating the secretion-promoting activation and cystic fibrosis transmembrane conductance regulator (CFTR) expression of the bioactive herbal monomer naringenin.	naringenin	236-246	CF transmembrane conductance regulator	Homo sapiens	187-191
29179179-10	2017	With lipopolysaccharide stimulation, CFTR expression was significantly reduced, and naringenin dose-dependently enhanced CFTR mRNA expression.	naringenin	84-94	CF transmembrane conductance regulator	Homo sapiens	121-125
29179179-11	2017	CONCLUSION: These results demonstrate that naringenin has the ability to stimulate Cl- secretion, which is mediated by CFTR through a signaling pathway by increasing cAMP content.	naringenin	43-53	CF transmembrane conductance regulator	Homo sapiens	119-123
29179179-12	2017	Moreover, naringenin can increase CFTR expression when organism CFTR expression is seriously hampered.	naringenin	10-20	CF transmembrane conductance regulator	Homo sapiens	34-38
29179179-12	2017	Moreover, naringenin can increase CFTR expression when organism CFTR expression is seriously hampered.	naringenin	10-20	CF transmembrane conductance regulator	Homo sapiens	64-68
28322845-7	2017	It has been shown that naringenin exerts its anti-diabetic effects by inhibition of gluconeogenesis through upregulations of AMPK hence metformin-like effects.	naringenin	23-33	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	125-129
27606834-0	2017	Naringenin-Induced Apoptotic Cell Death in Prostate Cancer Cells Is Mediated via the PI3K/AKT and MAPK Signaling Pathways.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	90-93
27606834-0	2017	Naringenin-Induced Apoptotic Cell Death in Prostate Cancer Cells Is Mediated via the PI3K/AKT and MAPK Signaling Pathways.	naringenin	0-10	mitogen-activated protein kinase 3	Homo sapiens	98-102
27606834-4	2017	In the present study, we investigated effects of naringenin, a natural anti-oxidant flavonoid derived from citrus, on prostate cancer cells (PC3 and LNCaP).	naringenin	49-59	keratin 6A	Homo sapiens	141-144
27606834-5	2017	Results of present study with PC3 and LNCaP cells revealed that naringenin inhibited proliferation and migration, while inducing apoptosis and ROS production by those cells.	naringenin	64-74	keratin 6A	Homo sapiens	30-33
27606834-6	2017	In addition, naringenin-induced loss of mitochondrial membrane potential and increased Bax and decreased Bcl-2 proteins in PC3 cells, but not LNCaP cells.	naringenin	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	87-90
27606834-6	2017	In addition, naringenin-induced loss of mitochondrial membrane potential and increased Bax and decreased Bcl-2 proteins in PC3 cells, but not LNCaP cells.	naringenin	13-23	BCL2 apoptosis regulator	Homo sapiens	105-110
27606834-6	2017	In addition, naringenin-induced loss of mitochondrial membrane potential and increased Bax and decreased Bcl-2 proteins in PC3 cells, but not LNCaP cells.	naringenin	13-23	keratin 6A	Homo sapiens	123-126
27606834-7	2017	In a dose-dependent manner, naringenin decreased phosphorylation of ERK1/2, P70S6K, S6, and P38 in PC3 cells, and reduced phosphorylation of ERK1/2, P53, P38, and JNK proteins in LNCaP cells.	naringenin	28-38	mitogen-activated protein kinase 3	Homo sapiens	68-74
27606834-7	2017	In a dose-dependent manner, naringenin decreased phosphorylation of ERK1/2, P70S6K, S6, and P38 in PC3 cells, and reduced phosphorylation of ERK1/2, P53, P38, and JNK proteins in LNCaP cells.	naringenin	28-38	ribosomal protein S6 kinase B1	Homo sapiens	76-82
27606834-7	2017	In a dose-dependent manner, naringenin decreased phosphorylation of ERK1/2, P70S6K, S6, and P38 in PC3 cells, and reduced phosphorylation of ERK1/2, P53, P38, and JNK proteins in LNCaP cells.	naringenin	28-38	mitogen-activated protein kinase 1	Homo sapiens	92-95
27606834-7	2017	In a dose-dependent manner, naringenin decreased phosphorylation of ERK1/2, P70S6K, S6, and P38 in PC3 cells, and reduced phosphorylation of ERK1/2, P53, P38, and JNK proteins in LNCaP cells.	naringenin	28-38	keratin 6A	Homo sapiens	99-102
27606834-7	2017	In a dose-dependent manner, naringenin decreased phosphorylation of ERK1/2, P70S6K, S6, and P38 in PC3 cells, and reduced phosphorylation of ERK1/2, P53, P38, and JNK proteins in LNCaP cells.	naringenin	28-38	mitogen-activated protein kinase 3	Homo sapiens	141-147
27606834-7	2017	In a dose-dependent manner, naringenin decreased phosphorylation of ERK1/2, P70S6K, S6, and P38 in PC3 cells, and reduced phosphorylation of ERK1/2, P53, P38, and JNK proteins in LNCaP cells.	naringenin	28-38	tumor protein p53	Homo sapiens	149-152
27606834-7	2017	In a dose-dependent manner, naringenin decreased phosphorylation of ERK1/2, P70S6K, S6, and P38 in PC3 cells, and reduced phosphorylation of ERK1/2, P53, P38, and JNK proteins in LNCaP cells.	naringenin	28-38	mitogen-activated protein kinase 1	Homo sapiens	154-157
27606834-8	2017	However, naringenin activated phosphorylation of AKT in both PC3 and LNCaP cells.	naringenin	9-19	AKT serine/threonine kinase 1	Homo sapiens	49-52
27606834-8	2017	However, naringenin activated phosphorylation of AKT in both PC3 and LNCaP cells.	naringenin	9-19	keratin 6A	Homo sapiens	61-64
27915399-2	2017	Naringenin is a citrus flavonoid with anti-inflammatory actions, which has been shown to prevent obesity-related diseases and to activate PPARgamma.	naringenin	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	138-147
28355351-4	2017	We studied the effect of naringenin on the transcriptional expression, secretion and enzymatic activity of MMP-3 in vivo in the murine monosodium iodoacetate (MIA) osteoarthritis model.	naringenin	25-35	matrix metallopeptidase 3	Mus musculus	107-112
28355351-7	2017	Moreover, the effect of naringenin was also studied in vitro in IL-1beta activated articular chondrocytes.	naringenin	24-34	interleukin 1 beta	Rattus norvegicus	64-72
28355351-10	2017	Moreover, a significant inhibition of MMP-3 expression in MIA rats was observed upon treatment with naringenin.	naringenin	100-110	matrix metallopeptidase 3	Rattus norvegicus	38-43
28264488-0	2017	Enantioselective Modulatory Effects of Naringenin  Enantiomers on the Expression Levels of miR-17-3p  Involved in Endogenous Antioxidant Defenses.	naringenin	39-49	microRNA 17	Homo sapiens	91-100
28264488-3	2017	This study aims to evaluate the effects of racemic and enantiomeric naringenin on the expression levels of miR-17-3p, miR-25-5p and relative mRNA targets, to elucidate the mechanisms underlying these antioxidant and anti-inflammatory properties.	naringenin	68-78	microRNA 17	Homo sapiens	107-116
28352360-8	2017	In addition, a zymography assay revealed that naringenin exhibited a concentration-dependent inhibition of matrix metalloproteinase (MMP)-2 and -9 activities.	naringenin	46-56	matrix metallopeptidase 2	Homo sapiens	107-146
28352360-9	2017	Furthermore, naringenin also inhibited the activities of AKT in a dose-dependent manner.	naringenin	13-23	AKT serine/threonine kinase 1	Homo sapiens	57-60
28352360-10	2017	These observations indicated that naringenin inhibited the migration of lung cancer A549 cells through several mechanisms, including the inhibition of AKT activities and reduction of MMP-2 and -9 activities.	naringenin	34-44	AKT serine/threonine kinase 1	Homo sapiens	151-154
28352360-10	2017	These observations indicated that naringenin inhibited the migration of lung cancer A549 cells through several mechanisms, including the inhibition of AKT activities and reduction of MMP-2 and -9 activities.	naringenin	34-44	matrix metallopeptidase 2	Homo sapiens	183-195
27838343-0	2017	Naringenin causes ASK1-induced apoptosis via reactive oxygen species in human pancreatic cancer cells.	naringenin	0-10	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	18-22
27838343-4	2017	Annexin V+/PI + marked cells increased from 5.10% to 8.29%, 25.06% and 35.31% in response to treatment with 200, 400, and 600 muM naringenin, respectively.	naringenin	130-140	annexin A5	Homo sapiens	0-9
27838343-7	2017	To obtain a broad understanding of the interactive mechanism of naringenin and Prdx-1, we observed changes in reactive oxygen species (ROS) in naringenin-treated SNU-213 cells.	naringenin	143-153	peroxiredoxin 1	Homo sapiens	79-85
27838343-11	2017	Overall, the results of this study suggest that naringenin causes ASK1-induced apoptosis mediated by ROS.	naringenin	48-58	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	66-70
27785700-4	2017	Our results showed that naringenin treatment resulted in obvious increases in the viability of H9c2 cells and the expression of Bcl-2 (anti-apoptotic protein), and decreases in the morphological changes of apoptotic cells, the activity of caspase-3 and the expression of Bax (pro-apoptotic protein) in H/R-treated H9c2 cells, implying the protective effects of naringenin against H/R-induced injury.	naringenin	24-34	BCL2, apoptosis regulator	Rattus norvegicus	128-133
27785700-4	2017	Our results showed that naringenin treatment resulted in obvious increases in the viability of H9c2 cells and the expression of Bcl-2 (anti-apoptotic protein), and decreases in the morphological changes of apoptotic cells, the activity of caspase-3 and the expression of Bax (pro-apoptotic protein) in H/R-treated H9c2 cells, implying the protective effects of naringenin against H/R-induced injury.	naringenin	24-34	caspase 3	Rattus norvegicus	239-248
27785700-4	2017	Our results showed that naringenin treatment resulted in obvious increases in the viability of H9c2 cells and the expression of Bcl-2 (anti-apoptotic protein), and decreases in the morphological changes of apoptotic cells, the activity of caspase-3 and the expression of Bax (pro-apoptotic protein) in H/R-treated H9c2 cells, implying the protective effects of naringenin against H/R-induced injury.	naringenin	24-34	BCL2 associated X, apoptosis regulator	Rattus norvegicus	271-274
27785700-5	2017	In addition, naringenin also significantly reversed H/R-induced ER stress as evidenced by the up-regulation of Glucose-regulated protein 78, C/EBP homologous protein and Cleaved caspase-12 proteins.	naringenin	13-23	DNA-damage inducible transcript 3	Rattus norvegicus	141-165
27785700-6	2017	Meanwhile, naringenin remarkably reversed H/R-induced the increases in the expression of cleaved activating transcription factor 6 (ATF6) and phosphorylation levels of phospho-extracellular regulated protein kinases (PERK) and inositol-requiring enzyme-1alpha (IRE1alpha) in H9c2 cells.	naringenin	11-21	activating transcription factor 6	Rattus norvegicus	97-130
27785700-6	2017	Meanwhile, naringenin remarkably reversed H/R-induced the increases in the expression of cleaved activating transcription factor 6 (ATF6) and phosphorylation levels of phospho-extracellular regulated protein kinases (PERK) and inositol-requiring enzyme-1alpha (IRE1alpha) in H9c2 cells.	naringenin	11-21	activating transcription factor 6	Rattus norvegicus	132-136
27785700-8	2017	In conclusion, these results confirmed that ER stress-mediated apoptosis contributes to the protection effects of naringenin against H/R injury, which is potentially involved in ATF6, IRE1alpha and PERK signaling activation.	naringenin	114-124	activating transcription factor 6	Rattus norvegicus	178-182
28386313-7	2017	Relevant cellular senescence markers, such as X-gal staining, cell cycle regulator levels, and the percentage of cell cycle-arrested cells, were found to be reduced in the presence of naringenin.	naringenin	184-194	cyclin-dependent kinase inhibitor 2A	Rattus norvegicus	62-82
27432064-0	2016	Naringenin inhibits spinal cord injury-induced activation of neutrophils through miR-223.	naringenin	0-10	microRNA 223	Rattus norvegicus	81-88
28480406-2	2017	MATERIALS AND METHODS: The purpose of this study was to investigate the mechanism by which citrus flavonoids, naringenin regulate the LDL receptor (LDLr) gene in human liver using the human hepatoma cell line, HepG2 as a model.	naringenin	110-120	low density lipoprotein receptor	Homo sapiens	134-146
28480406-2	2017	MATERIALS AND METHODS: The purpose of this study was to investigate the mechanism by which citrus flavonoids, naringenin regulate the LDL receptor (LDLr) gene in human liver using the human hepatoma cell line, HepG2 as a model.	naringenin	110-120	low density lipoprotein receptor	Homo sapiens	148-152
28480406-3	2017	RESULTS: Time-course transient transfection of HepG2 cells with luciferase reporter-gene constructs incorporating the promoters of SREBP-1a,-1c, -2 and LDLr, revealed that in lipoprotein-deficient medium (LPDM), only SREBP-1a promoter activity was increased significantly after 4h exposure to 200muM naringenin respectively.	naringenin	300-310	sterol regulatory element binding transcription factor 1	Homo sapiens	131-139
28480406-4	2017	However, after 24h incubation with 200muM naringenin the gene expression activities of all the SREBP-1a, -1c, -2 and LDLr promoter-constructs were increased significantly.	naringenin	42-52	sterol regulatory element binding transcription factor 1	Homo sapiens	95-112
28480406-4	2017	However, after 24h incubation with 200muM naringenin the gene expression activities of all the SREBP-1a, -1c, -2 and LDLr promoter-constructs were increased significantly.	naringenin	42-52	low density lipoprotein receptor	Homo sapiens	117-121
28480406-5	2017	The effects of both 200muM naringenin on elevating LDLr mRNA are possibly due to regulation of gene transcription by SREBP-la and SREBP-2.	naringenin	27-37	low density lipoprotein receptor	Homo sapiens	51-55
28480406-5	2017	The effects of both 200muM naringenin on elevating LDLr mRNA are possibly due to regulation of gene transcription by SREBP-la and SREBP-2.	naringenin	27-37	sterol regulatory element binding transcription factor 2	Homo sapiens	130-137
28480406-6	2017	However, the suppression effect of 200muM naringenin on hepatic SREBP-1c mRNA expression is likely associated with the reduction in mRNA expression of both acetyl-CoA carboxylase and fatty acid synthase in human hepatoma HepG2 cells.	naringenin	42-52	sterol regulatory element binding transcription factor 1	Homo sapiens	64-72
28480406-6	2017	However, the suppression effect of 200muM naringenin on hepatic SREBP-1c mRNA expression is likely associated with the reduction in mRNA expression of both acetyl-CoA carboxylase and fatty acid synthase in human hepatoma HepG2 cells.	naringenin	42-52	fatty acid synthase	Homo sapiens	183-202
28480406-7	2017	It was found that, 200muM naringenin was likely to stimulate LDLr gene expression via increase phosphorylation of PI3K and ERK1/2 which enhance the transcription factors SREBP-1a and SREBP-2 mRNA levels and increased their protein maturation in human hepatoma HepG2 cell.	naringenin	26-36	low density lipoprotein receptor	Homo sapiens	61-65
28480406-7	2017	It was found that, 200muM naringenin was likely to stimulate LDLr gene expression via increase phosphorylation of PI3K and ERK1/2 which enhance the transcription factors SREBP-1a and SREBP-2 mRNA levels and increased their protein maturation in human hepatoma HepG2 cell.	naringenin	26-36	mitogen-activated protein kinase 3	Homo sapiens	123-129
28480406-7	2017	It was found that, 200muM naringenin was likely to stimulate LDLr gene expression via increase phosphorylation of PI3K and ERK1/2 which enhance the transcription factors SREBP-1a and SREBP-2 mRNA levels and increased their protein maturation in human hepatoma HepG2 cell.	naringenin	26-36	sterol regulatory element binding transcription factor 1	Homo sapiens	170-178
28480406-7	2017	It was found that, 200muM naringenin was likely to stimulate LDLr gene expression via increase phosphorylation of PI3K and ERK1/2 which enhance the transcription factors SREBP-1a and SREBP-2 mRNA levels and increased their protein maturation in human hepatoma HepG2 cell.	naringenin	26-36	sterol regulatory element binding transcription factor 2	Homo sapiens	183-190
28004841-0	2016	The citrus flavonoid naringenin confers protection in a murine endotoxaemia model through AMPK-ATF3-dependent negative regulation of the TLR4 signalling pathway.	naringenin	21-31	activating transcription factor 3	Mus musculus	95-99
28004841-0	2016	The citrus flavonoid naringenin confers protection in a murine endotoxaemia model through AMPK-ATF3-dependent negative regulation of the TLR4 signalling pathway.	naringenin	21-31	toll-like receptor 4	Mus musculus	137-141
28004841-2	2016	Naringenin is a citrus flavonoid with remarkable anti-inflammatory activity, but the mechanisms underlying its inhibition of LPS/TLR4 signalling are less clear.	naringenin	0-10	toll-like receptor 4	Mus musculus	129-133
28004841-4	2016	In LPS-stimulated murine macrophages, naringenin suppressed the expression of TNF-alpha, IL-6, TLR4, inducible NO synthase (iNOS), cyclo-oxygenase-2 (COX2) and NADPH oxidase-2 (NOX2).	naringenin	38-48	tumor necrosis factor	Mus musculus	78-87
28004841-4	2016	In LPS-stimulated murine macrophages, naringenin suppressed the expression of TNF-alpha, IL-6, TLR4, inducible NO synthase (iNOS), cyclo-oxygenase-2 (COX2) and NADPH oxidase-2 (NOX2).	naringenin	38-48	interleukin 6	Mus musculus	89-93
28004841-4	2016	In LPS-stimulated murine macrophages, naringenin suppressed the expression of TNF-alpha, IL-6, TLR4, inducible NO synthase (iNOS), cyclo-oxygenase-2 (COX2) and NADPH oxidase-2 (NOX2).	naringenin	38-48	toll-like receptor 4	Mus musculus	95-99
28004841-4	2016	In LPS-stimulated murine macrophages, naringenin suppressed the expression of TNF-alpha, IL-6, TLR4, inducible NO synthase (iNOS), cyclo-oxygenase-2 (COX2) and NADPH oxidase-2 (NOX2).	naringenin	38-48	nitric oxide synthase 2, inducible	Mus musculus	101-122
28004841-4	2016	In LPS-stimulated murine macrophages, naringenin suppressed the expression of TNF-alpha, IL-6, TLR4, inducible NO synthase (iNOS), cyclo-oxygenase-2 (COX2) and NADPH oxidase-2 (NOX2).	naringenin	38-48	nitric oxide synthase 2, inducible	Mus musculus	124-128
28004841-4	2016	In LPS-stimulated murine macrophages, naringenin suppressed the expression of TNF-alpha, IL-6, TLR4, inducible NO synthase (iNOS), cyclo-oxygenase-2 (COX2) and NADPH oxidase-2 (NOX2).	naringenin	38-48	cytochrome b-245, beta polypeptide	Mus musculus	160-175
28004841-4	2016	In LPS-stimulated murine macrophages, naringenin suppressed the expression of TNF-alpha, IL-6, TLR4, inducible NO synthase (iNOS), cyclo-oxygenase-2 (COX2) and NADPH oxidase-2 (NOX2).	naringenin	38-48	cytochrome b-245, beta polypeptide	Mus musculus	177-181
28004841-7	2016	Naringenin was demonstrated to directly increase ATF3 expression.	naringenin	0-10	activating transcription factor 3	Mus musculus	49-53
28004841-11	2016	Overall, this study reveals a novel mechanism of naringenin through AMPK-ATF3-dependent negative regulation of the LPS/TLR4 signalling pathway, which thereby confers protection against murine endotoxaemia.	naringenin	49-59	activating transcription factor 3	Mus musculus	73-77
28004841-11	2016	Overall, this study reveals a novel mechanism of naringenin through AMPK-ATF3-dependent negative regulation of the LPS/TLR4 signalling pathway, which thereby confers protection against murine endotoxaemia.	naringenin	49-59	toll-like receptor 4	Mus musculus	119-123
27572468-0	2016	Naringenin pre-treatment inhibits neuroapoptosis and ameliorates cognitive impairment in rats exposed to isoflurane anesthesia by regulating the PI3/Akt/PTEN signalling pathway and suppressing NF-kappaB-mediated inflammation.	naringenin	0-10	WAP four-disulfide core domain 15B	Rattus norvegicus	145-148
27572468-0	2016	Naringenin pre-treatment inhibits neuroapoptosis and ameliorates cognitive impairment in rats exposed to isoflurane anesthesia by regulating the PI3/Akt/PTEN signalling pathway and suppressing NF-kappaB-mediated inflammation.	naringenin	0-10	AKT serine/threonine kinase 1	Rattus norvegicus	149-152
27572468-0	2016	Naringenin pre-treatment inhibits neuroapoptosis and ameliorates cognitive impairment in rats exposed to isoflurane anesthesia by regulating the PI3/Akt/PTEN signalling pathway and suppressing NF-kappaB-mediated inflammation.	naringenin	0-10	phosphatase and tensin homolog	Rattus norvegicus	153-157
27572468-10	2016	Naringenin significantly inhibited isoflurane-induced neuroapoptosis and markedly decreased the protein expression of caspase-3, Bad, Bax, NF-kappaB, tumor necrosis factor-alpha, interleukin (IL)-6 and IL-1beta.	naringenin	0-10	caspase 3	Rattus norvegicus	118-127
27572468-10	2016	Naringenin significantly inhibited isoflurane-induced neuroapoptosis and markedly decreased the protein expression of caspase-3, Bad, Bax, NF-kappaB, tumor necrosis factor-alpha, interleukin (IL)-6 and IL-1beta.	naringenin	0-10	BCL2 associated X, apoptosis regulator	Rattus norvegicus	134-137
27572468-10	2016	Naringenin significantly inhibited isoflurane-induced neuroapoptosis and markedly decreased the protein expression of caspase-3, Bad, Bax, NF-kappaB, tumor necrosis factor-alpha, interleukin (IL)-6 and IL-1beta.	naringenin	0-10	tumor necrosis factor	Rattus norvegicus	139-177
27572468-10	2016	Naringenin significantly inhibited isoflurane-induced neuroapoptosis and markedly decreased the protein expression of caspase-3, Bad, Bax, NF-kappaB, tumor necrosis factor-alpha, interleukin (IL)-6 and IL-1beta.	naringenin	0-10	interleukin 1 beta	Rattus norvegicus	202-210
27572468-11	2016	Furthermore, naringenin increased the expression of Bcl-xL and Bcl-2 and activated the PI3K/Akt pathway.	naringenin	13-23	Bcl2-like 1	Rattus norvegicus	52-58
27572468-11	2016	Furthermore, naringenin increased the expression of Bcl-xL and Bcl-2 and activated the PI3K/Akt pathway.	naringenin	13-23	BCL2, apoptosis regulator	Rattus norvegicus	63-68
27572468-11	2016	Furthermore, naringenin increased the expression of Bcl-xL and Bcl-2 and activated the PI3K/Akt pathway.	naringenin	13-23	AKT serine/threonine kinase 1	Rattus norvegicus	92-95
27572468-13	2016	Naringenin effectively ameliorated cognitive dysfunction and reduced isoflurane-induced apoptosis as well as modulating the PI3/Akt/PTEN and NF-kappaB signalling pathways.	naringenin	0-10	WAP four-disulfide core domain 15B	Rattus norvegicus	124-127
27572468-13	2016	Naringenin effectively ameliorated cognitive dysfunction and reduced isoflurane-induced apoptosis as well as modulating the PI3/Akt/PTEN and NF-kappaB signalling pathways.	naringenin	0-10	AKT serine/threonine kinase 1	Rattus norvegicus	128-131
27572468-13	2016	Naringenin effectively ameliorated cognitive dysfunction and reduced isoflurane-induced apoptosis as well as modulating the PI3/Akt/PTEN and NF-kappaB signalling pathways.	naringenin	0-10	phosphatase and tensin homolog	Rattus norvegicus	132-136
26928632-0	2016	Naringenin ameliorates streptozotocin-induced diabetic rat renal impairment by downregulation of TGF-beta1 and IL-1 via modulation of oxidative stress correlates with decreased apoptotic events.	naringenin	0-10	transforming growth factor, beta 1	Rattus norvegicus	97-106
27449398-0	2016	Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors.	naringenin	15-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
27449398-0	2016	Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors.	naringenin	15-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
27473516-0	2016	Apigenin and naringenin ameliorate PKCbetaII-associated endothelial dysfunction via regulating ROS/caspase-3 and NO pathway in endothelial cells exposed to high glucose.	naringenin	13-23	phospholipase C, beta 2	Rattus norvegicus	35-44
27473516-0	2016	Apigenin and naringenin ameliorate PKCbetaII-associated endothelial dysfunction via regulating ROS/caspase-3 and NO pathway in endothelial cells exposed to high glucose.	naringenin	13-23	caspase 3	Rattus norvegicus	99-108
27473516-5	2016	We showed that apigenin and naringenin protected against endothelial dysfunction via inhibiting phosphorylation of protein kinase C betaII (PKCbetaII) expression and downstream reactive oxygen species (ROS) production in endothelial cells exposed to high glucose.	naringenin	28-38	phospholipase C, beta 2	Rattus norvegicus	140-149
27473516-6	2016	Furthermore, we demonstrated that apigenin and naringenin reduced high glucose-increased apoptosis, Bax expression, caspase-3 activity and phosphorylation of NF-kappaB in endothelial cells.	naringenin	47-57	BCL2 associated X, apoptosis regulator	Rattus norvegicus	100-103
27473516-6	2016	Furthermore, we demonstrated that apigenin and naringenin reduced high glucose-increased apoptosis, Bax expression, caspase-3 activity and phosphorylation of NF-kappaB in endothelial cells.	naringenin	47-57	caspase 3	Rattus norvegicus	116-125
27473516-7	2016	Moreover, apigenin and naringenin effectively restored high glucose-reduced Bcl-2 expression and Akt phosphorylation.	naringenin	23-33	BCL2, apoptosis regulator	Rattus norvegicus	76-81
27473516-10	2016	Taken together, our results manifest that apigenin and naringenin can ameliorate endothelial dysfunction via regulating ROS/caspase-3 and NO pathway.	naringenin	55-65	caspase 3	Rattus norvegicus	124-133
27444380-3	2016	Based on its previously reported CYP inhibitory properties, we studied the effects of two molecules contained within grapefruit juice, naringenin and 6",7"-dihydroxybergamottin, on human and rat CYP1A1 activity.	naringenin	135-145	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	195-201
27444380-5	2016	Naringenin and 6",7"-dihydroxybergamottin were found to be competitive inhibitors of human and rat CYP1A1.	naringenin	0-10	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	99-105
27444380-6	2016	Additionally, naringenin exerted a mixed type inhibition effect on rat CYP1A1.	naringenin	14-24	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	71-77
26928632-7	2016	RESULTS: Naringenin treatment with 5 and 10 mg/kg significantly decreased (p &lt; 0.05) the serum biochemical parameters, elevated tissue malondialdehyde levels and increased (p &lt; 0.01) the reduced superoxide dismutase, catalase and reduced glutathione enzyme activities in the diabetic kidney.	naringenin	9-19	catalase	Rattus norvegicus	223-231
26928632-8	2016	Diabetes-induced naringenin-treated groups showed an improved histology and revealed a significant reduction in apoptosis activity (7.2 +- 0.01 and 1.8 +- 0.05) and in expression of TGF-beta1 (18.9 +- 3.4 and 10.2 +- 2.1) at a dose of 5 and 10 mg/kg, respectively.	naringenin	17-27	transforming growth factor, beta 1	Rattus norvegicus	182-191
27107807-0	2016	In vitro effects of the citrus flavonoids diosmin, naringenin and naringin on the hepatic drug-metabolizing CYP3A enzyme in human, pig, mouse and fish.	naringenin	51-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-113
27219053-4	2016	In this study, we cloned the full-length cDNA of R. trigyna LDOX (RtLDOX), and found RtLDOX recombinant protein was able to replace flavanone-3-hydroxylase (F3H, EC 1.14.11.9), another dioxygenase in the flavonoid pathway, to convert naringenin to dihydrokaempferol in vitro.	naringenin	234-244	leucoanthocyanidin dioxygenase	Arabidopsis thaliana	60-64
27219053-4	2016	In this study, we cloned the full-length cDNA of R. trigyna LDOX (RtLDOX), and found RtLDOX recombinant protein was able to replace flavanone-3-hydroxylase (F3H, EC 1.14.11.9), another dioxygenase in the flavonoid pathway, to convert naringenin to dihydrokaempferol in vitro.	naringenin	234-244	flavanone 3-hydroxylase	Arabidopsis thaliana	157-160
26960693-0	2016	Naringenin inhibits proliferation, migration, and invasion as well as induces apoptosis of gastric cancer SGC7901 cell line by downregulation of AKT pathway.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	145-148
27260463-4	2016	We found that naringenin reduced hyperalgesia to mechanical and thermal stimuli, myeloperoxidase (MPO, a neutrophil and macrophage marker) and N-acetyl-beta-D-glucosaminidase (NAG, a macrophage marker) activities, oxidative stress and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production in the paw skin.	naringenin	14-24	myeloperoxidase	Mus musculus	81-96
27260463-4	2016	We found that naringenin reduced hyperalgesia to mechanical and thermal stimuli, myeloperoxidase (MPO, a neutrophil and macrophage marker) and N-acetyl-beta-D-glucosaminidase (NAG, a macrophage marker) activities, oxidative stress and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production in the paw skin.	naringenin	14-24	myeloperoxidase	Mus musculus	98-101
27260463-4	2016	We found that naringenin reduced hyperalgesia to mechanical and thermal stimuli, myeloperoxidase (MPO, a neutrophil and macrophage marker) and N-acetyl-beta-D-glucosaminidase (NAG, a macrophage marker) activities, oxidative stress and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production in the paw skin.	naringenin	14-24	O-GlcNAcase	Mus musculus	143-174
27260463-4	2016	We found that naringenin reduced hyperalgesia to mechanical and thermal stimuli, myeloperoxidase (MPO, a neutrophil and macrophage marker) and N-acetyl-beta-D-glucosaminidase (NAG, a macrophage marker) activities, oxidative stress and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production in the paw skin.	naringenin	14-24	O-GlcNAcase	Mus musculus	176-179
27260463-4	2016	We found that naringenin reduced hyperalgesia to mechanical and thermal stimuli, myeloperoxidase (MPO, a neutrophil and macrophage marker) and N-acetyl-beta-D-glucosaminidase (NAG, a macrophage marker) activities, oxidative stress and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production in the paw skin.	naringenin	14-24	tumor necrosis factor	Mus musculus	245-254
27260463-4	2016	We found that naringenin reduced hyperalgesia to mechanical and thermal stimuli, myeloperoxidase (MPO, a neutrophil and macrophage marker) and N-acetyl-beta-D-glucosaminidase (NAG, a macrophage marker) activities, oxidative stress and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production in the paw skin.	naringenin	14-24	interleukin 1 beta	Mus musculus	256-264
27260463-4	2016	We found that naringenin reduced hyperalgesia to mechanical and thermal stimuli, myeloperoxidase (MPO, a neutrophil and macrophage marker) and N-acetyl-beta-D-glucosaminidase (NAG, a macrophage marker) activities, oxidative stress and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production in the paw skin.	naringenin	14-24	interleukin 6	Mus musculus	266-270
27260463-5	2016	In the peritoneal cavity, naringenin reduced neutrophil and mononuclear cell recruitment, and abrogated MPO and NAG activity, cytokine and superoxide anion production, and lipid peroxidation.	naringenin	26-36	myeloperoxidase	Mus musculus	104-107
27260463-5	2016	In the peritoneal cavity, naringenin reduced neutrophil and mononuclear cell recruitment, and abrogated MPO and NAG activity, cytokine and superoxide anion production, and lipid peroxidation.	naringenin	26-36	O-GlcNAcase	Mus musculus	112-115
27260463-6	2016	In vitro, pre-treatment with naringenin inhibited superoxide anion and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production by LPS-stimulated RAW 264.7 macrophages.	naringenin	29-39	tumor necrosis factor	Mus musculus	81-90
27260463-6	2016	In vitro, pre-treatment with naringenin inhibited superoxide anion and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production by LPS-stimulated RAW 264.7 macrophages.	naringenin	29-39	interleukin 1 beta	Mus musculus	92-100
27260463-6	2016	In vitro, pre-treatment with naringenin inhibited superoxide anion and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production by LPS-stimulated RAW 264.7 macrophages.	naringenin	29-39	interleukin 6	Mus musculus	102-106
28905572-6	2016	The wavelength was set at 226 nm and column temperature was 25 C. The HPLC method showed good linearity within the range of 3.90-250.00 g mL-1 (r = 0.999 9) for naringenin.	naringenin	161-171	L1 cell adhesion molecule	Mus musculus	138-142
27363651-6	2016	In addition, NG significantly inhibited the increase of cardiac expression of IL-1beta, IL-6, and interferon gamma.	naringenin	13-15	interleukin 1 beta	Rattus norvegicus	78-86
26994515-0	2016	Naringenin-induced migration of embrynoic trophectoderm cells is mediated via PI3K/AKT and ERK1/2 MAPK signaling cascades.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	83-86
26994515-0	2016	Naringenin-induced migration of embrynoic trophectoderm cells is mediated via PI3K/AKT and ERK1/2 MAPK signaling cascades.	naringenin	0-10	mitogen-activated protein kinase 3	Homo sapiens	91-97
26994515-0	2016	Naringenin-induced migration of embrynoic trophectoderm cells is mediated via PI3K/AKT and ERK1/2 MAPK signaling cascades.	naringenin	0-10	mitogen-activated protein kinase 3	Homo sapiens	98-102
26994515-6	2016	Also, naringenin activated the phosphorylation of AKT and ERK1/2 proteins in a dose-dependent manner and those proteins were abundant mainly in the cytoplasm of naringenin-treated pTr cells.	naringenin	6-16	AKT serine/threonine kinase 1	Homo sapiens	50-53
27363651-6	2016	In addition, NG significantly inhibited the increase of cardiac expression of IL-1beta, IL-6, and interferon gamma.	naringenin	13-15	interleukin 6	Rattus norvegicus	88-92
26994515-6	2016	Also, naringenin activated the phosphorylation of AKT and ERK1/2 proteins in a dose-dependent manner and those proteins were abundant mainly in the cytoplasm of naringenin-treated pTr cells.	naringenin	6-16	mitogen-activated protein kinase 3	Homo sapiens	58-64
27363651-9	2016	Inhibition of Nrf2 markedly suppressed NG-induced increase of GCLc expression in Ang II-treated cardiac fibroblasts.	naringenin	39-41	NFE2 like bZIP transcription factor 2	Rattus norvegicus	14-18
26994515-6	2016	Also, naringenin activated the phosphorylation of AKT and ERK1/2 proteins in a dose-dependent manner and those proteins were abundant mainly in the cytoplasm of naringenin-treated pTr cells.	naringenin	161-171	AKT serine/threonine kinase 1	Homo sapiens	50-53
27363651-9	2016	Inhibition of Nrf2 markedly suppressed NG-induced increase of GCLc expression in Ang II-treated cardiac fibroblasts.	naringenin	39-41	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	62-66
26994515-6	2016	Also, naringenin activated the phosphorylation of AKT and ERK1/2 proteins in a dose-dependent manner and those proteins were abundant mainly in the cytoplasm of naringenin-treated pTr cells.	naringenin	161-171	mitogen-activated protein kinase 3	Homo sapiens	58-64
27036297-0	2016	Naringenin prevents TGF-beta1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation.	naringenin	0-10	transforming growth factor, beta 1	Mus musculus	20-29
26994515-7	2016	Within 30 min after treatment with 20 muM naringenin, the abundance of phosphorylated EKR1/2, P70S6K, P90RSK and S6K proteins increased, and then returned to basal levels by 120 min whereas the abundance of AKT increased gradually to 120 min post-treatment.	naringenin	42-52	ribosomal protein S6 kinase B1	Homo sapiens	94-100
26994515-7	2016	Within 30 min after treatment with 20 muM naringenin, the abundance of phosphorylated EKR1/2, P70S6K, P90RSK and S6K proteins increased, and then returned to basal levels by 120 min whereas the abundance of AKT increased gradually to 120 min post-treatment.	naringenin	42-52	ribosomal protein S6 kinase A1	Homo sapiens	102-108
26994515-7	2016	Within 30 min after treatment with 20 muM naringenin, the abundance of phosphorylated EKR1/2, P70S6K, P90RSK and S6K proteins increased, and then returned to basal levels by 120 min whereas the abundance of AKT increased gradually to 120 min post-treatment.	naringenin	42-52	ribosomal protein S6 kinase B1	Homo sapiens	97-100
26994515-7	2016	Within 30 min after treatment with 20 muM naringenin, the abundance of phosphorylated EKR1/2, P70S6K, P90RSK and S6K proteins increased, and then returned to basal levels by 120 min whereas the abundance of AKT increased gradually to 120 min post-treatment.	naringenin	42-52	AKT serine/threonine kinase 1	Homo sapiens	207-210
26994515-8	2016	However, the phosphorylation of AKT, P70S6K, P90RSK and S6K was reduced in naringenin-induced pTr cells pre-treated with a PI3K inhibitor (LY294002).	naringenin	75-85	AKT serine/threonine kinase 1	Homo sapiens	32-35
26994515-8	2016	However, the phosphorylation of AKT, P70S6K, P90RSK and S6K was reduced in naringenin-induced pTr cells pre-treated with a PI3K inhibitor (LY294002).	naringenin	75-85	ribosomal protein S6 kinase B1	Homo sapiens	37-43
26994515-8	2016	However, the phosphorylation of AKT, P70S6K, P90RSK and S6K was reduced in naringenin-induced pTr cells pre-treated with a PI3K inhibitor (LY294002).	naringenin	75-85	ribosomal protein S6 kinase A1	Homo sapiens	45-51
26994515-8	2016	However, the phosphorylation of AKT, P70S6K, P90RSK and S6K was reduced in naringenin-induced pTr cells pre-treated with a PI3K inhibitor (LY294002).	naringenin	75-85	ribosomal protein S6 kinase B1	Homo sapiens	40-43
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	naringenin	57-67	mitogen-activated protein kinase kinase 1	Homo sapiens	8-14
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	naringenin	57-67	mitogen-activated protein kinase 3	Homo sapiens	95-101
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	naringenin	57-67	ribosomal protein S6 kinase B1	Homo sapiens	103-109
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	naringenin	57-67	ribosomal protein S6 kinase B1	Homo sapiens	106-109
26994515-11	2016	Collectively, results of the present study suggest that naringenin supports migration of pTr cells through PI3K/AKT and ERK1/2 MAPK signaling pathways crucial for orchestrating conceptus-uterine interactions.	naringenin	56-66	AKT serine/threonine kinase 1	Homo sapiens	112-115
26994515-11	2016	Collectively, results of the present study suggest that naringenin supports migration of pTr cells through PI3K/AKT and ERK1/2 MAPK signaling pathways crucial for orchestrating conceptus-uterine interactions.	naringenin	56-66	mitogen-activated protein kinase 3	Homo sapiens	120-126
26994515-11	2016	Collectively, results of the present study suggest that naringenin supports migration of pTr cells through PI3K/AKT and ERK1/2 MAPK signaling pathways crucial for orchestrating conceptus-uterine interactions.	naringenin	56-66	mitogen-activated protein kinase 3	Homo sapiens	127-131
27105956-0	2016	Naringenin exerts anti-angiogenic effects in human endothelial cells: Involvement of ERRalpha/VEGF/KDR signaling pathway.	naringenin	0-10	estrogen related receptor alpha	Homo sapiens	85-93
27105956-0	2016	Naringenin exerts anti-angiogenic effects in human endothelial cells: Involvement of ERRalpha/VEGF/KDR signaling pathway.	naringenin	0-10	vascular endothelial growth factor A	Homo sapiens	94-98
27105956-0	2016	Naringenin exerts anti-angiogenic effects in human endothelial cells: Involvement of ERRalpha/VEGF/KDR signaling pathway.	naringenin	0-10	kinase insert domain receptor	Homo sapiens	99-102
26861188-0	2016	Naringenin targets ERK2 and suppresses UVB-induced photoaging.	naringenin	0-10	mitogen-activated protein kinase 1	Homo sapiens	19-23
26861188-2	2016	We investigated the effect of naringenin, a major flavonoid found in citrus, on UVB-induced MMP-1 expression and identified its direct target.	naringenin	30-40	matrix metallopeptidase 1	Homo sapiens	92-97
26861188-7	2016	Naringenin suppressed UVB-induced MMP-1 expression and AP-1 activity, and strongly suppressed UVB-induced phosphorylation of Fos-related antigen (FRA)-1 at Ser265.	naringenin	0-10	matrix metallopeptidase 1	Homo sapiens	34-39
26861188-7	2016	Naringenin suppressed UVB-induced MMP-1 expression and AP-1 activity, and strongly suppressed UVB-induced phosphorylation of Fos-related antigen (FRA)-1 at Ser265.	naringenin	0-10	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	125-152
26861188-8	2016	Importantly, UVB irradiation-induced FRA1 protein stability was reduced by treatment with naringenin, as well as with a mitogen-activated protein kinase (MEK) inhibitor.	naringenin	90-100	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	37-41
26861188-9	2016	Naringenin significantly suppressed UVB-induced extracellular signal-regulated kinase 2 (ERK2) activity and subsequently attenuated UVB-induced phosphorylation of p90(RSK) by competitively binding with ATP.	naringenin	0-10	mitogen-activated protein kinase 1	Homo sapiens	48-87
26861188-9	2016	Naringenin significantly suppressed UVB-induced extracellular signal-regulated kinase 2 (ERK2) activity and subsequently attenuated UVB-induced phosphorylation of p90(RSK) by competitively binding with ATP.	naringenin	0-10	mitogen-activated protein kinase 1	Homo sapiens	89-93
26861188-9	2016	Naringenin significantly suppressed UVB-induced extracellular signal-regulated kinase 2 (ERK2) activity and subsequently attenuated UVB-induced phosphorylation of p90(RSK) by competitively binding with ATP.	naringenin	0-10	transferrin receptor	Homo sapiens	163-166
26861188-9	2016	Naringenin significantly suppressed UVB-induced extracellular signal-regulated kinase 2 (ERK2) activity and subsequently attenuated UVB-induced phosphorylation of p90(RSK) by competitively binding with ATP.	naringenin	0-10	ribosomal protein S6 kinase A2	Homo sapiens	167-170
26861188-12	2016	The photoaging data obtained from mice clearly demonstrated that naringenin significantly inhibited UVB-induced wrinkle formation, trans-epidermal water loss and MMP-13 expression.	naringenin	65-75	matrix metallopeptidase 13	Mus musculus	162-168
26861188-13	2016	Naringenin exerts potent anti-photoaging effects by suppressing ERK2 activity and decreasing FRA1 stability, followed by down-regulation of AP-1 transactivation and MMP-1 expression.	naringenin	0-10	mitogen-activated protein kinase 1	Homo sapiens	64-68
26861188-13	2016	Naringenin exerts potent anti-photoaging effects by suppressing ERK2 activity and decreasing FRA1 stability, followed by down-regulation of AP-1 transactivation and MMP-1 expression.	naringenin	0-10	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	93-97
26861188-13	2016	Naringenin exerts potent anti-photoaging effects by suppressing ERK2 activity and decreasing FRA1 stability, followed by down-regulation of AP-1 transactivation and MMP-1 expression.	naringenin	0-10	matrix metallopeptidase 1	Homo sapiens	165-170
27071308-5	2016	The 3-dimensional structure of nsP3 was retrieved from the Protein Data Bank, prepared and, using AutoDock Vina, docked with baicalin, naringenin and quercetagetin as ligands.	naringenin	135-145	SH2 domain containing 3C	Homo sapiens	31-35
26907804-10	2016	The mechanisms of naringenin involve the inhibition of carrageenan-induced oxidative stress, hyperalgesic cytokines (IL-33, TNF-alpha, and IL-1beta) production and NF-kappaB activation in the paw skin.	naringenin	18-28	interleukin 33	Mus musculus	117-122
26907804-10	2016	The mechanisms of naringenin involve the inhibition of carrageenan-induced oxidative stress, hyperalgesic cytokines (IL-33, TNF-alpha, and IL-1beta) production and NF-kappaB activation in the paw skin.	naringenin	18-28	tumor necrosis factor	Mus musculus	124-133
26907804-10	2016	The mechanisms of naringenin involve the inhibition of carrageenan-induced oxidative stress, hyperalgesic cytokines (IL-33, TNF-alpha, and IL-1beta) production and NF-kappaB activation in the paw skin.	naringenin	18-28	interleukin 1 beta	Mus musculus	139-147
27045367-0	2016	Naringenin Inhibits Superoxide Anion-Induced Inflammatory Pain: Role of Oxidative Stress, Cytokines, Nrf-2 and the NO-cGMP-PKG-KATP Channel Signaling Pathway.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	101-106
27045367-5	2016	Furthermore, naringenin downregulated KO2-induced mRNA expression of gp91phox, cyclooxygenase (COX)-2, and preproendothelin-1.	naringenin	13-23	cytochrome b-245 beta chain	Homo sapiens	69-77
27045367-5	2016	Furthermore, naringenin downregulated KO2-induced mRNA expression of gp91phox, cyclooxygenase (COX)-2, and preproendothelin-1.	naringenin	13-23	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	79-101
27045367-5	2016	Furthermore, naringenin downregulated KO2-induced mRNA expression of gp91phox, cyclooxygenase (COX)-2, and preproendothelin-1.	naringenin	13-23	endothelin 1	Homo sapiens	107-125
27045367-6	2016	Besides, naringenin upregulated KO2-reduced nuclear factor (erythroid-derived 2)-like 2 (Nrf2) mRNA expression coupled with enhanced heme oxygenase (HO-1) mRNA expression.	naringenin	9-19	NFE2 like bZIP transcription factor 2	Homo sapiens	89-93
27036297-2	2016	We have previously demonstrated that naringenin significantly reduced TGF-beta1 levels in bleomycin-induced lung fibrosis and effectively prevented pulmonary metastases of tumors.	naringenin	37-47	transforming growth factor, beta 1	Mus musculus	70-79
27036297-3	2016	This raised the question of whether naringenin can block TGF-beta1 secretion from breast cancer cells and inhibit their pulmonary metastasis.	naringenin	36-46	transforming growth factor, beta 1	Mus musculus	57-66
27036297-7	2016	The mechanism whereby naringenin decreases TGF-beta1 secretion from breast cancer cells was investigated at different levels, including Tgf-beta1 transcription, mRNA stability, translation, and extracellular release.	naringenin	22-32	transforming growth factor, beta 1	Mus musculus	43-52
27036297-9	2016	Administration of the TGF-beta1 blocking antibody 1D11 or naringenin showed an inhibition of pulmonary metastasis for both 4T1/TGF-beta1 tumors and 4T1/RFP tumors, resulting in increased survival of the mice.	naringenin	58-68	transforming growth factor, beta 1	Mus musculus	127-136
27036297-13	2016	Further experiments revealed that naringenin had no effect on Tgf-beta1 transcription, mRNA decay or protein translation, but prevented TGF-beta1 transport from the trans-Golgi network by inhibiting PKC activity.	naringenin	34-44	transforming growth factor, beta 1	Mus musculus	136-145
27036297-14	2016	CONCLUSIONS: Naringenin blocks TGF-beta1 trafficking from the trans-Golgi network by suppressing PKC activity, resulting in a reduction of TGF-beta1 secretion from breast cancer cells.	naringenin	13-23	transforming growth factor, beta 1	Mus musculus	31-40
27036297-14	2016	CONCLUSIONS: Naringenin blocks TGF-beta1 trafficking from the trans-Golgi network by suppressing PKC activity, resulting in a reduction of TGF-beta1 secretion from breast cancer cells.	naringenin	13-23	transforming growth factor, beta 1	Mus musculus	139-148
27036297-15	2016	This finding suggests that naringenin may be an attractive therapeutic candidate for TGF-beta1 related diseases.	naringenin	27-37	transforming growth factor, beta 1	Mus musculus	85-94
26801071-8	2016	Compared with diabetic control group, apigenin and naringenin significantly decreased the levels of blood glucose, serum lipid, malonaldehyde, ICAM-1 and insulin resistance index, increased SOD activity and improved impaired glucose tolerance.	naringenin	51-61	intercellular adhesion molecule 1	Rattus norvegicus	143-149
26881453-5	2016	Although naringenin induces apoptosis in cancer cells we found that it can protect against radiation-induced apoptosis in normal cells by modulating the expression of p53, Bax, and Bcl-2.	naringenin	9-19	transformation related protein 53, pseudogene	Mus musculus	167-170
26881453-5	2016	Although naringenin induces apoptosis in cancer cells we found that it can protect against radiation-induced apoptosis in normal cells by modulating the expression of p53, Bax, and Bcl-2.	naringenin	9-19	BCL2-associated X protein	Mus musculus	172-175
26881453-5	2016	Although naringenin induces apoptosis in cancer cells we found that it can protect against radiation-induced apoptosis in normal cells by modulating the expression of p53, Bax, and Bcl-2.	naringenin	9-19	B cell leukemia/lymphoma 2	Mus musculus	181-186
26797111-0	2016	Naringenin-Mediated ATF3 Expression Contributes to Apoptosis in Human Colon Cancer.	naringenin	0-10	activating transcription factor 3	Homo sapiens	20-24
25579382-7	2016	In this study, we demonstrated that naringenin inhibites the release of nitric oxide (NO), the expression of inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), as well as pro-inflammatory cytokines in microglial cells.	naringenin	36-46	nitric oxide synthase 2, inducible	Mus musculus	109-140
25579382-7	2016	In this study, we demonstrated that naringenin inhibites the release of nitric oxide (NO), the expression of inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), as well as pro-inflammatory cytokines in microglial cells.	naringenin	36-46	nitric oxide synthase 2, inducible	Mus musculus	142-146
25579382-7	2016	In this study, we demonstrated that naringenin inhibites the release of nitric oxide (NO), the expression of inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), as well as pro-inflammatory cytokines in microglial cells.	naringenin	36-46	prostaglandin-endoperoxide synthase 2	Mus musculus	153-169
25579382-7	2016	In this study, we demonstrated that naringenin inhibites the release of nitric oxide (NO), the expression of inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), as well as pro-inflammatory cytokines in microglial cells.	naringenin	36-46	prostaglandin-endoperoxide synthase 2	Mus musculus	171-176
25579382-8	2016	Treatment of naringenin also induced suppressors of cytokine signaling (SOCS)-3 expression in microglia.	naringenin	13-23	suppressor of cytokine signaling 3	Mus musculus	37-79
25579382-9	2016	The SOCS-3 expression and anti-inflammatory effects of naringenin were found to be regulated by adenosine monophosphate-activated protein kinase alpha (AMPKalpha) and protein kinase C delta (PKCdelta).	naringenin	55-65	suppressor of cytokine signaling 3	Mus musculus	4-10
25579382-9	2016	The SOCS-3 expression and anti-inflammatory effects of naringenin were found to be regulated by adenosine monophosphate-activated protein kinase alpha (AMPKalpha) and protein kinase C delta (PKCdelta).	naringenin	55-65	protein kinase C, delta	Mus musculus	167-189
25579382-9	2016	The SOCS-3 expression and anti-inflammatory effects of naringenin were found to be regulated by adenosine monophosphate-activated protein kinase alpha (AMPKalpha) and protein kinase C delta (PKCdelta).	naringenin	55-65	protein kinase C, delta	Mus musculus	191-199
25579382-11	2016	Our findings suggest that naringenin-inhibited iNOS and COX-2 expression is mediated by SOCS-3 activation through AMPKalpha and PKCdelta signaling pathways.	naringenin	26-36	nitric oxide synthase 2, inducible	Mus musculus	47-51
25579382-11	2016	Our findings suggest that naringenin-inhibited iNOS and COX-2 expression is mediated by SOCS-3 activation through AMPKalpha and PKCdelta signaling pathways.	naringenin	26-36	prostaglandin-endoperoxide synthase 2	Mus musculus	56-61
25579382-11	2016	Our findings suggest that naringenin-inhibited iNOS and COX-2 expression is mediated by SOCS-3 activation through AMPKalpha and PKCdelta signaling pathways.	naringenin	26-36	suppressor of cytokine signaling 3	Mus musculus	88-94
25579382-11	2016	Our findings suggest that naringenin-inhibited iNOS and COX-2 expression is mediated by SOCS-3 activation through AMPKalpha and PKCdelta signaling pathways.	naringenin	26-36	protein kinase C, delta	Mus musculus	128-136
26801071-11	2016	In vitro, apigenin and naringenin inhibited NF-kappaB activation and ICAM-1 mRNA expression in PA-treated endothelial cells and improved nitric oxide production in the presence of insulin.	naringenin	23-33	intercellular adhesion molecule 1	Rattus norvegicus	69-75
26722818-6	2016	Then, inhibitory effects of 10 flavonoid compounds including 8 derivatives of 2-benzylidenebenzofuran-3(2H)-ones, as well as naringenin and ellagic acid on the activity of aldehyde oxidase were assessed compared with the specific inhibitor of AO, menadione.	naringenin	125-135	aldehyde oxidase 1	Homo sapiens	172-188
26893664-8	2016	Naringenin and ABT-737 also decreased Akt activation and increased p53 expression, suggesting the involvement of these pathways in the inhibition of gastric cell growth.	naringenin	0-10	tumor protein p53	Homo sapiens	67-70
27904048-1	2016	Hesperetin (HET) and naringenin (NGR) are flavanones found in citrus (oranges and grapefruit) and Aurantii Fructus Immaturus.	naringenin	21-31	reticulon 4 receptor	Homo sapiens	33-36
26530401-3	2016	Hesperetin and naringenin are naturally occurring flavanones and are reported as modulators of CYP enzymes and P-gp.	naringenin	15-25	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	95-98
26530401-3	2016	Hesperetin and naringenin are naturally occurring flavanones and are reported as modulators of CYP enzymes and P-gp.	naringenin	15-25	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	111-115
26530401-10	2016	Our findings suggested that hesperetin and naringenin enhanced the systemic exposure of rasagiline might be through the inhibition of CYP1A2 but not P-gp.	naringenin	43-53	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	134-140
26530401-10	2016	Our findings suggested that hesperetin and naringenin enhanced the systemic exposure of rasagiline might be through the inhibition of CYP1A2 but not P-gp.	naringenin	43-53	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	149-153
26872264-10	2016	Naringenin significantly decreased the LPS-induced expression of nuclear factor-x03BA;B, inducible NO synthase, tumor necrosis factor-alpha, caspase-3, and significantly increased heat shock protein 70 expression in the lungs.	naringenin	0-10	tumor necrosis factor	Rattus norvegicus	112-139
27446963-0	2016	Naringenin Ameliorated Kidney Injury through Let-7a/TGFBR1 Signaling in Diabetic Nephropathy.	naringenin	0-10	transforming growth factor, beta receptor 1	Rattus norvegicus	52-58
26656314-0	2016	Effect of apigenin-7-glucoside, genkwanin and naringenin on tyrosinase activity and melanin synthesis in B16F10 melanoma cells.	naringenin	46-56	tyrosinase	Mus musculus	60-70
26656314-9	2016	Moreover, apigenin-7-glucoside and naringenin revealed an ability to enhance melanogenesis synthesis and tyrosinase activity of B16F10 melanoma cells.	naringenin	35-45	tyrosinase	Mus musculus	105-115
26655880-0	2016	Naringenin ameliorates inflammation and cell proliferation in benzo(a)pyrene induced pulmonary carcinogenesis by modulating CYP1A1, NFkappaB and PCNA expression.	naringenin	0-10	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	124-130
26655880-0	2016	Naringenin ameliorates inflammation and cell proliferation in benzo(a)pyrene induced pulmonary carcinogenesis by modulating CYP1A1, NFkappaB and PCNA expression.	naringenin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	132-140
26655880-0	2016	Naringenin ameliorates inflammation and cell proliferation in benzo(a)pyrene induced pulmonary carcinogenesis by modulating CYP1A1, NFkappaB and PCNA expression.	naringenin	0-10	proliferating cell nuclear antigen	Mus musculus	145-149
25774442-0	2016	Naringenin and quercetin--potential anti-HCV agents for NS2 protease targets.	naringenin	0-10	NS2	Homo sapiens	56-59
25774442-4	2016	Among the molecules tested for docking study, naringenin and quercetin revealed minimum binding energy of - 7.97 and - 7.95 kcal/mol with NS2 protease.	naringenin	46-56	NS2	Homo sapiens	138-141
26872264-10	2016	Naringenin significantly decreased the LPS-induced expression of nuclear factor-x03BA;B, inducible NO synthase, tumor necrosis factor-alpha, caspase-3, and significantly increased heat shock protein 70 expression in the lungs.	naringenin	0-10	caspase 3	Rattus norvegicus	141-150
26872264-10	2016	Naringenin significantly decreased the LPS-induced expression of nuclear factor-x03BA;B, inducible NO synthase, tumor necrosis factor-alpha, caspase-3, and significantly increased heat shock protein 70 expression in the lungs.	naringenin	0-10	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	180-201
26668617-7	2015	Naringenin also inhibited the expression of transforming growth factor-beta1, connective tissue growth factor, collagen Ialpha and collagen IIIalpha, and attenuated interstitial fibrosis.	naringenin	0-10	transforming growth factor, beta 1	Mus musculus	44-76
26668617-8	2015	In addition, naringenin downregulated the activation of the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathways.	naringenin	13-23	mitogen-activated protein kinase 1	Mus musculus	60-97
26668617-8	2015	In addition, naringenin downregulated the activation of the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathways.	naringenin	13-23	mitogen-activated protein kinase 1	Mus musculus	99-102
26668617-8	2015	In addition, naringenin downregulated the activation of the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathways.	naringenin	13-23	mitogen-activated protein kinase 8	Mus musculus	105-128
26668617-8	2015	In addition, naringenin downregulated the activation of the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathways.	naringenin	13-23	mitogen-activated protein kinase 8	Mus musculus	130-133
26668617-8	2015	In addition, naringenin downregulated the activation of the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathways.	naringenin	13-23	thymoma viral proto-oncogene 1	Mus musculus	190-193
26668617-10	2015	The cardioprotective effect exerted by naringenin may be associated with the inhibition of PI3K/Akt, ERK and JNK signaling pathways.	naringenin	39-49	thymoma viral proto-oncogene 1	Mus musculus	96-99
26668617-10	2015	The cardioprotective effect exerted by naringenin may be associated with the inhibition of PI3K/Akt, ERK and JNK signaling pathways.	naringenin	39-49	mitogen-activated protein kinase 1	Mus musculus	101-104
26668617-10	2015	The cardioprotective effect exerted by naringenin may be associated with the inhibition of PI3K/Akt, ERK and JNK signaling pathways.	naringenin	39-49	mitogen-activated protein kinase 8	Mus musculus	109-112
26474462-0	2015	Treatment of renal fibrosis by rebalancing TGF-beta/Smad signaling with the combination of asiatic acid and naringenin.	naringenin	108-118	transforming growth factor, beta 1	Mus musculus	43-51
26350255-4	2015	In mice with CIA, the oral administration of naringenin ameliorated the severity of arthritis, reduced the levels of anticollagen Type II (CII) IgG and limited the proliferation of T cells, observed as a lower frequency of Th1 and Th17 cells in the spleen after restimulation with CII.	naringenin	45-55	negative elongation factor complex member C/D, Th1l	Mus musculus	223-226
26496980-8	2015	Numerous pathways, including p53, c-Jun N-terminal kinases (JNK), Akt and extracellular signal-regulated kinases (ERK)1/2 pathways were markedly altered following treatment of THP-1 cells with curcumin and naringenin.	naringenin	206-216	tumor protein p53	Homo sapiens	29-32
26496980-8	2015	Numerous pathways, including p53, c-Jun N-terminal kinases (JNK), Akt and extracellular signal-regulated kinases (ERK)1/2 pathways were markedly altered following treatment of THP-1 cells with curcumin and naringenin.	naringenin	206-216	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	34-39
26496980-8	2015	Numerous pathways, including p53, c-Jun N-terminal kinases (JNK), Akt and extracellular signal-regulated kinases (ERK)1/2 pathways were markedly altered following treatment of THP-1 cells with curcumin and naringenin.	naringenin	206-216	AKT serine/threonine kinase 1	Homo sapiens	66-69
26496980-8	2015	Numerous pathways, including p53, c-Jun N-terminal kinases (JNK), Akt and extracellular signal-regulated kinases (ERK)1/2 pathways were markedly altered following treatment of THP-1 cells with curcumin and naringenin.	naringenin	206-216	mitogen-activated protein kinase 3	Homo sapiens	74-121
26496980-9	2015	These results indicated that naringenin may enhance curcumin-induced apoptosis through inhibiting the Akt and ERK pathways, and promoting the JNK and p53 pathways.	naringenin	29-39	AKT serine/threonine kinase 1	Homo sapiens	102-105
26496980-9	2015	These results indicated that naringenin may enhance curcumin-induced apoptosis through inhibiting the Akt and ERK pathways, and promoting the JNK and p53 pathways.	naringenin	29-39	mitogen-activated protein kinase 1	Homo sapiens	110-113
26496980-9	2015	These results indicated that naringenin may enhance curcumin-induced apoptosis through inhibiting the Akt and ERK pathways, and promoting the JNK and p53 pathways.	naringenin	29-39	tumor protein p53	Homo sapiens	150-153
26474462-2	2015	In the present study, we report here that inhibition of Smad3 with naringenin (NG) and upregulation of Smad7 with asiatic acid (AA) produced an additive effect on inhibition of renal fibrosis in a mouse model of obstructive nephropathy.	naringenin	67-77	SMAD family member 3	Mus musculus	56-61
26474462-2	2015	In the present study, we report here that inhibition of Smad3 with naringenin (NG) and upregulation of Smad7 with asiatic acid (AA) produced an additive effect on inhibition of renal fibrosis in a mouse model of obstructive nephropathy.	naringenin	79-81	SMAD family member 3	Mus musculus	56-61
26187552-0	2015	Naringenin neutralises oxidative stress and nerve growth factor discrepancy in experimental diabetic neuropathy.	naringenin	0-10	nerve growth factor	Rattus norvegicus	44-63
26466635-2	2015	Rats were fed diets containing 0, 1, or 2.5 g/kg naringenin for 15 d. Naringenin at a dietary level of 2.5 g/kg significantly decreased the activities and the mRNA levels of various lipogenic enzymes and sterol regulatory element binding protein-1c (SREBP-1c) mRNA level.	naringenin	49-59	sterol regulatory element binding transcription factor 1	Rattus norvegicus	204-248
26466635-2	2015	Rats were fed diets containing 0, 1, or 2.5 g/kg naringenin for 15 d. Naringenin at a dietary level of 2.5 g/kg significantly decreased the activities and the mRNA levels of various lipogenic enzymes and sterol regulatory element binding protein-1c (SREBP-1c) mRNA level.	naringenin	70-80	sterol regulatory element binding transcription factor 1	Rattus norvegicus	204-248
26466635-2	2015	Rats were fed diets containing 0, 1, or 2.5 g/kg naringenin for 15 d. Naringenin at a dietary level of 2.5 g/kg significantly decreased the activities and the mRNA levels of various lipogenic enzymes and sterol regulatory element binding protein-1c (SREBP-1c) mRNA level.	naringenin	70-80	sterol regulatory element binding transcription factor 1	Rattus norvegicus	250-258
26100136-0	2015	Naringenin enhances NK cell lysis activity by increasing the expression of NKG2D ligands on Burkitt"s lymphoma cells.	naringenin	0-10	killer cell lectin like receptor K1	Homo sapiens	75-80
26100136-7	2015	The activity of naringenin was due to enhanced NKG2D ligand expression.	naringenin	16-26	killer cell lectin like receptor K1	Homo sapiens	47-52
26148826-4	2015	Naringenin, but not a combination of naringenin and fulvestrant (an estrogenic receptor antagonist) significantly improved the performance of Abeta-injected rats in passive avoidance and RAM tasks.	naringenin	0-10	amyloid beta precursor protein	Rattus norvegicus	142-147
26148826-5	2015	Naringenin pretreatment of Abeta-injected rats also lowered hippocampal malondialdehyde (MDA) with no significant effect on nitrite and superoxide dismutase (SOD) activity in addition to lowering apoptosis.	naringenin	0-10	amyloid beta precursor protein	Rattus norvegicus	27-32
26148826-6	2015	These results suggest naringenin pretreatment attenuates Abeta-induced impairment of learning and memory through mitigation of lipid peroxidation and apoptosis and its beneficial effect is somewhat mediated via estrogenic pathway.	naringenin	22-32	amyloid beta precursor protein	Rattus norvegicus	57-62
26157550-0	2015	Anti-Proliferative Effect of Naringenin through p38-Dependent Downregulation of Cyclin D1 in Human Colorectal Cancer Cells.	naringenin	29-39	mitogen-activated protein kinase 14	Homo sapiens	48-51
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	matrix metallopeptidase 9	Mus musculus	122-127
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	tumor necrosis factor	Mus musculus	160-169
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interferon gamma	Mus musculus	171-180
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 1 beta	Mus musculus	182-190
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 4	Mus musculus	192-196
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 5	Mus musculus	198-202
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 6	Mus musculus	204-208
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 13	Mus musculus	217-222
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 17A	Mus musculus	224-229
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 22	Mus musculus	231-236
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 23, alpha subunit p19	Mus musculus	242-247
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	transforming growth factor, beta 1	Mus musculus	272-280
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 10	Mus musculus	285-290
26154512-7	2015	Naringenin also inhibited oxidative stress by reducing superoxide anion production and the mRNA expression of gp91phox.	naringenin	0-10	cytochrome b-245, beta polypeptide	Mus musculus	110-118
26072060-0	2015	Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFkappaB p65 mediated inflammation.	naringenin	0-10	angiotensin II receptor, type 1a	Rattus norvegicus	73-77
26072060-0	2015	Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFkappaB p65 mediated inflammation.	naringenin	0-10	mitogen activated protein kinase 3	Rattus norvegicus	79-85
26072060-0	2015	Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFkappaB p65 mediated inflammation.	naringenin	0-10	synaptotagmin 1	Rattus norvegicus	95-98
26072060-12	2015	Furthermore, naringenin up regulated PPARgamma and down regulated AT1R, ET1, ETAR, p-ERK1/2, p-NFkappaB p65, ER stress, apoptosis, and inflammatory markers.	naringenin	13-23	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	37-46
26072060-12	2015	Furthermore, naringenin up regulated PPARgamma and down regulated AT1R, ET1, ETAR, p-ERK1/2, p-NFkappaB p65, ER stress, apoptosis, and inflammatory markers.	naringenin	13-23	angiotensin II receptor, type 1a	Rattus norvegicus	66-70
26072060-12	2015	Furthermore, naringenin up regulated PPARgamma and down regulated AT1R, ET1, ETAR, p-ERK1/2, p-NFkappaB p65, ER stress, apoptosis, and inflammatory markers.	naringenin	13-23	endothelin 1	Rattus norvegicus	72-75
26072060-12	2015	Furthermore, naringenin up regulated PPARgamma and down regulated AT1R, ET1, ETAR, p-ERK1/2, p-NFkappaB p65, ER stress, apoptosis, and inflammatory markers.	naringenin	13-23	endothelin receptor type A	Rattus norvegicus	77-81
26072060-12	2015	Furthermore, naringenin up regulated PPARgamma and down regulated AT1R, ET1, ETAR, p-ERK1/2, p-NFkappaB p65, ER stress, apoptosis, and inflammatory markers.	naringenin	13-23	mitogen activated protein kinase 3	Rattus norvegicus	85-91
26072060-12	2015	Furthermore, naringenin up regulated PPARgamma and down regulated AT1R, ET1, ETAR, p-ERK1/2, p-NFkappaB p65, ER stress, apoptosis, and inflammatory markers.	naringenin	13-23	synaptotagmin 1	Rattus norvegicus	104-107
26072060-13	2015	Our results suggest that naringenin has an ability to improve renal function and attenuates AT1R, ERK1/2-NFkappaB p65 signaling pathway in DNR induced nephrotoxicity in rats.	naringenin	25-35	angiotensin II receptor, type 1a	Rattus norvegicus	92-96
26072060-13	2015	Our results suggest that naringenin has an ability to improve renal function and attenuates AT1R, ERK1/2-NFkappaB p65 signaling pathway in DNR induced nephrotoxicity in rats.	naringenin	25-35	mitogen activated protein kinase 3	Rattus norvegicus	98-104
26072060-13	2015	Our results suggest that naringenin has an ability to improve renal function and attenuates AT1R, ERK1/2-NFkappaB p65 signaling pathway in DNR induced nephrotoxicity in rats.	naringenin	25-35	synaptotagmin 1	Rattus norvegicus	114-117
26050208-0	2015	Naringenin Mitigates Iron-Induced Anxiety-Like Behavioral Impairment, Mitochondrial Dysfunctions, Ectonucleotidases and Acetylcholinesterase Alteration Activities in Rat Hippocampus.	naringenin	0-10	acetylcholinesterase	Rattus norvegicus	120-140
26050208-4	2015	Results showed that administration of NGEN (50 mg/kg/day) by gavage significantly ameliorated anxiogenic-like behaviour impairment induced by the exposure to 50 mg of Fe-dextran/kg/day intraperitoneally for 28 days in rats, decreased iron-induced reactive oxygen species formation and restored the iron-induced decrease of the acetylcholinesterase expression level, mitochondrial membrane potential and mitochondrial complexes activities in the hippocampus of rats.	naringenin	38-42	acetylcholinesterase	Rattus norvegicus	327-347
26157550-0	2015	Anti-Proliferative Effect of Naringenin through p38-Dependent Downregulation of Cyclin D1 in Human Colorectal Cancer Cells.	naringenin	29-39	cyclin D1	Homo sapiens	80-89
25866363-3	2015	In this study, we investigated the mechanisms underlying naringenin-mediated inhibition of 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced cell invasion and inhibition of secreted and cytosolic MMP-9 production in human hepatoma cells (HepG2, Huh-7, and HA22T) and murine embryonic liver cells (BNL CL2).	naringenin	57-67	matrix metallopeptidase 9	Homo sapiens	197-202
25866363-3	2015	In this study, we investigated the mechanisms underlying naringenin-mediated inhibition of 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced cell invasion and inhibition of secreted and cytosolic MMP-9 production in human hepatoma cells (HepG2, Huh-7, and HA22T) and murine embryonic liver cells (BNL CL2).	naringenin	57-67	MIR7-3 host gene	Homo sapiens	246-251
25866363-4	2015	Naringenin suppressed MMP-9 transcription by inhibiting activator protein (AP)-1 and nuclear factor-kappaB (NF-kappaB) activity.	naringenin	0-10	matrix metallopeptidase 9	Homo sapiens	22-27
25866363-3	2015	In this study, we investigated the mechanisms underlying naringenin-mediated inhibition of 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced cell invasion and inhibition of secreted and cytosolic MMP-9 production in human hepatoma cells (HepG2, Huh-7, and HA22T) and murine embryonic liver cells (BNL CL2).	naringenin	57-67	doublecortin-like kinase 2	Mus musculus	302-305
25774553-4	2015	Because naringenin is a potent activator of hepatic FA oxidation, we hypothesized that induction of FGF21 might be an integral part of naringenin"s mechanism of action.	naringenin	8-18	fibroblast growth factor 21	Mus musculus	100-105
25774553-4	2015	Because naringenin is a potent activator of hepatic FA oxidation, we hypothesized that induction of FGF21 might be an integral part of naringenin"s mechanism of action.	naringenin	135-145	fibroblast growth factor 21	Mus musculus	100-105
25774553-5	2015	Furthermore, we predicted that FGF21 deficiency would potentiate high-fat diet (HFD)-induced metabolic dysregulation and compromise metabolic protection by naringenin.	naringenin	156-166	fibroblast growth factor 21	Mus musculus	31-36
25774553-9	2015	Naringenin corrected hepatic triglyceride concentrations and normalized hepatic expression of Pgc1a, Cpt1a, and Srebf1c in both wild-type and Fgf21(-/-) mice.	naringenin	0-10	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	94-99
25774553-9	2015	Naringenin corrected hepatic triglyceride concentrations and normalized hepatic expression of Pgc1a, Cpt1a, and Srebf1c in both wild-type and Fgf21(-/-) mice.	naringenin	0-10	carnitine palmitoyltransferase 1a, liver	Mus musculus	101-106
25774553-9	2015	Naringenin corrected hepatic triglyceride concentrations and normalized hepatic expression of Pgc1a, Cpt1a, and Srebf1c in both wild-type and Fgf21(-/-) mice.	naringenin	0-10	fibroblast growth factor 21	Mus musculus	142-147
25907027-5	2015	The IC50 values of eriodictyol, naringenin, and pinocembrin were 17.4 +- 0.40, 30.2 +- 0.61, and 44.9 +- 0.57 muM, respectively.	naringenin	32-42	latexin	Homo sapiens	110-113
26226761-4	2015	Western blotting was adopted to investigate the effect of naringenin on protein expressions of MDA-MB-231 cell Integrin beta3, beta1 and matrix metalloproteinase MMP-2 and MMP-9.	naringenin	58-68	integrin subunit beta 3	Homo sapiens	111-125
25735399-3	2015	The ability of compounds 1-23, together with the nonprenylated flavanones eriodictyol (24) and naringenin (25), to reduce the production of the pro-inflammatory cytokine TNF-alpha in THP-1 cells after bacterial lipopolysaccharide stimulation was evaluated using an in vitro screening test.	naringenin	95-105	tumor necrosis factor	Homo sapiens	170-179
25667616-10	2015	Furthermore, in the naringenin-treated K562 cells, the labeling index of proliferating cell nuclear antigen was observed to be increased by immunochemical staining, the mRNA and protein expression levels of p21/WAF1 were strongly upregulated in reverse transcription-polymerase chain reaction and western blot analyses, whereas p53 gene expression was not significantly changed.	naringenin	20-30	cyclin dependent kinase inhibitor 1A	Homo sapiens	207-210
25667616-10	2015	Furthermore, in the naringenin-treated K562 cells, the labeling index of proliferating cell nuclear antigen was observed to be increased by immunochemical staining, the mRNA and protein expression levels of p21/WAF1 were strongly upregulated in reverse transcription-polymerase chain reaction and western blot analyses, whereas p53 gene expression was not significantly changed.	naringenin	20-30	cyclin dependent kinase inhibitor 1A	Homo sapiens	211-215
25667616-10	2015	Furthermore, in the naringenin-treated K562 cells, the labeling index of proliferating cell nuclear antigen was observed to be increased by immunochemical staining, the mRNA and protein expression levels of p21/WAF1 were strongly upregulated in reverse transcription-polymerase chain reaction and western blot analyses, whereas p53 gene expression was not significantly changed.	naringenin	20-30	tumor protein p53	Homo sapiens	328-331
25667616-16	2015	Cell cycle arrest and apoptosis-inducing effects, achieved through p53-independent p21/WAF1 upregulation, are likely to be the mechanism of the antileukemic effects of naringenin, and the protective effect against ADM chemotherapy-induced damage in PMNs may be due to the antioxidant capability of this agent at low concentrations.	naringenin	168-178	tumor protein p53	Homo sapiens	67-70
25667616-16	2015	Cell cycle arrest and apoptosis-inducing effects, achieved through p53-independent p21/WAF1 upregulation, are likely to be the mechanism of the antileukemic effects of naringenin, and the protective effect against ADM chemotherapy-induced damage in PMNs may be due to the antioxidant capability of this agent at low concentrations.	naringenin	168-178	cyclin dependent kinase inhibitor 1A	Homo sapiens	83-86
25667616-16	2015	Cell cycle arrest and apoptosis-inducing effects, achieved through p53-independent p21/WAF1 upregulation, are likely to be the mechanism of the antileukemic effects of naringenin, and the protective effect against ADM chemotherapy-induced damage in PMNs may be due to the antioxidant capability of this agent at low concentrations.	naringenin	168-178	cyclin dependent kinase inhibitor 1A	Homo sapiens	87-91
26226761-4	2015	Western blotting was adopted to investigate the effect of naringenin on protein expressions of MDA-MB-231 cell Integrin beta3, beta1 and matrix metalloproteinase MMP-2 and MMP-9.	naringenin	58-68	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	127-132
26226761-4	2015	Western blotting was adopted to investigate the effect of naringenin on protein expressions of MDA-MB-231 cell Integrin beta3, beta1 and matrix metalloproteinase MMP-2 and MMP-9.	naringenin	58-68	matrix metallopeptidase 2	Homo sapiens	162-167
26226761-4	2015	Western blotting was adopted to investigate the effect of naringenin on protein expressions of MDA-MB-231 cell Integrin beta3, beta1 and matrix metalloproteinase MMP-2 and MMP-9.	naringenin	58-68	matrix metallopeptidase 9	Homo sapiens	172-177
26226761-8	2015	Naringenin could inhibit the protein expression of Integrin beta3 in a dose-dependent manner, but with unobvious effect on expression of Integrin beta1.	naringenin	0-10	integrin subunit beta 3	Homo sapiens	51-65
26226761-9	2015	Besides, naringenin could significantly inhibit the protein expressions of MMP-2 and MMP-9.	naringenin	9-19	matrix metallopeptidase 2	Homo sapiens	75-80
26226761-9	2015	Besides, naringenin could significantly inhibit the protein expressions of MMP-2 and MMP-9.	naringenin	9-19	matrix metallopeptidase 9	Homo sapiens	85-90
26226761-10	2015	The results of the computer virtual docking showed a negative value in the combining capacity between naringenin and Integrin beta3, indicating the high affinity between them.	naringenin	102-112	integrin subunit beta 3	Homo sapiens	117-131
25303878-0	2015	Protective effect of naringenin against lipopolysaccharide-induced injury in normal human bronchial epithelium via suppression of MAPK signaling.	naringenin	21-31	mitogen-activated protein kinase 3	Homo sapiens	130-134
26165014-0	2015	[Naringenin may block RSV-induced mucous hypersecretion in A549 cell via JNK/AP-1 signaling pathway].	naringenin	1-11	mitogen-activated protein kinase 8	Homo sapiens	73-76
26165014-0	2015	[Naringenin may block RSV-induced mucous hypersecretion in A549 cell via JNK/AP-1 signaling pathway].	naringenin	1-11	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	77-81
26165014-1	2015	OBJECTIVE: Naringenin has been reported to attenuate Mucin (MUC) 5AC secretion in many pathological models.	naringenin	11-21	LOC100508689	Homo sapiens	53-58
26165014-1	2015	OBJECTIVE: Naringenin has been reported to attenuate Mucin (MUC) 5AC secretion in many pathological models.	naringenin	11-21	LOC100508689	Homo sapiens	60-63
26165014-3	2015	We hypothesized that naringenin may have inhibitory effects on mucous hypersecretion by modulating MUC5AC production and inhibiting JNK/AP-1 signaling pathways.	naringenin	21-31	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	99-105
26165014-3	2015	We hypothesized that naringenin may have inhibitory effects on mucous hypersecretion by modulating MUC5AC production and inhibiting JNK/AP-1 signaling pathways.	naringenin	21-31	mitogen-activated protein kinase 8	Homo sapiens	132-135
26165014-3	2015	We hypothesized that naringenin may have inhibitory effects on mucous hypersecretion by modulating MUC5AC production and inhibiting JNK/AP-1 signaling pathways.	naringenin	21-31	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	136-140
25303878-3	2015	In vitro treatment with naringenin led to a significant attenuation in the LPS-induced NHBE secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), superoxidase dismutase (SOD), nitricoxide synthase (NOS), myeloperoxidase (MPO), and nitric oxide (NO).	naringenin	24-34	tumor necrosis factor	Homo sapiens	105-132
25256150-0	2015	Effects of Naringenin on inflammation in complete freund"s adjuvant-induced arthritis by regulating Bax/Bcl-2 balance.	naringenin	11-21	BCL2 associated X, apoptosis regulator	Rattus norvegicus	100-103
25256150-0	2015	Effects of Naringenin on inflammation in complete freund"s adjuvant-induced arthritis by regulating Bax/Bcl-2 balance.	naringenin	11-21	BCL2, apoptosis regulator	Rattus norvegicus	104-109
25303878-3	2015	In vitro treatment with naringenin led to a significant attenuation in the LPS-induced NHBE secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), superoxidase dismutase (SOD), nitricoxide synthase (NOS), myeloperoxidase (MPO), and nitric oxide (NO).	naringenin	24-34	tumor necrosis factor	Homo sapiens	134-143
25303878-3	2015	In vitro treatment with naringenin led to a significant attenuation in the LPS-induced NHBE secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), superoxidase dismutase (SOD), nitricoxide synthase (NOS), myeloperoxidase (MPO), and nitric oxide (NO).	naringenin	24-34	interleukin 6	Homo sapiens	146-159
25303878-3	2015	In vitro treatment with naringenin led to a significant attenuation in the LPS-induced NHBE secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), superoxidase dismutase (SOD), nitricoxide synthase (NOS), myeloperoxidase (MPO), and nitric oxide (NO).	naringenin	24-34	interleukin 6	Homo sapiens	161-165
25303878-3	2015	In vitro treatment with naringenin led to a significant attenuation in the LPS-induced NHBE secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), superoxidase dismutase (SOD), nitricoxide synthase (NOS), myeloperoxidase (MPO), and nitric oxide (NO).	naringenin	24-34	superoxide dismutase 1	Homo sapiens	168-190
25303878-3	2015	In vitro treatment with naringenin led to a significant attenuation in the LPS-induced NHBE secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), superoxidase dismutase (SOD), nitricoxide synthase (NOS), myeloperoxidase (MPO), and nitric oxide (NO).	naringenin	24-34	superoxide dismutase 1	Homo sapiens	192-195
25303878-3	2015	In vitro treatment with naringenin led to a significant attenuation in the LPS-induced NHBE secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), superoxidase dismutase (SOD), nitricoxide synthase (NOS), myeloperoxidase (MPO), and nitric oxide (NO).	naringenin	24-34	nitric oxide synthase 2	Homo sapiens	198-218
25303878-3	2015	In vitro treatment with naringenin led to a significant attenuation in the LPS-induced NHBE secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), superoxidase dismutase (SOD), nitricoxide synthase (NOS), myeloperoxidase (MPO), and nitric oxide (NO).	naringenin	24-34	myeloperoxidase	Homo sapiens	226-241
25303878-3	2015	In vitro treatment with naringenin led to a significant attenuation in the LPS-induced NHBE secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), superoxidase dismutase (SOD), nitricoxide synthase (NOS), myeloperoxidase (MPO), and nitric oxide (NO).	naringenin	24-34	myeloperoxidase	Homo sapiens	243-246
25303878-4	2015	RT-qPCR demonstrated that naringenin significantly reduced the LPS-induced upregulation of TNF-alpha, IL-6, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) p65 mRNA expression in a dose-dependent manner.	naringenin	26-36	tumor necrosis factor	Homo sapiens	91-100
25303878-4	2015	RT-qPCR demonstrated that naringenin significantly reduced the LPS-induced upregulation of TNF-alpha, IL-6, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) p65 mRNA expression in a dose-dependent manner.	naringenin	26-36	interleukin 6	Homo sapiens	102-106
25303878-4	2015	RT-qPCR demonstrated that naringenin significantly reduced the LPS-induced upregulation of TNF-alpha, IL-6, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) p65 mRNA expression in a dose-dependent manner.	naringenin	26-36	RELA proto-oncogene, NF-kB subunit	Homo sapiens	187-190
25303878-5	2015	Additionally, Western blot analysis revealed that naringenin effectively suppressed NF-kappaB activation by inhibiting the degradation of IkappaB-alpha and the translocation of p65.	naringenin	50-60	NFKB inhibitor alpha	Homo sapiens	138-151
25303878-5	2015	Additionally, Western blot analysis revealed that naringenin effectively suppressed NF-kappaB activation by inhibiting the degradation of IkappaB-alpha and the translocation of p65.	naringenin	50-60	RELA proto-oncogene, NF-kB subunit	Homo sapiens	177-180
25303878-6	2015	Naringenin also attenuated mitogen-activated protein kinase (MAPK) activation by inhibiting the phosphorylation of ERK1/2, c-Jun NH(2)-terminal kinase (JNK), and p38 MAPK.	naringenin	0-10	mitogen-activated protein kinase 3	Homo sapiens	61-65
25303878-6	2015	Naringenin also attenuated mitogen-activated protein kinase (MAPK) activation by inhibiting the phosphorylation of ERK1/2, c-Jun NH(2)-terminal kinase (JNK), and p38 MAPK.	naringenin	0-10	mitogen-activated protein kinase 3	Homo sapiens	115-121
25303878-6	2015	Naringenin also attenuated mitogen-activated protein kinase (MAPK) activation by inhibiting the phosphorylation of ERK1/2, c-Jun NH(2)-terminal kinase (JNK), and p38 MAPK.	naringenin	0-10	mitogen-activated protein kinase 8	Homo sapiens	123-150
25303878-6	2015	Naringenin also attenuated mitogen-activated protein kinase (MAPK) activation by inhibiting the phosphorylation of ERK1/2, c-Jun NH(2)-terminal kinase (JNK), and p38 MAPK.	naringenin	0-10	mitogen-activated protein kinase 8	Homo sapiens	152-155
25303878-7	2015	Taken together, these demonstrate that naringenin reduces TNF-alpha and IL-6 secretion and mRNA expression, possibly by blocking the activation of the NF-kappaB and MAPK signaling pathways in LPS-treated NHBE.	naringenin	39-49	tumor necrosis factor	Homo sapiens	58-67
25303878-7	2015	Taken together, these demonstrate that naringenin reduces TNF-alpha and IL-6 secretion and mRNA expression, possibly by blocking the activation of the NF-kappaB and MAPK signaling pathways in LPS-treated NHBE.	naringenin	39-49	interleukin 6	Homo sapiens	72-76
25303878-7	2015	Taken together, these demonstrate that naringenin reduces TNF-alpha and IL-6 secretion and mRNA expression, possibly by blocking the activation of the NF-kappaB and MAPK signaling pathways in LPS-treated NHBE.	naringenin	39-49	mitogen-activated protein kinase 3	Homo sapiens	165-169
25745505-11	2015	Plasma leptin and leptin mRNA in adipose depots were also decreased in mice fed a naringenin diet.	naringenin	82-92	leptin	Mus musculus	7-13
25745505-11	2015	Plasma leptin and leptin mRNA in adipose depots were also decreased in mice fed a naringenin diet.	naringenin	82-92	leptin	Mus musculus	18-24
25745505-12	2015	Monocyte chemoattractant protein-1 (MCP1/Ccl2) and interleukin 6 (IL-6/Il6) mRNA expression levels were significantly lower in perigonadal adipose tissue of naringenin-supplemented mice.	naringenin	157-167	chemokine (C-C motif) ligand 2	Mus musculus	0-34
25745505-12	2015	Monocyte chemoattractant protein-1 (MCP1/Ccl2) and interleukin 6 (IL-6/Il6) mRNA expression levels were significantly lower in perigonadal adipose tissue of naringenin-supplemented mice.	naringenin	157-167	chemokine (C-C motif) ligand 2	Mus musculus	36-40
25745505-12	2015	Monocyte chemoattractant protein-1 (MCP1/Ccl2) and interleukin 6 (IL-6/Il6) mRNA expression levels were significantly lower in perigonadal adipose tissue of naringenin-supplemented mice.	naringenin	157-167	chemokine (C-C motif) ligand 2	Mus musculus	41-45
25745505-12	2015	Monocyte chemoattractant protein-1 (MCP1/Ccl2) and interleukin 6 (IL-6/Il6) mRNA expression levels were significantly lower in perigonadal adipose tissue of naringenin-supplemented mice.	naringenin	157-167	interleukin 6	Mus musculus	51-64
25745505-12	2015	Monocyte chemoattractant protein-1 (MCP1/Ccl2) and interleukin 6 (IL-6/Il6) mRNA expression levels were significantly lower in perigonadal adipose tissue of naringenin-supplemented mice.	naringenin	157-167	interleukin 6	Mus musculus	66-70
25745505-12	2015	Monocyte chemoattractant protein-1 (MCP1/Ccl2) and interleukin 6 (IL-6/Il6) mRNA expression levels were significantly lower in perigonadal adipose tissue of naringenin-supplemented mice.	naringenin	157-167	interleukin 6	Mus musculus	71-74
25450363-4	2014	Naringenin suppressed monocyte chemoattractant protein-1 (MCP-1) in adipose tissue, and this effect was mediated in part through inhibition of c-Jun NH2-terminal kinase pathway.	naringenin	0-10	chemokine (C-C motif) ligand 2	Mus musculus	22-56
26146123-8	2015	Naringenin has represented its antidepressant effect by elevation of serotonin (5-HT), norepinephrine, brain-derived neurotrophic factor (BDNF), and glucocorticoid receptors.	naringenin	0-10	brain derived neurotrophic factor	Homo sapiens	103-136
26146123-8	2015	Naringenin has represented its antidepressant effect by elevation of serotonin (5-HT), norepinephrine, brain-derived neurotrophic factor (BDNF), and glucocorticoid receptors.	naringenin	0-10	brain derived neurotrophic factor	Homo sapiens	138-142
26557712-6	2015	GC-MS analysis of FCE showed the presence of fourteen bioactive compounds such as Terpenoids and Flavonoids, including two main constituents with anticancer activity, Squalene and Naringenin (27.71% and 24.05%), respectively.	naringenin	180-190	ferrochelatase	Homo sapiens	18-21
25228019-0	2015	Examination of changes in enzyme activities of erythrocyte glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase in rats given Naringenin and Lead acetate.	naringenin	144-154	glucose-6-phosphate dehydrogenase	Rattus norvegicus	59-92
25228019-1	2015	In our study, controlled experimental groups were performed by giving substances Lead acetate, Naringenin and Naringenin + Lead acetate to rats in vivo conditions Changes in the glucose 6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD) enzyme activities in erythrocytes of rats in these groups were compared to the Control group.	naringenin	95-105	glucose-6-phosphate dehydrogenase	Rattus norvegicus	178-211
25228019-1	2015	In our study, controlled experimental groups were performed by giving substances Lead acetate, Naringenin and Naringenin + Lead acetate to rats in vivo conditions Changes in the glucose 6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD) enzyme activities in erythrocytes of rats in these groups were compared to the Control group.	naringenin	110-120	glucose-6-phosphate dehydrogenase	Rattus norvegicus	178-211
25228019-1	2015	In our study, controlled experimental groups were performed by giving substances Lead acetate, Naringenin and Naringenin + Lead acetate to rats in vivo conditions Changes in the glucose 6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD) enzyme activities in erythrocytes of rats in these groups were compared to the Control group.	naringenin	110-120	glucose-6-phosphate dehydrogenase	Rattus norvegicus	213-217
25464380-0	2014	The inhibition of RANKL-induced osteoclastogenesis through the suppression of p38 signaling pathway by naringenin and attenuation of titanium-particle-induced osteolysis.	naringenin	103-113	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	18-23
25464380-0	2014	The inhibition of RANKL-induced osteoclastogenesis through the suppression of p38 signaling pathway by naringenin and attenuation of titanium-particle-induced osteolysis.	naringenin	103-113	mitogen-activated protein kinase 14	Mus musculus	78-81
25464380-4	2014	Through in vitro studies, we demonstrated that naringenin, a naturally occurring flavanone in grapefruit and tomatoes, exerts potent inhibitory effects on the ligand of the receptor activator of nuclear factor-kappaB (RANKL)-induced osteoclastogenesis and revealed that the mechanism of action of naringenin, which inhibited osteoclastogenesis by suppression of the p38 signaling pathway.	naringenin	47-57	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	218-223
25464380-4	2014	Through in vitro studies, we demonstrated that naringenin, a naturally occurring flavanone in grapefruit and tomatoes, exerts potent inhibitory effects on the ligand of the receptor activator of nuclear factor-kappaB (RANKL)-induced osteoclastogenesis and revealed that the mechanism of action of naringenin, which inhibited osteoclastogenesis by suppression of the p38 signaling pathway.	naringenin	47-57	mitogen-activated protein kinase 14	Mus musculus	366-369
25464380-4	2014	Through in vitro studies, we demonstrated that naringenin, a naturally occurring flavanone in grapefruit and tomatoes, exerts potent inhibitory effects on the ligand of the receptor activator of nuclear factor-kappaB (RANKL)-induced osteoclastogenesis and revealed that the mechanism of action of naringenin, which inhibited osteoclastogenesis by suppression of the p38 signaling pathway.	naringenin	297-307	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	218-223
25464380-6	2014	In general, we demonstrated that naringenin inhibited osteoclastogenesis via suppression of p38 signaling in vitro and attenuated titanium particle-induced osteolysis in vivo.	naringenin	33-43	mitogen-activated protein kinase 14	Mus musculus	92-95
25450363-4	2014	Naringenin suppressed monocyte chemoattractant protein-1 (MCP-1) in adipose tissue, and this effect was mediated in part through inhibition of c-Jun NH2-terminal kinase pathway.	naringenin	0-10	chemokine (C-C motif) ligand 2	Mus musculus	58-63
25450363-5	2014	Naringenin also inhibited MCP-1 expression in adipocytes, macrophages, and a co-culture of adipocytes and macrophages.	naringenin	0-10	chemokine (C-C motif) ligand 2	Mus musculus	26-31
25752139-7	2014	RESULTS: Four bacterial strains, named AUH-JLD3, AUH-JLD7, AUH-JLD104 and AUH-JLD109, capable of biotransforming naringin to naringenin, were isolated and identified as Blautia sp.	naringenin	125-135	AU RNA binding methylglutaconyl-CoA hydratase	Homo sapiens	39-42
25752139-7	2014	RESULTS: Four bacterial strains, named AUH-JLD3, AUH-JLD7, AUH-JLD104 and AUH-JLD109, capable of biotransforming naringin to naringenin, were isolated and identified as Blautia sp.	naringenin	125-135	AU RNA binding methylglutaconyl-CoA hydratase	Homo sapiens	49-52
25752139-7	2014	RESULTS: Four bacterial strains, named AUH-JLD3, AUH-JLD7, AUH-JLD104 and AUH-JLD109, capable of biotransforming naringin to naringenin, were isolated and identified as Blautia sp.	naringenin	125-135	AU RNA binding methylglutaconyl-CoA hydratase	Homo sapiens	49-52
25752139-12	2014	Study on biotransforming kinetics showed that all the four isolated bacterial strains were able to convert naringin (0.2 mmol/L) to naringenin within 12 h. The maximal concentration of the substrate naringin that strain AUH-JLD3, strain AUH-JLD7, strain AUH-JLD104 and strain AUH-JLD109 could biotransform efficiently were 0.	naringenin	132-142	AU RNA binding methylglutaconyl-CoA hydratase	Homo sapiens	220-223
25330158-7	2014	Cell cycle study showed that naringenin induced cell cycle arrest in G0/G1 phase of cell cycle and caspase-3 analysis revealed a dose dependent increment in caspase-3 activity which led to cell apoptosis.	naringenin	29-39	caspase 3	Homo sapiens	99-108
25130191-7	2014	Naringenin, caffeic acid, ellagic acid, ferulic acid, and sinapic acid against two enzymes, hesperidin and polydatin, only on G6PD activity and chrysin solely against 6PGD showed inhibitory effect.	naringenin	0-10	glucose-6-phosphate dehydrogenase	Homo sapiens	126-130
25130191-7	2014	Naringenin, caffeic acid, ellagic acid, ferulic acid, and sinapic acid against two enzymes, hesperidin and polydatin, only on G6PD activity and chrysin solely against 6PGD showed inhibitory effect.	naringenin	0-10	phosphogluconate dehydrogenase	Homo sapiens	167-171
25330158-7	2014	Cell cycle study showed that naringenin induced cell cycle arrest in G0/G1 phase of cell cycle and caspase-3 analysis revealed a dose dependent increment in caspase-3 activity which led to cell apoptosis.	naringenin	29-39	caspase 3	Homo sapiens	157-166
25330158-8	2014	This study confirms the efficacy of naringenin that lead to cell death in epidermoid carcinoma cells via inducing ROS generation, mitochondrial depolarization, nuclear condensation, DNA fragmentation, cell cycle arrest in G0/G1 phase and caspase-3 activation.	naringenin	36-46	caspase 3	Homo sapiens	238-247
25128772-7	2014	Immunohistochemical examinations showed that naringenin significantly reduced the gentamicin-induced expression of kidney injury molecule-1, vascular endothelial growth factor, inducible nitric oxide synthase, and caspase-9, and increased survivin expression in the kidney tissue.	naringenin	45-55	hepatitis A virus cellular receptor 1	Rattus norvegicus	115-139
23883365-11	2014	The permeability of felodipine was increased in presence of naringenin and ritonavir (standard P-glycoprotein (P-gp) and Cytochrome P450 (CYP)3A4 inhibitor).	naringenin	60-70	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	95-109
23883365-11	2014	The permeability of felodipine was increased in presence of naringenin and ritonavir (standard P-glycoprotein (P-gp) and Cytochrome P450 (CYP)3A4 inhibitor).	naringenin	60-70	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	111-115
23883365-12	2014	Felodipine is a substrate of CYP3A4, and naringenin was reported to be a modulator of P-gp and CYP3A4.	naringenin	41-51	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	86-90
23883365-13	2014	These results suggest that naringenin significantly increased the Cmax and AUC of felodipine is due to P-gp and CYP3A4 inhibition.	naringenin	27-37	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	103-107
24997391-10	2014	In rat colonic SMCs, naringenin-induced membrane potential hyperpolarization was sensitive to TEA and selective large-conductance calcium-activated K(+) (BKCa) channel inhibitor iberiotoxin.	naringenin	21-31	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	154-158
24997391-11	2014	Under whole cell patch-clamp condition, naringenin stimulated an iberiotoxin-sensitive BKCa current, which was insensitive to changes in the [Ca(2+)]i concentration.	naringenin	40-50	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	87-91
24997391-14	2014	The relaxant effect of naringenin was attributed to direct activation of BKCa channels, which subsequently hyperpolarized the colonic SMCs and decreased Ca(2+) influx through VDCC.	naringenin	23-33	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	73-77
25006027-3	2014	Complementation of are with the p35S:F3H transgene reduced naringenin and increased flavonols to wild-type levels.	naringenin	59-69	flavanone 3-dioxygenase	Solanum lycopersicum	32-40
25128772-7	2014	Immunohistochemical examinations showed that naringenin significantly reduced the gentamicin-induced expression of kidney injury molecule-1, vascular endothelial growth factor, inducible nitric oxide synthase, and caspase-9, and increased survivin expression in the kidney tissue.	naringenin	45-55	caspase 9	Rattus norvegicus	214-223
25101847-0	2014	TNF-alpha blocker effect of naringenin-loaded sericin microparticles that are potentially useful in the treatment of psoriasis.	naringenin	28-38	tumor necrosis factor	Homo sapiens	0-9
25017119-0	2014	Naringenin inhibits migration of bladder cancer cells through downregulation of AKT and MMP-2.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	80-83
25017119-0	2014	Naringenin inhibits migration of bladder cancer cells through downregulation of AKT and MMP-2.	naringenin	0-10	matrix metallopeptidase 2	Homo sapiens	88-93
25017119-6	2014	Furthermore, zymography and western blot analysis revealed that naringenin reduced the expression of matrix metalloproteinase (MMP)-2 in a dose-dependent manner, and repressed its activity.	naringenin	64-74	matrix metallopeptidase 2	Homo sapiens	101-133
25017119-8	2014	In addition, naringenin was found to inhibit AKT activity and block the nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B cells.	naringenin	13-23	AKT serine/threonine kinase 1	Homo sapiens	45-48
25017119-9	2014	In conclusion, the findings of the present study show that naringenin is capable of inhibiting bladder cancer cell migration through the downregulation of the AKT and MMP-2 pathways.	naringenin	59-69	AKT serine/threonine kinase 1	Homo sapiens	159-162
25017119-9	2014	In conclusion, the findings of the present study show that naringenin is capable of inhibiting bladder cancer cell migration through the downregulation of the AKT and MMP-2 pathways.	naringenin	59-69	matrix metallopeptidase 2	Homo sapiens	167-172
25156241-0	2014	Naringenin modulates skeletal muscle differentiation via estrogen receptor alpha and beta signal pathway regulation.	naringenin	0-10	estrogen receptor 1 (alpha)	Mus musculus	57-80
28962252-5	2014	Yet, only NAR (3 and 10 muM), COU (10 and 30 muM) and QUE (10 muM) also statistically significantly induced aromatase activity in KGN cells after 24 h. 8-PN, aromatase inhibitor letrozole and estrogen receptor antagonist ICI 182,780 concentration-dependently inhibited aromatase activity with IC50 values of 8 nM, 10 nM and 72 nM, respectively.	naringenin	10-13	latexin	Homo sapiens	24-27
24842554-0	2014	Protective effect of naringenin in experimental ischemic stroke: down-regulated NOD2, RIP2, NF-kappaB, MMP-9 and up-regulated claudin-5 expression.	naringenin	21-31	nucleotide-binding oligomerization domain containing 2	Rattus norvegicus	80-84
24842554-0	2014	Protective effect of naringenin in experimental ischemic stroke: down-regulated NOD2, RIP2, NF-kappaB, MMP-9 and up-regulated claudin-5 expression.	naringenin	21-31	matrix metallopeptidase 9	Rattus norvegicus	103-108
24842554-0	2014	Protective effect of naringenin in experimental ischemic stroke: down-regulated NOD2, RIP2, NF-kappaB, MMP-9 and up-regulated claudin-5 expression.	naringenin	21-31	claudin 5	Rattus norvegicus	126-135
24526395-0	2014	Naringenin confers protection against oxidative stress through upregulation of Nrf2 target genes in cardiomyoblast cells.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	79-83
24684352-0	2014	Naringenin attenuates CCl4 -induced hepatic inflammation by the activation of an Nrf2-mediated pathway in rats.	naringenin	0-10	C-C motif chemokine ligand 4	Rattus norvegicus	22-26
24684352-0	2014	Naringenin attenuates CCl4 -induced hepatic inflammation by the activation of an Nrf2-mediated pathway in rats.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	81-85
24684352-1	2014	The possible protective effects of naringenin, a naturally occurring citrus flavonone, on carbon tetrachloride (CCl4 )-induced liver injury in rats and the mechanism underlying its effects were investigated.	naringenin	35-45	C-C motif chemokine ligand 4	Rattus norvegicus	112-116
24684352-5	2014	Naringenin inhibited lipid peroxidation and reduced serum levels of hepatic enzymes induced by CCl4 .	naringenin	0-10	C-C motif chemokine ligand 4	Rattus norvegicus	95-99
24684352-6	2014	In addition, naringenin increased the liver content of reduced glutathione and the activity of anti-oxidant enzymes in rats treated with CCl4 .	naringenin	13-23	C-C motif chemokine ligand 4	Rattus norvegicus	137-141
24684352-7	2014	Naringenin attenuated liver inflammation by downregulating CCl4 -induced activation of tumour necrosis factor (TNF)-alpha, inducible nitric oxide synthase (iNOS) and cyclo-oxygenase (COX-2) at both the protein and mRNA levels.	naringenin	0-10	C-C motif chemokine ligand 4	Rattus norvegicus	59-63
24684352-7	2014	Naringenin attenuated liver inflammation by downregulating CCl4 -induced activation of tumour necrosis factor (TNF)-alpha, inducible nitric oxide synthase (iNOS) and cyclo-oxygenase (COX-2) at both the protein and mRNA levels.	naringenin	0-10	tumor necrosis factor	Rattus norvegicus	87-121
24684352-7	2014	Naringenin attenuated liver inflammation by downregulating CCl4 -induced activation of tumour necrosis factor (TNF)-alpha, inducible nitric oxide synthase (iNOS) and cyclo-oxygenase (COX-2) at both the protein and mRNA levels.	naringenin	0-10	nitric oxide synthase 2	Rattus norvegicus	123-154
24684352-7	2014	Naringenin attenuated liver inflammation by downregulating CCl4 -induced activation of tumour necrosis factor (TNF)-alpha, inducible nitric oxide synthase (iNOS) and cyclo-oxygenase (COX-2) at both the protein and mRNA levels.	naringenin	0-10	nitric oxide synthase 2	Rattus norvegicus	156-160
24684352-7	2014	Naringenin attenuated liver inflammation by downregulating CCl4 -induced activation of tumour necrosis factor (TNF)-alpha, inducible nitric oxide synthase (iNOS) and cyclo-oxygenase (COX-2) at both the protein and mRNA levels.	naringenin	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	183-188
24684352-8	2014	Naringenin treatment significantly increased NF-E2-related factor 2 (Nrf2) and heme oxygenase (HO-1) expression in injured livers.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	45-67
24684352-8	2014	Naringenin treatment significantly increased NF-E2-related factor 2 (Nrf2) and heme oxygenase (HO-1) expression in injured livers.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	69-73
24684352-10	2014	Together, the results suggest that naringenin can protect the liver against oxidative stress, presumably by activating the nuclear translocation of Nrf2 as well as attenuating the TNF-alpha pathway to elicit an anti-inflammatory response in liver tissue.	naringenin	35-45	NFE2 like bZIP transcription factor 2	Rattus norvegicus	148-152
24684352-10	2014	Together, the results suggest that naringenin can protect the liver against oxidative stress, presumably by activating the nuclear translocation of Nrf2 as well as attenuating the TNF-alpha pathway to elicit an anti-inflammatory response in liver tissue.	naringenin	35-45	tumor necrosis factor	Rattus norvegicus	180-189
24526395-5	2014	In the present study, we investigated whether naringenin (NGN) supplementation would improve the antioxidant defence under oxidative stress through the activation of Nrf2 signaling in cultured cardiomyoblast.	naringenin	46-56	NFE2 like bZIP transcription factor 2	Homo sapiens	166-170
24526395-5	2014	In the present study, we investigated whether naringenin (NGN) supplementation would improve the antioxidant defence under oxidative stress through the activation of Nrf2 signaling in cultured cardiomyoblast.	naringenin	58-61	NFE2 like bZIP transcription factor 2	Homo sapiens	166-170
24526395-10	2014	Taken together, the present study revealed that NGN elicits potent cytoprotective effect against oxidative stress by regulating Nrf2 and its target genes.	naringenin	48-51	NFE2 like bZIP transcription factor 2	Homo sapiens	128-132
24526395-11	2014	In conclusion, the present work suggests that improving Nrf2 signaling by NGN supplementation would be a rational approach to facilitate ROS detoxification by augmenting both expression and activity of phase II detoxification enzymes for the alleviation of cardiac complications.	naringenin	74-77	NFE2 like bZIP transcription factor 2	Homo sapiens	56-60
24116661-0	2014	Naringenin inhibits the growth of Dictyostelium and MDCK-derived cysts in a TRPP2 (polycystin-2)-dependent manner.	naringenin	0-10	polycystin 2, transient receptor potential cation channel	Homo sapiens	76-81
24611872-8	2014	In conclusion, both NGN and NGN/beta-cyclodextrin complex showed antioxidant and hepatoprotective effects against injuries induced by CCl4.	naringenin	20-23	chemokine (C-C motif) ligand 4	Mus musculus	134-138
24611872-8	2014	In conclusion, both NGN and NGN/beta-cyclodextrin complex showed antioxidant and hepatoprotective effects against injuries induced by CCl4.	naringenin	28-31	chemokine (C-C motif) ligand 4	Mus musculus	134-138
24116661-0	2014	Naringenin inhibits the growth of Dictyostelium and MDCK-derived cysts in a TRPP2 (polycystin-2)-dependent manner.	naringenin	0-10	polycystin 2, transient receptor potential cation channel	Canis lupus familiaris	83-95
24773265-4	2014	Other papers highlight the differences in TRPV3 pharmacology between recombinant and native systems, the mechanisms of TRPM3 activation/inhibition and TRPP2 as a target of naringenin, a dietary flavonoid with anticancer actions.	naringenin	172-182	transient receptor potential cation channel subfamily M member 3	Homo sapiens	119-124
24773265-4	2014	Other papers highlight the differences in TRPV3 pharmacology between recombinant and native systems, the mechanisms of TRPM3 activation/inhibition and TRPP2 as a target of naringenin, a dietary flavonoid with anticancer actions.	naringenin	172-182	polycystin 2, transient receptor potential cation channel	Homo sapiens	151-156
24116661-5	2014	Screening of a library of random gene knockout mutants identified a mutant lacking TRPP2 (polycystin-2) that was resistant to the effect of naringenin on growth and random cell movement.	naringenin	140-150	polycystin 2, transient receptor potential cation channel	Homo sapiens	83-88
24116661-5	2014	Screening of a library of random gene knockout mutants identified a mutant lacking TRPP2 (polycystin-2) that was resistant to the effect of naringenin on growth and random cell movement.	naringenin	140-150	polycystin 2, transient receptor potential cation channel	Canis lupus familiaris	90-102
24116661-8	2014	Knockdown of TRPP2 levels by siRNA in this model conferred partial resistance to naringenin such that cysts treated with 3 and 10 muM naringenin were larger following TRPP2 knockdown compared with controls.	naringenin	81-91	polycystin 2, transient receptor potential cation channel	Homo sapiens	13-18
24116661-8	2014	Knockdown of TRPP2 levels by siRNA in this model conferred partial resistance to naringenin such that cysts treated with 3 and 10 muM naringenin were larger following TRPP2 knockdown compared with controls.	naringenin	134-144	polycystin 2, transient receptor potential cation channel	Homo sapiens	13-18
24116661-8	2014	Knockdown of TRPP2 levels by siRNA in this model conferred partial resistance to naringenin such that cysts treated with 3 and 10 muM naringenin were larger following TRPP2 knockdown compared with controls.	naringenin	134-144	polycystin 2, transient receptor potential cation channel	Homo sapiens	167-172
24116661-10	2014	CONCLUSIONS AND IMPLICATIONS: The action of naringenin on cell growth in the phylogenetically diverse systems of Dictyostelium and mammalian kidney cells, suggests a conserved effect mediated by TRPP2 (polycystin-2).	naringenin	44-54	polycystin 2, transient receptor potential cation channel	Homo sapiens	195-200
24116661-10	2014	CONCLUSIONS AND IMPLICATIONS: The action of naringenin on cell growth in the phylogenetically diverse systems of Dictyostelium and mammalian kidney cells, suggests a conserved effect mediated by TRPP2 (polycystin-2).	naringenin	44-54	polycystin 2, transient receptor potential cation channel	Homo sapiens	202-214
24561720-0	2014	Naringenin exerts cytoprotective effect against paraquat-induced toxicity in human bronchial epithelial BEAS-2B cells through NRF2 activation.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	126-130
24561720-6	2014	We also observed that treatment with NG in PQ-exposed BEAS-2B cells can significantly induce the expression of antioxidant-related genes, including GPX2, GPX3, GPX5, and GPX7.	naringenin	37-39	glutathione peroxidase 2	Homo sapiens	148-152
24561720-6	2014	We also observed that treatment with NG in PQ-exposed BEAS-2B cells can significantly induce the expression of antioxidant-related genes, including GPX2, GPX3, GPX5, and GPX7.	naringenin	37-39	glutathione peroxidase 3	Homo sapiens	154-158
24561720-6	2014	We also observed that treatment with NG in PQ-exposed BEAS-2B cells can significantly induce the expression of antioxidant-related genes, including GPX2, GPX3, GPX5, and GPX7.	naringenin	37-39	glutathione peroxidase 5	Homo sapiens	160-164
24561720-6	2014	We also observed that treatment with NG in PQ-exposed BEAS-2B cells can significantly induce the expression of antioxidant-related genes, including GPX2, GPX3, GPX5, and GPX7.	naringenin	37-39	glutathione peroxidase 7	Homo sapiens	170-174
24561720-9	2014	A small interfering RNA study revealed that the knockdown of NRF2 can abrogate NG-mediated protection of the cells from PQ-induced cellular toxicity.	naringenin	79-81	NFE2 like bZIP transcription factor 2	Homo sapiens	61-65
24534822-5	2014	Compared to OVA-sensitized and -challenged mice, those treated with naringenin showed markedly attenuated chronic inflammation, persistent AHR and airway remodeling.	naringenin	68-78	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	12-15
24333330-0	2014	Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	79-83
24333330-4	2014	Naringenin treatment resulted in an increase in nuclear factor E2-related factor 2 (Nrf2) protein levels and subsequent activation of antioxidant response element (ARE) pathway genes in SH-SY5Y cells and in mice.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	48-82
24333330-4	2014	Naringenin treatment resulted in an increase in nuclear factor E2-related factor 2 (Nrf2) protein levels and subsequent activation of antioxidant response element (ARE) pathway genes in SH-SY5Y cells and in mice.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	84-88
24333330-5	2014	Exposure of SH-SY5Y cells to naringenin provided protection against 6-OHDA-induced oxidative insults that was dependent on Nrf2, since treatment with Nrf2 siRNA failed to block against 6-OHDA neurotoxicity or induce Nrf2-dependent cytoprotective genes in SH-SY5Y cells.	naringenin	29-39	NFE2 like bZIP transcription factor 2	Homo sapiens	123-127
24333330-7	2014	Our results indicate that activation of Nrf2/ARE signaling by naringenin is strongly associated with its neuroprotective effects against 6-OHDA neurotoxicity and suggest that targeting the Nrf2/ARE pathway may be a promising approach for therapeutic intervention in PD.	naringenin	62-72	NFE2 like bZIP transcription factor 2	Homo sapiens	40-44
24333330-7	2014	Our results indicate that activation of Nrf2/ARE signaling by naringenin is strongly associated with its neuroprotective effects against 6-OHDA neurotoxicity and suggest that targeting the Nrf2/ARE pathway may be a promising approach for therapeutic intervention in PD.	naringenin	62-72	NFE2 like bZIP transcription factor 2	Homo sapiens	189-193
24741397-0	2014	Naringenin stimulates cholecystokinin secretion in STC-1 cells.	naringenin	0-10	cholecystokinin	Homo sapiens	22-37
24741397-4	2014	In the current study, we investigated the question of whether naringenin and naringin could stimulate CCK secretion and then examined the mechanisms involved in CCK release.	naringenin	62-72	cholecystokinin	Homo sapiens	102-105
24741397-6	2014	CCK release and changes in intracellular Ca(2+) ([Ca(2+)]i) were measured after incubation of cells with naringenin and naringin for 1 h. RESULTS: Naringenin caused significant (P &lt; 0.05) stimulation of CCK secretion, but naringin did not.	naringenin	147-157	cholecystokinin	Homo sapiens	206-209
24741397-7	2014	In addition, regarding the secretory mechanisms, naringenin-induced CCK secretion involved increases in [Ca(2+)]i, influx of extracellular Ca(2+), at least in part, and activation of TRP channels, including TRPA1.	naringenin	49-59	cholecystokinin	Homo sapiens	68-71
24741397-7	2014	In addition, regarding the secretory mechanisms, naringenin-induced CCK secretion involved increases in [Ca(2+)]i, influx of extracellular Ca(2+), at least in part, and activation of TRP channels, including TRPA1.	naringenin	49-59	transient receptor potential cation channel subfamily A member 1	Homo sapiens	207-212
24239187-5	2013	Our results demonstrated that naringenin bound transferrin with an affinity almost 100 times higher than that of apigenin attributed to its higher structural flexibility and lower acidity compared with apigenin.	naringenin	30-40	transferrin	Homo sapiens	47-58
24530705-0	2014	Exploring binding properties of naringenin with bovine beta-lactoglobulin: a fluorescence, molecular docking and molecular dynamics simulation study.	naringenin	32-42	beta-lactoglobulin	Bos taurus	55-73
24530705-1	2014	In the present study, the binding properties of naringenin (NG) to beta-lactoglobulin (BLG) were explored using spectrofluorimetric and molecular modeling techniques.	naringenin	48-58	beta-lactoglobulin	Bos taurus	67-85
24530705-1	2014	In the present study, the binding properties of naringenin (NG) to beta-lactoglobulin (BLG) were explored using spectrofluorimetric and molecular modeling techniques.	naringenin	48-58	beta-lactoglobulin	Bos taurus	87-90
24530705-2	2014	Analysis of spectrofluorimetric titration data represented the formation of 1:1 complex, significant binding affinity, negative values of entropy and enthalpy changes and the essential role of hydrogen bonding and van der Waals interactions in binding of NG to BLG.	naringenin	255-257	beta-lactoglobulin	Bos taurus	261-264
24530705-3	2014	The value of determined Forster"s distance represents the static mechanism for quenching of BLG by NG.	naringenin	99-101	beta-lactoglobulin	Bos taurus	92-95
24530705-4	2014	The results of fluorescence competitive binding experiments characterize the location of NG binding site in the outer surface of BLG.	naringenin	89-91	beta-lactoglobulin	Bos taurus	129-132
24530705-5	2014	Molecular docking study showed that NG binds in the outer surface site of BLG which is accompanied with three hydrogen bonds.	naringenin	36-38	beta-lactoglobulin	Bos taurus	74-77
24424324-4	2014	We demonstrate that Af encodes an isoform (SlCHI1) of the flavonoid biosynthetic enzyme chalcone isomerase (CHI), which catalyzes the conversion of naringenin chalcone to naringenin and is strictly required for flavonoid production in multiple tissues of tomato.	naringenin	148-158	chalcone--flavonone isomerase	Solanum lycopersicum	43-49
24121063-0	2014	BDNF signaling is necessary for the antidepressant-like effect of naringenin.	naringenin	66-76	brain derived neurotrophic factor	Mus musculus	0-4
24121063-3	2014	The present study extends earlier works on the role of brain-derived neurotrophic factor (BDNF) in regulating the antidepressant-like actions of naringenin in chronic unpredictable mild stress (CUMS).	naringenin	145-155	brain derived neurotrophic factor	Mus musculus	55-88
24121063-3	2014	The present study extends earlier works on the role of brain-derived neurotrophic factor (BDNF) in regulating the antidepressant-like actions of naringenin in chronic unpredictable mild stress (CUMS).	naringenin	145-155	brain derived neurotrophic factor	Mus musculus	90-94
24121063-5	2014	In addition, we also found that naringenin promoted BDNF expression in the hippocampus but not in the frontal cortex in both non-stressed and CUMS mice.	naringenin	32-42	brain derived neurotrophic factor	Mus musculus	52-56
24121063-6	2014	Moreover, the antidepressant-like effect of naringenin in SPT and NSFT induced by naringenin administration were totally abolished by K252a, an inhibitor of BDNF receptor tropomyosin-related kinase receptor B (TrkB).	naringenin	44-54	brain derived neurotrophic factor	Mus musculus	157-161
24121063-6	2014	Moreover, the antidepressant-like effect of naringenin in SPT and NSFT induced by naringenin administration were totally abolished by K252a, an inhibitor of BDNF receptor tropomyosin-related kinase receptor B (TrkB).	naringenin	44-54	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	171-208
24121063-6	2014	Moreover, the antidepressant-like effect of naringenin in SPT and NSFT induced by naringenin administration were totally abolished by K252a, an inhibitor of BDNF receptor tropomyosin-related kinase receptor B (TrkB).	naringenin	44-54	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	210-214
24121063-6	2014	Moreover, the antidepressant-like effect of naringenin in SPT and NSFT induced by naringenin administration were totally abolished by K252a, an inhibitor of BDNF receptor tropomyosin-related kinase receptor B (TrkB).	naringenin	82-92	brain derived neurotrophic factor	Mus musculus	157-161
24121063-6	2014	Moreover, the antidepressant-like effect of naringenin in SPT and NSFT induced by naringenin administration were totally abolished by K252a, an inhibitor of BDNF receptor tropomyosin-related kinase receptor B (TrkB).	naringenin	82-92	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	171-208
24121063-6	2014	Moreover, the antidepressant-like effect of naringenin in SPT and NSFT induced by naringenin administration were totally abolished by K252a, an inhibitor of BDNF receptor tropomyosin-related kinase receptor B (TrkB).	naringenin	82-92	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	210-214
24121063-7	2014	In conclusion, our findings suggest that the antidepressant-like effect of naringenin may be mediated, at least in part, by the activation of BDNF signaling in the hippocampus.	naringenin	75-85	brain derived neurotrophic factor	Mus musculus	142-146
24412302-0	2014	Naringenin inhibits alpha-glucosidase activity: a promising strategy for the regulation of postprandial hyperglycemia in high fat diet fed streptozotocin induced diabetic rats.	naringenin	0-10	sucrase-isomaltase	Homo sapiens	20-37
24412302-4	2014	The present study aims to demonstrate the potent inhibitory role of naringenin against alpha-glucosidase activity.	naringenin	68-78	sucrase-isomaltase	Homo sapiens	87-104
24412302-7	2014	Similar results have been obtained from the molecular docking analyses, where naringenin shows preferential binding for the active sites in each of the evaluated human intestinal alpha-glucosidase enzymes.	naringenin	78-88	sucrase-isomaltase	Homo sapiens	179-196
24412302-9	2014	Naringenin"s docked pose in the C-terminal maltase glucoamylase active site does not show any particular water mediated interaction similar to the co-crystallized acarbose.	naringenin	0-10	maltase-glucoamylase 2	Rattus norvegicus	43-63
24412302-10	2014	Further, our results suggest that naringenin (25 mg/kg) exerts significant inhibition of intestinal alpha-glucosidase activity in vivo thereby delaying the absorption of carbohydrates in T2D rats, thus resulting in significant lowering of postprandial blood glucose levels.	naringenin	34-44	sucrase-isomaltase	Homo sapiens	100-117
24586459-4	2014	Here, the effects of bisphenol A (BPA) and naringenin (Nar), prototypes of synthetic and plant-derived ERalpha ligands, have been evaluated on ERalpha levels in MCF-7 cells.	naringenin	43-53	estrogen receptor 1	Homo sapiens	143-150
24586459-4	2014	Here, the effects of bisphenol A (BPA) and naringenin (Nar), prototypes of synthetic and plant-derived ERalpha ligands, have been evaluated on ERalpha levels in MCF-7 cells.	naringenin	55-58	estrogen receptor 1	Homo sapiens	143-150
24586459-10	2014	Mechanistically, Nar induces ERalpha protein accumulation by preventing proteasomal receptor degradation via persistent activation of p38/MAPK pathway.	naringenin	17-20	estrogen receptor 1	Homo sapiens	29-36
24586459-10	2014	Mechanistically, Nar induces ERalpha protein accumulation by preventing proteasomal receptor degradation via persistent activation of p38/MAPK pathway.	naringenin	17-20	mitogen-activated protein kinase 14	Homo sapiens	134-137
24795889-9	2014	Furthermore, naringenin and its beta-CD complex significantly inhibited the mRNA and protein expression of VEGF, COX-2, PI3K, p38MAPK, MMP-2, and MMP-9 in retina and choroid tissues.	naringenin	13-23	vascular endothelial growth factor A	Rattus norvegicus	107-111
24795889-9	2014	Furthermore, naringenin and its beta-CD complex significantly inhibited the mRNA and protein expression of VEGF, COX-2, PI3K, p38MAPK, MMP-2, and MMP-9 in retina and choroid tissues.	naringenin	13-23	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	113-118
24795889-9	2014	Furthermore, naringenin and its beta-CD complex significantly inhibited the mRNA and protein expression of VEGF, COX-2, PI3K, p38MAPK, MMP-2, and MMP-9 in retina and choroid tissues.	naringenin	13-23	matrix metallopeptidase 2	Rattus norvegicus	135-140
24795889-9	2014	Furthermore, naringenin and its beta-CD complex significantly inhibited the mRNA and protein expression of VEGF, COX-2, PI3K, p38MAPK, MMP-2, and MMP-9 in retina and choroid tissues.	naringenin	13-23	matrix metallopeptidase 9	Rattus norvegicus	146-151
24795889-10	2014	Naringenin/beta-CD complex showed more significant inhibitory effect on VEGF and COX-2 expression than naringenin.	naringenin	0-10	vascular endothelial growth factor A	Rattus norvegicus	72-76
24795889-10	2014	Naringenin/beta-CD complex showed more significant inhibitory effect on VEGF and COX-2 expression than naringenin.	naringenin	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	81-86
24479689-6	2014	Moreover, an integrated in silico approach for the prediction of Phase I metabolism of the flavonoids quercetin, rutin, naringenin and naringin, which provided useful information about the most likely metabolites of these flavonoids and their interactions with amino acid residues of CYP2C9, is described.	naringenin	120-130	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	284-290
24239187-6	2013	Our docking study showed that naringenin had stronger van der Waals interactions with transferrin, which was believed to contribute to its higher binding affinity.	naringenin	30-40	transferrin	Homo sapiens	86-97
24239187-7	2013	We also found that naringenin-binding induced greater increase in the alpha-helix content in transferrin than apigenin, suggesting that transferrin became more compact upon association with naringenin.	naringenin	19-29	transferrin	Homo sapiens	93-104
24239187-7	2013	We also found that naringenin-binding induced greater increase in the alpha-helix content in transferrin than apigenin, suggesting that transferrin became more compact upon association with naringenin.	naringenin	19-29	transferrin	Homo sapiens	136-147
24239187-7	2013	We also found that naringenin-binding induced greater increase in the alpha-helix content in transferrin than apigenin, suggesting that transferrin became more compact upon association with naringenin.	naringenin	190-200	transferrin	Homo sapiens	136-147
24239187-8	2013	Our study demonstrated that naringenin was a ligand for transferrin with good affinity.	naringenin	28-38	transferrin	Homo sapiens	56-67
24006495-4	2013	We have previously shown that TRPM3 is blocked by the citrus fruit flavanones hesperetin, naringenin, and eriodictyol as well as by ononetin, a deoxybenzoin from Ononis spinosa.	naringenin	90-100	transient receptor potential cation channel, subfamily M, member 3	Mus musculus	30-35
23868418-2	2013	This study investigated the naringenin-mediated effect in Caco-2 cells with a particular focus on the modulation of TJ structure and claudin-4 transcriptional regulation.	naringenin	28-38	claudin 4	Homo sapiens	133-142
24260594-3	2013	Naringenin (at 5 muM) was found to repress both luciferase activity and pS2 mRNA expression, which was induced by E2 (at 0.1 muM) or genistein (at 5 muM).	naringenin	0-10	latexin	Homo sapiens	125-128
23868418-3	2013	METHODS AND RESULTS: Naringenin (10~100 muM) dose-dependently enhanced TJ barrier integrity of Caco-2 cells, indicated by transepithelial electrical resistance and FITC-dextran flux.	naringenin	21-31	latexin	Homo sapiens	40-43
23868418-4	2013	Immunoblot analysis showed that naringenin increased the cytoskeletal association of TJ proteins, zonula occludens-2, occludin, claudin-1, and claudin-4, simultaneously with increased occludin phosphorylation.	naringenin	32-42	occludin	Homo sapiens	118-126
23868418-4	2013	Immunoblot analysis showed that naringenin increased the cytoskeletal association of TJ proteins, zonula occludens-2, occludin, claudin-1, and claudin-4, simultaneously with increased occludin phosphorylation.	naringenin	32-42	claudin 1	Homo sapiens	128-137
23868418-4	2013	Immunoblot analysis showed that naringenin increased the cytoskeletal association of TJ proteins, zonula occludens-2, occludin, claudin-1, and claudin-4, simultaneously with increased occludin phosphorylation.	naringenin	32-42	claudin 4	Homo sapiens	143-152
23868418-4	2013	Immunoblot analysis showed that naringenin increased the cytoskeletal association of TJ proteins, zonula occludens-2, occludin, claudin-1, and claudin-4, simultaneously with increased occludin phosphorylation.	naringenin	32-42	occludin	Homo sapiens	184-192
23868418-5	2013	The total expression of claudin-4 was also increased by naringenin.	naringenin	56-66	claudin 4	Homo sapiens	24-33
23868418-6	2013	Quantitative RT-PCR and luciferase reporter assay revealed that naringenin transcriptionally increased the claudin-4 expression with activation of claudin-4 promoter.	naringenin	64-74	claudin 4	Homo sapiens	107-116
23868418-6	2013	Quantitative RT-PCR and luciferase reporter assay revealed that naringenin transcriptionally increased the claudin-4 expression with activation of claudin-4 promoter.	naringenin	64-74	claudin 4	Homo sapiens	147-156
23868418-7	2013	The mutation of the binding site of the transcriptional factor Sp1 in the claudin-4 promoter sequence and the pharmacological inhibition of Sp1 partially suppressed the naringenin-mediated activation of the claudin-4 promoter.	naringenin	169-179	claudin 4	Homo sapiens	74-83
23868418-7	2013	The mutation of the binding site of the transcriptional factor Sp1 in the claudin-4 promoter sequence and the pharmacological inhibition of Sp1 partially suppressed the naringenin-mediated activation of the claudin-4 promoter.	naringenin	169-179	claudin 4	Homo sapiens	207-216
23868418-10	2013	Naringenin-mediated claudin-4 expression occurs, at least partially, through Sp1-dependent transcriptional regulation.	naringenin	0-10	claudin 4	Homo sapiens	20-29
24260594-0	2013	Naringenin: a partial agonist on estrogen receptor in T47D-KBluc breast cancer cells.	naringenin	0-10	estrogen receptor 1	Homo sapiens	33-50
24260594-3	2013	Naringenin (at 5 muM) was found to repress both luciferase activity and pS2 mRNA expression, which was induced by E2 (at 0.1 muM) or genistein (at 5 muM).	naringenin	0-10	latexin	Homo sapiens	17-20
24260594-3	2013	Naringenin (at 5 muM) was found to repress both luciferase activity and pS2 mRNA expression, which was induced by E2 (at 0.1 muM) or genistein (at 5 muM).	naringenin	0-10	latexin	Homo sapiens	125-128
24260594-4	2013	Naringenin, as well as E2 and genistein, was found to modulate the transcription of pS2 and TGFbeta3 in T47D-KBluc cells through an estrogen receptor-dependent mechanism.	naringenin	0-10	taste 2 receptor member 64 pseudogene	Homo sapiens	84-87
24260594-3	2013	Naringenin (at 5 muM) was found to repress both luciferase activity and pS2 mRNA expression, which was induced by E2 (at 0.1 muM) or genistein (at 5 muM).	naringenin	0-10	taste 2 receptor member 64 pseudogene	Homo sapiens	72-75
24260594-4	2013	Naringenin, as well as E2 and genistein, was found to modulate the transcription of pS2 and TGFbeta3 in T47D-KBluc cells through an estrogen receptor-dependent mechanism.	naringenin	0-10	transforming growth factor beta 3	Homo sapiens	92-100
24260594-4	2013	Naringenin, as well as E2 and genistein, was found to modulate the transcription of pS2 and TGFbeta3 in T47D-KBluc cells through an estrogen receptor-dependent mechanism.	naringenin	0-10	estrogen receptor 1	Homo sapiens	132-149
23845967-1	2013	The ability of naringenin (NGN) to protect the kidney against CCl4-induced renal toxicity in male Swiss mice was investigated.	naringenin	15-25	chemokine (C-C motif) ligand 4	Mus musculus	62-66
23987422-1	2013	The inclusion complexation behavior, characterization and binding ability of naringenin with beta-cyclodextrin and its derivatives were investigated in both solution and the solid state by means of XRD, DSC, SEM, (1)H and 2D NMR and UV-vis spectroscopy.	naringenin	77-87	desmocollin 3	Homo sapiens	203-206
23933131-5	2013	In addition, naringenin significantly suppressed production of interferon-gamma (IFN-gamma) by activated CD4(+) T cells and serum IgE level.	naringenin	13-23	interferon gamma	Mus musculus	63-79
23933131-5	2013	In addition, naringenin significantly suppressed production of interferon-gamma (IFN-gamma) by activated CD4(+) T cells and serum IgE level.	naringenin	13-23	interferon gamma	Mus musculus	81-90
23933131-5	2013	In addition, naringenin significantly suppressed production of interferon-gamma (IFN-gamma) by activated CD4(+) T cells and serum IgE level.	naringenin	13-23	CD4 antigen	Mus musculus	105-108
23933131-6	2013	Furthermore, naringenin reduced DNFB-induced infiltration of eosinophils, mast cells, CD4(+) T cells, and CD8(+) T cells in skin lesions.	naringenin	13-23	CD4 antigen	Mus musculus	86-89
23933131-7	2013	SIGNIFICANCE: Naringenin may suppress the development of AD-like skin lesions in DNFB-treated NC/Nga mice by reducing IFN-gamma production of activated CD4(+) T cells, serum IgE levels and infiltration of immune cells to skin lesion.	naringenin	14-24	interferon gamma	Mus musculus	118-127
23933131-7	2013	SIGNIFICANCE: Naringenin may suppress the development of AD-like skin lesions in DNFB-treated NC/Nga mice by reducing IFN-gamma production of activated CD4(+) T cells, serum IgE levels and infiltration of immune cells to skin lesion.	naringenin	14-24	CD4 antigen	Mus musculus	152-155
23661153-7	2013	Naringenin induced a rapid accumulation of p53, which might account for the naringenin-induced G0/G1 and G2/M phase arrests in Hep G2 cells.	naringenin	0-10	tumor protein p53	Homo sapiens	43-46
23661153-7	2013	Naringenin induced a rapid accumulation of p53, which might account for the naringenin-induced G0/G1 and G2/M phase arrests in Hep G2 cells.	naringenin	0-10	proline rich protein BstNI subfamily 3	Homo sapiens	76-107
23661153-9	2013	Naringenin triggered the mitochondrial-mediated apoptosis pathway as shown by an increased ratio of Bax/Bcl-2, subsequent release of cytochrome C, and sequential activation of caspase-3.	naringenin	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	100-103
23661153-9	2013	Naringenin triggered the mitochondrial-mediated apoptosis pathway as shown by an increased ratio of Bax/Bcl-2, subsequent release of cytochrome C, and sequential activation of caspase-3.	naringenin	0-10	BCL2 apoptosis regulator	Homo sapiens	104-109
23661153-9	2013	Naringenin triggered the mitochondrial-mediated apoptosis pathway as shown by an increased ratio of Bax/Bcl-2, subsequent release of cytochrome C, and sequential activation of caspase-3.	naringenin	0-10	cytochrome c, somatic	Homo sapiens	133-145
23661153-9	2013	Naringenin triggered the mitochondrial-mediated apoptosis pathway as shown by an increased ratio of Bax/Bcl-2, subsequent release of cytochrome C, and sequential activation of caspase-3.	naringenin	0-10	caspase 3	Homo sapiens	176-185
23845967-1	2013	The ability of naringenin (NGN) to protect the kidney against CCl4-induced renal toxicity in male Swiss mice was investigated.	naringenin	27-30	chemokine (C-C motif) ligand 4	Mus musculus	62-66
23845967-9	2013	In conclusion, NGN showed antioxidant and renal protective effects against injuries induced by CCl4.	naringenin	15-18	chemokine (C-C motif) ligand 4	Mus musculus	95-99
23506745-8	2013	In addition, in vitro NF-kappaB reporter assays performed on human colonic HT-29 cells exposed to naringenin demonstrated a significant inhibition of TNF-alpha-induced NF-kappaB luciferase expression.	naringenin	98-108	nuclear factor kappa B subunit 1	Homo sapiens	22-31
23782265-5	2013	Both naringenin and flavone also effectively suppressed IL-6-stimulated phosphorylation of STAT3 (Tyr705) which led to suppression of IL-6-induction of the atherogenic STAT3 target gene MCP1 (monocyte chemotactic protein-1), suggesting that their ability to induce SOCS3 gene expression is STAT3-independent.	naringenin	5-15	interleukin 6	Homo sapiens	134-138
23782265-5	2013	Both naringenin and flavone also effectively suppressed IL-6-stimulated phosphorylation of STAT3 (Tyr705) which led to suppression of IL-6-induction of the atherogenic STAT3 target gene MCP1 (monocyte chemotactic protein-1), suggesting that their ability to induce SOCS3 gene expression is STAT3-independent.	naringenin	5-15	signal transducer and activator of transcription 3	Homo sapiens	168-173
23782265-5	2013	Both naringenin and flavone also effectively suppressed IL-6-stimulated phosphorylation of STAT3 (Tyr705) which led to suppression of IL-6-induction of the atherogenic STAT3 target gene MCP1 (monocyte chemotactic protein-1), suggesting that their ability to induce SOCS3 gene expression is STAT3-independent.	naringenin	5-15	C-C motif chemokine ligand 2	Homo sapiens	186-190
23782265-5	2013	Both naringenin and flavone also effectively suppressed IL-6-stimulated phosphorylation of STAT3 (Tyr705) which led to suppression of IL-6-induction of the atherogenic STAT3 target gene MCP1 (monocyte chemotactic protein-1), suggesting that their ability to induce SOCS3 gene expression is STAT3-independent.	naringenin	5-15	C-C motif chemokine ligand 2	Homo sapiens	192-222
23782265-5	2013	Both naringenin and flavone also effectively suppressed IL-6-stimulated phosphorylation of STAT3 (Tyr705) which led to suppression of IL-6-induction of the atherogenic STAT3 target gene MCP1 (monocyte chemotactic protein-1), suggesting that their ability to induce SOCS3 gene expression is STAT3-independent.	naringenin	5-15	suppressor of cytokine signaling 3	Homo sapiens	265-270
23782265-5	2013	Both naringenin and flavone also effectively suppressed IL-6-stimulated phosphorylation of STAT3 (Tyr705) which led to suppression of IL-6-induction of the atherogenic STAT3 target gene MCP1 (monocyte chemotactic protein-1), suggesting that their ability to induce SOCS3 gene expression is STAT3-independent.	naringenin	5-15	signal transducer and activator of transcription 3	Homo sapiens	168-173
23506745-0	2013	Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-kappaB signalling.	naringenin	21-31	toll-like receptor 4	Mus musculus	80-100
23506745-0	2013	Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-kappaB signalling.	naringenin	21-31	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	101-110
23782265-3	2013	To this end we carried out a screen of 1031 existing medicinal compounds to identify inducers of SOCS3 gene expression and identified the flavanoids naringenin and flavone as effective inducers of SOCS3 protein, mRNA and promoter activity.	naringenin	149-159	suppressor of cytokine signaling 3	Homo sapiens	197-202
23782265-5	2013	Both naringenin and flavone also effectively suppressed IL-6-stimulated phosphorylation of STAT3 (Tyr705) which led to suppression of IL-6-induction of the atherogenic STAT3 target gene MCP1 (monocyte chemotactic protein-1), suggesting that their ability to induce SOCS3 gene expression is STAT3-independent.	naringenin	5-15	interleukin 6	Homo sapiens	56-60
23782265-5	2013	Both naringenin and flavone also effectively suppressed IL-6-stimulated phosphorylation of STAT3 (Tyr705) which led to suppression of IL-6-induction of the atherogenic STAT3 target gene MCP1 (monocyte chemotactic protein-1), suggesting that their ability to induce SOCS3 gene expression is STAT3-independent.	naringenin	5-15	signal transducer and activator of transcription 3	Homo sapiens	91-96
23506745-4	2013	Pre-administration of naringenin significantly reduced the severity of colitis and resulted in down-regulation of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), cyclo-oxygenase-2 (Cox2), TNF-alpha and IL-6 mRNA) in the colon mucosa.	naringenin	22-32	nitric oxide synthase 2, inducible	Mus musculus	142-163
23506745-4	2013	Pre-administration of naringenin significantly reduced the severity of colitis and resulted in down-regulation of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), cyclo-oxygenase-2 (Cox2), TNF-alpha and IL-6 mRNA) in the colon mucosa.	naringenin	22-32	nitric oxide synthase 2, inducible	Mus musculus	165-169
23506745-4	2013	Pre-administration of naringenin significantly reduced the severity of colitis and resulted in down-regulation of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), cyclo-oxygenase-2 (Cox2), TNF-alpha and IL-6 mRNA) in the colon mucosa.	naringenin	22-32	intercellular adhesion molecule 1	Mus musculus	172-205
23506745-8	2013	In addition, in vitro NF-kappaB reporter assays performed on human colonic HT-29 cells exposed to naringenin demonstrated a significant inhibition of TNF-alpha-induced NF-kappaB luciferase expression.	naringenin	98-108	tumor necrosis factor	Mus musculus	150-159
23506745-8	2013	In addition, in vitro NF-kappaB reporter assays performed on human colonic HT-29 cells exposed to naringenin demonstrated a significant inhibition of TNF-alpha-induced NF-kappaB luciferase expression.	naringenin	98-108	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	168-177
23506745-9	2013	Thus, for the first time, the present study indicates that targeted inhibition of the TLR4/NF-kappaB signalling pathway might be an important mechanism for naringenin in abrogating experimental colitis.	naringenin	156-166	toll-like receptor 4	Mus musculus	86-90
23506745-9	2013	Thus, for the first time, the present study indicates that targeted inhibition of the TLR4/NF-kappaB signalling pathway might be an important mechanism for naringenin in abrogating experimental colitis.	naringenin	156-166	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	91-100
22903244-3	2013	The targets of hesperetin and naringenin were found: hesperetin inhibited phosphorylation of Syk and Akt, while naringenin suppressed the expression of Lyn and inhibited the phosphorylation of Akt.	naringenin	30-40	spleen associated tyrosine kinase	Rattus norvegicus	93-96
23506745-4	2013	Pre-administration of naringenin significantly reduced the severity of colitis and resulted in down-regulation of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), cyclo-oxygenase-2 (Cox2), TNF-alpha and IL-6 mRNA) in the colon mucosa.	naringenin	22-32	intercellular adhesion molecule 1	Mus musculus	207-213
23506745-4	2013	Pre-administration of naringenin significantly reduced the severity of colitis and resulted in down-regulation of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), cyclo-oxygenase-2 (Cox2), TNF-alpha and IL-6 mRNA) in the colon mucosa.	naringenin	22-32	chemokine (C-C motif) ligand 2	Mus musculus	216-250
23506745-4	2013	Pre-administration of naringenin significantly reduced the severity of colitis and resulted in down-regulation of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), cyclo-oxygenase-2 (Cox2), TNF-alpha and IL-6 mRNA) in the colon mucosa.	naringenin	22-32	chemokine (C-C motif) ligand 2	Mus musculus	252-257
23506745-4	2013	Pre-administration of naringenin significantly reduced the severity of colitis and resulted in down-regulation of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), cyclo-oxygenase-2 (Cox2), TNF-alpha and IL-6 mRNA) in the colon mucosa.	naringenin	22-32	tumor necrosis factor	Mus musculus	286-295
23506745-4	2013	Pre-administration of naringenin significantly reduced the severity of colitis and resulted in down-regulation of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), cyclo-oxygenase-2 (Cox2), TNF-alpha and IL-6 mRNA) in the colon mucosa.	naringenin	22-32	interleukin 6	Mus musculus	300-304
23506745-7	2013	Consistent with the in vivo results, naringenin exposure blocked lipopolysaccharide-stimulated nuclear translocation of NF-kappaB p65 in mouse macrophage RAW264.7 cells.	naringenin	37-47	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	120-129
23506745-7	2013	Consistent with the in vivo results, naringenin exposure blocked lipopolysaccharide-stimulated nuclear translocation of NF-kappaB p65 in mouse macrophage RAW264.7 cells.	naringenin	37-47	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	130-133
23172681-4	2013	In this study, we examined the molecular mechanisms by which naringenin inhibited NDEA-induced hepatocellular carcinoma in rats by analysing the expression patterns of proliferating cell nuclear antigen, Bcl-2, NF-kappaB, VEGF and MMP-2/9.	naringenin	61-71	vascular endothelial growth factor A	Rattus norvegicus	222-226
23172681-4	2013	In this study, we examined the molecular mechanisms by which naringenin inhibited NDEA-induced hepatocellular carcinoma in rats by analysing the expression patterns of proliferating cell nuclear antigen, Bcl-2, NF-kappaB, VEGF and MMP-2/9.	naringenin	61-71	matrix metallopeptidase 2	Rattus norvegicus	231-238
23172681-6	2013	Administration of pretreatment and posttreatment of naringenin decreased the expression of PCNA and Bcl-2 and increased the expression of Bax and caspase-3, indicating antiproliferative and apoptotic effects, respectively.	naringenin	52-62	proliferating cell nuclear antigen	Rattus norvegicus	91-95
23172681-6	2013	Administration of pretreatment and posttreatment of naringenin decreased the expression of PCNA and Bcl-2 and increased the expression of Bax and caspase-3, indicating antiproliferative and apoptotic effects, respectively.	naringenin	52-62	BCL2, apoptosis regulator	Rattus norvegicus	100-105
23172681-6	2013	Administration of pretreatment and posttreatment of naringenin decreased the expression of PCNA and Bcl-2 and increased the expression of Bax and caspase-3, indicating antiproliferative and apoptotic effects, respectively.	naringenin	52-62	BCL2 associated X, apoptosis regulator	Rattus norvegicus	138-141
23172681-6	2013	Administration of pretreatment and posttreatment of naringenin decreased the expression of PCNA and Bcl-2 and increased the expression of Bax and caspase-3, indicating antiproliferative and apoptotic effects, respectively.	naringenin	52-62	caspase 3	Rattus norvegicus	146-155
23172681-8	2013	Downregulation of NF-kappaB, VEGF and MMPs by naringenin seen in the present study were correlated with the inhibition of liver tumour induced by NDEA.	naringenin	46-56	vascular endothelial growth factor A	Rattus norvegicus	29-33
23172681-8	2013	Downregulation of NF-kappaB, VEGF and MMPs by naringenin seen in the present study were correlated with the inhibition of liver tumour induced by NDEA.	naringenin	46-56	matrix metallopeptidase 2	Rattus norvegicus	38-42
22903244-3	2013	The targets of hesperetin and naringenin were found: hesperetin inhibited phosphorylation of Syk and Akt, while naringenin suppressed the expression of Lyn and inhibited the phosphorylation of Akt.	naringenin	30-40	AKT serine/threonine kinase 1	Rattus norvegicus	101-104
23333096-0	2013	Citrus flavonoid naringenin inhibits TLR2 expression in adipocytes.	naringenin	17-27	toll-like receptor 2	Mus musculus	37-41
22903244-3	2013	The targets of hesperetin and naringenin were found: hesperetin inhibited phosphorylation of Syk and Akt, while naringenin suppressed the expression of Lyn and inhibited the phosphorylation of Akt.	naringenin	30-40	LYN proto-oncogene, Src family tyrosine kinase	Rattus norvegicus	152-155
23333096-3	2013	In this report, we show that naringenin, a citrus flavonoid, inhibits TLR2 expression during adipocyte differentiation.	naringenin	29-39	toll-like receptor 2	Mus musculus	70-74
23333096-5	2013	In addition, naringenin suppresses TLR2 expression induced by the co-culture of differentiated adipocytes and macrophages and also inhibits tumor necrosis factor-alpha (TNF-alpha)-induced TLR2 expression by inhibiting the activation of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways in differentiated adipocytes.	naringenin	13-23	toll-like receptor 2	Mus musculus	35-39
23333096-5	2013	In addition, naringenin suppresses TLR2 expression induced by the co-culture of differentiated adipocytes and macrophages and also inhibits tumor necrosis factor-alpha (TNF-alpha)-induced TLR2 expression by inhibiting the activation of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways in differentiated adipocytes.	naringenin	13-23	tumor necrosis factor	Mus musculus	140-167
23333096-5	2013	In addition, naringenin suppresses TLR2 expression induced by the co-culture of differentiated adipocytes and macrophages and also inhibits tumor necrosis factor-alpha (TNF-alpha)-induced TLR2 expression by inhibiting the activation of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways in differentiated adipocytes.	naringenin	13-23	tumor necrosis factor	Mus musculus	169-178
22903244-3	2013	The targets of hesperetin and naringenin were found: hesperetin inhibited phosphorylation of Syk and Akt, while naringenin suppressed the expression of Lyn and inhibited the phosphorylation of Akt.	naringenin	30-40	AKT serine/threonine kinase 1	Rattus norvegicus	193-196
22903244-3	2013	The targets of hesperetin and naringenin were found: hesperetin inhibited phosphorylation of Syk and Akt, while naringenin suppressed the expression of Lyn and inhibited the phosphorylation of Akt.	naringenin	112-122	LYN proto-oncogene, Src family tyrosine kinase	Rattus norvegicus	152-155
23333096-5	2013	In addition, naringenin suppresses TLR2 expression induced by the co-culture of differentiated adipocytes and macrophages and also inhibits tumor necrosis factor-alpha (TNF-alpha)-induced TLR2 expression by inhibiting the activation of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways in differentiated adipocytes.	naringenin	13-23	toll-like receptor 2	Mus musculus	188-192
23333096-6	2013	Furthermore, naringenin decreases TLR2 expression in adipose tissue of high-fat diet-fed mice.	naringenin	13-23	toll-like receptor 2	Mus musculus	34-38
22903244-3	2013	The targets of hesperetin and naringenin were found: hesperetin inhibited phosphorylation of Syk and Akt, while naringenin suppressed the expression of Lyn and inhibited the phosphorylation of Akt.	naringenin	112-122	AKT serine/threonine kinase 1	Rattus norvegicus	193-196
23333096-8	2013	Taken together, these data suggest that naringenin exhibits anti-inflammatory properties, presumably by inhibiting TLR2 expression in adipocytes.	naringenin	40-50	toll-like receptor 2	Mus musculus	115-119
22903244-4	2013	These results suggest that hesperetin and naringenin inhibit degranulation by suppression of pathway signals and reduce the symptoms of allergy by inhibiting phosphorylation of Akt, which leads to the suppression of cytokines.	naringenin	42-52	AKT serine/threonine kinase 1	Rattus norvegicus	177-180
23233294-2	2013	The present study is designed to evaluate the chemopreventive efficacy of prepared naringenin-loaded nanoparticles (NARNPs) relative to efficacy of free naringenin (NAR) against 7,12-dimethyl benz(a)anthracene (DMBA)-induced oral carcinogenesis by evaluating the status of lipid peroxidation, antioxidants and immunoexpression patterns of proliferating cell nuclear antigen (PCNA) and p53 proteins.	naringenin	83-93	proliferating cell nuclear antigen	Mesocricetus auratus	339-373
23475986-8	2013	Although naringenin significantly attenuated IL-1beta-induced IL-6 and IL-8 mRNA expression and release, there was no effect of curcumin and apigenin.	naringenin	9-19	interleukin 1 beta	Homo sapiens	45-53
23475986-8	2013	Although naringenin significantly attenuated IL-1beta-induced IL-6 and IL-8 mRNA expression and release, there was no effect of curcumin and apigenin.	naringenin	9-19	interleukin 6	Homo sapiens	62-66
23475986-8	2013	Although naringenin significantly attenuated IL-1beta-induced IL-6 and IL-8 mRNA expression and release, there was no effect of curcumin and apigenin.	naringenin	9-19	C-X-C motif chemokine ligand 8	Homo sapiens	71-75
22935222-0	2013	The citrus flavanone naringenin suppresses CYP1B1 transactivation through antagonising xenobiotic-responsive element binding.	naringenin	21-31	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	43-49
22935222-5	2013	In the present study, the effect of naringenin on the regulation of CYP1B1 was investigated in MCF-7 cells.	naringenin	36-46	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	68-74
22935222-6	2013	Enzyme inhibition assays revealed that naringenin inhibited CYP1B1 at or above 5 mum but not CYP1A1 activity.	naringenin	39-49	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	60-66
22935222-7	2013	Quantitative PCR analysis also demonstrated that 1 mum-naringenin reduced CYP1B1 mRNA expression induced by 7,12-dimethylbenz(alpha)anthracene (DMBA).	naringenin	55-65	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	74-80
22850125-3	2013	Conversely, in vitro, naringenin and quercetin are described to inhibit phosphoinositide-3-kinase (PI3K), an enzyme that is essential for the neuronal control of whole body glucose homoeostasis.	naringenin	22-32	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	72-97
22850125-6	2013	In Djungarian hamsters (Phodopus sungorus) naringenin and quercetin (10 mg/kg administered orally) diminished insulin-induced phosphorylation of Akt (Ser473) in the arcuate nucleus, indicating a reduction in hypothalamic PI3K activity.	naringenin	43-53	thymoma viral proto-oncogene 1	Mus musculus	145-148
23233294-2	2013	The present study is designed to evaluate the chemopreventive efficacy of prepared naringenin-loaded nanoparticles (NARNPs) relative to efficacy of free naringenin (NAR) against 7,12-dimethyl benz(a)anthracene (DMBA)-induced oral carcinogenesis by evaluating the status of lipid peroxidation, antioxidants and immunoexpression patterns of proliferating cell nuclear antigen (PCNA) and p53 proteins.	naringenin	83-93	proliferating cell nuclear antigen	Mesocricetus auratus	375-379
23233294-2	2013	The present study is designed to evaluate the chemopreventive efficacy of prepared naringenin-loaded nanoparticles (NARNPs) relative to efficacy of free naringenin (NAR) against 7,12-dimethyl benz(a)anthracene (DMBA)-induced oral carcinogenesis by evaluating the status of lipid peroxidation, antioxidants and immunoexpression patterns of proliferating cell nuclear antigen (PCNA) and p53 proteins.	naringenin	83-93	cellular tumor antigen p53	Mesocricetus auratus	385-388
23269394-0	2013	Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr-/- mice.	naringenin	0-10	low density lipoprotein receptor	Mus musculus	111-115
23263903-4	2013	The present study was embarked to demonstrate the effect of naringenin (50 mg/kg bw for 30 days administrated orally) on PI3K, protein kinase B, and cyclooxygenase-2 in cerebrally implanted rat C6 glioma model.	naringenin	60-70	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	149-165
23263903-7	2013	The results showed that the naringenin could down-regulate the expressions of PI3K and protein kinase B along with activity and expression of cyclooxygenase-2 in C6 glioma cells implanted rat brain.	naringenin	28-38	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	142-158
23263903-8	2013	In conclusion, it can be argued that the reduced expressions of phosphatidylinositol 3-kinase and protein kinase B in naringenin-treated glioma-induced rat brain might be involved in the down-regulation of cyclooxygenase-2 expression and activity.	naringenin	118-128	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	64-93
23263903-8	2013	In conclusion, it can be argued that the reduced expressions of phosphatidylinositol 3-kinase and protein kinase B in naringenin-treated glioma-induced rat brain might be involved in the down-regulation of cyclooxygenase-2 expression and activity.	naringenin	118-128	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	206-222
22933043-7	2012	Of the naringenin derivatives tested to date, 8-prenylnaringenin is the most potent inhibitor of the Kv1.3 channels.	naringenin	7-17	potassium voltage-gated channel subfamily A member 3	Homo sapiens	101-106
22674629-6	2013	Naringenin inhibits expression of an indicator of myofibroblast differentiation (alpha-SMA) and ECM production, including collagen type 1 and fibronectin.	naringenin	0-10	fibronectin 1	Homo sapiens	122-153
23192364-0	2013	Naringenin prevents high glucose-induced mitochondria-mediated apoptosis involving AIF, Endo-G and caspases.	naringenin	0-10	apoptosis inducing factor, mitochondria associated 1	Rattus norvegicus	83-86
23192364-0	2013	Naringenin prevents high glucose-induced mitochondria-mediated apoptosis involving AIF, Endo-G and caspases.	naringenin	0-10	endonuclease G	Rattus norvegicus	88-107
23192364-9	2013	Translocation of AIF, Endo-G, and Cyt-c from mitochondria was also inhibited by naringenin in glucose-stressed cells.	naringenin	80-90	apoptosis inducing factor, mitochondria associated 1	Rattus norvegicus	17-20
23192364-9	2013	Translocation of AIF, Endo-G, and Cyt-c from mitochondria was also inhibited by naringenin in glucose-stressed cells.	naringenin	80-90	endonuclease G	Rattus norvegicus	22-28
23370353-6	2013	We found that daidzein, genistein, apigenin, hesperetin, naringenin, and eriodictyol significantly reduced deoxycorticosterone and androstenedione levels (p&lt;0.05), suggesting inhibition of 3beta-HSD by these polyphenols.	naringenin	57-67	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Homo sapiens	192-201
23983791-0	2013	Naringenin inhibits adipogenesis and reduces insulin sensitivity and adiponectin expression in adipocytes.	naringenin	0-10	insulin	Homo sapiens	45-52
23983791-0	2013	Naringenin inhibits adipogenesis and reduces insulin sensitivity and adiponectin expression in adipocytes.	naringenin	0-10	adiponectin, C1Q and collagen domain containing	Homo sapiens	69-80
23983791-8	2013	In mature 3T3-L1 adipocytes, naringenin reduced the ability of insulin to induce IRS-1 tyrosine phosphorylation and substantially inhibited insulin-stimulated glucose uptake in a dose-dependent manner and over a time frame of 1.5 to 24 hours.	naringenin	29-39	insulin	Homo sapiens	63-70
23983791-8	2013	In mature 3T3-L1 adipocytes, naringenin reduced the ability of insulin to induce IRS-1 tyrosine phosphorylation and substantially inhibited insulin-stimulated glucose uptake in a dose-dependent manner and over a time frame of 1.5 to 24 hours.	naringenin	29-39	insulin receptor substrate 1	Homo sapiens	81-86
23983791-8	2013	In mature 3T3-L1 adipocytes, naringenin reduced the ability of insulin to induce IRS-1 tyrosine phosphorylation and substantially inhibited insulin-stimulated glucose uptake in a dose-dependent manner and over a time frame of 1.5 to 24 hours.	naringenin	29-39	insulin	Homo sapiens	140-147
23983791-9	2013	Exposure to naringenin also inhibited adiponectin protein expression in mature murine and human adipocytes.	naringenin	12-22	adiponectin, C1Q and collagen domain containing	Mus musculus	38-49
23983791-10	2013	Our studies have revealed that naringenin may have a negative impact on adipocyte-related diseases by limiting differentiation of preadipocytes, by significantly inducing insulin resistance, and by decreasing adiponectin expression in mature fat cells.	naringenin	31-41	insulin	Homo sapiens	171-178
23983791-10	2013	Our studies have revealed that naringenin may have a negative impact on adipocyte-related diseases by limiting differentiation of preadipocytes, by significantly inducing insulin resistance, and by decreasing adiponectin expression in mature fat cells.	naringenin	31-41	adiponectin, C1Q and collagen domain containing	Homo sapiens	209-220
22999973-10	2012	Cholinergic function was improved by naringenin through the inhibition of elevated ChE activity.	naringenin	37-47	butyrylcholinesterase	Rattus norvegicus	83-86
22999973-11	2012	In conclusion, the present study suggests that naringenin acts as an antioxidant and ChE inhibitor against type-2 diabetes-induced memory dysfunction.	naringenin	47-57	butyrylcholinesterase	Rattus norvegicus	85-88
23103795-0	2013	Neuroprotective effect of naringenin is mediated through suppression of NF-kappaB signaling pathway in experimental stroke.	naringenin	26-36	nuclear factor kappa B subunit 1	Homo sapiens	72-81
23103795-5	2013	In this study we undertook a pharmacological approach to investigate the ability of naringenin, a potent flavonoid, to prevent oxidative stress and NF-kappaB-mediated inflammatory brain damage in the rat model of focal cerebral I/R injury.	naringenin	84-94	nuclear factor kappa B subunit 1	Homo sapiens	148-157
23103795-7	2013	Naringenin treatment successfully upregulates the antioxidant status, decreases the infarct size and lowers the levels of myeloperoxidase, nitric oxide and cytokines, besides functional recovery returned close to the baseline.	naringenin	0-10	myeloperoxidase	Homo sapiens	122-137
23103795-8	2013	Moreover, immunohistochemical and Western blot analyses clearly demonstrated that naringenin treatment limits glial activation and downregulates the NF-kappaB expression level and their target genes.	naringenin	82-92	nuclear factor kappa B subunit 1	Homo sapiens	149-158
23103795-9	2013	These results show, prophylactic treatment with naringenin improved functional outcomes and abrogated the ischemic brain injury by suppressing NF-kappaB-mediated neuroinflammation.	naringenin	48-58	nuclear factor kappa B subunit 1	Homo sapiens	143-152
23912743-0	2013	Naringenin inhibits angiotensin II-induced vascular smooth muscle cells proliferation and migration and decreases neointimal hyperplasia in balloon injured rat carotid arteries through suppressing oxidative stress.	naringenin	0-10	angiotensinogen	Rattus norvegicus	20-34
23912743-3	2013	This study was designed to explore whether naringenin could inhibit angiotensin II-induced VSMCs proliferation and migration and decrease neointimal hyperplasia in balloon injured rat carotid arteries.	naringenin	43-53	angiotensinogen	Rattus norvegicus	68-82
23912743-5	2013	The results showed naringenin led to a significant inhibition of angiotensin II-induced VSMCs proliferation and migration.	naringenin	19-29	angiotensinogen	Rattus norvegicus	65-79
23912743-6	2013	Naringenin significantly attenuated the reactive oxygen species production, increased the superoxide dismutase activity and decreased the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, reduced phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) and the nuclear translocation of nuclear factor (NF)-kappaB p65 in angiotensin II-treated VSMCs.	naringenin	0-10	mitogen activated protein kinase 3	Rattus norvegicus	235-281
23912743-6	2013	Naringenin significantly attenuated the reactive oxygen species production, increased the superoxide dismutase activity and decreased the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, reduced phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) and the nuclear translocation of nuclear factor (NF)-kappaB p65 in angiotensin II-treated VSMCs.	naringenin	0-10	mitogen activated protein kinase 3	Rattus norvegicus	283-289
23912743-6	2013	Naringenin significantly attenuated the reactive oxygen species production, increased the superoxide dismutase activity and decreased the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, reduced phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) and the nuclear translocation of nuclear factor (NF)-kappaB p65 in angiotensin II-treated VSMCs.	naringenin	0-10	mitogen activated protein kinase 14	Rattus norvegicus	295-331
23912743-6	2013	Naringenin significantly attenuated the reactive oxygen species production, increased the superoxide dismutase activity and decreased the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, reduced phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) and the nuclear translocation of nuclear factor (NF)-kappaB p65 in angiotensin II-treated VSMCs.	naringenin	0-10	mitogen activated protein kinase 3	Rattus norvegicus	333-337
23912743-6	2013	Naringenin significantly attenuated the reactive oxygen species production, increased the superoxide dismutase activity and decreased the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, reduced phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) and the nuclear translocation of nuclear factor (NF)-kappaB p65 in angiotensin II-treated VSMCs.	naringenin	0-10	synaptotagmin 1	Rattus norvegicus	399-402
23912743-6	2013	Naringenin significantly attenuated the reactive oxygen species production, increased the superoxide dismutase activity and decreased the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, reduced phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) and the nuclear translocation of nuclear factor (NF)-kappaB p65 in angiotensin II-treated VSMCs.	naringenin	0-10	angiotensinogen	Rattus norvegicus	406-420
23912743-8	2013	These results indicated naringenin exhibited antioxidant activity on angiotensin II-treated VSMCs and balloon injured rat carotid arteries and could be a potential protective agent for restenosis after angioplasty.	naringenin	24-34	angiotensinogen	Rattus norvegicus	69-83
23177257-2	2013	The half maximal inhibitory concentrations (IC(50)) of five naringenin derivatives ranged between 1.20 muM and 20.01 muM which are much better than naringenin used as a control.	naringenin	60-70	latexin	Homo sapiens	103-106
23177257-2	2013	The half maximal inhibitory concentrations (IC(50)) of five naringenin derivatives ranged between 1.20 muM and 20.01 muM which are much better than naringenin used as a control.	naringenin	60-70	latexin	Homo sapiens	117-120
23177257-5	2013	To elucidate the possible interaction between naringenin derivatives and CDK2, in silico docking study was performed.	naringenin	46-56	cyclin dependent kinase 2	Homo sapiens	73-77
22213181-7	2012	In line with E2, mRNA expression of Nefm and Zdhhc-2 was down-regulated following 8-PN, GEN, DAI, EQ and naringenin treatment.	naringenin	105-115	neurofilament medium chain	Rattus norvegicus	36-40
23064111-6	2012	Naringenin (50-100 muM) showed a low protective effect and epicatechin (200 muM) was not efficacious.	naringenin	0-10	latexin	Homo sapiens	19-22
22213181-7	2012	In line with E2, mRNA expression of Nefm and Zdhhc-2 was down-regulated following 8-PN, GEN, DAI, EQ and naringenin treatment.	naringenin	105-115	zinc finger DHHC-type palmitoyltransferase 2	Rattus norvegicus	45-52
22900548-7	2012	Supplementation with naringenin for the last 30 days to ethanol-fed rats, significantly decreased the levels/activities/expression of serum aspartate and alanine transaminases, iron, ferritin, TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, CD14 and iNOS protein adducts in the liver as compared to the untreated ethanol fed rats.	naringenin	21-31	tumor necrosis factor	Rattus norvegicus	193-202
22709719-4	2012	Moreover, administration of naringenin for 14 days (20 mg/kg) increased hippocampal serotonin (5-HT), norepinephrine (NE) and GR levels, and reduced serum corticosterone levels in mice exposed to the repeated TST.	naringenin	28-38	nuclear receptor subfamily 3, group C, member 1	Mus musculus	126-128
22766066-1	2012	Naringenin, the aglycone of naringin, has been reported to attenuate MUC5AC secretion by inhibiting activity of nuclear factor kappa B (NF-kappaB) via EGFR-PI3K-Akt/ERK MAPKinase signaling pathways.	naringenin	0-10	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	69-75
22766066-1	2012	Naringenin, the aglycone of naringin, has been reported to attenuate MUC5AC secretion by inhibiting activity of nuclear factor kappa B (NF-kappaB) via EGFR-PI3K-Akt/ERK MAPKinase signaling pathways.	naringenin	0-10	nuclear factor kappa B subunit 1	Homo sapiens	112-134
22766066-1	2012	Naringenin, the aglycone of naringin, has been reported to attenuate MUC5AC secretion by inhibiting activity of nuclear factor kappa B (NF-kappaB) via EGFR-PI3K-Akt/ERK MAPKinase signaling pathways.	naringenin	0-10	nuclear factor kappa B subunit 1	Homo sapiens	136-145
22766066-1	2012	Naringenin, the aglycone of naringin, has been reported to attenuate MUC5AC secretion by inhibiting activity of nuclear factor kappa B (NF-kappaB) via EGFR-PI3K-Akt/ERK MAPKinase signaling pathways.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	161-164
22766066-1	2012	Naringenin, the aglycone of naringin, has been reported to attenuate MUC5AC secretion by inhibiting activity of nuclear factor kappa B (NF-kappaB) via EGFR-PI3K-Akt/ERK MAPKinase signaling pathways.	naringenin	0-10	mitogen-activated protein kinase 1	Homo sapiens	165-168
22709785-0	2012	Naringenin inhibits TNF-alpha induced VSMC proliferation and migration via induction of HO-1.	naringenin	0-10	tumor necrosis factor	Rattus norvegicus	20-29
22709785-0	2012	Naringenin inhibits TNF-alpha induced VSMC proliferation and migration via induction of HO-1.	naringenin	0-10	heme oxygenase 1	Rattus norvegicus	88-92
22709785-5	2012	We found that naringenin induced HO-1 mRNA and protein levels, as well as its activity, in VSMCs.	naringenin	14-24	heme oxygenase 1	Rattus norvegicus	33-37
22709785-6	2012	Naringenin inhibited TNF-alpha-induced VSMC proliferation and migration in a dose-dependent manner.	naringenin	0-10	tumor necrosis factor	Rattus norvegicus	21-30
22709785-7	2012	Mechanistic study demonstrated that naringenin prevented ERK/MAPK and Akt phosphorylation while left p38 MAPK and JNK unchanged.	naringenin	36-46	Eph receptor B1	Rattus norvegicus	57-60
22709785-7	2012	Mechanistic study demonstrated that naringenin prevented ERK/MAPK and Akt phosphorylation while left p38 MAPK and JNK unchanged.	naringenin	36-46	AKT serine/threonine kinase 1	Rattus norvegicus	70-73
22709785-8	2012	Naringenin also blocked the increase of ROS generation induced by TNF-alpha.	naringenin	0-10	tumor necrosis factor	Rattus norvegicus	66-75
22709785-9	2012	More importantly, the specific HO-1 inhibitor ZnPP IX or HO-1 siRNA partially abolished the beneficial effects of naringenin on VSMCs.	naringenin	114-124	heme oxygenase 1	Rattus norvegicus	31-35
22709785-9	2012	More importantly, the specific HO-1 inhibitor ZnPP IX or HO-1 siRNA partially abolished the beneficial effects of naringenin on VSMCs.	naringenin	114-124	heme oxygenase 1	Rattus norvegicus	57-61
22709785-10	2012	These results suggest that naringenin may serve as a novel drug in the treatment of these pathologies by inducing HO-1 expression/activity and subsequently decreasing VSMC proliferation and migration.	naringenin	27-37	heme oxygenase 1	Rattus norvegicus	114-118
22900548-7	2012	Supplementation with naringenin for the last 30 days to ethanol-fed rats, significantly decreased the levels/activities/expression of serum aspartate and alanine transaminases, iron, ferritin, TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, CD14 and iNOS protein adducts in the liver as compared to the untreated ethanol fed rats.	naringenin	21-31	C-X-C motif chemokine ligand 2	Rattus norvegicus	228-233
22900548-7	2012	Supplementation with naringenin for the last 30 days to ethanol-fed rats, significantly decreased the levels/activities/expression of serum aspartate and alanine transaminases, iron, ferritin, TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, CD14 and iNOS protein adducts in the liver as compared to the untreated ethanol fed rats.	naringenin	21-31	CD14 molecule	Rattus norvegicus	235-239
22900548-7	2012	Supplementation with naringenin for the last 30 days to ethanol-fed rats, significantly decreased the levels/activities/expression of serum aspartate and alanine transaminases, iron, ferritin, TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, CD14 and iNOS protein adducts in the liver as compared to the untreated ethanol fed rats.	naringenin	21-31	nitric oxide synthase 2	Rattus norvegicus	244-248
22900548-8	2012	The inhibition of TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, iNOS and CD14 by naringenin may contribute to its antiinflammatory activity in ethanol fed rats.	naringenin	77-87	tumor necrosis factor	Rattus norvegicus	18-27
22900548-8	2012	The inhibition of TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, iNOS and CD14 by naringenin may contribute to its antiinflammatory activity in ethanol fed rats.	naringenin	77-87	interleukin 6	Rattus norvegicus	29-33
22900548-8	2012	The inhibition of TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, iNOS and CD14 by naringenin may contribute to its antiinflammatory activity in ethanol fed rats.	naringenin	77-87	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	46-51
22900548-7	2012	Supplementation with naringenin for the last 30 days to ethanol-fed rats, significantly decreased the levels/activities/expression of serum aspartate and alanine transaminases, iron, ferritin, TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, CD14 and iNOS protein adducts in the liver as compared to the untreated ethanol fed rats.	naringenin	21-31	interleukin 6	Rattus norvegicus	204-208
22900548-8	2012	The inhibition of TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, iNOS and CD14 by naringenin may contribute to its antiinflammatory activity in ethanol fed rats.	naringenin	77-87	C-X-C motif chemokine ligand 2	Rattus norvegicus	53-58
22900548-8	2012	The inhibition of TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, iNOS and CD14 by naringenin may contribute to its antiinflammatory activity in ethanol fed rats.	naringenin	77-87	nitric oxide synthase 2	Rattus norvegicus	60-64
22900548-7	2012	Supplementation with naringenin for the last 30 days to ethanol-fed rats, significantly decreased the levels/activities/expression of serum aspartate and alanine transaminases, iron, ferritin, TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, CD14 and iNOS protein adducts in the liver as compared to the untreated ethanol fed rats.	naringenin	21-31	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	221-226
22900548-8	2012	The inhibition of TNF-alpha, IL-6, NF-kappaB, COX-2, MIP-2, iNOS and CD14 by naringenin may contribute to its antiinflammatory activity in ethanol fed rats.	naringenin	77-87	CD14 molecule	Rattus norvegicus	69-73
22579112-9	2012	These results suggest that quercetin or naringenin might possibly be able to protect beta-cells from cytokines toxicity by enhancing cell survival through PI3-kinase pathway, independent of p-p38 MAPK or iNOS.	naringenin	40-50	mitogen-activated protein kinase 14	Homo sapiens	192-195
22410438-10	2012	In fact, in the presence of ERalpha, both naringenin and quercetin decouple ERalpha activities by specifically interfering with ERalpha membrane initiating signals.	naringenin	42-52	estrogen receptor 1	Homo sapiens	28-35
22410438-10	2012	In fact, in the presence of ERalpha, both naringenin and quercetin decouple ERalpha activities by specifically interfering with ERalpha membrane initiating signals.	naringenin	42-52	estrogen receptor 1	Homo sapiens	76-83
22410438-10	2012	In fact, in the presence of ERalpha, both naringenin and quercetin decouple ERalpha activities by specifically interfering with ERalpha membrane initiating signals.	naringenin	42-52	estrogen receptor 1	Homo sapiens	76-83
22579112-9	2012	These results suggest that quercetin or naringenin might possibly be able to protect beta-cells from cytokines toxicity by enhancing cell survival through PI3-kinase pathway, independent of p-p38 MAPK or iNOS.	naringenin	40-50	nitric oxide synthase 2	Homo sapiens	204-208
22249996-9	2012	The dependence of the PAL feedback inhibition on flavonols was confirmed by chemical complementation of tt4 ugt78d1 ugt78d2 using naringenin, a downstream flavonoid intermediate, which restored the PAL repression.	naringenin	130-140	UDP-glucosyl transferase 78D1	Arabidopsis thaliana	108-115
22394605-8	2012	Among the grapefruit flavonoids, naringenin was the most potent inhibitor of the OATP1B1- and OATP1B3-mediated [3H]BSP transport with IC(50)-values of 81.6+-1.1muM and 101.1+-1.1muM, respectively.	naringenin	33-43	solute carrier organic anion transporter family member 1B1	Homo sapiens	81-88
22394605-8	2012	Among the grapefruit flavonoids, naringenin was the most potent inhibitor of the OATP1B1- and OATP1B3-mediated [3H]BSP transport with IC(50)-values of 81.6+-1.1muM and 101.1+-1.1muM, respectively.	naringenin	33-43	solute carrier organic anion transporter family member 1B3	Homo sapiens	94-101
22552813-6	2012	Naringenin also             attenuated the production of pro-inflammatory cytokines and chemokines, including             interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant             protein-1 (MCP-1) by suppressing expression of mRNAs for these proteins.	naringenin	0-10	interleukin 1 beta	Mus musculus	122-139
22552813-6	2012	Naringenin also             attenuated the production of pro-inflammatory cytokines and chemokines, including             interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant             protein-1 (MCP-1) by suppressing expression of mRNAs for these proteins.	naringenin	0-10	interleukin 1 beta	Mus musculus	141-149
22552813-6	2012	Naringenin also             attenuated the production of pro-inflammatory cytokines and chemokines, including             interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant             protein-1 (MCP-1) by suppressing expression of mRNAs for these proteins.	naringenin	0-10	tumor necrosis factor	Mus musculus	152-179
22552813-6	2012	Naringenin also             attenuated the production of pro-inflammatory cytokines and chemokines, including             interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant             protein-1 (MCP-1) by suppressing expression of mRNAs for these proteins.	naringenin	0-10	tumor necrosis factor	Mus musculus	181-190
22552813-6	2012	Naringenin also             attenuated the production of pro-inflammatory cytokines and chemokines, including             interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant             protein-1 (MCP-1) by suppressing expression of mRNAs for these proteins.	naringenin	0-10	chemokine (C-C motif) ligand 2	Mus musculus	196-242
22552813-6	2012	Naringenin also             attenuated the production of pro-inflammatory cytokines and chemokines, including             interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant             protein-1 (MCP-1) by suppressing expression of mRNAs for these proteins.	naringenin	0-10	chemokine (C-C motif) ligand 2	Mus musculus	244-249
22552813-7	2012	In addition,             the molecular mechanism underlying naringenin-mediated attenuation in BV2 cells             has a close relationship to suppressing translocation of the nuclear factor-kappaB             (NF-kappaB) p65 subunit into the nucleus and the phosphorylation of Akt and mitogen-activated             protein kinases (MAPKs).	naringenin	60-70	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	224-227
22552813-7	2012	In addition,             the molecular mechanism underlying naringenin-mediated attenuation in BV2 cells             has a close relationship to suppressing translocation of the nuclear factor-kappaB             (NF-kappaB) p65 subunit into the nucleus and the phosphorylation of Akt and mitogen-activated             protein kinases (MAPKs).	naringenin	60-70	thymoma viral proto-oncogene 1	Mus musculus	280-283
22249996-9	2012	The dependence of the PAL feedback inhibition on flavonols was confirmed by chemical complementation of tt4 ugt78d1 ugt78d2 using naringenin, a downstream flavonoid intermediate, which restored the PAL repression.	naringenin	130-140	UDP-glucosyl transferase 78D2	Arabidopsis thaliana	116-123
23037174-0	2012	Naringenin inhibits the aggregation of expanded polyglutamine tract-containing protein through the induction of endoplasmic reticulum chaperone GRP78.	naringenin	0-10	heat shock protein family A (Hsp70) member 5	Homo sapiens	144-149
22324845-0	2012	Dietary flavonoid naringenin induces regulatory T cells via an aryl hydrocarbon receptor mediated pathway.	naringenin	18-28	aryl hydrocarbon receptor	Homo sapiens	63-88
22324845-5	2012	The subsequent T cell proliferation suppression assay identified naringenin as the only sample capable of stimulating Treg induction; notably, this induction was eliminated by cotreatment with AhR antagonists.	naringenin	65-75	aryl hydrocarbon receptor	Homo sapiens	193-196
22324845-6	2012	Indeed, naringenin induced CD4(+)Foxp3(+) Tregs, irrespective of the presence of the transforming growth factor-beta (TGF-beta), indicating that the conventional TGF-beta-dependent signaling pathway might not be involved.	naringenin	8-18	CD4 molecule	Homo sapiens	27-30
22324845-6	2012	Indeed, naringenin induced CD4(+)Foxp3(+) Tregs, irrespective of the presence of the transforming growth factor-beta (TGF-beta), indicating that the conventional TGF-beta-dependent signaling pathway might not be involved.	naringenin	8-18	transforming growth factor beta 1	Homo sapiens	162-170
22117528-4	2012	Naringenin treatments dose-dependently reduced renal tumor necrosis factor-alpha level and expression (P &lt; 0.05) but only at 1 and 2% significantly decreased production and expression of interleukin (IL)-1beta, IL-6, and monocyte chemoattractant protein-1 (P &lt; 0.05).	naringenin	0-10	tumor necrosis factor	Mus musculus	53-80
22117528-4	2012	Naringenin treatments dose-dependently reduced renal tumor necrosis factor-alpha level and expression (P &lt; 0.05) but only at 1 and 2% significantly decreased production and expression of interleukin (IL)-1beta, IL-6, and monocyte chemoattractant protein-1 (P &lt; 0.05).	naringenin	0-10	interleukin 1 beta	Mus musculus	190-212
22117528-4	2012	Naringenin treatments dose-dependently reduced renal tumor necrosis factor-alpha level and expression (P &lt; 0.05) but only at 1 and 2% significantly decreased production and expression of interleukin (IL)-1beta, IL-6, and monocyte chemoattractant protein-1 (P &lt; 0.05).	naringenin	0-10	interleukin 6	Mus musculus	214-218
22117528-4	2012	Naringenin treatments dose-dependently reduced renal tumor necrosis factor-alpha level and expression (P &lt; 0.05) but only at 1 and 2% significantly decreased production and expression of interleukin (IL)-1beta, IL-6, and monocyte chemoattractant protein-1 (P &lt; 0.05).	naringenin	0-10	chemokine (C-C motif) ligand 2	Mus musculus	224-258
22117528-5	2012	Naringenin intake at 2% decreased renal formation and expression of type IV collagen, fibronectin, and transforming growth factor-beta1 (P &lt; 0.05).	naringenin	0-10	transforming growth factor, beta 1	Mus musculus	68-135
23037174-5	2012	These findings suggested that naringenin seemed to be a new inducer of GRP78 in mammalian cells, and may be a potential therapeutic agent for diseases caused by ER stress such as polyQ diseases.	naringenin	30-40	heat shock protein family A (Hsp70) member 5	Homo sapiens	71-76
23037174-3	2012	In this study, we performed the screening for compounds that modulate the GRP78 expression in herbal medicines, and found that naringenin, one of the major constitutions of Kanzo (Glycyrrhizae Radix), induced the expression of GRP78 in several mammalian cells.	naringenin	127-137	heat shock protein family A (Hsp70) member 5	Homo sapiens	74-79
23037174-3	2012	In this study, we performed the screening for compounds that modulate the GRP78 expression in herbal medicines, and found that naringenin, one of the major constitutions of Kanzo (Glycyrrhizae Radix), induced the expression of GRP78 in several mammalian cells.	naringenin	127-137	heat shock protein family A (Hsp70) member 5	Homo sapiens	227-232
21802267-0	2011	Citrus flavanone naringenin enhances melanogenesis through the activation of Wnt/beta-catenin signalling in mouse melanoma cells.	naringenin	17-27	catenin (cadherin associated protein), beta 1	Mus musculus	81-93
23300530-0	2012	Naringenin decreases invasiveness and metastasis by inhibiting TGF-beta-induced epithelial to mesenchymal transition in pancreatic cancer cells.	naringenin	0-10	transforming growth factor beta 1	Homo sapiens	63-71
23300530-5	2012	Naringenin (Nar) down-regulated EMT markers expression in both mRNA and protein levels by inhibiting TGF-beta1/Smad3 signal pathway in the pancreatic cancer cells.	naringenin	0-10	transforming growth factor beta 1	Homo sapiens	101-110
23300530-5	2012	Naringenin (Nar) down-regulated EMT markers expression in both mRNA and protein levels by inhibiting TGF-beta1/Smad3 signal pathway in the pancreatic cancer cells.	naringenin	0-10	SMAD family member 3	Homo sapiens	111-116
23300530-5	2012	Naringenin (Nar) down-regulated EMT markers expression in both mRNA and protein levels by inhibiting TGF-beta1/Smad3 signal pathway in the pancreatic cancer cells.	naringenin	0-3	transforming growth factor beta 1	Homo sapiens	101-110
23300530-5	2012	Naringenin (Nar) down-regulated EMT markers expression in both mRNA and protein levels by inhibiting TGF-beta1/Smad3 signal pathway in the pancreatic cancer cells.	naringenin	0-3	SMAD family member 3	Homo sapiens	111-116
21963452-0	2011	Naringenin suppresses the production of thymic stromal lymphopoietin through the blockade of RIP2 and caspase-1 signal cascade in mast cells.	naringenin	0-10	caspase 1	Homo sapiens	102-111
21963452-3	2011	However, the effect of naringenin on the production of TSLP has not been clarified.	naringenin	23-33	thymic stromal lymphopoietin	Homo sapiens	55-59
21963452-4	2011	Thus, we investigated how naringenin inhibits the production of TSLP in the human mast cell line (HMC-1) cells.	naringenin	26-36	thymic stromal lymphopoietin	Homo sapiens	64-68
21963452-5	2011	Naringenin inhibited the production and mRNA expression of TSLP in HMC-1 cells.	naringenin	0-10	thymic stromal lymphopoietin	Homo sapiens	59-63
21963452-6	2011	The maximal inhibition rate of TSLP production by naringenin (100 muM) was 62.27 +- 10.79%.	naringenin	50-60	thymic stromal lymphopoietin	Homo sapiens	31-35
21963452-6	2011	The maximal inhibition rate of TSLP production by naringenin (100 muM) was 62.27 +- 10.79%.	naringenin	50-60	latexin	Homo sapiens	66-69
21963452-8	2011	In the activated HMC-1 cells, the activations of receptor-interacting protein (RIP)2 and caspase-1 were increased, whereas the activations of RIP2 and caspase-1 were decreased by pretreatment with naringenin.	naringenin	197-207	receptor interacting serine/threonine kinase 2	Homo sapiens	49-84
21963452-8	2011	In the activated HMC-1 cells, the activations of receptor-interacting protein (RIP)2 and caspase-1 were increased, whereas the activations of RIP2 and caspase-1 were decreased by pretreatment with naringenin.	naringenin	197-207	caspase 1	Homo sapiens	89-98
21963452-8	2011	In the activated HMC-1 cells, the activations of receptor-interacting protein (RIP)2 and caspase-1 were increased, whereas the activations of RIP2 and caspase-1 were decreased by pretreatment with naringenin.	naringenin	197-207	receptor interacting serine/threonine kinase 2	Homo sapiens	142-146
21963452-8	2011	In the activated HMC-1 cells, the activations of receptor-interacting protein (RIP)2 and caspase-1 were increased, whereas the activations of RIP2 and caspase-1 were decreased by pretreatment with naringenin.	naringenin	197-207	caspase 1	Homo sapiens	151-160
21963452-9	2011	These results suggest that naringenin can be used to treat inflammatory and atopic diseases through the inhibition of TSLP.	naringenin	27-37	thymic stromal lymphopoietin	Homo sapiens	118-122
21963452-0	2011	Naringenin suppresses the production of thymic stromal lymphopoietin through the blockade of RIP2 and caspase-1 signal cascade in mast cells.	naringenin	0-10	thymic stromal lymphopoietin	Homo sapiens	40-68
21963452-0	2011	Naringenin suppresses the production of thymic stromal lymphopoietin through the blockade of RIP2 and caspase-1 signal cascade in mast cells.	naringenin	0-10	receptor interacting serine/threonine kinase 2	Homo sapiens	93-97
21105911-5	2011	Supplementation with naringenin for the last 30 days of the experiment to ethanol-fed rats, significantly decreased the levels/activities of bilirubin, ALP, LDH, TBARS, LOOH, CD and phase I enzymes, and significantly elevated the activities of ADH, ALDH, SOD, CAT and phase II enzymes as compared to control rats.	naringenin	21-31	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	249-253
21105911-5	2011	Supplementation with naringenin for the last 30 days of the experiment to ethanol-fed rats, significantly decreased the levels/activities of bilirubin, ALP, LDH, TBARS, LOOH, CD and phase I enzymes, and significantly elevated the activities of ADH, ALDH, SOD, CAT and phase II enzymes as compared to control rats.	naringenin	21-31	catalase	Rattus norvegicus	260-263
21964193-9	2011	Naringin and naringenin exhibited higher binding capacity to estrogen receptor beta (ERbeta) than estrogen receptor alpha (ERalpha) in yeast two-hybrid experiments and nuclear receptor cofactor assays (RCAS) experiment.	naringenin	13-23	estrogen receptor 2	Homo sapiens	61-83
21964193-9	2011	Naringin and naringenin exhibited higher binding capacity to estrogen receptor beta (ERbeta) than estrogen receptor alpha (ERalpha) in yeast two-hybrid experiments and nuclear receptor cofactor assays (RCAS) experiment.	naringenin	13-23	estrogen receptor 2	Homo sapiens	85-91
21802267-5	2011	Exposure of melanoma cells to naringenin resulted in morphological changes accompanied by the induction of melanocyte differentiation-related markers, such as melanin synthesis, tyrosinase activity, and the expression of tyrosinase and microphthalmia-associated transcription factor (MITF).	naringenin	30-40	tyrosinase	Mus musculus	178-188
21802267-5	2011	Exposure of melanoma cells to naringenin resulted in morphological changes accompanied by the induction of melanocyte differentiation-related markers, such as melanin synthesis, tyrosinase activity, and the expression of tyrosinase and microphthalmia-associated transcription factor (MITF).	naringenin	30-40	tyrosinase	Mus musculus	221-231
21802267-5	2011	Exposure of melanoma cells to naringenin resulted in morphological changes accompanied by the induction of melanocyte differentiation-related markers, such as melanin synthesis, tyrosinase activity, and the expression of tyrosinase and microphthalmia-associated transcription factor (MITF).	naringenin	30-40	melanogenesis associated transcription factor	Mus musculus	236-282
21802267-5	2011	Exposure of melanoma cells to naringenin resulted in morphological changes accompanied by the induction of melanocyte differentiation-related markers, such as melanin synthesis, tyrosinase activity, and the expression of tyrosinase and microphthalmia-associated transcription factor (MITF).	naringenin	30-40	melanogenesis associated transcription factor	Mus musculus	284-288
21802267-6	2011	We also observed an increase in the intracellular accumulation of beta-catenin as well as the phosphorylation of glycogen synthase kinase-3beta (GSK3beta) protein after treatment with naringenin.	naringenin	184-194	catenin (cadherin associated protein), beta 1	Mus musculus	66-78
21802267-6	2011	We also observed an increase in the intracellular accumulation of beta-catenin as well as the phosphorylation of glycogen synthase kinase-3beta (GSK3beta) protein after treatment with naringenin.	naringenin	184-194	glycogen synthase kinase 3 beta	Mus musculus	113-143
21802267-6	2011	We also observed an increase in the intracellular accumulation of beta-catenin as well as the phosphorylation of glycogen synthase kinase-3beta (GSK3beta) protein after treatment with naringenin.	naringenin	184-194	glycogen synthase kinase 3 beta	Mus musculus	145-153
21802267-7	2011	Moreover, the activity of phosphatidylinositol 3-kinase (PI3K) was up-regulated by naringenin since the phosphorylated level of downstream Akt protein was enhanced.	naringenin	83-93	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	26-55
21802267-7	2011	Moreover, the activity of phosphatidylinositol 3-kinase (PI3K) was up-regulated by naringenin since the phosphorylated level of downstream Akt protein was enhanced.	naringenin	83-93	thymoma viral proto-oncogene 1	Mus musculus	139-142
21802267-8	2011	Based on these results, we concluded that naringenin induced melanogenesis through the Wnt-beta-catenin-signalling pathway.	naringenin	42-52	catenin (cadherin associated protein), beta 1	Mus musculus	91-103
25205946-7	2011	CONCLUSION: In C6 glioma cells-implanted rats, increased expression of GFAP was noted on treatment with Naringenin.	naringenin	104-114	glial fibrillary acidic protein	Rattus norvegicus	71-75
21953762-1	2011	Interactions between naringenin and the cytochrome P450 (CYP) system have been of interest since the first demonstration that grapefruit juice reduced CYP3A activity.	naringenin	21-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	151-156
21953762-5	2011	Naringenin was able to inhibit CYP19, CYP2C9, and CYP2C19 with IC50 values below 5 muM.	naringenin	0-10	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	31-36
21953762-5	2011	Naringenin was able to inhibit CYP19, CYP2C9, and CYP2C19 with IC50 values below 5 muM.	naringenin	0-10	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	38-44
21953762-5	2011	Naringenin was able to inhibit CYP19, CYP2C9, and CYP2C19 with IC50 values below 5 muM.	naringenin	0-10	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	50-57
21953762-7	2011	Whereas (S)-naringenin was 2-fold more potent as an inhibitor of CYP19 and CYP2C19 than (R)-naringenin, (R)-naringenin was 2-fold more potent for CYP2C9 and CYP3A.	naringenin	8-22	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	65-70
21953762-7	2011	Whereas (S)-naringenin was 2-fold more potent as an inhibitor of CYP19 and CYP2C19 than (R)-naringenin, (R)-naringenin was 2-fold more potent for CYP2C9 and CYP3A.	naringenin	8-22	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	75-82
22086792-0	2011	Naringenin is an inhibitor of human serum paraoxonase (PON1): an in vitro study.	naringenin	0-10	paraoxonase 1	Homo sapiens	55-59
22086792-2	2011	This study is aimed at examining the in vitro effects of the flavonoid naringenin on PON1 activity in human serum and purified enzyme.	naringenin	71-81	paraoxonase 1	Homo sapiens	85-89
22086792-3	2011	METHODS: The inhibition kinetics of the interaction of naringenin with human PON1 in serum and purified enzyme was determined spectrophotometrically using paraoxon and phenylacetate as the substrates.	naringenin	55-65	paraoxonase 1	Homo sapiens	77-81
22086792-4	2011	RESULTS: Naringenin could be introduced as an effective inhibitor on purified human PON1 activity for phenylacetate as the substrate with an IC(50) value of 10 microM.	naringenin	9-19	paraoxonase 1	Homo sapiens	84-88
22086792-5	2011	Paraoxonase and arylesterase activities of PON1, in the serum assay, were also inhibited by naringenin with IC(50) values of 37.9 and 34.6 microM, respectively.	naringenin	92-102	paraoxonase 1	Homo sapiens	43-47
22086792-6	2011	PON1, according to acompetitive-type inhibition pattern, was inhibited by naringenin with K(i) constant of 14.5 microM for serum paraoxonase activity.	naringenin	74-84	paraoxonase 1	Homo sapiens	0-4
22086792-8	2011	We believe (to our knowledge) that this is the first reported study for kinetic parameters of PON1 inhibition by naringenin.	naringenin	113-123	paraoxonase 1	Homo sapiens	94-98
22086792-10	2011	Comparison of our findings and other authors showed that the induction of PON1 gene by naringenin and its inhibitory effects on the enzyme protein are probably two different mechanisms by which the flavonoid affects PON1.	naringenin	87-97	paraoxonase 1	Homo sapiens	74-78
22086792-10	2011	Comparison of our findings and other authors showed that the induction of PON1 gene by naringenin and its inhibitory effects on the enzyme protein are probably two different mechanisms by which the flavonoid affects PON1.	naringenin	87-97	paraoxonase 1	Homo sapiens	216-220
21604275-7	2011	Solubility enhancement was due to the incorporation of drugs into Hsp-G micelle, with naringenin being more soluble than flurbiprofen.	naringenin	86-96	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	66-69
21762688-9	2011	We propose that the antisecretory action of naringenin is due to inhibition of basolateral NKCC1 in rat and human colon.	naringenin	44-54	solute carrier family 12 member 2	Rattus norvegicus	91-96
21952533-2	2011	Naringenin and hesperetin glucuronides (resulting from conjugation at the A- or B-ring) are the main circulating metabolites in humans and their binding to human serum albumin (HSA) is expected to modulate their half-life in plasma and tissue distribution.	naringenin	0-10	albumin	Homo sapiens	162-175
21877710-0	2011	A synthetic naringenin derivative, 5-hydroxy-7,4"-diacetyloxyflavanone-N-phenyl hydrazone (N101-43), induces apoptosis through up-regulation of Fas/FasL expression and inhibition of PI3K/Akt signaling pathways in non-small-cell lung cancer cells.	naringenin	12-22	Fas ligand	Homo sapiens	148-152
21877710-0	2011	A synthetic naringenin derivative, 5-hydroxy-7,4"-diacetyloxyflavanone-N-phenyl hydrazone (N101-43), induces apoptosis through up-regulation of Fas/FasL expression and inhibition of PI3K/Akt signaling pathways in non-small-cell lung cancer cells.	naringenin	12-22	AKT serine/threonine kinase 1	Homo sapiens	187-190
21877710-8	2011	Cumulatively, these investigations show that the naringenin derivative N101-43 induces apoptosis via up-regulation of Fas/FasL expression, activation of caspase cascades, and inhibition of PI3K/Akt survival signaling pathways in NCI-H460 and A549 cells.	naringenin	49-59	Fas ligand	Homo sapiens	122-126
21877710-8	2011	Cumulatively, these investigations show that the naringenin derivative N101-43 induces apoptosis via up-regulation of Fas/FasL expression, activation of caspase cascades, and inhibition of PI3K/Akt survival signaling pathways in NCI-H460 and A549 cells.	naringenin	49-59	caspase 8	Homo sapiens	153-160
21877710-8	2011	Cumulatively, these investigations show that the naringenin derivative N101-43 induces apoptosis via up-regulation of Fas/FasL expression, activation of caspase cascades, and inhibition of PI3K/Akt survival signaling pathways in NCI-H460 and A549 cells.	naringenin	49-59	AKT serine/threonine kinase 1	Homo sapiens	194-197
21674787-5	2011	Interesting results were also obtained for naringenin, a flavonoid isolated from the AcOEt extract, which exhibited a strong cytotoxic activity against the C32, LNCaP, and COR-L23 cell lines (IC(50) values of 2.2, 7.7, and 33.4 muM, resp.), compared to vinblastine (IC(50) values of 3.3, 32.2, 50.0 muM, resp.).	naringenin	43-53	chemokine like factor	Homo sapiens	156-159
21546585-4	2011	Consistently, naringenin and taxifolin reduced the expression of several QS-controlled genes (i.e. lasI, lasR, rhlI, rhlR, lasA, lasB, phzA1 and rhlA) in P. aeruginosa PAO1.	naringenin	14-24	acyl-homoserine-lactone synthase	Pseudomonas aeruginosa PAO1	111-115
21546585-4	2011	Consistently, naringenin and taxifolin reduced the expression of several QS-controlled genes (i.e. lasI, lasR, rhlI, rhlR, lasA, lasB, phzA1 and rhlA) in P. aeruginosa PAO1.	naringenin	14-24	phenazine biosynthesis protein	Pseudomonas aeruginosa PAO1	135-140
21546585-5	2011	Naringenin also dramatically reduced the production of the acylhomoserine lactones N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL) and N-butanoyl-L-homoserine lactone (C4-HSL), which is driven by the lasI and rhlI gene products, respectively.	naringenin	0-10	acyl-homoserine-lactone synthase	Pseudomonas aeruginosa PAO1	218-222
21620532-1	2011	3alpha-Methoxyserrat-14-en-21beta-ol (PJ-1) and 3beta-methoxyserrat-14-en-21beta-ol (PJ-2) were conjugated with well-known phenolic compounds, narigenin, hesperetin, genistein, and daidzein (1-8).	naringenin	143-152	paralysis, JHMV-induced 1	Mus musculus	38-42
21425871-4	2011	Other PMFs (e.g., sinensetin) and non-PMFs (e.g., hesperetin and naringenin) had only weak effects on CH and TG syntheses and apoB secretion (IC(50) &gt; 100 muM).	naringenin	65-75	apolipoprotein B	Homo sapiens	126-130
21748601-7	2011	Flow cytometry analysis revealed that T cells displayed enhanced antitumor activity in naringenin treated mice, with an increased proportion of IFN-gamma and IL-2 expressing T cells.	naringenin	87-97	interleukin 2	Mus musculus	158-162
21229383-0	2011	Naringenin attenuates mucous hypersecretion by modulating reactive oxygen species production and inhibiting NF-kappaB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling in human airway epithelial cells.	naringenin	0-10	epidermal growth factor receptor	Homo sapiens	131-135
21229383-6	2011	Our study has also investigated whether naringenin could inhibit production of ROS and the activity of NF-kappaB on the inflammatory pulmonary diseases induced by human neutrophil elastase (HNE) and reduce the mRNA and protein levels of MUC5AC as shown by reverse transcriptase-polymerase chain reaction and real-time PCR (RT-PCR).	naringenin	40-50	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	237-243
21229383-0	2011	Naringenin attenuates mucous hypersecretion by modulating reactive oxygen species production and inhibiting NF-kappaB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling in human airway epithelial cells.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	141-144
21229383-10	2011	Our data revealed that naringenin inhibited the activation of EGFR resulting in the downregulation of the enzyme activities.	naringenin	23-33	epidermal growth factor receptor	Homo sapiens	62-66
21280205-6	2011	A screening of representative flavonoids of different structural classes revealed the flavanone naringenin and the isoflavone daidzein to affect glucose transport significantly with half-maximal inhibition at concentrations of around 60-80 muM for basal and 70-110 muM for insulin-stimulated glucose uptake in both 3T3-L1 adipocytes and mature human adipocytes.	naringenin	96-106	insulin	Homo sapiens	273-280
21229383-0	2011	Naringenin attenuates mucous hypersecretion by modulating reactive oxygen species production and inhibiting NF-kappaB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling in human airway epithelial cells.	naringenin	0-10	mitogen-activated protein kinase 1	Homo sapiens	145-148
21229383-11	2011	Naringenin also reduced the protein expressions of p-EGFR, PI3K, p-Akt, p-ERK1/2, and NF-kappaB as shown by western blotting.	naringenin	0-10	epidermal growth factor receptor	Homo sapiens	53-57
21229383-11	2011	Naringenin also reduced the protein expressions of p-EGFR, PI3K, p-Akt, p-ERK1/2, and NF-kappaB as shown by western blotting.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	67-70
21229383-11	2011	Naringenin also reduced the protein expressions of p-EGFR, PI3K, p-Akt, p-ERK1/2, and NF-kappaB as shown by western blotting.	naringenin	0-10	mitogen-activated protein kinase 3	Homo sapiens	74-80
21229383-12	2011	Furthermore, naringenin significantly inhibited PI3K/Akt and ERK MAPKinase signaling with a concurrent reduction in production of ROS and NF-kappaB activities.	naringenin	13-23	AKT serine/threonine kinase 1	Homo sapiens	53-56
21229383-12	2011	Furthermore, naringenin significantly inhibited PI3K/Akt and ERK MAPKinase signaling with a concurrent reduction in production of ROS and NF-kappaB activities.	naringenin	13-23	mitogen-activated protein kinase 1	Homo sapiens	61-64
21229383-13	2011	These results suggest that naringenin may play a protective role by minimizing mucous production during airway inflammation by down-regulating ROS production and inhibiting the NF-kappaB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling pathway.	naringenin	27-37	epidermal growth factor receptor	Homo sapiens	200-204
21229383-13	2011	These results suggest that naringenin may play a protective role by minimizing mucous production during airway inflammation by down-regulating ROS production and inhibiting the NF-kappaB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling pathway.	naringenin	27-37	AKT serine/threonine kinase 1	Homo sapiens	210-213
21247706-8	2011	Common flavonoids of honey like chrysin, genistein, biochanin, quercetin, kaempferol, and naringenin have found to interact with P-gp transporters.	naringenin	90-100	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
21229383-13	2011	These results suggest that naringenin may play a protective role by minimizing mucous production during airway inflammation by down-regulating ROS production and inhibiting the NF-kappaB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling pathway.	naringenin	27-37	mitogen-activated protein kinase 1	Homo sapiens	214-217
20567977-8	2011	Naringenin-fed animals showed a significant increase in PPARalpha protein expression in the liver.	naringenin	0-10	peroxisome proliferator activated receptor alpha	Rattus norvegicus	56-65
20567977-9	2011	Furthermore, expression of CPT-1 and UCP2, both of which are known to be regulated by PPARalpha, was markedly enhanced by naringenin treatment.	naringenin	122-132	uncoupling protein 2	Rattus norvegicus	37-41
20567977-9	2011	Furthermore, expression of CPT-1 and UCP2, both of which are known to be regulated by PPARalpha, was markedly enhanced by naringenin treatment.	naringenin	122-132	peroxisome proliferator activated receptor alpha	Rattus norvegicus	86-95
20567977-10	2011	CONCLUSIONS: Our results indicate that the activation of PPARalpha transcription factor and upregulation of its fatty acid oxidation target genes by dietary naringenin may contribute to the hypolipidemic and anti-adiposity effects in vivo.	naringenin	157-167	peroxisome proliferator activated receptor alpha	Rattus norvegicus	57-66
20932960-6	2011	There was a significant decrease in the expressions of protein kinase C, nuclear factor kappaB, cyclin D1 and cyclin dependent kinase 4 on naringenin treatment.	naringenin	139-149	cyclin D1	Rattus norvegicus	55-105
20669244-0	2011	Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells.	naringenin	0-10	TNF receptor superfamily member 10b	Homo sapiens	42-58
20669244-0	2011	Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells.	naringenin	0-10	TNF superfamily member 10	Homo sapiens	72-77
20669244-3	2011	Here, we report that in combination with naringenin exposure to TRAIL induced apoptosis in TRAIL-resistant NSCLC A549 cells with no detectable inhibitory effects on cell proliferation of normal lung fibroblast cells.	naringenin	41-51	TNF superfamily member 10	Homo sapiens	64-69
20669244-3	2011	Here, we report that in combination with naringenin exposure to TRAIL induced apoptosis in TRAIL-resistant NSCLC A549 cells with no detectable inhibitory effects on cell proliferation of normal lung fibroblast cells.	naringenin	41-51	TNF superfamily member 10	Homo sapiens	91-96
20669244-9	2011	We could show that following exposure to naringenin, DR5 proteins were up-regulated and knockdown of DR5 expression by siRNA attenuated naringenin plus TRAIL-induced apoptosis.	naringenin	41-51	TNF receptor superfamily member 10b	Homo sapiens	53-56
20669244-9	2011	We could show that following exposure to naringenin, DR5 proteins were up-regulated and knockdown of DR5 expression by siRNA attenuated naringenin plus TRAIL-induced apoptosis.	naringenin	41-51	TNF receptor superfamily member 10b	Homo sapiens	101-104
20669244-9	2011	We could show that following exposure to naringenin, DR5 proteins were up-regulated and knockdown of DR5 expression by siRNA attenuated naringenin plus TRAIL-induced apoptosis.	naringenin	41-51	TNF superfamily member 10	Homo sapiens	152-157
20669244-9	2011	We could show that following exposure to naringenin, DR5 proteins were up-regulated and knockdown of DR5 expression by siRNA attenuated naringenin plus TRAIL-induced apoptosis.	naringenin	136-146	TNF receptor superfamily member 10b	Homo sapiens	101-104
20669244-10	2011	Naringenin and TRAIL effectively induced Bid cleavage and siRNA-mediated silencing of Bid reduced the sensitizing effect of naringenin.	naringenin	0-10	BH3 interacting domain death agonist	Homo sapiens	41-44
20669244-10	2011	Naringenin and TRAIL effectively induced Bid cleavage and siRNA-mediated silencing of Bid reduced the sensitizing effect of naringenin.	naringenin	0-10	BH3 interacting domain death agonist	Homo sapiens	86-89
20669244-10	2011	Naringenin and TRAIL effectively induced Bid cleavage and siRNA-mediated silencing of Bid reduced the sensitizing effect of naringenin.	naringenin	124-134	TNF superfamily member 10	Homo sapiens	15-20
20669244-10	2011	Naringenin and TRAIL effectively induced Bid cleavage and siRNA-mediated silencing of Bid reduced the sensitizing effect of naringenin.	naringenin	124-134	BH3 interacting domain death agonist	Homo sapiens	86-89
20669244-11	2011	Furthermore, co-treatment with naringenin and TRAIL resulted in reduction of the clonogenic capacity of A549 cells, and surviving clones could be re-sensitized for repeated TRAIL treatment.	naringenin	31-41	TNF superfamily member 10	Homo sapiens	173-178
20932960-6	2011	There was a significant decrease in the expressions of protein kinase C, nuclear factor kappaB, cyclin D1 and cyclin dependent kinase 4 on naringenin treatment.	naringenin	139-149	cyclin-dependent kinase 4	Rattus norvegicus	110-135
20811644-4	2010	Here, we demonstrate that naringenin regulates the activity of nuclear receptors PPARalpha, PPARgamma, and LXRalpha.	naringenin	26-36	peroxisome proliferator activated receptor alpha	Homo sapiens	81-90
20655900-0	2010	Suppression of hepatic oxidative events and regulation of eNOS expression in the liver by naringenin in fructose-administered rats.	naringenin	90-100	nitric oxide synthase 3	Rattus norvegicus	58-62
21147369-0	2010	Naringenin more effectively inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in macrophages than in microglia.	naringenin	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	73-89
21147369-6	2010	Under LPS (1 mug/mL) stimulation in both cell types, naringenin (up to 200 mumol/L in macrophages and 100 mumol/L in microglia) inhibited nitrite production and inducible nitric oxide synthase and cyclooxygenase-2 expression in a dose-dependent manner.	naringenin	53-63	prostaglandin-endoperoxide synthase 2	Homo sapiens	197-213
21147369-9	2010	In conclusion, naringenin more effectively inhibits the LPS-induced inflammatory status, including nitrite production and inducible nitric oxide synthase and cyclooxygenase-2 expression, in macrophages than in microglia.	naringenin	15-25	prostaglandin-endoperoxide synthase 2	Homo sapiens	158-174
20811644-6	2010	Using TR-FRET, we show that naringenin is a partial agonist of LXRalpha, inhibiting its association with Trap220 co-activator in the presence of TO901317.	naringenin	28-38	mediator complex subunit 1	Homo sapiens	105-112
20811644-7	2010	In addition, naringenin induces the expression of PPARalpha co-activator, PGC1alpha.	naringenin	13-23	peroxisome proliferator activated receptor alpha	Homo sapiens	50-59
20811644-7	2010	In addition, naringenin induces the expression of PPARalpha co-activator, PGC1alpha.	naringenin	13-23	PPARG coactivator 1 alpha	Homo sapiens	74-83
20811644-4	2010	Here, we demonstrate that naringenin regulates the activity of nuclear receptors PPARalpha, PPARgamma, and LXRalpha.	naringenin	26-36	peroxisome proliferator activated receptor gamma	Homo sapiens	92-101
20811644-4	2010	Here, we demonstrate that naringenin regulates the activity of nuclear receptors PPARalpha, PPARgamma, and LXRalpha.	naringenin	26-36	nuclear receptor subfamily 1 group H member 3	Homo sapiens	107-115
20811644-6	2010	Using TR-FRET, we show that naringenin is a partial agonist of LXRalpha, inhibiting its association with Trap220 co-activator in the presence of TO901317.	naringenin	28-38	nuclear receptor subfamily 1 group H member 3	Homo sapiens	63-71
20110573-0	2010	Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.	naringenin	0-10	low density lipoprotein receptor	Mus musculus	94-126
20599706-3	2010	Here, the affinity of daidzein and daidzein metabolites as well as of genistein, naringenin, and quercetin for human serum albumin (HSA) has been assessed in the absence and presence of oleate.	naringenin	81-91	albumin	Homo sapiens	117-130
20230793-0	2010	The citrus flavonoids hesperetin and naringenin block the lipolytic actions of TNF-alpha in mouse adipocytes.	naringenin	37-47	tumor necrosis factor	Mus musculus	79-88
20230793-3	2010	In this report, we show that hesperetin and naringenin, two citrus flavonoids, inhibit TNF-alpha-stimulated FFA secretion from mouse adipocytes.	naringenin	44-54	tumor necrosis factor	Mus musculus	87-96
20230793-5	2010	Moreover, hesperetin and naringenin prevent TNF-alpha from downregulating the transcription of two antilipolytic genes, perilipin and PDE3B.	naringenin	25-35	tumor necrosis factor	Mus musculus	44-53
20230793-5	2010	Moreover, hesperetin and naringenin prevent TNF-alpha from downregulating the transcription of two antilipolytic genes, perilipin and PDE3B.	naringenin	25-35	phosphodiesterase 3B, cGMP-inhibited	Mus musculus	134-139
20230793-7	2010	In contrast, the inhibition of the NF-kappaB pathway by hesperetin and naringenin suppresses the transcription of IL-6, which induces FFA secretion in an autocrine manner.	naringenin	71-81	interleukin 6	Mus musculus	114-118
20230793-8	2010	Our results provide novel evidence that hesperetin and naringenin directly inhibit TNF-alpha-stimulated FFA secretion.	naringenin	55-65	tumor necrosis factor	Mus musculus	83-92
21346872-7	2010	Our study demonstrates that flavonoids (particularly Naringenin, Daidzein, and Hesperetin) are the effective drugs to inhibit function of mutant H-Ras P21 protein, which in turn arrests the process of cell growth and proliferation of the cancer cell.	naringenin	53-63	HRas proto-oncogene, GTPase	Homo sapiens	145-150
21346872-7	2010	Our study demonstrates that flavonoids (particularly Naringenin, Daidzein, and Hesperetin) are the effective drugs to inhibit function of mutant H-Ras P21 protein, which in turn arrests the process of cell growth and proliferation of the cancer cell.	naringenin	53-63	H3 histone pseudogene 16	Homo sapiens	151-154
20110573-13	2010	CONCLUSIONS: These in vivo studies demonstrate that the citrus flavonoid naringenin ameliorates the dyslipidemia in Western-fed low-density lipoprotein receptor-null mice, leading to decreased atherosclerosis; and suggests a potential therapeutic strategy for the hyperlipidemia and increased risk of atherosclerosis associated with insulin resistance.	naringenin	73-83	low density lipoprotein receptor	Mus musculus	128-160
20930378-2	2010	Some flavonoids (apigenin, chrysin, flavone, flavanone, galangin, luteolin, and naringenin) by themselves induced CYP1A1 mRNA expression, especially flavone which was even more effective than beta-NF.	naringenin	80-90	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	114-120
19960539-3	2010	In particular, our previous results indicate that the flavanone naringenin (Nar), decoupling estrogen receptor alpha (ERalpha) action mechanisms, drives cancer cells to apoptosis.	naringenin	64-74	estrogen receptor 1	Homo sapiens	93-116
20010407-10	2010	The levels of PDGF-BB, and TNFalpha were lower in naringenin treated groups at both 2 weeks (PDGF-BB [0.21% +/- 0.03% versus 0.39% +/- 0.05% in control group, P &lt; 0.001), TNFalpha (21.2% +/- 0.8% vs. 36.1% +/- 1.9% in control group, P &lt; 0.001]) and 4 weeks (PDGF-BB [0.25% +/- 0.03% vs. 0.57% +/- 0.09% in control group, P &lt; 0.001], TNFalpha [25.5% +/- 1.8% vs. 45.0% +/- 2.9% in control group, P &lt; 0.001]).	naringenin	50-60	tumor necrosis factor	Rattus norvegicus	27-35
20010407-10	2010	The levels of PDGF-BB, and TNFalpha were lower in naringenin treated groups at both 2 weeks (PDGF-BB [0.21% +/- 0.03% versus 0.39% +/- 0.05% in control group, P &lt; 0.001), TNFalpha (21.2% +/- 0.8% vs. 36.1% +/- 1.9% in control group, P &lt; 0.001]) and 4 weeks (PDGF-BB [0.25% +/- 0.03% vs. 0.57% +/- 0.09% in control group, P &lt; 0.001], TNFalpha [25.5% +/- 1.8% vs. 45.0% +/- 2.9% in control group, P &lt; 0.001]).	naringenin	50-60	tumor necrosis factor	Rattus norvegicus	174-182
20010407-10	2010	The levels of PDGF-BB, and TNFalpha were lower in naringenin treated groups at both 2 weeks (PDGF-BB [0.21% +/- 0.03% versus 0.39% +/- 0.05% in control group, P &lt; 0.001), TNFalpha (21.2% +/- 0.8% vs. 36.1% +/- 1.9% in control group, P &lt; 0.001]) and 4 weeks (PDGF-BB [0.25% +/- 0.03% vs. 0.57% +/- 0.09% in control group, P &lt; 0.001], TNFalpha [25.5% +/- 1.8% vs. 45.0% +/- 2.9% in control group, P &lt; 0.001]).	naringenin	50-60	tumor necrosis factor	Rattus norvegicus	174-182
19960539-3	2010	In particular, our previous results indicate that the flavanone naringenin (Nar), decoupling estrogen receptor alpha (ERalpha) action mechanisms, drives cancer cells to apoptosis.	naringenin	64-74	estrogen receptor 1	Homo sapiens	118-125
19960539-3	2010	In particular, our previous results indicate that the flavanone naringenin (Nar), decoupling estrogen receptor alpha (ERalpha) action mechanisms, drives cancer cells to apoptosis.	naringenin	76-79	estrogen receptor 1	Homo sapiens	93-116
19960539-3	2010	In particular, our previous results indicate that the flavanone naringenin (Nar), decoupling estrogen receptor alpha (ERalpha) action mechanisms, drives cancer cells to apoptosis.	naringenin	76-79	estrogen receptor 1	Homo sapiens	118-125
19810018-9	2009	Treatment of aglycone naringenin (10-25 microM) had same effect on the levels of MMP-9 expression, invasion, migration, and AKT phosphorylation in TNF-alpha-induced VSMC, compared with naringin treatment.	naringenin	22-32	matrix metallopeptidase 9	Homo sapiens	81-86
19810018-9	2009	Treatment of aglycone naringenin (10-25 microM) had same effect on the levels of MMP-9 expression, invasion, migration, and AKT phosphorylation in TNF-alpha-induced VSMC, compared with naringin treatment.	naringenin	22-32	AKT serine/threonine kinase 1	Homo sapiens	124-127
19810018-9	2009	Treatment of aglycone naringenin (10-25 microM) had same effect on the levels of MMP-9 expression, invasion, migration, and AKT phosphorylation in TNF-alpha-induced VSMC, compared with naringin treatment.	naringenin	22-32	tumor necrosis factor	Homo sapiens	147-156
19148864-5	2009	Of the tested constituents, only 10 microM bergamottin and 200 microM naringenin induced MDR1 mRNA levels 2.9- and 4.0-fold, respectively (P&lt;0.01 for both), and CYP3A4 mRNA levels 3.2- and 15.6-fold (P&lt;0.01 for both), respectively.	naringenin	70-80	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
19794524-10	2009	Naringenin attenuated ovalbumin-induced airway inflammation and airway reactivity in experimental mice.	naringenin	0-10	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	22-31
19467635-6	2009	Naringenin also inhibited LPS/IFN-gamma-induced p38 mitogen-activated protein kinase (MAPK) phosphorylation and downstream signal transducer and activator of transcription-1 (STAT-1) in LPS/IFN-gamma stimulated primary mixed glial cells.	naringenin	0-10	interferon regulatory factor 6	Homo sapiens	26-29
19467635-6	2009	Naringenin also inhibited LPS/IFN-gamma-induced p38 mitogen-activated protein kinase (MAPK) phosphorylation and downstream signal transducer and activator of transcription-1 (STAT-1) in LPS/IFN-gamma stimulated primary mixed glial cells.	naringenin	0-10	interferon gamma	Homo sapiens	30-39
19467635-6	2009	Naringenin also inhibited LPS/IFN-gamma-induced p38 mitogen-activated protein kinase (MAPK) phosphorylation and downstream signal transducer and activator of transcription-1 (STAT-1) in LPS/IFN-gamma stimulated primary mixed glial cells.	naringenin	0-10	mitogen-activated protein kinase 14	Homo sapiens	48-51
19467635-6	2009	Naringenin also inhibited LPS/IFN-gamma-induced p38 mitogen-activated protein kinase (MAPK) phosphorylation and downstream signal transducer and activator of transcription-1 (STAT-1) in LPS/IFN-gamma stimulated primary mixed glial cells.	naringenin	0-10	signal transducer and activator of transcription 1	Homo sapiens	123-173
19467635-6	2009	Naringenin also inhibited LPS/IFN-gamma-induced p38 mitogen-activated protein kinase (MAPK) phosphorylation and downstream signal transducer and activator of transcription-1 (STAT-1) in LPS/IFN-gamma stimulated primary mixed glial cells.	naringenin	0-10	signal transducer and activator of transcription 1	Homo sapiens	175-181
19467635-6	2009	Naringenin also inhibited LPS/IFN-gamma-induced p38 mitogen-activated protein kinase (MAPK) phosphorylation and downstream signal transducer and activator of transcription-1 (STAT-1) in LPS/IFN-gamma stimulated primary mixed glial cells.	naringenin	0-10	interferon regulatory factor 6	Homo sapiens	186-189
19467635-6	2009	Naringenin also inhibited LPS/IFN-gamma-induced p38 mitogen-activated protein kinase (MAPK) phosphorylation and downstream signal transducer and activator of transcription-1 (STAT-1) in LPS/IFN-gamma stimulated primary mixed glial cells.	naringenin	0-10	interferon gamma	Homo sapiens	190-199
19467635-7	2009	Taken together, our results suggest that naringenin may produce an anti-inflammatory effect in LPS/IFN-gamma stimulated glial cells that may be due to its interaction with p38 signalling cascades and the STAT-1 transcription factor.	naringenin	41-51	interferon regulatory factor 6	Homo sapiens	95-98
19467635-7	2009	Taken together, our results suggest that naringenin may produce an anti-inflammatory effect in LPS/IFN-gamma stimulated glial cells that may be due to its interaction with p38 signalling cascades and the STAT-1 transcription factor.	naringenin	41-51	interferon gamma	Homo sapiens	99-108
19467635-7	2009	Taken together, our results suggest that naringenin may produce an anti-inflammatory effect in LPS/IFN-gamma stimulated glial cells that may be due to its interaction with p38 signalling cascades and the STAT-1 transcription factor.	naringenin	41-51	mitogen-activated protein kinase 14	Homo sapiens	172-175
19467635-7	2009	Taken together, our results suggest that naringenin may produce an anti-inflammatory effect in LPS/IFN-gamma stimulated glial cells that may be due to its interaction with p38 signalling cascades and the STAT-1 transcription factor.	naringenin	41-51	signal transducer and activator of transcription 1	Homo sapiens	204-210
19318568-9	2009	Naringenin significantly reduces lung metastases in mice with pulmonary fibrosis and increases their survival by improving the immunosuppressive environment through down-regulating transforming growth factor-beta1 and reducing regulatory T cells.	naringenin	0-10	transforming growth factor, beta 1	Mus musculus	181-213
19903372-10	2009	Naringenin, partially absorbed by passive diffusion, was also an ATP-dependent transport substrate mediated by MRP1, but was not an OATP-B substrate.	naringenin	0-10	ATP binding cassette subfamily C member 1	Homo sapiens	111-115
19903372-11	2009	However, naringenin was secreted via active P-gp and MRP2 efflux transporters.	naringenin	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
19903372-11	2009	However, naringenin was secreted via active P-gp and MRP2 efflux transporters.	naringenin	9-19	ATP binding cassette subfamily C member 2	Homo sapiens	53-57
19736994-8	2009	In conclusion, efflux transporters Mrp2 and Bcrp1 are shown to compensate for each other and enable the intestinal excretion of flavonoid (i.e., naringenin) glucuronides.	naringenin	145-155	ATP binding cassette subfamily C member 2	Rattus norvegicus	35-39
19736994-8	2009	In conclusion, efflux transporters Mrp2 and Bcrp1 are shown to compensate for each other and enable the intestinal excretion of flavonoid (i.e., naringenin) glucuronides.	naringenin	145-155	ATP binding cassette subfamily G member 2	Rattus norvegicus	44-49
19592617-0	2009	Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.	naringenin	0-10	apolipoprotein B	Mus musculus	34-50
19592617-0	2009	Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.	naringenin	0-10	low density lipoprotein receptor	Mus musculus	91-103
19592617-3	2009	The citrus-derived flavonoid, naringenin, has lipid-lowering properties and inhibits VLDL secretion from cultured hepatocytes in a manner resembling insulin.	naringenin	30-40	CD320 antigen	Mus musculus	85-89
19592617-8	2009	RESULTS: We report that naringenin treatment of Ldlr(-/-) mice fed a Western diet corrected VLDL overproduction, ameliorated hepatic steatosis, and attenuated dyslipidemia without affecting caloric intake or fat absorption.	naringenin	24-34	low density lipoprotein receptor	Mus musculus	48-52
19592617-8	2009	RESULTS: We report that naringenin treatment of Ldlr(-/-) mice fed a Western diet corrected VLDL overproduction, ameliorated hepatic steatosis, and attenuated dyslipidemia without affecting caloric intake or fat absorption.	naringenin	24-34	CD320 antigen	Mus musculus	92-96
19794524-11	2009	The naringenin-treated mice had lower levels of IL4 and IL13 in the bronchoalveolar lavage fluid and lower serum total IgE.	naringenin	4-14	interleukin 4	Mus musculus	48-51
19794524-11	2009	The naringenin-treated mice had lower levels of IL4 and IL13 in the bronchoalveolar lavage fluid and lower serum total IgE.	naringenin	4-14	interleukin 13	Mus musculus	56-60
19794524-12	2009	Furthermore, naringenin inhibited pulmonary IkappaBalpha degradation and NF-kappaB DNA-binding activity.	naringenin	13-23	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	44-56
19467635-4	2009	Naringenin also inhibited LPS/IFN-gamma-induced iNOS expression and nitric oxide production in glial cells, thus showing the strongest anti-inflammatory activity among all flavonoids tested.	naringenin	0-10	interferon regulatory factor 6	Homo sapiens	26-29
19467635-4	2009	Naringenin also inhibited LPS/IFN-gamma-induced iNOS expression and nitric oxide production in glial cells, thus showing the strongest anti-inflammatory activity among all flavonoids tested.	naringenin	0-10	interferon gamma	Homo sapiens	30-39
19467635-4	2009	Naringenin also inhibited LPS/IFN-gamma-induced iNOS expression and nitric oxide production in glial cells, thus showing the strongest anti-inflammatory activity among all flavonoids tested.	naringenin	0-10	inositol-3-phosphate synthase 1	Homo sapiens	48-52
18705650-3	2009	MATERIAL AND METHODS: Naringenin was tested in a human osteoclastogenesis model using primary osteoclast precursor cells activated by receptor activator of nuclear factor-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) for 6 days.	naringenin	22-32	TNF superfamily member 11	Homo sapiens	134-184
18705650-3	2009	MATERIAL AND METHODS: Naringenin was tested in a human osteoclastogenesis model using primary osteoclast precursor cells activated by receptor activator of nuclear factor-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) for 6 days.	naringenin	22-32	TNF superfamily member 11	Homo sapiens	186-191
18705650-3	2009	MATERIAL AND METHODS: Naringenin was tested in a human osteoclastogenesis model using primary osteoclast precursor cells activated by receptor activator of nuclear factor-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) for 6 days.	naringenin	22-32	colony stimulating factor 1	Homo sapiens	197-233
18705650-3	2009	MATERIAL AND METHODS: Naringenin was tested in a human osteoclastogenesis model using primary osteoclast precursor cells activated by receptor activator of nuclear factor-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) for 6 days.	naringenin	22-32	colony stimulating factor 1	Homo sapiens	235-240
18705650-8	2009	Naringenin also markedly inhibited the secretion of interleukin (IL)-1alpha (by 59%), IL-23 (by 87%) and monocyte chemoattractant protein-1 (by 58%).	naringenin	0-10	interleukin 1 alpha	Homo sapiens	52-75
18705650-8	2009	Naringenin also markedly inhibited the secretion of interleukin (IL)-1alpha (by 59%), IL-23 (by 87%) and monocyte chemoattractant protein-1 (by 58%).	naringenin	0-10	interleukin 23 subunit alpha	Homo sapiens	86-91
18705650-8	2009	Naringenin also markedly inhibited the secretion of interleukin (IL)-1alpha (by 59%), IL-23 (by 87%) and monocyte chemoattractant protein-1 (by 58%).	naringenin	0-10	C-C motif chemokine ligand 2	Homo sapiens	105-139
19148864-5	2009	Of the tested constituents, only 10 microM bergamottin and 200 microM naringenin induced MDR1 mRNA levels 2.9- and 4.0-fold, respectively (P&lt;0.01 for both), and CYP3A4 mRNA levels 3.2- and 15.6-fold (P&lt;0.01 for both), respectively.	naringenin	70-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	164-170
18930780-0	2008	Naringenin induces apoptosis through downregulation of Akt and caspase-3 activation in human leukemia THP-1 cells.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	55-58
19124070-0	2009	Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells.	naringenin	0-10	BCL2 apoptosis regulator	Homo sapiens	46-51
19124070-0	2009	Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells.	naringenin	0-10	BCL2 apoptosis regulator	Homo sapiens	87-92
19124070-2	2009	In this study, the effect of ectopic Bcl-2 expression on naringenin-induced apoptosis was investigated.	naringenin	57-67	BCL2 apoptosis regulator	Homo sapiens	37-42
19124070-3	2009	We found that Bcl-2 overexpression markedly protected human leukemia U937 cells from time- and dose-dependent induction of apoptosis by naringenin, as did caspase-3 and caspase-9 inhibitors.	naringenin	136-146	BCL2 apoptosis regulator	Homo sapiens	14-19
19124070-4	2009	Additionally, Bcl-2 overexpression attenuated naringenin-induced Bax translocation and cytosolic release of cytochrome c.	naringenin	46-56	BCL2 apoptosis regulator	Homo sapiens	14-19
19124070-4	2009	Additionally, Bcl-2 overexpression attenuated naringenin-induced Bax translocation and cytosolic release of cytochrome c.	naringenin	46-56	BCL2 associated X, apoptosis regulator	Homo sapiens	65-68
19124070-4	2009	Additionally, Bcl-2 overexpression attenuated naringenin-induced Bax translocation and cytosolic release of cytochrome c.	naringenin	46-56	cytochrome c, somatic	Homo sapiens	108-120
19124070-5	2009	Our results also indicated that co-administration of HA14-1 and naringenin increased apoptosis in Bcl-2 overexpressing U937 cells by restoring mitochondrial dysfunction and activation of caspase-9 and caspase-3, as well as by cleavage of poly (ADP-ribose) polymerase.	naringenin	64-74	BCL2 apoptosis regulator	Homo sapiens	98-103
19124070-5	2009	Our results also indicated that co-administration of HA14-1 and naringenin increased apoptosis in Bcl-2 overexpressing U937 cells by restoring mitochondrial dysfunction and activation of caspase-9 and caspase-3, as well as by cleavage of poly (ADP-ribose) polymerase.	naringenin	64-74	caspase 9	Homo sapiens	187-196
19124070-5	2009	Our results also indicated that co-administration of HA14-1 and naringenin increased apoptosis in Bcl-2 overexpressing U937 cells by restoring mitochondrial dysfunction and activation of caspase-9 and caspase-3, as well as by cleavage of poly (ADP-ribose) polymerase.	naringenin	64-74	caspase 3	Homo sapiens	201-210
19124070-5	2009	Our results also indicated that co-administration of HA14-1 and naringenin increased apoptosis in Bcl-2 overexpressing U937 cells by restoring mitochondrial dysfunction and activation of caspase-9 and caspase-3, as well as by cleavage of poly (ADP-ribose) polymerase.	naringenin	64-74	poly(ADP-ribose) polymerase 1	Homo sapiens	238-266
19124070-6	2009	Taken together, these observations indicate that Bcl-2 confers apoptosis resistance to naringenin by inhibiting a mitochondrial amplification step in U937 cells.	naringenin	87-97	BCL2 apoptosis regulator	Homo sapiens	49-54
18930780-0	2008	Naringenin induces apoptosis through downregulation of Akt and caspase-3 activation in human leukemia THP-1 cells.	naringenin	0-10	caspase 3	Homo sapiens	63-72
18930780-4	2008	NGEN-induced apoptosis was accompanied by increased hyperpolarization of the mitochondrial membrane potential, downregulation of Bcl-2, upregulation of Bax, activation of caspases and subsequent poly(ADP-ribose)polymerase (PARP) cleavages.	naringenin	0-4	BCL2 apoptosis regulator	Homo sapiens	129-134
18930780-4	2008	NGEN-induced apoptosis was accompanied by increased hyperpolarization of the mitochondrial membrane potential, downregulation of Bcl-2, upregulation of Bax, activation of caspases and subsequent poly(ADP-ribose)polymerase (PARP) cleavages.	naringenin	0-4	BCL2 associated X, apoptosis regulator	Homo sapiens	152-155
18930780-4	2008	NGEN-induced apoptosis was accompanied by increased hyperpolarization of the mitochondrial membrane potential, downregulation of Bcl-2, upregulation of Bax, activation of caspases and subsequent poly(ADP-ribose)polymerase (PARP) cleavages.	naringenin	0-4	poly(ADP-ribose) polymerase 1	Homo sapiens	195-221
18930780-4	2008	NGEN-induced apoptosis was accompanied by increased hyperpolarization of the mitochondrial membrane potential, downregulation of Bcl-2, upregulation of Bax, activation of caspases and subsequent poly(ADP-ribose)polymerase (PARP) cleavages.	naringenin	0-4	poly(ADP-ribose) polymerase 1	Homo sapiens	223-227
17869316-3	2008	Among the compounds tested, marked AhR activation was exhibited by isoflavones such as daidzein, resveratrol (a stilbene) structure, some flavanones such as naringenin, and flavones such as baicalein.	naringenin	157-167	aryl hydrocarbon receptor	Homo sapiens	35-38
18951251-11	2008	In conclusion, quercetin, naringenin, genistein, and xanthohumol reduced P-gp-mediated transport and increased the basolateral uptake rate of cimetidine.	naringenin	26-36	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
18980325-6	2008	In the study of apoptosis-related protein in the naringenin-treated cells, anti-apoptotic proteins such as p-Akt, NF-kappaB, and Bcl-2 were decreased, and pro-apoptotic protein Bad was accumulated by Western blot analysis.	naringenin	49-59	BCL2 apoptosis regulator	Homo sapiens	129-134
18980325-8	2008	Furthermore, expression of fatty acid synthase (FAS) and peroxisome proliferator activated receptor (PPAR)-gamma was enhanced in naringenin-treated cells.	naringenin	129-139	fatty acid synthase	Homo sapiens	27-46
18980325-8	2008	Furthermore, expression of fatty acid synthase (FAS) and peroxisome proliferator activated receptor (PPAR)-gamma was enhanced in naringenin-treated cells.	naringenin	129-139	fatty acid synthase	Homo sapiens	48-51
18980325-8	2008	Furthermore, expression of fatty acid synthase (FAS) and peroxisome proliferator activated receptor (PPAR)-gamma was enhanced in naringenin-treated cells.	naringenin	129-139	peroxisome proliferator activated receptor gamma	Homo sapiens	57-112
18625698-8	2008	KEY RESULTS: Among the flavonoid biosynthetic genes analysed, the expression of CHS was strongly inhibited in the later stages of anther development in sterility cytoplasm; accumulation of putative naringenin derivatives was also inhibited.	naringenin	198-208	chalcone synthase	Raphanus sativus	80-83
18826284-3	2008	On the basis of the biological activities of the first batch of labeled compounds, further optimization at the C-6 position of naringenin finally afforded naringenin-flu (27), which acquired 20% of the potency of naringenin and presented good optical properties.	naringenin	127-137	complement C6	Homo sapiens	111-114
18355329-6	2008	The inhibitory effect of a single concentration of NG (10 microM) on 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activity in vitro was determined.	naringenin	51-53	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 5	Rattus norvegicus	69-124
18355329-12	2008	However, NG (10 microM) was shown to inhibit 11beta-HSD1 activity by 39.49% in a cellular enzyme assay.	naringenin	9-11	hydroxysteroid 11-beta dehydrogenase 1	Rattus norvegicus	45-56
18833323-6	2008	Naringenin-evoked whole cell current which exhibited a linear I-V relationship and time-and voltage- independent characteristics was inhibited by DPC, indicating that the cAMP activated Cl- conductance most likely CFTR (cystic fibrosis transmembrane conductance regulator) was involved.	naringenin	0-10	CF transmembrane conductance regulator	Rattus norvegicus	214-218
18833323-6	2008	Naringenin-evoked whole cell current which exhibited a linear I-V relationship and time-and voltage- independent characteristics was inhibited by DPC, indicating that the cAMP activated Cl- conductance most likely CFTR (cystic fibrosis transmembrane conductance regulator) was involved.	naringenin	0-10	CF transmembrane conductance regulator	Rattus norvegicus	220-271
18426650-0	2008	[Relation of apoptosis of K562 cells induced by naringenin in vitro to enzyme activity changes of caspase-3 and caspase-8 and expression of FAS/FASL proteins].	naringenin	48-58	caspase 3	Homo sapiens	98-107
18690615-0	2008	Naringenin and hesperetin, two flavonoids derived from Citrus aurantium up-regulate transcription of adiponectin.	naringenin	0-10	adiponectin, C1Q and collagen domain containing	Mus musculus	101-112
18690615-3	2008	The aim of this study is to test whether naringenin and hesperetin influence adiponectin expression, which plays an important role in glucose and lipid metabolism with antiatherogenic and anti-inflammatory properties.	naringenin	41-51	adiponectin, C1Q and collagen domain containing	Mus musculus	77-88
18690615-4	2008	Treatment with naringenin and hesperetin enhanced adiponectin transcription in differentiated 3T3-L1 cells.	naringenin	15-25	adiponectin, C1Q and collagen domain containing	Mus musculus	50-61
18573104-5	2008	The recombinant MdPGT1 enzyme expressed in Escherichia coli glycosylated phloretin in the presence of [(3)H]-UDP-glucose, but not other apple antioxidants, including quercetin, naringenin and cyanidin.	naringenin	177-187	phloretin 2'-O-glucosyltransferase	Malus domestica	16-22
19704584-4	2008	The localised application of selective flavonoids to tt4 mutants such as naringenin, dihydrokaempferol and dihydroquercetin showed that they were taken up at the root tip, mid-root or cotyledons and travelled long distances via cell-to-cell movement to distal tissues and converted to quercetin and kaempferol.	naringenin	73-83	Chalcone and stilbene synthase family protein	Arabidopsis thaliana	53-56
18248513-6	2008	Both of naringenin and elacridar separately enhanced the sensitivity for CPT-11 and SN-38 in KYN-2 cells abundantly expressing BCRP, CYP3A4/5 and UGT1A1, but not in KYN-1 cells expressing lower levels.	naringenin	8-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	127-131
18248513-6	2008	Both of naringenin and elacridar separately enhanced the sensitivity for CPT-11 and SN-38 in KYN-2 cells abundantly expressing BCRP, CYP3A4/5 and UGT1A1, but not in KYN-1 cells expressing lower levels.	naringenin	8-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-139
18248513-6	2008	Both of naringenin and elacridar separately enhanced the sensitivity for CPT-11 and SN-38 in KYN-2 cells abundantly expressing BCRP, CYP3A4/5 and UGT1A1, but not in KYN-1 cells expressing lower levels.	naringenin	8-18	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	146-152
18248513-8	2008	On the other hand, naringenin and elacridar significantly increased the chemosensitivity for CPT-11 and SN-38 in the KYN-1-derived cells artificially overexpressing BCRP.	naringenin	19-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	165-169
18587069-0	2008	Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor.	naringenin	73-83	apolipoprotein B	Homo sapiens	14-18
18587069-0	2008	Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor.	naringenin	73-83	insulin	Homo sapiens	49-56
18587069-2	2008	Recently, we demonstrated that the flavonoid naringenin, like insulin, decreased apoB secretion from HepG2 cells by activation of both the phosphoinositide-3-kinase (PI3-K) pathway and the mitogen-activated protein kinase/extracellular-regulated kinase (MAPK(erk)) pathway.	naringenin	45-55	insulin	Homo sapiens	62-69
18587069-2	2008	Recently, we demonstrated that the flavonoid naringenin, like insulin, decreased apoB secretion from HepG2 cells by activation of both the phosphoinositide-3-kinase (PI3-K) pathway and the mitogen-activated protein kinase/extracellular-regulated kinase (MAPK(erk)) pathway.	naringenin	45-55	apolipoprotein B	Homo sapiens	81-85
18587069-2	2008	Recently, we demonstrated that the flavonoid naringenin, like insulin, decreased apoB secretion from HepG2 cells by activation of both the phosphoinositide-3-kinase (PI3-K) pathway and the mitogen-activated protein kinase/extracellular-regulated kinase (MAPK(erk)) pathway.	naringenin	45-55	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	139-164
18587069-2	2008	Recently, we demonstrated that the flavonoid naringenin, like insulin, decreased apoB secretion from HepG2 cells by activation of both the phosphoinositide-3-kinase (PI3-K) pathway and the mitogen-activated protein kinase/extracellular-regulated kinase (MAPK(erk)) pathway.	naringenin	45-55	mitogen-activated protein kinase 1	Homo sapiens	259-262
18587069-3	2008	In the present study, we determined whether naringenin-induced signaling required the insulin receptor (IR) and sensitized the cell to the effects of insulin, and whether the kinetics of apoB assembly and secretion in cells exposed to naringenin were similar to those of insulin.	naringenin	44-54	insulin	Homo sapiens	86-93
18587069-3	2008	In the present study, we determined whether naringenin-induced signaling required the insulin receptor (IR) and sensitized the cell to the effects of insulin, and whether the kinetics of apoB assembly and secretion in cells exposed to naringenin were similar to those of insulin.	naringenin	44-54	insulin	Homo sapiens	150-157
18587069-5	2008	The combination of naringenin and submaximal concentrations of insulin potentiated extracellular-regulated kinase 1/2 activation and enhanced upregulation of the LDL receptor, downregulation of microsomal triglyceride transfer protein expression, and inhibition of apoB-100 secretion.	naringenin	19-29	low density lipoprotein receptor	Homo sapiens	162-174
18587069-5	2008	The combination of naringenin and submaximal concentrations of insulin potentiated extracellular-regulated kinase 1/2 activation and enhanced upregulation of the LDL receptor, downregulation of microsomal triglyceride transfer protein expression, and inhibition of apoB-100 secretion.	naringenin	19-29	apolipoprotein B	Homo sapiens	265-273
18587069-6	2008	Multicompartmental modeling of apoB pulse-chase studies revealed that attenuation of secreted radiolabeled apoB in naringenin- or insulin-treated cells was similar under lipoprotein-deficient or oleate-stimulated conditions.	naringenin	115-125	apolipoprotein B	Homo sapiens	107-111
18587069-7	2008	Naringenin and insulin both stimulated intracellular apoB degradation via a kinetically defined rapid pathway.	naringenin	0-10	apolipoprotein B	Homo sapiens	53-57
18587069-8	2008	Therefore, naringenin, like insulin, inhibits apoB secretion through activation of both PI3-K and MAPK(erk) signaling, resulting in similar kinetics of apoB secretion.	naringenin	11-21	apolipoprotein B	Homo sapiens	46-50
18587069-8	2008	Therefore, naringenin, like insulin, inhibits apoB secretion through activation of both PI3-K and MAPK(erk) signaling, resulting in similar kinetics of apoB secretion.	naringenin	11-21	mitogen-activated protein kinase 1	Homo sapiens	103-106
18587069-8	2008	Therefore, naringenin, like insulin, inhibits apoB secretion through activation of both PI3-K and MAPK(erk) signaling, resulting in similar kinetics of apoB secretion.	naringenin	11-21	apolipoprotein B	Homo sapiens	152-156
18587069-10	2008	Naringenin represents a possible strategy for reduction of hepatic apoB secretion, particularly in the setting of insulin resistance.	naringenin	0-10	apolipoprotein B	Homo sapiens	67-71
18587069-10	2008	Naringenin represents a possible strategy for reduction of hepatic apoB secretion, particularly in the setting of insulin resistance.	naringenin	0-10	insulin	Homo sapiens	114-121
18372132-0	2008	Isolation of the MAO-inhibitor naringenin from Mentha aquatica L. AIMS OF THE STUDY: To isolate the compound(s) responsible for the MAO-inhibitory activity.	naringenin	31-41	monoamine oxidase A	Rattus norvegicus	17-20
18372132-0	2008	Isolation of the MAO-inhibitor naringenin from Mentha aquatica L. AIMS OF THE STUDY: To isolate the compound(s) responsible for the MAO-inhibitory activity.	naringenin	31-41	monoamine oxidase A	Rattus norvegicus	132-135
18372132-5	2008	RESULTS: The IC(50) values for MAO inhibition by naringenin were 342+/-33 microM for the rat liver mitochondrial fraction, 955+/-129 microM for MAO-A and 288+/-18 microM for MAO-B.	naringenin	49-59	monoamine oxidase A	Rattus norvegicus	31-34
18372132-5	2008	RESULTS: The IC(50) values for MAO inhibition by naringenin were 342+/-33 microM for the rat liver mitochondrial fraction, 955+/-129 microM for MAO-A and 288+/-18 microM for MAO-B.	naringenin	49-59	monoamine oxidase A	Rattus norvegicus	144-149
18372132-5	2008	RESULTS: The IC(50) values for MAO inhibition by naringenin were 342+/-33 microM for the rat liver mitochondrial fraction, 955+/-129 microM for MAO-A and 288+/-18 microM for MAO-B.	naringenin	49-59	monoamine oxidase B	Rattus norvegicus	174-179
18239068-0	2008	The nutritional flavanone naringenin triggers antiestrogenic effects by regulating estrogen receptor alpha-palmitoylation.	naringenin	26-36	estrogen receptor 1	Homo sapiens	83-106
18426650-0	2008	[Relation of apoptosis of K562 cells induced by naringenin in vitro to enzyme activity changes of caspase-3 and caspase-8 and expression of FAS/FASL proteins].	naringenin	48-58	caspase 8	Homo sapiens	112-121
18426650-0	2008	[Relation of apoptosis of K562 cells induced by naringenin in vitro to enzyme activity changes of caspase-3 and caspase-8 and expression of FAS/FASL proteins].	naringenin	48-58	Fas ligand	Homo sapiens	144-148
18086244-2	2008	In this study, we have investigated the effects of naringenin (NG), a naturally occurring citrus flavonone, on the removal of UVB-induced cyclobutane pyrimidine dimers (CPD) from the genome and apoptosis in immortalized p53-mutant human keratinocyte HaCaT cells.	naringenin	51-61	tumor protein p53	Homo sapiens	220-223
18086244-2	2008	In this study, we have investigated the effects of naringenin (NG), a naturally occurring citrus flavonone, on the removal of UVB-induced cyclobutane pyrimidine dimers (CPD) from the genome and apoptosis in immortalized p53-mutant human keratinocyte HaCaT cells.	naringenin	63-65	tumor protein p53	Homo sapiens	220-223
17961621-3	2008	In our preliminary study, we use HGF as an invasive inducer to investigate the effect of flavonoids including apigenin, naringenin, genistein and kaempferol on HGF-dependent invasive growth of MDA-MB-231 human breast cancer cells.	naringenin	120-130	hepatocyte growth factor	Homo sapiens	160-163
18197618-4	2008	Naringenin activated both ERalpha and ERbeta, whereas hesperetin exhibited stronger potential to activate ERalpha rather than ERbeta.	naringenin	0-10	estrogen receptor 1	Homo sapiens	26-33
18197618-4	2008	Naringenin activated both ERalpha and ERbeta, whereas hesperetin exhibited stronger potential to activate ERalpha rather than ERbeta.	naringenin	0-10	estrogen receptor 2	Homo sapiens	38-44
18197618-9	2008	Distinct effects of naringenin and hesperetin on NO production also imply that ERalpha might play the major role in estrogen-induced eNOS expression.	naringenin	20-30	estrogen receptor 1	Homo sapiens	79-86
18225583-4	2007	RESULTS: Effective MRP1 inhibitors were identified among the stilbenes (piceatannol and its derivatives) and the flavonoids (aromadendrin, naringenin and its derivatives).	naringenin	139-149	ATP binding cassette subfamily C member 1	Homo sapiens	19-23
18057881-0	2008	The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition.	naringenin	66-76	potassium voltage-gated channel subfamily H member 2	Homo sapiens	106-110
18057881-1	2008	BACKGROUND: Grapefruit juice causes significant QT prolongation in healthy volunteers and naringenin has been identified as the most potent human ether-a-go-go-related gene (HERG) channel blocker among several dietary flavonoids.	naringenin	90-100	potassium voltage-gated channel subfamily H member 2	Homo sapiens	174-178
18057881-7	2008	Naringenin blocked HERG current dose dependently with an IC(50) of 173.3 +/- 3.1 microM.	naringenin	0-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	19-23
18057881-8	2008	Naringenin 100 microM alone inhibited HERG current by 31 +/- 6%, and this inhibitory effect was increased with coadministration of 1 or 10 microM antiarrhythmic drugs.	naringenin	0-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	38-42
18057881-9	2008	When 100 microM naringenin was added to antiarrhythmic drugs, greater HERG inhibition was demonstrated, compared to the current inhibition caused by antiarrhythmic drugs alone.	naringenin	16-26	potassium voltage-gated channel subfamily H member 2	Homo sapiens	70-74
18057881-11	2008	CONCLUSIONS: There is an additive inhibitory effect on HERG current when naringenin is combined with I(Kr)-blocking antiarrhythmic drugs.	naringenin	73-83	potassium voltage-gated channel subfamily H member 2	Homo sapiens	55-59
17664077-4	2008	And the effect of naringenin on the secretion of mucin and lysozyme was performed in the rat tracheal ring explants.	naringenin	18-28	solute carrier family 13 member 2	Rattus norvegicus	49-54
17664077-9	2008	Treatment with naringenin at higher concentration (10 micromol/l) could inhibit the 100 ng/ml lipopolysaccharide (LPS)-induced mucin increase.	naringenin	15-25	solute carrier family 13 member 2	Rattus norvegicus	127-132
17315884-5	2007	Also, Hox rats exhibited severalfold higher liver NAD(P)H:quinone oxidoreductase-1 activity, which was further elevated in proportion to naringenin intake, but this was not sufficient to protect against oxidative stress indicated by higher liver total aldehydes.	naringenin	137-147	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	50-82
17886198-4	2007	In addition, quercetin, kaempferol, apigenin and wogonin (12.5-25.0 microM) strongly inhibited MMP-1 induction in 12-O-tetradecanoylphorbol 13-acetate-treated human dermal fibroblasts, but naringenin (a flavanone) did not.	naringenin	189-199	matrix metallopeptidase 1	Homo sapiens	95-100
17976262-5	2007	Kinetic analysis indicated that the inhibition mode of naringenin and silybin on MCT1 activity was competitive with a Ki of 15-20 microM.	naringenin	55-65	solute carrier family 16 member 1	Homo sapiens	81-85
17701137-9	2007	Experimental results on PLA2-inhibition showed good inhibitory activity for quercetin, kaempferol, and galangin, but relatively poor for naringenin.	naringenin	137-147	phospholipase A2 group IB	Homo sapiens	24-28
16924535-3	2007	The IFS2 transformed lines had very low IFS enzyme activity in microsomal fractions as measured by the conversion of naringenin to genistein.	naringenin	117-127	2-hydroxyisoflavanone synthase	Glycine max	4-8
17288463-8	2007	On-column APPI LODs (at S/N = 3) were 83, 16, 17, 95, and 7 pg for enantiomer #1, and 104, 23, 19, 122, and 17 pg for enantiomer #2 for benzoin, naringenin, mianserin, mephenesin, and diperodon, respectively, on a Waters ZQ.	naringenin	145-155	amyloid beta precursor protein	Homo sapiens	10-14
17268053-5	2007	In addition, isoflavone and flavanone such as daidzein and naringenin, respectively, exhibited weak antioxidative activities against H2O2 without any effect on the catalase activity over a wide range of flavonoid concentrations (0.04-0.4 microM).	naringenin	59-69	catalase	Homo sapiens	164-172
17159770-5	2006	RESULTS: Of the natural flavonoids tested, induction of CYP1A1 was elicited by the typical citrus flavonoid naringenin in the colon, as well as by flavone in the liver.	naringenin	108-118	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	56-62
17088866-0	2006	(+/-)-Naringenin as large conductance Ca(2+)-activated K+ (BKCa) channel opener in vascular smooth muscle cells.	naringenin	0-16	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	59-63
16956892-12	2006	Naringenin or CP-346086 treatments indicated that apolipoprotein O secretion requires microsomal triglyceride transfer protein activity.	naringenin	0-10	apolipoprotein O	Homo sapiens	50-66
16934962-3	2006	With respect to the inhibition of P-gp function, among others, naringenin and isoquercitrin were identified as inhibitors, yet estimation of the inhibitory constant was only possible for uptake values corrected for non-P-glycoprotein-mediated processes.	naringenin	63-73	phosphoglycolate phosphatase	Homo sapiens	34-38
16934962-7	2006	It is concluded that flavonoids, such as naringenin and isoquercitrin, inhibit an inside-directed process in addition to their inhibition of P-glycoprotein-mediated exsorption.	naringenin	41-51	ATP binding cassette subfamily B member 1	Homo sapiens	141-155
16289744-9	2006	Flavones (chrysin, baicalein, and galangin), flavanones (naringenin) and isoflavones (genistein, biochanin A) inhibit the activity of aromatase (CYP19), thus decreasing estrogen biosynthesis and producing antiestrogenic effects, important in breast and prostate cancers.	naringenin	57-67	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	145-150
16860949-0	2006	Naringenin-induced apoptosis via activation of NF-kappaB and necrosis involving the loss of ATP in human promyeloleukemia HL-60 cells.	naringenin	0-10	ATPase phospholipid transporting 8A2	Homo sapiens	92-95
16860949-4	2006	An extensive inhibitor for caspases, abolished the NGEN-induced apoptosis.	naringenin	51-55	caspase 8	Homo sapiens	27-35
16635103-7	2006	In addition, naringenin significantly increased the activities of superoxide dismutase, catalase and GSH peroxidase as well as the level of GSH, vitamin C and vitamin E in liver of the oxytetracycline-treated rats.	naringenin	13-23	catalase	Rattus norvegicus	88-96
16860949-5	2006	The apoptosis-triggering concentration of NGEN was shown to markedly promote the activation of caspase-3, and slightly promote that of caspase-9, but had no effect on caspase-8.	naringenin	42-46	caspase 3	Homo sapiens	95-104
16860949-5	2006	The apoptosis-triggering concentration of NGEN was shown to markedly promote the activation of caspase-3, and slightly promote that of caspase-9, but had no effect on caspase-8.	naringenin	42-46	caspase 9	Homo sapiens	135-144
16860949-6	2006	NGEN-induced apoptosis caused by induction of specific NF-kappaB-binding activity and involving the degradation of IkappaBalpha.	naringenin	0-4	NFKB inhibitor alpha	Homo sapiens	115-127
16860949-7	2006	Incubation with a high concentration of NGEN (1mM) reduced intracellular ATP levels, but no change was observed at lower concentrations.	naringenin	40-44	ATPase phospholipid transporting 8A2	Homo sapiens	73-76
16860949-10	2006	One of the mechanisms by NGEN-induced apoptosis may relate to the activation of NF-kappaB that correlates with degradation of IkappaBalpha.	naringenin	25-29	NFKB inhibitor alpha	Homo sapiens	126-138
16860949-11	2006	Induction of necrosis by NGEN suggests causing by intracellular ATP depletion and mitochondria dysfunctions.	naringenin	25-29	ATPase phospholipid transporting 8A2	Homo sapiens	64-67
16376383-9	2006	Among flavonoids tested, fisetin, apigenin, naringenin, luteolin, quercetin and kaempferol exhibited high inhibitory potencies for the 20alpha-HSD activity.	naringenin	44-54	aldo-keto reductase family 1, member C18	Mus musculus	135-146
16285913-4	2005	The inhibition of aromatase activity by direct interaction with the dietary phytoestrogens genistein, daidzein, chrysin, and naringenin was tested in a cell free assay.	naringenin	125-135	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	18-27
16341574-0	2006	Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells.	naringenin	26-36	SMAD family member 3	Rattus norvegicus	0-5
16341574-0	2006	Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells.	naringenin	26-36	transforming growth factor, beta 1	Rattus norvegicus	98-107
16341574-2	2006	Naringenin showed a significantly protective effect on experimental rat liver fibrosis, in our efforts to elucidate its antifibrosis molecular mechanisms and to find a novel target based on Smad3 signaling for challenging fibrosis diseases.	naringenin	0-10	SMAD family member 3	Rattus norvegicus	190-195
16341574-3	2006	METHODS: In this study, reverse transcription-polymerase chain reaction and Western blot assays were used to investigate the inhibitory effect of naringenin on ECM formation induced by TGF-beta1 in the HSC-T6 cells.	naringenin	146-156	transforming growth factor, beta 1	Rattus norvegicus	185-194
16341574-4	2006	RESULTS: Naringenin reduced not only the accumulation of ECM, including collagen Ialpha1 (Col Ialpha1), fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1), but also the production of Smad3 induced by TGF-beta1 in both mRNA and protein levels in a dose-dependent manner.	naringenin	9-19	fibronectin 1	Rattus norvegicus	104-115
16341574-4	2006	RESULTS: Naringenin reduced not only the accumulation of ECM, including collagen Ialpha1 (Col Ialpha1), fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1), but also the production of Smad3 induced by TGF-beta1 in both mRNA and protein levels in a dose-dependent manner.	naringenin	9-19	fibronectin 1	Rattus norvegicus	117-119
16341574-4	2006	RESULTS: Naringenin reduced not only the accumulation of ECM, including collagen Ialpha1 (Col Ialpha1), fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1), but also the production of Smad3 induced by TGF-beta1 in both mRNA and protein levels in a dose-dependent manner.	naringenin	9-19	serpin family E member 1	Rattus norvegicus	126-159
16341574-4	2006	RESULTS: Naringenin reduced not only the accumulation of ECM, including collagen Ialpha1 (Col Ialpha1), fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1), but also the production of Smad3 induced by TGF-beta1 in both mRNA and protein levels in a dose-dependent manner.	naringenin	9-19	serpin family E member 1	Rattus norvegicus	161-166
16341574-4	2006	RESULTS: Naringenin reduced not only the accumulation of ECM, including collagen Ialpha1 (Col Ialpha1), fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1), but also the production of Smad3 induced by TGF-beta1 in both mRNA and protein levels in a dose-dependent manner.	naringenin	9-19	SMAD family member 3	Rattus norvegicus	196-201
16341574-4	2006	RESULTS: Naringenin reduced not only the accumulation of ECM, including collagen Ialpha1 (Col Ialpha1), fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1), but also the production of Smad3 induced by TGF-beta1 in both mRNA and protein levels in a dose-dependent manner.	naringenin	9-19	transforming growth factor, beta 1	Rattus norvegicus	213-222
16341574-5	2006	Moreover, naringenin selectively inhibited the transcription of Smad3, but not other Smads involved in TGF-beta1 signaling pathways.	naringenin	10-20	SMAD family member 3	Rattus norvegicus	64-69
16341574-6	2006	CONCLUSION: Our data demonstrate that naringenin can exert antifibrogenic effects by directly or indirectly down-regulating Smad3 protein expression and phosphorylation through TGF-beta signaling.	naringenin	38-48	SMAD family member 3	Rattus norvegicus	124-129
16341574-6	2006	CONCLUSION: Our data demonstrate that naringenin can exert antifibrogenic effects by directly or indirectly down-regulating Smad3 protein expression and phosphorylation through TGF-beta signaling.	naringenin	38-48	transforming growth factor, beta 1	Rattus norvegicus	177-185
16507512-1	2006	The hypothesis tested was that specific flavonoids such as epicatechin gallate, epigallocatechin gallate, genistein, genistin, naringenin, naringin, quercetin and xanthohumol will modulate cellular uptake and permeability (P(e)) of multidrug-resistant substrates, cyclosporin A (CSA) and digoxin, across Caco-2 and MDCKII-MDR1 cell transport models.	naringenin	127-137	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	279-282
16507512-1	2006	The hypothesis tested was that specific flavonoids such as epicatechin gallate, epigallocatechin gallate, genistein, genistin, naringenin, naringin, quercetin and xanthohumol will modulate cellular uptake and permeability (P(e)) of multidrug-resistant substrates, cyclosporin A (CSA) and digoxin, across Caco-2 and MDCKII-MDR1 cell transport models.	naringenin	127-137	ATP binding cassette subfamily B member 1	Homo sapiens	322-326
16285913-6	2005	Genistein and daidzein were inactive in the human recombinant aromatase assay whereas naringenin and chrysin inhibited aromatase activity.	naringenin	86-96	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	119-128
16298737-5	2005	Rats pretreated with curcumin or naringenin showed a clear protection of the number of TH-positive cells in the SN and DA levels in the striata.	naringenin	33-43	tyrosine hydroxylase	Rattus norvegicus	87-89
16102728-8	2005	Taken together, these data suggest that naringenin inhibits beta-catenin/Tcf signaling in gastric cancer with unknown mechanisms.	naringenin	40-50	catenin beta 1	Homo sapiens	60-72
16102728-0	2005	Negative regulation of beta-catenin/Tcf signaling by naringenin in AGS gastric cancer cell.	naringenin	53-63	catenin beta 1	Homo sapiens	23-35
16102728-8	2005	Taken together, these data suggest that naringenin inhibits beta-catenin/Tcf signaling in gastric cancer with unknown mechanisms.	naringenin	40-50	hepatocyte nuclear factor 4 alpha	Homo sapiens	73-76
16102728-0	2005	Negative regulation of beta-catenin/Tcf signaling by naringenin in AGS gastric cancer cell.	naringenin	53-63	hepatocyte nuclear factor 4 alpha	Homo sapiens	36-39
16156793-3	2005	This study investigates the interactions of six common polyphenols; quercetin, silymarin, resveratrol, naringenin, daidzein and hesperetin with the multidrug-resistance-associated proteins, MRP1, MRP4 and MRP5.	naringenin	103-113	ATP binding cassette subfamily C member 1	Homo sapiens	190-194
16102728-2	2005	We examined the effect of naringenin against beta-catenin/Tcf signaling in gastric cancer cells.	naringenin	26-36	hepatocyte nuclear factor 4 alpha	Homo sapiens	58-61
16102728-3	2005	Reporter gene assay showed that naringenin inhibited beta-catenin/Tcf signaling efficiently.	naringenin	32-42	catenin beta 1	Homo sapiens	53-65
16102728-3	2005	Reporter gene assay showed that naringenin inhibited beta-catenin/Tcf signaling efficiently.	naringenin	32-42	hepatocyte nuclear factor 4 alpha	Homo sapiens	66-69
16102728-4	2005	In addition, the inhibition of beta-catenin/Tcf signaling by naringenin in HEK293 cells transiently transfected with constitutively mutant beta-catenin gene, whose product is not phosphorylated by GSK3beta, indicates that its inhibitory mechanism was related to beta-catenin itself or downstream components.	naringenin	61-71	catenin beta 1	Homo sapiens	31-43
16102728-4	2005	In addition, the inhibition of beta-catenin/Tcf signaling by naringenin in HEK293 cells transiently transfected with constitutively mutant beta-catenin gene, whose product is not phosphorylated by GSK3beta, indicates that its inhibitory mechanism was related to beta-catenin itself or downstream components.	naringenin	61-71	hepatocyte nuclear factor 4 alpha	Homo sapiens	44-47
16102728-4	2005	In addition, the inhibition of beta-catenin/Tcf signaling by naringenin in HEK293 cells transiently transfected with constitutively mutant beta-catenin gene, whose product is not phosphorylated by GSK3beta, indicates that its inhibitory mechanism was related to beta-catenin itself or downstream components.	naringenin	61-71	catenin beta 1	Homo sapiens	139-151
16102728-4	2005	In addition, the inhibition of beta-catenin/Tcf signaling by naringenin in HEK293 cells transiently transfected with constitutively mutant beta-catenin gene, whose product is not phosphorylated by GSK3beta, indicates that its inhibitory mechanism was related to beta-catenin itself or downstream components.	naringenin	61-71	catenin beta 1	Homo sapiens	139-151
16106293-3	2005	In comparison, flavanone 3beta-hydroxylase catalyses hydroxylation at the C-3 pro-R position of 2S-naringenin.	naringenin	96-109	complement C3	Homo sapiens	74-77
16106293-4	2005	Incubation of ANS with the unnatural substrate (+/-)-naringenin results in predominantly C-3 hydroxylation to give cis-dihydrokaempferol as the major product; trans-dihydrokaempferol and the desaturation product, apigenin are also observed.	naringenin	47-63	complement C3	Homo sapiens	89-92
16106293-7	2005	Together the results reveal that for the "natural" C-2 stereochemistry of 2S-naringenin, C-3 hydroxylation predominates (&gt;9 : 1) over desaturation, probably due to the inaccessibility of the C-2 hydrogen to the iron centre.	naringenin	74-87	complement C2	Homo sapiens	51-54
16106293-7	2005	Together the results reveal that for the "natural" C-2 stereochemistry of 2S-naringenin, C-3 hydroxylation predominates (&gt;9 : 1) over desaturation, probably due to the inaccessibility of the C-2 hydrogen to the iron centre.	naringenin	74-87	complement C3	Homo sapiens	89-92
16106293-7	2005	Together the results reveal that for the "natural" C-2 stereochemistry of 2S-naringenin, C-3 hydroxylation predominates (&gt;9 : 1) over desaturation, probably due to the inaccessibility of the C-2 hydrogen to the iron centre.	naringenin	74-87	complement C2	Homo sapiens	194-197
16156793-3	2005	This study investigates the interactions of six common polyphenols; quercetin, silymarin, resveratrol, naringenin, daidzein and hesperetin with the multidrug-resistance-associated proteins, MRP1, MRP4 and MRP5.	naringenin	103-113	ATP binding cassette subfamily C member 4	Homo sapiens	196-200
16156793-3	2005	This study investigates the interactions of six common polyphenols; quercetin, silymarin, resveratrol, naringenin, daidzein and hesperetin with the multidrug-resistance-associated proteins, MRP1, MRP4 and MRP5.	naringenin	103-113	ATP binding cassette subfamily C member 5	Homo sapiens	205-209
15974445-5	2005	On immunomodulatory properties, catechin, epigallocatechin (EGC), naringenin, and fisetin repressed NO production and TNF-alpha secretion.	naringenin	66-76	tumor necrosis factor	Homo sapiens	118-127
15919788-0	2005	Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes.	naringenin	124-134	microsomal triglyceride transfer protein	Homo sapiens	14-54
15919788-0	2005	Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes.	naringenin	124-134	apolipoprotein B	Homo sapiens	70-89
15919788-2	2005	The citrus flavonoid naringenin, like insulin, decreased MTP expression in HepG2 cells, resulting in inhibition of apoB100 secretion; however, the mechanism for naringenin is independent of insulin receptor substrate-1/2.	naringenin	21-31	microsomal triglyceride transfer protein	Homo sapiens	57-60
15919788-2	2005	The citrus flavonoid naringenin, like insulin, decreased MTP expression in HepG2 cells, resulting in inhibition of apoB100 secretion; however, the mechanism for naringenin is independent of insulin receptor substrate-1/2.	naringenin	21-31	apolipoprotein B	Homo sapiens	115-122
15919788-2	2005	The citrus flavonoid naringenin, like insulin, decreased MTP expression in HepG2 cells, resulting in inhibition of apoB100 secretion; however, the mechanism for naringenin is independent of insulin receptor substrate-1/2.	naringenin	21-31	insulin receptor substrate 1	Homo sapiens	190-218
15919788-5	2005	Inhibition of MAPK kinase (MEK) 1/2 in HepG2 cells significantly attenuated the naringenin- and insulin-induced reduction in MTP expression.	naringenin	80-90	mitogen-activated protein kinase kinase 1	Homo sapiens	14-35
15919788-5	2005	Inhibition of MAPK kinase (MEK) 1/2 in HepG2 cells significantly attenuated the naringenin- and insulin-induced reduction in MTP expression.	naringenin	80-90	microsomal triglyceride transfer protein	Homo sapiens	125-128
15919788-6	2005	Both naringenin and insulin increased ERK1/2 phosphorylation, which was completely inhibited by MEK1/2 inhibition and enhanced by inhibition of MAPK(p38), a negative regulator of MAPK(erk) activity.	naringenin	5-15	mitogen-activated protein kinase 3	Homo sapiens	38-44
15919788-6	2005	Both naringenin and insulin increased ERK1/2 phosphorylation, which was completely inhibited by MEK1/2 inhibition and enhanced by inhibition of MAPK(p38), a negative regulator of MAPK(erk) activity.	naringenin	5-15	mitogen-activated protein kinase kinase 1	Homo sapiens	96-102
15919788-6	2005	Both naringenin and insulin increased ERK1/2 phosphorylation, which was completely inhibited by MEK1/2 inhibition and enhanced by inhibition of MAPK(p38), a negative regulator of MAPK(erk) activity.	naringenin	5-15	mitogen-activated protein kinase 1	Homo sapiens	149-152
15919788-6	2005	Both naringenin and insulin increased ERK1/2 phosphorylation, which was completely inhibited by MEK1/2 inhibition and enhanced by inhibition of MAPK(p38), a negative regulator of MAPK(erk) activity.	naringenin	5-15	mitogen-activated protein kinase 1	Homo sapiens	184-187
15919788-7	2005	Inhibition of MEK1/2 significantly attenuated both the naringenin- and insulin-induced decrease in apoB100 secretion demonstrating a direct link between MAPK(erk) activation and apoB100 secretion.	naringenin	55-65	mitogen-activated protein kinase kinase 1	Homo sapiens	14-20
15919788-7	2005	Inhibition of MEK1/2 significantly attenuated both the naringenin- and insulin-induced decrease in apoB100 secretion demonstrating a direct link between MAPK(erk) activation and apoB100 secretion.	naringenin	55-65	apolipoprotein B	Homo sapiens	99-106
15919788-7	2005	Inhibition of MEK1/2 significantly attenuated both the naringenin- and insulin-induced decrease in apoB100 secretion demonstrating a direct link between MAPK(erk) activation and apoB100 secretion.	naringenin	55-65	mitogen-activated protein kinase 1	Homo sapiens	158-161
15919788-7	2005	Inhibition of MEK1/2 significantly attenuated both the naringenin- and insulin-induced decrease in apoB100 secretion demonstrating a direct link between MAPK(erk) activation and apoB100 secretion.	naringenin	55-65	apolipoprotein B	Homo sapiens	178-185
15919788-9	2005	We conclude that MAPK(erk) signaling in hepatocytes is critical for inhibition of apoB100 secretion by naringenin and insulin.	naringenin	103-113	mitogen-activated protein kinase 1	Homo sapiens	22-25
15919788-9	2005	We conclude that MAPK(erk) signaling in hepatocytes is critical for inhibition of apoB100 secretion by naringenin and insulin.	naringenin	103-113	apolipoprotein B	Homo sapiens	82-89
15919788-10	2005	Therefore, naringenin may prove useful for activating insulin-signaling pathways important for regulation of hepatocyte lipid homeostasis.	naringenin	11-21	insulin	Homo sapiens	54-61
16007460-0	2005	Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation.	naringenin	60-70	potassium voltage-gated channel subfamily H member 2	Homo sapiens	22-26
16007460-4	2005	HERG blockade by grapefruit flavonoid naringenin is most likely to be the mechanism underlying this effect.	naringenin	38-48	potassium voltage-gated channel subfamily H member 2	Homo sapiens	0-4
16007460-5	2005	Therefore, the electrophysiological properties of HERG blockade by naringenin were analysed in detail.	naringenin	67-77	potassium voltage-gated channel subfamily H member 2	Homo sapiens	50-54
16007460-7	2005	Naringenin blocked HERG potassium channels with an IC50 value of 102.6 microM in Xenopus oocytes.	naringenin	0-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	19-23
16007460-10	2005	Naringenin binding to HERG required aromatic residue F656 in the putative pore binding site.	naringenin	0-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	22-26
16007460-15	2005	Naringenin inhibits HERG channels with pharmacological characteristics similar to those of well-known HERG antagonists.	naringenin	0-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	20-24
16007460-15	2005	Naringenin inhibits HERG channels with pharmacological characteristics similar to those of well-known HERG antagonists.	naringenin	0-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	102-106
15911222-6	2005	However, the investigated flavonoids did show potency to inhibit OCT-mediated transport (IC50-values: quercetin&lt;kaempferol&lt;&lt;naringenin&lt;isoquercitrin&lt;spiraeoside&lt;&lt;rutin&lt;hesperetin&lt;naringin).	naringenin	133-143	plexin A2	Homo sapiens	65-68
15750342-6	2005	The expression profiles of three enzymes that convert naringenin to the isoflavone, genistein, chalcone isomerase (CHI), isoflavone synthase (IFS) and flavanone 3-hydroxylase (F3H) were examined.	naringenin	54-64	chalcone--flavonone isomerase 1A	Glycine max	95-113
15826879-8	2005	In cisplatin-NAR combined treatment group, antioxidant enzymes namely superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) were significantly increased to 54.5, 30.3 and 35.6%, respectively compared to cisplatin treated group.	naringenin	13-16	glutathione peroxidase 1	Rattus norvegicus	122-128
15750342-6	2005	The expression profiles of three enzymes that convert naringenin to the isoflavone, genistein, chalcone isomerase (CHI), isoflavone synthase (IFS) and flavanone 3-hydroxylase (F3H) were examined.	naringenin	54-64	flavanone 3-hydroxylase	Glycine max	176-179
15750342-6	2005	The expression profiles of three enzymes that convert naringenin to the isoflavone, genistein, chalcone isomerase (CHI), isoflavone synthase (IFS) and flavanone 3-hydroxylase (F3H) were examined.	naringenin	54-64	chalcone--flavonone isomerase 1A	Glycine max	115-118
15750342-6	2005	The expression profiles of three enzymes that convert naringenin to the isoflavone, genistein, chalcone isomerase (CHI), isoflavone synthase (IFS) and flavanone 3-hydroxylase (F3H) were examined.	naringenin	54-64	flavanone 3-hydroxylase	Glycine max	151-174
15531381-6	2004	Both kaempferol and naringenin were also able to significantly decrease Pgp immunoblottable amount.	naringenin	20-30	phosphoglycolate phosphatase	Homo sapiens	72-75
15678369-2	2005	Naringenin, hesperetin and ponciretin potently inhibited IgE-induced beta-hexosaminidase release from RBL-2H3 cells and the PCA reaction.	naringenin	0-10	O-GlcNAcase	Rattus norvegicus	69-88
15678369-2	2005	Naringenin, hesperetin and ponciretin potently inhibited IgE-induced beta-hexosaminidase release from RBL-2H3 cells and the PCA reaction.	naringenin	0-10	RB transcriptional corepressor like 2	Rattus norvegicus	102-107
15678369-3	2005	Among the flavanones examined, naringenin was the most potent with an IC50 value for beta-hexosaminidase release from RBL-2H3 cells of 0.029 mM.	naringenin	31-41	O-GlcNAcase	Rattus norvegicus	85-104
15678369-3	2005	Among the flavanones examined, naringenin was the most potent with an IC50 value for beta-hexosaminidase release from RBL-2H3 cells of 0.029 mM.	naringenin	31-41	RB transcriptional corepressor like 2	Rattus norvegicus	118-123
15729616-0	2005	Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin.	naringenin	122-138	phosphodiesterase 3A	Rattus norvegicus	15-50
15729616-1	2005	The potential vasorelaxant, antioxidant and cyclic nucleotide phosphodiesterase (PDE) inhibitory effects of the citrus-fruit flavonoids naringin and (+/-)-naringenin were comparatively studied for the first time in this work.	naringenin	149-165	phosphodiesterase 3A	Rattus norvegicus	44-79
15531381-9	2004	The calcein-AM test in untreated cells showed that GFJ, kaempferol or naringenin inhibited Pgp activity.	naringenin	70-80	phosphoglycolate phosphatase	Homo sapiens	91-94
15545229-0	2004	Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling.	naringenin	14-24	estrogen receptor 1	Homo sapiens	83-106
15460448-0	2004	Suppression of CYP1A1 expression by naringenin in murine Hepa-1c1c7 cells.	naringenin	36-46	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	15-21
15460448-2	2004	In the present study, we investigated the effect of naringenin on 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible CYP1A1 gene expression in mouse hepatoma Hepa-1c1c7 cells.	naringenin	52-62	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	119-125
15460448-5	2004	TCDD-induced CYP1A1 mRNA level was also markedly suppressed by naringenin.	naringenin	63-73	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	13-19
15460448-6	2004	A transient transfection assay using dioxin-response element (DRE)-linked luciferase and electrophoretic mobility shift assay revealed that naringenin reduced transformation of the aryl hydrocarbons receptor(AhR) to a form capable of specifically binding to the DRE sequence in the promoter of the CYP1A1 gene.	naringenin	140-150	aryl-hydrocarbon receptor	Mus musculus	208-211
15460448-6	2004	A transient transfection assay using dioxin-response element (DRE)-linked luciferase and electrophoretic mobility shift assay revealed that naringenin reduced transformation of the aryl hydrocarbons receptor(AhR) to a form capable of specifically binding to the DRE sequence in the promoter of the CYP1A1 gene.	naringenin	140-150	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	298-304
15460448-7	2004	These results suggest the down regulation of the CYP1A1 gene expression by either naringenin in Hepa-1c1c7 cells might be antagonism of the DRE binding potential of nuclear AhR.	naringenin	82-92	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	49-55
15460448-7	2004	These results suggest the down regulation of the CYP1A1 gene expression by either naringenin in Hepa-1c1c7 cells might be antagonism of the DRE binding potential of nuclear AhR.	naringenin	82-92	aryl-hydrocarbon receptor	Mus musculus	173-176
14514640-0	2003	Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation.	naringenin	80-90	apolipoprotein B	Homo sapiens	29-45
15111768-2	2004	In this report, we show that the grapefruit flava-none naringenin inhibited insulin-stimulated glucose uptake in proliferating and growth-arrested MCF-7 breast cancer cells.	naringenin	55-65	insulin	Homo sapiens	76-83
15111768-3	2004	Our findings indicate that naringenin inhibits the activity of phosphoinositide 3-kinase (PI3K), a key regulator of insulin-induced GLUT4 translocation, as shown by impaired phosphorylation of the downstream signaling molecule Akt.	naringenin	27-37	insulin	Homo sapiens	116-123
15111768-3	2004	Our findings indicate that naringenin inhibits the activity of phosphoinositide 3-kinase (PI3K), a key regulator of insulin-induced GLUT4 translocation, as shown by impaired phosphorylation of the downstream signaling molecule Akt.	naringenin	27-37	solute carrier family 2 member 4	Homo sapiens	132-137
15111768-3	2004	Our findings indicate that naringenin inhibits the activity of phosphoinositide 3-kinase (PI3K), a key regulator of insulin-induced GLUT4 translocation, as shown by impaired phosphorylation of the downstream signaling molecule Akt.	naringenin	27-37	AKT serine/threonine kinase 1	Homo sapiens	227-230
15111768-4	2004	Naringenin also inhibited the phosphorylation of p44/p42 mitogen-activated protein kinase (MAPK).	naringenin	0-10	interferon induced protein 44	Homo sapiens	49-52
15111768-9	2004	Because a physiologically attainable dose of 10 micro M naringenin reduced insulin-stimulated glucose uptake by nearly 25% and also reduced cell proliferation, naringenin may possess therapeutic potential as an anti-proliferative agent.	naringenin	56-66	insulin	Homo sapiens	75-82
15111768-9	2004	Because a physiologically attainable dose of 10 micro M naringenin reduced insulin-stimulated glucose uptake by nearly 25% and also reduced cell proliferation, naringenin may possess therapeutic potential as an anti-proliferative agent.	naringenin	160-170	insulin	Homo sapiens	75-82
15030205-3	2004	The protective effect of naringenin, a major flavanone constituent isolated from Citrus junos, against Abeta-induced neurotoxicity was investigated using PC12 cells.	naringenin	25-35	amyloid beta precursor protein	Rattus norvegicus	103-108
15030205-4	2004	Pretreatment with isolated naringenin and vitamin C prevented the generation of the Abeta-induced reactive oxygen species.	naringenin	27-37	amyloid beta precursor protein	Rattus norvegicus	84-89
15030205-9	2004	Therefore, these results indicate that micromolecular Abeta-induced in vitro oxidative cell stress is reduced by naringenin and naringenin may be a useful chemopreventive agent against a neurodegenerative disease such as Alzheimer"s disease.	naringenin	113-123	amyloid beta precursor protein	Rattus norvegicus	54-59
15030205-9	2004	Therefore, these results indicate that micromolecular Abeta-induced in vitro oxidative cell stress is reduced by naringenin and naringenin may be a useful chemopreventive agent against a neurodegenerative disease such as Alzheimer"s disease.	naringenin	128-138	amyloid beta precursor protein	Rattus norvegicus	54-59
14514640-11	2003	We conclude that naringenin increases LDLr expression in HepG2 cells via PI3K-mediated upregulation of SREBP-1, independent of IRS-1 phosphorylation.	naringenin	17-27	low density lipoprotein receptor	Homo sapiens	38-42
14514640-11	2003	We conclude that naringenin increases LDLr expression in HepG2 cells via PI3K-mediated upregulation of SREBP-1, independent of IRS-1 phosphorylation.	naringenin	17-27	sterol regulatory element binding transcription factor 1	Homo sapiens	103-110
14514640-12	2003	Although this pathway may not regulate apoB secretion in primary hepatocytes, PI3K activation by this novel mechanism may explain the insulin-like effects of naringenin in vivo.	naringenin	158-168	insulin	Homo sapiens	134-141
15276617-8	2004	The phytoestrogens coumestrol, genistein, genistin, daidzein, daidzin and naringenin were relatively more potent with ERbeta.	naringenin	74-84	estrogen receptor 2	Homo sapiens	118-124
15276617-10	2004	The ranking with the ERbeta was: 17beta-estradiol &gt;&gt; coumestrol &gt; genistein &gt; zearalenone &gt; 8-prenylnaringen &gt;&gt; daidzein &gt; naringenin &gt; genistin &gt;&gt; daidzin.	naringenin	147-157	estrogen receptor 2	Homo sapiens	21-27
15205350-4	2004	In this study, we show that phytoestrogens/flavonoids, such as genistein, naringenin, acacetin, and kaempferol, potentiated the cytotoxicity of SN-38 and mitoxantrone in BCRP-transduced K562 (K562/BCRP) cells.	naringenin	74-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	170-174
15205350-4	2004	In this study, we show that phytoestrogens/flavonoids, such as genistein, naringenin, acacetin, and kaempferol, potentiated the cytotoxicity of SN-38 and mitoxantrone in BCRP-transduced K562 (K562/BCRP) cells.	naringenin	74-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	197-201
15205350-8	2004	Genistein and naringenin increased cellular accumulation of topotecan in K562/BCRP cells.	naringenin	14-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	78-82
14698415-0	2004	Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5.	naringenin	49-59	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	188-207
14698415-0	2004	Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5.	naringenin	49-59	cytochrome p450 oxidoreductase	Homo sapiens	209-240
14698415-0	2004	Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5.	naringenin	49-59	cytochrome b5 type A	Homo sapiens	246-259
14698415-10	2004	These results indicate that quercetin and naringenin can exhibit inhibitory or stimulating effects on CYP1A2 mediated mutagenesis by MeIQ, depending on their concentrations.	naringenin	42-52	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	102-108
14514640-2	2003	In HepG2 human hepatoma cells, naringenin inhibits apolipoprotein B (apoB) secretion primarily by inhibiting microsomal triglyceride transfer protein and enhances LDL receptor (LDLr)-mediated apoB-containing lipoprotein uptake.	naringenin	31-41	apolipoprotein B	Homo sapiens	51-67
14514640-2	2003	In HepG2 human hepatoma cells, naringenin inhibits apolipoprotein B (apoB) secretion primarily by inhibiting microsomal triglyceride transfer protein and enhances LDL receptor (LDLr)-mediated apoB-containing lipoprotein uptake.	naringenin	31-41	apolipoprotein B	Homo sapiens	69-73
14514640-2	2003	In HepG2 human hepatoma cells, naringenin inhibits apolipoprotein B (apoB) secretion primarily by inhibiting microsomal triglyceride transfer protein and enhances LDL receptor (LDLr)-mediated apoB-containing lipoprotein uptake.	naringenin	31-41	low density lipoprotein receptor	Homo sapiens	163-175
14514640-2	2003	In HepG2 human hepatoma cells, naringenin inhibits apolipoprotein B (apoB) secretion primarily by inhibiting microsomal triglyceride transfer protein and enhances LDL receptor (LDLr)-mediated apoB-containing lipoprotein uptake.	naringenin	31-41	low density lipoprotein receptor	Homo sapiens	177-181
14514640-2	2003	In HepG2 human hepatoma cells, naringenin inhibits apolipoprotein B (apoB) secretion primarily by inhibiting microsomal triglyceride transfer protein and enhances LDL receptor (LDLr)-mediated apoB-containing lipoprotein uptake.	naringenin	31-41	apolipoprotein B	Homo sapiens	192-196
14514640-5	2003	Insulin and naringenin induced PI3K-dependent increases in cytosolic and nuclear SREBP-1 and LDLr expression.	naringenin	12-22	sterol regulatory element binding transcription factor 1	Homo sapiens	81-88
14514640-5	2003	Insulin and naringenin induced PI3K-dependent increases in cytosolic and nuclear SREBP-1 and LDLr expression.	naringenin	12-22	low density lipoprotein receptor	Homo sapiens	93-97
14514640-7	2003	Reductions in HepG2 cell media apoB with naringenin were partially attenuated by wortmannin, whereas the effect of insulin was completely blocked.	naringenin	41-51	apolipoprotein B	Homo sapiens	31-35
14514640-9	2003	Insulin and naringenin increased HepG2 cell PI3K activity and decreased insulin receptor substrate (IRS)-2 levels.	naringenin	12-22	insulin receptor substrate 2	Homo sapiens	72-106
11352979-0	2001	Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP.	naringenin	61-71	apolipoprotein B	Homo sapiens	24-28
12967034-0	2003	Naringin and naringenin inhibit nitrite-induced methemoglobin formation.	naringenin	13-23	hemoglobin subunit gamma 2	Homo sapiens	48-61
12967034-1	2003	Naringin and naringenin protect hemoglobin from nitrite-induced oxidation to methemoglobin.	naringenin	13-23	hemoglobin subunit gamma 2	Homo sapiens	77-90
12673038-4	2003	Among them, isoflavones such as daidzein, resveratrol having a stilbene structure, and some flavonoids such as naringenin, hesperetin, and baicalein showed AhR activation.	naringenin	111-121	aryl hydrocarbon receptor	Homo sapiens	156-159
12485947-6	2003	In the present study, we found that stimulation of GSH transport in inside-out MRP1-enriched membrane vesicles by apigenin, naringenin, genistein, and quercetin was maximum at a concentration of 30 microM.	naringenin	124-134	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
12235187-0	2002	Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters.	naringenin	43-53	apolipoprotein B	Homo sapiens	25-29
11396955-0	2001	Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits.	naringenin	59-69	sterol O-acyltransferase 1	Oryctolagus cuniculus	95-99
11396955-0	2001	Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits.	naringenin	59-69	vascular cell adhesion protein 1	Oryctolagus cuniculus	111-117
11396955-0	2001	Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits.	naringenin	59-69	C-C motif chemokine 2	Oryctolagus cuniculus	122-127
11396955-5	2001	Hepatic acyl-CoA:cholesterol acyltransferase (ACAT) activity was slightly low in naringin (5.0%)- and naringenin (15.0%)-fed rabbits, compared to control group.	naringenin	102-112	sterol O-acyltransferase 1	Oryctolagus cuniculus	8-44
11396955-5	2001	Hepatic acyl-CoA:cholesterol acyltransferase (ACAT) activity was slightly low in naringin (5.0%)- and naringenin (15.0%)-fed rabbits, compared to control group.	naringenin	102-112	sterol O-acyltransferase 1	Oryctolagus cuniculus	46-50
11396955-8	2001	These results suggest that the anti-atherogenic effect of the citrus flavonoids, naringin and naringenin, is involved with a decreased hepatic ACAT activity and with the downregulation of VCAM-1 and MCP-1 gene expression.	naringenin	94-104	vascular cell adhesion protein 1	Oryctolagus cuniculus	188-194
11396955-8	2001	These results suggest that the anti-atherogenic effect of the citrus flavonoids, naringin and naringenin, is involved with a decreased hepatic ACAT activity and with the downregulation of VCAM-1 and MCP-1 gene expression.	naringenin	94-104	C-C motif chemokine 2	Oryctolagus cuniculus	199-204
12564931-0	2003	Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation.	naringenin	91-101	apolipoprotein B	Homo sapiens	11-15
12564931-0	2003	Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation.	naringenin	91-101	metallothionein 1B	Homo sapiens	121-124
12564931-1	2003	Naringenin, the principal flavonoid in grapefruit, reduces plasma lipids in vivo and inhibits apoB secretion, cholesterol esterification, and MTP activity in HepG2 human hepatoma cells.	naringenin	0-10	apolipoprotein B	Homo sapiens	94-98
12564931-1	2003	Naringenin, the principal flavonoid in grapefruit, reduces plasma lipids in vivo and inhibits apoB secretion, cholesterol esterification, and MTP activity in HepG2 human hepatoma cells.	naringenin	0-10	metallothionein 1B	Homo sapiens	142-145
12564931-3	2003	We therefore hypothesized that inhibition of TG accumulation in the ER lumen, secondary to MTP inhibition, is the primary mechanism whereby naringenin blocks lipidation and subsequent secretion of apoB.	naringenin	140-150	metallothionein 1B	Homo sapiens	91-94
12564931-3	2003	We therefore hypothesized that inhibition of TG accumulation in the ER lumen, secondary to MTP inhibition, is the primary mechanism whereby naringenin blocks lipidation and subsequent secretion of apoB.	naringenin	140-150	apolipoprotein B	Homo sapiens	197-201
12564931-4	2003	Multicompartmental modeling of pulse-chase studies was used to compare cellular apoB kinetics in the presence of either naringenin or the specific MTP inhibitor, BMS-197636.	naringenin	120-130	apolipoprotein B	Homo sapiens	80-84
12564931-7	2003	Newly synthesized CE accumulation in the lumen was reduced by 80% and 33% with naringenin and BMS-197636, respectively, demonstrating for the first time that MTP is involved in CE accumulation in the microsomal lumen.	naringenin	79-89	metallothionein 1B	Homo sapiens	158-161
12564931-9	2003	Both naringenin and BMS-197636 were most effective in reducing secretion of IDL and LDL, but also inhibited secretion of apoB-containing HDL-sized particles.	naringenin	5-15	apolipoprotein B	Homo sapiens	121-125
12564931-11	2003	Taken together, our results indicate that naringenin inhibits the lipidation and subsequent secretion of apoB-containing lipoproteins primarily by limiting the accumulation of TG in the ER lumen, secondary to MTP inhibition.	naringenin	42-52	apolipoprotein B	Homo sapiens	105-109
12564931-11	2003	Taken together, our results indicate that naringenin inhibits the lipidation and subsequent secretion of apoB-containing lipoproteins primarily by limiting the accumulation of TG in the ER lumen, secondary to MTP inhibition.	naringenin	42-52	metallothionein 1B	Homo sapiens	209-212
12235187-1	2002	The grapefruit flavonoid, naringenin, is hypocholesterolemic in vivo, and inhibits basal apolipoprotein B (apoB) secretion and the expression and activities of both ACAT and microsomal triglyceride transfer protein (MTP) in human hepatoma cells (HepG2).	naringenin	26-36	apolipoprotein B	Homo sapiens	107-111
12235187-1	2002	The grapefruit flavonoid, naringenin, is hypocholesterolemic in vivo, and inhibits basal apolipoprotein B (apoB) secretion and the expression and activities of both ACAT and microsomal triglyceride transfer protein (MTP) in human hepatoma cells (HepG2).	naringenin	26-36	acetyl-CoA acetyltransferase 1	Homo sapiens	165-169
12235187-1	2002	The grapefruit flavonoid, naringenin, is hypocholesterolemic in vivo, and inhibits basal apolipoprotein B (apoB) secretion and the expression and activities of both ACAT and microsomal triglyceride transfer protein (MTP) in human hepatoma cells (HepG2).	naringenin	26-36	microsomal triglyceride transfer protein	Homo sapiens	216-219
12235187-5	2002	In the presence of 0.1 mM oleic acid, naringenin (200 micro M) reduced the secretion of newly synthesized apoB by 52%, due to a 56% reduction in the rate constant for secretion.	naringenin	38-48	apolipoprotein B	Homo sapiens	106-110
12235187-10	2002	We conclude that naringenin inhibits apoB secretion in oleate-stimulated HepG2 cells and selectively increases intracellular degradation via a largely proteasomal, rapid kinetic pathway.	naringenin	17-27	apolipoprotein B	Homo sapiens	37-41
12235187-11	2002	Although naringenin inhibits ACAT, CE availability in the endoplasmic reticulum (ER) lumen does not appear to regulate apoB secretion in HepG2 cells.	naringenin	9-19	acetyl-CoA acetyltransferase 1	Homo sapiens	29-33
12224631-2	2002	In the binding assay, pharmaceuticals had a stronger binding activity to hERbeta than that of some phytoestrogens (coumestrol, daidzein, genistein, luteolin, chrysin, flavone, and naringenin) or industrial chemicals, but phytoestrogens such as coumestrol had a binding activity as strong as pharmaceuticals such as 17alpha-ethynylestradiol (EE), tamoxifen (Tam), and mestranol.	naringenin	180-190	estrogen receptor 2	Homo sapiens	73-80
11454723-6	2001	Cotreatment of cells with TCDD and GTE, naringenin, and apigenin resulted in 58, 77, and 74% reductions, respectively, in TCDD-mediated CYP1A1 induction, indicating that these flavonoids exhibit potential antagonist activity toward the aryl hydrocarbon (Ah) receptor.	naringenin	40-50	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	136-142
11454723-6	2001	Cotreatment of cells with TCDD and GTE, naringenin, and apigenin resulted in 58, 77, and 74% reductions, respectively, in TCDD-mediated CYP1A1 induction, indicating that these flavonoids exhibit potential antagonist activity toward the aryl hydrocarbon (Ah) receptor.	naringenin	40-50	aryl hydrocarbon receptor	Homo sapiens	236-266
11352979-0	2001	Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP.	naringenin	61-71	acetyl-CoA acetyltransferase 2	Homo sapiens	127-132
11352979-0	2001	Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP.	naringenin	61-71	microsomal triglyceride transfer protein	Homo sapiens	137-140
11352979-4	2001	apoB accumulation in the media decreased in a dose-dependent manner following 24-h incubations with naringenin (up to 82%, P &lt; 0.00001) or hesperetin (up to 74%, P &lt; 0.002).	naringenin	100-110	apolipoprotein B	Homo sapiens	0-4
11352979-9	2001	In addition, naringenin and hesperetin decreased both the activity (- 20% to - 40%, P &lt; 0.00004) and expression (- 30% to - 40%, P &lt; 0.02) of microsomal triglyceride transfer protein (MTP).	naringenin	13-23	microsomal triglyceride transfer protein	Homo sapiens	148-188
11352979-9	2001	In addition, naringenin and hesperetin decreased both the activity (- 20% to - 40%, P &lt; 0.00004) and expression (- 30% to - 40%, P &lt; 0.02) of microsomal triglyceride transfer protein (MTP).	naringenin	13-23	microsomal triglyceride transfer protein	Homo sapiens	190-193
11352979-11	2001	We conclude that both naringenin and hesperetin decrease the availability of lipids for assembly of apoB-containing lipoproteins, an effect mediated by 1) reduced activities of ACAT1 and ACAT2, 2) a selective decrease in ACAT2 expression, and 3) reduced MTP activity.	naringenin	22-32	apolipoprotein B	Homo sapiens	100-104
11352979-11	2001	We conclude that both naringenin and hesperetin decrease the availability of lipids for assembly of apoB-containing lipoproteins, an effect mediated by 1) reduced activities of ACAT1 and ACAT2, 2) a selective decrease in ACAT2 expression, and 3) reduced MTP activity.	naringenin	22-32	acetyl-CoA acetyltransferase 1	Homo sapiens	177-182
11352979-11	2001	We conclude that both naringenin and hesperetin decrease the availability of lipids for assembly of apoB-containing lipoproteins, an effect mediated by 1) reduced activities of ACAT1 and ACAT2, 2) a selective decrease in ACAT2 expression, and 3) reduced MTP activity.	naringenin	22-32	acetyl-CoA acetyltransferase 2	Homo sapiens	187-192
11306701-7	2001	Several flavonoids, especially naringenin and apigenin, markedly stimulated GSH transport by MRP1, suggesting they may be cotransported with this tripeptide.	naringenin	31-41	ATP binding cassette subfamily B member 1	Homo sapiens	93-97
11352979-11	2001	We conclude that both naringenin and hesperetin decrease the availability of lipids for assembly of apoB-containing lipoproteins, an effect mediated by 1) reduced activities of ACAT1 and ACAT2, 2) a selective decrease in ACAT2 expression, and 3) reduced MTP activity.	naringenin	22-32	acetyl-CoA acetyltransferase 2	Homo sapiens	221-226
11306701-9	2001	In contrast, kaempferol and naringenin stimulated both MRP1 ATPase activity and trapping of ADP.	naringenin	28-38	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
11352979-11	2001	We conclude that both naringenin and hesperetin decrease the availability of lipids for assembly of apoB-containing lipoproteins, an effect mediated by 1) reduced activities of ACAT1 and ACAT2, 2) a selective decrease in ACAT2 expression, and 3) reduced MTP activity.	naringenin	22-32	microsomal triglyceride transfer protein	Homo sapiens	254-257
10545673-6	1999	These results show that naringenin lowers the plasma and hepatic cholesterol concentrations by suppressing HMG-CoA reductase and ACAT in rats fed a high-cholesterol diet.	naringenin	24-34	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	107-124
11213362-6	2001	Quercetin, galangin, apigenin, and naringenin markedly decreased PGE2 release and COX-2 expression in a concentration-dependent manner.	naringenin	35-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	82-87
10781868-1	2000	Interactions of six naturally occurring flavonoids (acacetin, diosmetin, eriodictyol, hesperetin, homoeriodictyol, and naringenin) with human cytochrome P450 (CYP1) enzymes were studied.	naringenin	119-129	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	159-163
10397250-7	1999	Diethylstilbestrol, coumestrol, genistein, naringenin, and endosulfan were able to activate the AF2 function of the ER in vitro and demonstrated agonist activity in estrogen-responsive myometrial cells, as determined by induction of proliferation and increased message levels of progesterone receptor.	naringenin	43-53	estrogen receptor 1	Homo sapiens	116-118
10397250-7	1999	Diethylstilbestrol, coumestrol, genistein, naringenin, and endosulfan were able to activate the AF2 function of the ER in vitro and demonstrated agonist activity in estrogen-responsive myometrial cells, as determined by induction of proliferation and increased message levels of progesterone receptor.	naringenin	43-53	progesterone receptor	Homo sapiens	279-300
10405973-6	1999	These in vitro studies suggest that hesperetin and naringenin may, in part, reduce net apoB secretion by HepG2 cells by inhibiting cholesteryl ester synthesis and that these compounds are good candidates for further in vivo studies to determine whether they are responsible for the cholesterol-lowering properties of dietary citrus juices.	naringenin	51-61	apolipoprotein B	Homo sapiens	87-91
10969720-5	2000	Dillapiol, hypericin, and naringenin had the lowest IC50 values among the pure plant compounds at &lt; 0.5 mM; dillapiol was the most potent inhibitor at 23.3 times the concentration of the positive CYP3A4 inhibitor ketoconazole.	naringenin	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	199-205
10405973-0	1999	Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin.	naringenin	93-103	apolipoprotein B	Homo sapiens	25-41
10406482-7	1999	Additionally, the flavonoid phytoestrogens genistein and naringenin were also identified as hSHBG ligands, whereas their glucoside derivatives, genistin and naringin, had no binding activity for hSHBG.	naringenin	57-67	sex hormone binding globulin	Homo sapiens	92-97
10545673-4	1999	HMG-CoA reductase (1,879.0 vs. 1,715.0 pmol/min/mg) and ACAT activities (806.0 vs. 563.0 pmol/min/mg) were significantly lower in the naringenin-supplemented group than in controls.	naringenin	134-144	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	0-17
9766878-5	1998	The glucuronide conjugate of naringenin was evaluated by the deconjugated enzyme beta-glucuronidase.	naringenin	29-39	glucuronidase, beta	Rattus norvegicus	81-99
9751507-6	1998	Some phytoestrogens such as coumestrol, genistein, apigenin, naringenin, and kaempferol compete stronger with E2 for binding to ER beta than to ER alpha.	naringenin	61-71	estrogen receptor 2	Homo sapiens	128-135
9751507-6	1998	Some phytoestrogens such as coumestrol, genistein, apigenin, naringenin, and kaempferol compete stronger with E2 for binding to ER beta than to ER alpha.	naringenin	61-71	estrogen receptor 1	Homo sapiens	144-152
7895601-7	1994	Other CYP3A substrates (cyclosporin A, naringenin, and midazolam) also demonstrated potent inhibition of terfenadine biotransformation in human liver microsomes (IC50 = 17-24 microM).	naringenin	39-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-11
9616184-7	1998	In addition to amines, expressed human UGT1A3 catalyzed the glucuronidation of opioids (e.g. morphine and buprenorphine), coumarins, flavonoids (e.g. naringenin and quercetin), anthraquinones, and small phenolic compounds (e.g. 4-nitrophenol).	naringenin	150-160	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	39-45
9616184-10	1998	Of the compounds tested, scopoletin, naringenin, and norbuprenorphine appeared to be the best xenobiotic substrates for human UGT1A3.	naringenin	37-47	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	126-132
9492341-4	1998	We found that naringenin, a flavanone, and quercetin and kaempferol, flavonols, inhibit estrogen binding to AFP with apparent Kds of about 5 x 10(-7) M. To our surprise, the two isoflavonoids, daidzein and genistein, have Kds of about 5 x 10(-6) M for AFP.	naringenin	14-24	alpha-fetoprotein	Rattus norvegicus	108-111
9492341-4	1998	We found that naringenin, a flavanone, and quercetin and kaempferol, flavonols, inhibit estrogen binding to AFP with apparent Kds of about 5 x 10(-7) M. To our surprise, the two isoflavonoids, daidzein and genistein, have Kds of about 5 x 10(-6) M for AFP.	naringenin	14-24	alpha-fetoprotein	Rattus norvegicus	252-255
9287415-3	1997	Eriodictyol was the most potent protective agent of all the flavonoids tested, while a 4"-hydroxyflavanone, naringenin, rather showed enhancement of TNF cytotoxicity.	naringenin	108-118	tumor necrosis factor	Mus musculus	149-152
7503800-3	1995	However, in rats cotreated with E2 (0.5 microgram/rat) plus naringenin (30 mg/rat); there was a significant decrease in E2-induced uterine wet weight, DNA synthesis, PR binding, and peroxidase activity, indicating that naringenin exhibits antiestrogenic activity in the immature rodent uterus.	naringenin	60-70	progesterone receptor	Rattus norvegicus	166-168
9449200-4	1997	The natural flavonoids, quercetin, kaempferol, and naringenin, significantly inhibited estrone sulfatase activity with I50 &lt; 10 microM for the most potent, quercetin.	naringenin	51-61	steroid sulfatase	Homo sapiens	87-104
8924586-4	1996	Inhibition by the more potent compounds, fisetin, kaempferol, naringenin, and quercetin, which contain a resorcinol moiety, was consistent with mechanism-based inactivation of TPO as previously observed for resorcinol and derivatives.	naringenin	62-72	thyroid peroxidase	Homo sapiens	176-179
8485024-0	1993	Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man.	naringenin	64-74	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	79-85
8161344-2	1994	Naringenin, a grapefruit aglycone and an inhibitor of cytochrome P450 3A4 (CYP3A4)-catalysed reactions, was found to inhibit ifosfamide activation and N-dechloroethylation by human liver microsomes.	naringenin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
8485024-2	1993	The effects of grapefruit juice and naringenin on the activity of the human cytochrome P450 isoform CYP1A2 were evaluated using caffeine as a probe substrate.	naringenin	36-46	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	100-106
8485024-8	1993	We conclude that grapefruit juice and naringenin inhibit CYP1A2 activity in man.	naringenin	38-48	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	57-63
33772317-2	2021	We aimed to investigate the protective effect of naringenin against AR induced in rats.	naringenin	49-59	ferredoxin reductase	Rattus norvegicus	68-70
8450317-4	1993	Capsimine and narigenin exhibited significant cytotoxic effect against human PLC/PRF/5 and KB cells in vitro, and capsicastrine and etioline exhibited significant cytotoxicity against human PLC/PRF/5 cells in vitro.	naringenin	14-23	heparan sulfate proteoglycan 2	Homo sapiens	77-80
33772317-14	2021	Serum total IgE, IL4 and IL5 values in the naringenin group were significantly lower than in the AR group, and significant histopathological improvement was observed compared to the AR group.	naringenin	43-53	interleukin 4	Rattus norvegicus	17-20
33772317-14	2021	Serum total IgE, IL4 and IL5 values in the naringenin group were significantly lower than in the AR group, and significant histopathological improvement was observed compared to the AR group.	naringenin	43-53	interleukin 5	Rattus norvegicus	25-28
33772317-15	2021	CONCLUSIONS: Naringenin produced significant clinical, biochemical and histopathological benefits in rats with induced AR.	naringenin	13-23	ferredoxin reductase	Rattus norvegicus	119-121
33772317-16	2021	These effects suggest that naringenin is a promising agent for the treatment of AR.	naringenin	27-37	ferredoxin reductase	Rattus norvegicus	80-82
34563970-5	2022	Enzyme assays revealed that flavonoids exhibited higher inhibitory activity against alpha-glucosidase than others with astilbin (IC50 = 6.14 mug mL-1), morin (IC50 = 8.46 mug mL-1), and naringenin (IC50 = 10.03 mug mL-1) showing 2- to 4-fold higher potency than the positive control acarbose.	naringenin	186-196	sucrase-isomaltase	Homo sapiens	84-101
34848084-5	2022	X-Ray Diffraction experiment revealed that the material state of the formed naringenin-beta-CD-CQDs nanoparticles is amorphous in opposition to the crystalline state of naringenin, beta-CD and naringenin-beta-CD inclusion complex.	naringenin	76-86	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	87-94
7835232-8	1994	Apparent KM and enzyme efficiency values for certain food-derived substrates (e.g., naringenin and eugenol) for expressed UGT2B15 were similar to those determined for endobiotic substrates, suggesting that some naturally occurring substances are good substrates for this enzyme and that glucuronidation of endogenous compounds could be affected by xenobiotics derived from dietary sources.	naringenin	84-94	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	122-129
34563970-5	2022	Enzyme assays revealed that flavonoids exhibited higher inhibitory activity against alpha-glucosidase than others with astilbin (IC50 = 6.14 mug mL-1), morin (IC50 = 8.46 mug mL-1), and naringenin (IC50 = 10.03 mug mL-1) showing 2- to 4-fold higher potency than the positive control acarbose.	naringenin	186-196	L1 cell adhesion molecule	Mus musculus	215-219
34348583-8	2022	Concurrent NAR supplement to ZnONPs- treated rats significantly declined liver enzymes activities, restored oxidant/antioxidant balance, reversed inflammation, induced fewer collagen fibers accumulation, and antagonized BAX-mediated apoptotic cell death in hepatic tissues.	naringenin	11-14	BCL2 associated X, apoptosis regulator	Rattus norvegicus	220-223
34959345-8	2021	Cyanidin-3O-sophoroside, catechin, naringenin, kuromanin and caffeic acid increased the ATPase activity of Pgp, while they had only a weaker effect on the intracellular accumulation of fluorescent Pgp substrates.	naringenin	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	107-110
34914851-0	2022	Naringenin protects swine testis cells from bisphenol A-induced apoptosis via Keap1/Nrf2 signaling pathway.	naringenin	0-10	kelch like ECH associated protein 1	Sus scrofa	78-83
34655599-10	2021	NAR treatment significantly modulated PQ-induced mRNA expressions of DRD2, DAT, LRRK2, SNCA, beta-catenin, caspase-3, BDNF genes.	naringenin	0-3	dopamine receptor D2	Rattus norvegicus	69-73
34655599-10	2021	NAR treatment significantly modulated PQ-induced mRNA expressions of DRD2, DAT, LRRK2, SNCA, beta-catenin, caspase-3, BDNF genes.	naringenin	0-3	solute carrier family 6 member 3	Rattus norvegicus	75-78
34655599-10	2021	NAR treatment significantly modulated PQ-induced mRNA expressions of DRD2, DAT, LRRK2, SNCA, beta-catenin, caspase-3, BDNF genes.	naringenin	0-3	leucine-rich repeat kinase 2	Rattus norvegicus	80-85
34655599-10	2021	NAR treatment significantly modulated PQ-induced mRNA expressions of DRD2, DAT, LRRK2, SNCA, beta-catenin, caspase-3, BDNF genes.	naringenin	0-3	synuclein alpha	Rattus norvegicus	87-91
34655599-10	2021	NAR treatment significantly modulated PQ-induced mRNA expressions of DRD2, DAT, LRRK2, SNCA, beta-catenin, caspase-3, BDNF genes.	naringenin	0-3	catenin beta 1	Rattus norvegicus	93-105
34655599-10	2021	NAR treatment significantly modulated PQ-induced mRNA expressions of DRD2, DAT, LRRK2, SNCA, beta-catenin, caspase-3, BDNF genes.	naringenin	0-3	caspase 3	Rattus norvegicus	107-116
34655599-10	2021	NAR treatment significantly modulated PQ-induced mRNA expressions of DRD2, DAT, LRRK2, SNCA, beta-catenin, caspase-3, BDNF genes.	naringenin	0-3	brain-derived neurotrophic factor	Rattus norvegicus	118-122
34655599-12	2021	Also, GFAP decreased in response to NAR treatment.	naringenin	36-39	glial fibrillary acidic protein	Rattus norvegicus	6-10
34899944-11	2021	Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways.	naringenin	145-155	AKT serine/threonine kinase 1	Homo sapiens	191-195
34899944-11	2021	Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways.	naringenin	145-155	matrix metallopeptidase 9	Homo sapiens	197-201
34899944-11	2021	Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways.	naringenin	145-155	interleukin 6	Homo sapiens	203-207
34899944-11	2021	Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways.	naringenin	145-155	cyclin D1	Homo sapiens	209-214
34899944-11	2021	Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways.	naringenin	145-155	BCL2 apoptosis regulator	Homo sapiens	216-220
34899944-11	2021	Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways.	naringenin	145-155	mechanistic target of rapamycin kinase	Homo sapiens	222-226
34899944-11	2021	Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways.	naringenin	145-155	MDM2 proto-oncogene	Homo sapiens	232-236
34899944-11	2021	Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways.	naringenin	145-155	AKT serine/threonine kinase 1	Homo sapiens	267-270
34899944-11	2021	Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways.	naringenin	145-155	interleukin 17A	Homo sapiens	275-280
34854271-3	2021	OBJECTIVE: This study examined the relationship between glucose uptake and AMP-activated protein kinase (AMPK) phosphorylation by naringenin and naringin in high glucose-treated HepG2 cells.	naringenin	130-140	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	75-103
34767997-13	2021	These naringenin-induced inhibitions were fully blocked in Cav3.2KO-VgatARH mice.	naringenin	6-16	caveolin 3	Mus musculus	59-63
34887704-0	2021	Synthesis and Evaluation of the Acetylcholinesterase Inhibitory Activities of Some Flavonoids Derived from Naringenin.	naringenin	107-117	acetylcholinesterase (Cartwright blood group)	Homo sapiens	32-52
34887704-5	2021	Naringenin is a flavonoid with the potential inhibitory activity against AChE.	naringenin	0-10	acetylcholinesterase (Cartwright blood group)	Homo sapiens	73-77
34887704-8	2021	The evaluation of AChE inhibitory activity by the Ellman method showed that there were four substances (2, 4, 5, and 7) with relatively good biological activities (IC50 < 100 muM), and these biological activities were better than that of naringenin.	naringenin	238-248	acetylcholinesterase (Cartwright blood group)	Homo sapiens	18-22
34840667-0	2021	Temporary Upregulation of Nrf2 by Naringenin Alleviates Oxidative Damage in the Retina and ARPE-19 Cells.	naringenin	34-44	NFE2 like bZIP transcription factor 2	Homo sapiens	26-30
34840667-3	2021	Our previous studies have showed that naringenin (NAR) protects RPE cells from oxidative damage partly through SIRT1-mediated antioxidation.	naringenin	38-48	sirtuin 1	Homo sapiens	111-116
34840667-3	2021	Our previous studies have showed that naringenin (NAR) protects RPE cells from oxidative damage partly through SIRT1-mediated antioxidation.	naringenin	50-53	sirtuin 1	Homo sapiens	111-116
34840667-9	2021	NAR treatment also resulted in a stronger activation of Nrf2 at the early stage in NaIO3-treated ARPE-19 cells.	naringenin	0-3	NFE2 like bZIP transcription factor 2	Homo sapiens	56-60
34840667-10	2021	Moreover, inhibition of HO-1 by ZnPP weakened the cytoprotective effect of NAR.	naringenin	75-78	heme oxygenase 1	Homo sapiens	24-28
34774104-4	2021	The present clinical trial aims to examine the efficacy of naringenin supplementation on plasma adiponectin and neurogulin-4 (NRG-4) concentrations, metabolic parameters, and liver function indices in overweight/obese patients with NAFLD.	naringenin	59-69	adiponectin, C1Q and collagen domain containing	Homo sapiens	96-107
34769415-7	2021	Together, the results of this study highlight the gastroprotective effect of naringenin in GU of mice by inhibiting gastric secretion and acidity, reducing inflammation and oxidative stress, suppressing NF-kappaB activity, and restoring the histological architecture.	naringenin	77-87	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	203-212
34854271-0	2021	The effects of naringenin and naringin on the glucose uptake and AMPK phosphorylation in high glucose treated HepG2 cells.	naringenin	15-25	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	65-69
34699317-0	2021	Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) /System xc-/ glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	79-129
34699317-0	2021	Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) /System xc-/ glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	131-135
34699317-0	2021	Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) /System xc-/ glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis.	naringenin	0-10	glutathione peroxidase 4	Rattus norvegicus	150-174
34699317-0	2021	Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) /System xc-/ glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis.	naringenin	0-10	glutathione peroxidase 4	Rattus norvegicus	176-180
34699317-10	2021	NAR adjusted the NRF2 /System xc -/GPX4 axis and improved ferroptosis.	naringenin	0-3	NFE2 like bZIP transcription factor 2	Rattus norvegicus	17-21
34699317-10	2021	NAR adjusted the NRF2 /System xc -/GPX4 axis and improved ferroptosis.	naringenin	0-3	glutathione peroxidase 4	Rattus norvegicus	35-39
34767997-12	2021	Lastly, we found that naringenin extract, a predominant flavanone found in various fruits and herbs and known to act on Cav3.2, decreased the firing activity of VgatARH neurons and reduced food intake and body weight.	naringenin	22-32	calcium channel, voltage-dependent, T type, alpha 1H subunit	Mus musculus	120-126
34769415-6	2021	In addition, pretreatment with naringenin might inhibit the secretion of TNF-alpha, IL-6, and IL-8, as well as the proteins cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) via the suppression of NF-kappaB and mitogen-activated protein kinase (MAPK) signaling in ethanol-stimulated stomach epithelial KATO III cells.	naringenin	31-41	tumor necrosis factor	Homo sapiens	73-82
34769415-6	2021	In addition, pretreatment with naringenin might inhibit the secretion of TNF-alpha, IL-6, and IL-8, as well as the proteins cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) via the suppression of NF-kappaB and mitogen-activated protein kinase (MAPK) signaling in ethanol-stimulated stomach epithelial KATO III cells.	naringenin	31-41	interleukin 6	Homo sapiens	84-88
34769415-6	2021	In addition, pretreatment with naringenin might inhibit the secretion of TNF-alpha, IL-6, and IL-8, as well as the proteins cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) via the suppression of NF-kappaB and mitogen-activated protein kinase (MAPK) signaling in ethanol-stimulated stomach epithelial KATO III cells.	naringenin	31-41	C-X-C motif chemokine ligand 8	Homo sapiens	94-98
34769415-6	2021	In addition, pretreatment with naringenin might inhibit the secretion of TNF-alpha, IL-6, and IL-8, as well as the proteins cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) via the suppression of NF-kappaB and mitogen-activated protein kinase (MAPK) signaling in ethanol-stimulated stomach epithelial KATO III cells.	naringenin	31-41	prostaglandin-endoperoxide synthase 2	Homo sapiens	124-140
34769415-6	2021	In addition, pretreatment with naringenin might inhibit the secretion of TNF-alpha, IL-6, and IL-8, as well as the proteins cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) via the suppression of NF-kappaB and mitogen-activated protein kinase (MAPK) signaling in ethanol-stimulated stomach epithelial KATO III cells.	naringenin	31-41	prostaglandin-endoperoxide synthase 2	Homo sapiens	142-147
34769415-6	2021	In addition, pretreatment with naringenin might inhibit the secretion of TNF-alpha, IL-6, and IL-8, as well as the proteins cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) via the suppression of NF-kappaB and mitogen-activated protein kinase (MAPK) signaling in ethanol-stimulated stomach epithelial KATO III cells.	naringenin	31-41	nitric oxide synthase 2	Homo sapiens	153-184
34769415-6	2021	In addition, pretreatment with naringenin might inhibit the secretion of TNF-alpha, IL-6, and IL-8, as well as the proteins cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) via the suppression of NF-kappaB and mitogen-activated protein kinase (MAPK) signaling in ethanol-stimulated stomach epithelial KATO III cells.	naringenin	31-41	nitric oxide synthase 2	Homo sapiens	186-190
34769415-6	2021	In addition, pretreatment with naringenin might inhibit the secretion of TNF-alpha, IL-6, and IL-8, as well as the proteins cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) via the suppression of NF-kappaB and mitogen-activated protein kinase (MAPK) signaling in ethanol-stimulated stomach epithelial KATO III cells.	naringenin	31-41	nuclear factor kappa B subunit 1	Homo sapiens	215-224
34596437-0	2021	Retraction of: Naringenin Inhibits Cell Migration, Invasion, and Tumor Growth by Regulating circFOXM1/miR-3619-5p/SPAG5 Axis in Lung Cancer (doi: 10.1089/cbr.2019.3520).	naringenin	15-25	microRNA 3619	Homo sapiens	102-110
34596437-0	2021	Retraction of: Naringenin Inhibits Cell Migration, Invasion, and Tumor Growth by Regulating circFOXM1/miR-3619-5p/SPAG5 Axis in Lung Cancer (doi: 10.1089/cbr.2019.3520).	naringenin	15-25	sperm associated antigen 5	Homo sapiens	114-119
34697266-0	2021	Beneficial effects of naringenin and morin on interleukin-5 and reactive oxygen species production in BALB/c mice with ovalbumin-induced asthma.	naringenin	22-32	interleukin 5	Mus musculus	46-59
34697266-7	2021	Our findings suggested that naringenin and morin significantly suppressed IL-5 and ROS production via various pathways.	naringenin	28-38	interleukin 5	Mus musculus	74-78
34697266-8	2021	Interestingly, by reducing NFAT activity, naringenin and morin stimulated HO-1 expression, thereby suppressing IL-5 secretion due to regulating the transcription factor Nrf2 via P13/Akt or ERK/JNK signalling pathways in EL-4 cells, demonstrating the involvement of HO-1 expression in inhibiting asthmatic inflammation.	naringenin	42-52	heme oxygenase 1	Mus musculus	74-78
34697266-8	2021	Interestingly, by reducing NFAT activity, naringenin and morin stimulated HO-1 expression, thereby suppressing IL-5 secretion due to regulating the transcription factor Nrf2 via P13/Akt or ERK/JNK signalling pathways in EL-4 cells, demonstrating the involvement of HO-1 expression in inhibiting asthmatic inflammation.	naringenin	42-52	interleukin 5	Mus musculus	111-115
34697266-8	2021	Interestingly, by reducing NFAT activity, naringenin and morin stimulated HO-1 expression, thereby suppressing IL-5 secretion due to regulating the transcription factor Nrf2 via P13/Akt or ERK/JNK signalling pathways in EL-4 cells, demonstrating the involvement of HO-1 expression in inhibiting asthmatic inflammation.	naringenin	42-52	nuclear factor, erythroid derived 2, like 2	Mus musculus	169-173
34697266-8	2021	Interestingly, by reducing NFAT activity, naringenin and morin stimulated HO-1 expression, thereby suppressing IL-5 secretion due to regulating the transcription factor Nrf2 via P13/Akt or ERK/JNK signalling pathways in EL-4 cells, demonstrating the involvement of HO-1 expression in inhibiting asthmatic inflammation.	naringenin	42-52	thymoma viral proto-oncogene 1	Mus musculus	182-185
34697266-8	2021	Interestingly, by reducing NFAT activity, naringenin and morin stimulated HO-1 expression, thereby suppressing IL-5 secretion due to regulating the transcription factor Nrf2 via P13/Akt or ERK/JNK signalling pathways in EL-4 cells, demonstrating the involvement of HO-1 expression in inhibiting asthmatic inflammation.	naringenin	42-52	mitogen-activated protein kinase 1	Mus musculus	189-192
34697266-8	2021	Interestingly, by reducing NFAT activity, naringenin and morin stimulated HO-1 expression, thereby suppressing IL-5 secretion due to regulating the transcription factor Nrf2 via P13/Akt or ERK/JNK signalling pathways in EL-4 cells, demonstrating the involvement of HO-1 expression in inhibiting asthmatic inflammation.	naringenin	42-52	mitogen-activated protein kinase 8	Mus musculus	193-196
34697266-8	2021	Interestingly, by reducing NFAT activity, naringenin and morin stimulated HO-1 expression, thereby suppressing IL-5 secretion due to regulating the transcription factor Nrf2 via P13/Akt or ERK/JNK signalling pathways in EL-4 cells, demonstrating the involvement of HO-1 expression in inhibiting asthmatic inflammation.	naringenin	42-52	heme oxygenase 1	Mus musculus	265-269
34490473-10	2021	In addition, naringenin notably inhibited the proliferation of RCC cells by decreasing Ki67 expression, blocked cell cycle progression in the G2 phase by regulating expression of cell cycle proteins, and increased apoptosis by upregulating caspase-8 expression, downregulating Bcl-2 expression and altering the cellular morphology.	naringenin	13-23	caspase 8	Homo sapiens	240-249
34490473-10	2021	In addition, naringenin notably inhibited the proliferation of RCC cells by decreasing Ki67 expression, blocked cell cycle progression in the G2 phase by regulating expression of cell cycle proteins, and increased apoptosis by upregulating caspase-8 expression, downregulating Bcl-2 expression and altering the cellular morphology.	naringenin	13-23	BCL2 apoptosis regulator	Homo sapiens	277-282
34490473-11	2021	Furthermore, naringenin inhibited cell proliferation and promoted apoptosis by upregulating the expression of PTEN at the protein level, downregulated the expression of PI3K and phosphorylated-(p-)AKT, but did not affect the expression of AKT, mTOR or p-mTOR.	naringenin	13-23	phosphatase and tensin homolog	Homo sapiens	110-114
34490473-11	2021	Furthermore, naringenin inhibited cell proliferation and promoted apoptosis by upregulating the expression of PTEN at the protein level, downregulated the expression of PI3K and phosphorylated-(p-)AKT, but did not affect the expression of AKT, mTOR or p-mTOR.	naringenin	13-23	AKT serine/threonine kinase 1	Homo sapiens	197-200
34490473-14	2021	However, naringenin showed potent anti-proliferative, apoptosis inducing and cell cycle arresting activity on RCC cells via regulation of the PTEN/PI3K/AKT signaling pathway.	naringenin	9-19	phosphatase and tensin homolog	Homo sapiens	142-146
34490473-14	2021	However, naringenin showed potent anti-proliferative, apoptosis inducing and cell cycle arresting activity on RCC cells via regulation of the PTEN/PI3K/AKT signaling pathway.	naringenin	9-19	AKT serine/threonine kinase 1	Homo sapiens	152-155
34854271-3	2021	OBJECTIVE: This study examined the relationship between glucose uptake and AMP-activated protein kinase (AMPK) phosphorylation by naringenin and naringin in high glucose-treated HepG2 cells.	naringenin	130-140	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	105-109
34854271-9	2021	Molecular docking analysis showed that both naringenin and naringin bind to the gamma-subunit of AMPK with high binding affinities.	naringenin	44-54	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	97-101
34854271-11	2021	Therefore, both naringenin and naringin could be positive modulators of AMPK activation, which enhance glucose uptake regardless of insulin stimulation in high glucose-treated HepG2 cells.	naringenin	16-26	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	72-76
34854271-12	2021	CONCLUSIONS: The increased phosphorylation of AMPK at Thr172 by naringenin and naringin might enhance glucose uptake regardless of insulin stimulation in high glucose treated HepG2 cells.	naringenin	64-74	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	46-50
34583226-5	2021	We found that the phytochemical compounds, such as curcumin, naringenin, sulforaphane, diallyl disulfide, mangiferin, oleanolic acid, umbelliferone, daphnetin, quercetin, isorhamnetin-3-O-galactoside, hesperidin, diammonium glycyrrhizinate, corilagin, shikonin, farrerol, and chenpi, had the potential to improve the Nrf2-ARE signaling thereby combat hepatotoxicity.	naringenin	61-71	NFE2 like bZIP transcription factor 2	Homo sapiens	317-321
34117816-0	2021	Naringenin prevents pregnancy-induced hypertension via suppression of JAK/STAT3 signaling pathway in mice.	naringenin	0-10	signal transducer and activator of transcription 3	Mus musculus	74-79
34411564-10	2021	Thus, the vasorelaxant effect shown by naringenin mostly involve the COX pathway, the endothelium-dependent pathway via NO/sGC/prostaglandin, calcium and potassium channels.	naringenin	39-49	guanylate cyclase 1 soluble subunit alpha 1	Rattus norvegicus	123-126
34117816-10	2021	Naringenin decreased serum levels of pro-inflammatory cytokines interleukin (IL)-2, IL-6 and tumor necrosis factor alpha (TNF-alpha), while increased IL-10.	naringenin	0-10	tumor necrosis factor	Mus musculus	93-120
34117816-10	2021	Naringenin decreased serum levels of pro-inflammatory cytokines interleukin (IL)-2, IL-6 and tumor necrosis factor alpha (TNF-alpha), while increased IL-10.	naringenin	0-10	tumor necrosis factor	Mus musculus	122-131
34754315-10	2021	Molecular docking results showed that quercetin, luteolin, kaempferol, tanshinone IIa, wogonin, naringenin, nobiletin, dihydrotanshinlactone, beta-sitosterol, and salviolone have good affinity with core target proteins IL6, PTGS2, MAPK1, MAPK3, and CGRP1.	naringenin	96-106	interleukin 6	Homo sapiens	219-222
34754315-10	2021	Molecular docking results showed that quercetin, luteolin, kaempferol, tanshinone IIa, wogonin, naringenin, nobiletin, dihydrotanshinlactone, beta-sitosterol, and salviolone have good affinity with core target proteins IL6, PTGS2, MAPK1, MAPK3, and CGRP1.	naringenin	96-106	prostaglandin-endoperoxide synthase 2	Homo sapiens	224-229
34754315-10	2021	Molecular docking results showed that quercetin, luteolin, kaempferol, tanshinone IIa, wogonin, naringenin, nobiletin, dihydrotanshinlactone, beta-sitosterol, and salviolone have good affinity with core target proteins IL6, PTGS2, MAPK1, MAPK3, and CGRP1.	naringenin	96-106	mitogen-activated protein kinase 1	Homo sapiens	231-236
34754315-10	2021	Molecular docking results showed that quercetin, luteolin, kaempferol, tanshinone IIa, wogonin, naringenin, nobiletin, dihydrotanshinlactone, beta-sitosterol, and salviolone have good affinity with core target proteins IL6, PTGS2, MAPK1, MAPK3, and CGRP1.	naringenin	96-106	mitogen-activated protein kinase 3	Homo sapiens	238-243
34754315-10	2021	Molecular docking results showed that quercetin, luteolin, kaempferol, tanshinone IIa, wogonin, naringenin, nobiletin, dihydrotanshinlactone, beta-sitosterol, and salviolone have good affinity with core target proteins IL6, PTGS2, MAPK1, MAPK3, and CGRP1.	naringenin	96-106	calcitonin related polypeptide alpha	Homo sapiens	249-254
34737698-10	2021	Through text mining and molecular docking, the target gene NR3C2 and its active compound naringenin were selected for further validation.	naringenin	89-99	nuclear receptor subfamily 3 group C member 2	Homo sapiens	59-64
34737698-12	2021	In vitro experiments indicated that naringenin presented an identical effect to XS, possibly by regulating the NR3C2 expression.	naringenin	36-46	nuclear receptor subfamily 3 group C member 2	Homo sapiens	111-116
34737698-13	2021	Overall, this study explored the effect of Xihuang pill in treating advanced TNBC cells and showed that naringenin, which is the key active compound of Xihuang pill, could lessen the stemness of TNBC cells to produce a synergistic effect on PTX by regulating the NR3C2 gene.	naringenin	104-114	nuclear receptor subfamily 3 group C member 2	Homo sapiens	263-268
34324877-7	2021	Further, Naringenin suppressed TBI-induced activation of the ER stress pathway (p-eIF2alpha, ATF4, and CHOP), oxidative stress and apoptosis on day 3 after TBI.	naringenin	9-19	eukaryotic translation initiation factor 2A	Mus musculus	82-91
34324877-7	2021	Further, Naringenin suppressed TBI-induced activation of the ER stress pathway (p-eIF2alpha, ATF4, and CHOP), oxidative stress and apoptosis on day 3 after TBI.	naringenin	9-19	activating transcription factor 4	Mus musculus	93-97
34324877-7	2021	Further, Naringenin suppressed TBI-induced activation of the ER stress pathway (p-eIF2alpha, ATF4, and CHOP), oxidative stress and apoptosis on day 3 after TBI.	naringenin	9-19	DNA-damage inducible transcript 3	Mus musculus	103-107
34613591-3	2022	The results demonstrated that Naringenin supplementation downregulated the expression of ER stress marker proteins, including p-PERK, p-eIF2alpha, XBP1s, ATF4 and CHOP during hyperglycemic renal toxicity in vitro and in vivo.	naringenin	30-40	eukaryotic translation initiation factor 2A	Rattus norvegicus	136-145
34613591-3	2022	The results demonstrated that Naringenin supplementation downregulated the expression of ER stress marker proteins, including p-PERK, p-eIF2alpha, XBP1s, ATF4 and CHOP during hyperglycemic renal toxicity in vitro and in vivo.	naringenin	30-40	activating transcription factor 4	Rattus norvegicus	154-158
34613591-3	2022	The results demonstrated that Naringenin supplementation downregulated the expression of ER stress marker proteins, including p-PERK, p-eIF2alpha, XBP1s, ATF4 and CHOP during hyperglycemic renal toxicity in vitro and in vivo.	naringenin	30-40	DNA-damage inducible transcript 3	Rattus norvegicus	163-167
34613591-5	2022	Interestingly, treatment of Naringenin prevented nuclear translocation of ATF4 and CHOP in hyperglycemic renal cells and diabetic kidneys.	naringenin	28-38	activating transcription factor 4	Rattus norvegicus	74-78
34613591-5	2022	Interestingly, treatment of Naringenin prevented nuclear translocation of ATF4 and CHOP in hyperglycemic renal cells and diabetic kidneys.	naringenin	28-38	DNA-damage inducible transcript 3	Rattus norvegicus	83-87
34117816-10	2021	Naringenin decreased serum levels of pro-inflammatory cytokines interleukin (IL)-2, IL-6 and tumor necrosis factor alpha (TNF-alpha), while increased IL-10.	naringenin	0-10	interleukin 10	Mus musculus	150-155
34117816-13	2021	In addition, western blot also showed that naringenin inhibited JAK2/STAT3 signaling by suppressing SHP-1 expression in vascular endothelial cells of mice.	naringenin	43-53	Janus kinase 2	Mus musculus	64-68
34117816-13	2021	In addition, western blot also showed that naringenin inhibited JAK2/STAT3 signaling by suppressing SHP-1 expression in vascular endothelial cells of mice.	naringenin	43-53	signal transducer and activator of transcription 3	Mus musculus	69-74
34117816-13	2021	In addition, western blot also showed that naringenin inhibited JAK2/STAT3 signaling by suppressing SHP-1 expression in vascular endothelial cells of mice.	naringenin	43-53	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	100-105
34117816-14	2021	CONCLUSION: Naringenin suppressed the activation of JAK2/STAT3 signaling pathway and promoted SHP-1 expression, leading to ameliorated hypertension in pregnancy.	naringenin	12-22	Janus kinase 2	Mus musculus	52-56
34117816-14	2021	CONCLUSION: Naringenin suppressed the activation of JAK2/STAT3 signaling pathway and promoted SHP-1 expression, leading to ameliorated hypertension in pregnancy.	naringenin	12-22	signal transducer and activator of transcription 3	Mus musculus	57-62
34117816-10	2021	Naringenin decreased serum levels of pro-inflammatory cytokines interleukin (IL)-2, IL-6 and tumor necrosis factor alpha (TNF-alpha), while increased IL-10.	naringenin	0-10	interleukin 2	Mus musculus	64-82
34117816-10	2021	Naringenin decreased serum levels of pro-inflammatory cytokines interleukin (IL)-2, IL-6 and tumor necrosis factor alpha (TNF-alpha), while increased IL-10.	naringenin	0-10	interleukin 6	Mus musculus	84-88
34252709-0	2021	Naringenin inhibits pro-inflammatory cytokine production in macrophages through inducing MT1G to suppress the activation of NF-kappaB.	naringenin	0-10	metallothionein 1G	Homo sapiens	89-93
34117816-14	2021	CONCLUSION: Naringenin suppressed the activation of JAK2/STAT3 signaling pathway and promoted SHP-1 expression, leading to ameliorated hypertension in pregnancy.	naringenin	12-22	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	94-99
34121218-0	2021	Structure-based investigation of MARK4 inhibitory potential of Naringenin for therapeutic management of cancer and neurodegenerative diseases.	naringenin	63-73	microtubule affinity regulating kinase 4	Homo sapiens	33-38
34121218-2	2021	Screening of Indian Medicinal Plants, Phytochemistry, and Therapeutics (IMPPAT) using virtual high-throughput screening coupled with enzyme assay suggested that Naringenin (NAG) could be a potent inhibitor of MARK4.	naringenin	161-171	microtubule affinity regulating kinase 4	Homo sapiens	209-214
34121218-2	2021	Screening of Indian Medicinal Plants, Phytochemistry, and Therapeutics (IMPPAT) using virtual high-throughput screening coupled with enzyme assay suggested that Naringenin (NAG) could be a potent inhibitor of MARK4.	naringenin	173-176	microtubule affinity regulating kinase 4	Homo sapiens	209-214
34121218-4	2021	Furthermore, molecular dynamics (MD) simulation studies for 100 ns have delineated the binding mechanism of NAG to MARK4.	naringenin	108-111	microtubule affinity regulating kinase 4	Homo sapiens	115-120
34121218-7	2021	Fluorescence binding and isothermal titration calorimetric measurements revealed an excellent binding affinity of NAG to MARK4 with a binding constant (K) = 0.13 x 106 M-1 obtained from fluorescence binding studies.	naringenin	114-117	microtubule affinity regulating kinase 4	Homo sapiens	121-126
34121218-9	2021	Together, these findings suggest that NAG could be an effective MARK4 inhibitor that can potentially be used to treat cancer and neurodegenerative diseases.	naringenin	38-41	microtubule affinity regulating kinase 4	Homo sapiens	64-69
34604344-5	2021	In addition, we tested the potential of Smad3-targeted therapy using 2 in vivo protocols - lentivirus-mediated Smad3 silencing in vivo and use of naringenin, a monomer used in traditional Chinese medicine and a natural inhibitor of Smad3.	naringenin	146-156	SMAD family member 3	Mus musculus	232-237
34252709-5	2021	In addition, Nar was also able to induce metallothionein 1 G (MT1G) expression, and the inhibitory effects of Nar on the production of pro-inflammatory cytokines was dependent on MT1G.	naringenin	13-16	metallothionein 1G	Homo sapiens	41-60
34252709-5	2021	In addition, Nar was also able to induce metallothionein 1 G (MT1G) expression, and the inhibitory effects of Nar on the production of pro-inflammatory cytokines was dependent on MT1G.	naringenin	13-16	metallothionein 1G	Homo sapiens	62-66
34252709-5	2021	In addition, Nar was also able to induce metallothionein 1 G (MT1G) expression, and the inhibitory effects of Nar on the production of pro-inflammatory cytokines was dependent on MT1G.	naringenin	13-16	metallothionein 1G	Homo sapiens	179-183
34252709-5	2021	In addition, Nar was also able to induce metallothionein 1 G (MT1G) expression, and the inhibitory effects of Nar on the production of pro-inflammatory cytokines was dependent on MT1G.	naringenin	110-113	metallothionein 1G	Homo sapiens	179-183
34514726-3	2021	Recently, we invented AANG, a natural compound formula containing traditional Chinese medicine (TCM) derived Smad3 inhibitor Naringenin (NG) and Smad7 activator Asiatic Acid (AA), for rebalancing TGF-beta/Smad signalling in the TME, and its implication on the multidrug resistance is still unexplored.	naringenin	125-135	SMAD family member 3	Homo sapiens	109-114
34514726-3	2021	Recently, we invented AANG, a natural compound formula containing traditional Chinese medicine (TCM) derived Smad3 inhibitor Naringenin (NG) and Smad7 activator Asiatic Acid (AA), for rebalancing TGF-beta/Smad signalling in the TME, and its implication on the multidrug resistance is still unexplored.	naringenin	125-135	transforming growth factor alpha	Homo sapiens	196-204
34514726-3	2021	Recently, we invented AANG, a natural compound formula containing traditional Chinese medicine (TCM) derived Smad3 inhibitor Naringenin (NG) and Smad7 activator Asiatic Acid (AA), for rebalancing TGF-beta/Smad signalling in the TME, and its implication on the multidrug resistance is still unexplored.	naringenin	125-135	SMAD family member 7	Homo sapiens	205-209
34738432-7	2021	The results showed that narirutin, naringin, naringenin, poncirin, oxypeucedanin, and eriodictyol-7-O-glucoside had significant correlations with and contributed to the expression of AQP2 in kidney, AQP3 in colon, and AQP5 in submandibular gland, which were the main dryness components in Aurantii Fructus.	naringenin	45-55	aquaporin 2	Rattus norvegicus	183-187
34252709-0	2021	Naringenin inhibits pro-inflammatory cytokine production in macrophages through inducing MT1G to suppress the activation of NF-kappaB.	naringenin	0-10	nuclear factor kappa B subunit 1	Homo sapiens	124-133
34252709-4	2021	In lipopolysaccharide (LPS)-stimulated human macrophages, Nar inhibited the activation of NF-kappaB pathway and suppressed the downstream expression of pro-inflammatory factors.	naringenin	58-61	nuclear factor kappa B subunit 1	Homo sapiens	90-99
34475824-8	2021	Mechanism studies indicated that naringenin suppressed PI3K-mediated signaling and phosphodiesterase activity in platelets, in addition to increasing cGMP levels and VASP phosphorylation at Ser239.	naringenin	33-43	vasodilator-stimulated phosphoprotein	Rattus norvegicus	166-170
34402084-0	2022	Naringenin inhibits autophagy and epithelial-mesenchymal transition of human lens epithelial cells by regulating the Smad2/3 pathway.	naringenin	0-10	SMAD family member 2	Homo sapiens	117-124
34402084-10	2022	We therefore thought Naringenin inhibited autophagy and EMT of human LECs by regulating the Smad2/3 pathway.	naringenin	21-31	SMAD family member 2	Homo sapiens	92-99
34427888-7	2021	METHODS: The anti-proliferative and apoptotic effects of naringenin against C6 and 3T3 fibroblast cells were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and annexin-V/PI dual staining assay, respectively.	naringenin	57-67	annexin A5	Mus musculus	198-207
34427888-13	2021	In addition, naringenin at a concentration of 114 microg/mL significantly decreased the expression of Gli-1 and Smo and elevated the expression of Sufu at the protein level in the C6 cell line.	naringenin	13-23	GLI-Kruppel family member GLI1	Mus musculus	102-107
34427888-13	2021	In addition, naringenin at a concentration of 114 microg/mL significantly decreased the expression of Gli-1 and Smo and elevated the expression of Sufu at the protein level in the C6 cell line.	naringenin	13-23	smoothened, frizzled class receptor	Mus musculus	112-115
34427888-13	2021	In addition, naringenin at a concentration of 114 microg/mL significantly decreased the expression of Gli-1 and Smo and elevated the expression of Sufu at the protein level in the C6 cell line.	naringenin	13-23	SUFU negative regulator of hedgehog signaling	Mus musculus	147-151
34475824-9	2021	Furthermore, naringenin-induced VASP phosphorylation and inhibition of platelet aggregation were reversed by a PKA inhibitor treatment.	naringenin	13-23	vasodilator-stimulated phosphoprotein	Rattus norvegicus	32-36
34138683-1	2021	The aim of the present study was to investigate the effect of naringenin (4, 5, 7-trihydroxy flavonone) on the pharmacokinetics of metoprolol, a substrate of Cytochrome P-450 3A4 (CYP3A4), CYP2C9, and CYP2D6 in rats.Male Wistar rats were treated orally with metoprolol (30 mg/kg) alone and in combination with naringenin (25, 50 and 100 mg/kg) once daily for 15 consecutive days.The plasma concentrations of metoprolol were determined using Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) on 1st day in single-dose pharmacokinetic (PK) study (SDS) and on 15th day in multiple dosing PK studies (MDS).Compared to the metoprolol control group, the Cmax, AUC and half-life (T1/2) of metoprolol increased in rats pretreated with naringenin, while there was no significant change in Tmax.	naringenin	62-72	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	201-207
34093766-0	2021	Naringenin alleviates myocardial ischemia reperfusion injury by enhancing the myocardial miR-126-PI3K/AKT axis in streptozotocin-induced diabetic rats.	naringenin	0-10	microRNA 126b	Rattus norvegicus	89-96
34093766-0	2021	Naringenin alleviates myocardial ischemia reperfusion injury by enhancing the myocardial miR-126-PI3K/AKT axis in streptozotocin-induced diabetic rats.	naringenin	0-10	AKT serine/threonine kinase 1	Rattus norvegicus	102-105
34093766-5	2021	The present study aimed to investigate the protection of Nar against D-MI/R injury and the role of the miR-126-PI3K/AKT axis.	naringenin	57-60	AKT serine/threonine kinase 1	Homo sapiens	116-119
34093766-8	2021	Furthermore, Nar upregulated the myocardial miR-126-PI3K/AKT axis in D-MI/R rats.	naringenin	13-16	microRNA 126b	Rattus norvegicus	44-51
34093766-8	2021	Furthermore, Nar upregulated the myocardial miR-126-PI3K/AKT axis in D-MI/R rats.	naringenin	13-16	AKT serine/threonine kinase 1	Rattus norvegicus	57-60
34093766-9	2021	These results indicated that Nar alleviated MI/R injury through upregulating the myocardial miR-126-PI3K/AKT axis in STZ-induced diabetic rats.	naringenin	29-32	microRNA 126b	Rattus norvegicus	92-99
34093766-9	2021	These results indicated that Nar alleviated MI/R injury through upregulating the myocardial miR-126-PI3K/AKT axis in STZ-induced diabetic rats.	naringenin	29-32	AKT serine/threonine kinase 1	Rattus norvegicus	105-108
35606804-0	2022	Naringenin and cryptotanshinone shift the immune response towards Th1 and modulate T regulatory cells via JAK2/STAT3 pathway in breast cancer.	naringenin	0-10	Janus kinase 2	Mus musculus	106-110
34313040-8	2021	RESULTS: Naringenin and naringin inhibited both lipid accumulation and TG content, increased phosphorylation levels of both AMPK and ACC and decreased the expression level of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) in 3T3-L1 adipocytes.	naringenin	9-19	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	175-215
34313040-8	2021	RESULTS: Naringenin and naringin inhibited both lipid accumulation and TG content, increased phosphorylation levels of both AMPK and ACC and decreased the expression level of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) in 3T3-L1 adipocytes.	naringenin	9-19	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	217-222
34313040-9	2021	RNA sequencing analysis revealed that 32 up-regulated (> 2-fold) and 17 down-regulated (< 0.6-fold) genes related to lipid metabolism, including Acaca, Fasn, Scd1, Mogat1, Dgat, Lipin1, Cpt1a, and Lepr, were normalized to the control level in naringenin-treated adipocytes.	naringenin	243-253	acetyl-Coenzyme A carboxylase alpha	Mus musculus	145-150
34313040-9	2021	RNA sequencing analysis revealed that 32 up-regulated (> 2-fold) and 17 down-regulated (< 0.6-fold) genes related to lipid metabolism, including Acaca, Fasn, Scd1, Mogat1, Dgat, Lipin1, Cpt1a, and Lepr, were normalized to the control level in naringenin-treated adipocytes.	naringenin	243-253	fatty acid synthase	Mus musculus	152-156
34313040-9	2021	RNA sequencing analysis revealed that 32 up-regulated (> 2-fold) and 17 down-regulated (< 0.6-fold) genes related to lipid metabolism, including Acaca, Fasn, Scd1, Mogat1, Dgat, Lipin1, Cpt1a, and Lepr, were normalized to the control level in naringenin-treated adipocytes.	naringenin	243-253	stearoyl-Coenzyme A desaturase 1	Mus musculus	158-162
34313040-9	2021	RNA sequencing analysis revealed that 32 up-regulated (> 2-fold) and 17 down-regulated (< 0.6-fold) genes related to lipid metabolism, including Acaca, Fasn, Scd1, Mogat1, Dgat, Lipin1, Cpt1a, and Lepr, were normalized to the control level in naringenin-treated adipocytes.	naringenin	243-253	monoacylglycerol O-acyltransferase 1	Mus musculus	164-170
34313040-9	2021	RNA sequencing analysis revealed that 32 up-regulated (> 2-fold) and 17 down-regulated (< 0.6-fold) genes related to lipid metabolism, including Acaca, Fasn, Scd1, Mogat1, Dgat, Lipin1, Cpt1a, and Lepr, were normalized to the control level in naringenin-treated adipocytes.	naringenin	243-253	diacylglycerol O-acyltransferase 1	Mus musculus	172-176
34313040-9	2021	RNA sequencing analysis revealed that 32 up-regulated (> 2-fold) and 17 down-regulated (< 0.6-fold) genes related to lipid metabolism, including Acaca, Fasn, Scd1, Mogat1, Dgat, Lipin1, Cpt1a, and Lepr, were normalized to the control level in naringenin-treated adipocytes.	naringenin	243-253	lipin 1	Mus musculus	178-184
34313040-9	2021	RNA sequencing analysis revealed that 32 up-regulated (> 2-fold) and 17 down-regulated (< 0.6-fold) genes related to lipid metabolism, including Acaca, Fasn, Scd1, Mogat1, Dgat, Lipin1, Cpt1a, and Lepr, were normalized to the control level in naringenin-treated adipocytes.	naringenin	243-253	carnitine palmitoyltransferase 1a, liver	Mus musculus	186-191
34313040-9	2021	RNA sequencing analysis revealed that 32 up-regulated (> 2-fold) and 17 down-regulated (< 0.6-fold) genes related to lipid metabolism, including Acaca, Fasn, Scd1, Mogat1, Dgat, Lipin1, Cpt1a, and Lepr, were normalized to the control level in naringenin-treated adipocytes.	naringenin	243-253	leptin receptor	Mus musculus	197-201
34306252-10	2021	The main compounds of XYS include Quercetin, Naringenin, Isorhamnetin, and Stigmasterol, which mainly regulate the targets such as TP53, Akt1, and MYC and PI3K/Akt, p53, and cell cycle signal pathways.	naringenin	45-55	tumor protein p53	Homo sapiens	131-135
34306252-10	2021	The main compounds of XYS include Quercetin, Naringenin, Isorhamnetin, and Stigmasterol, which mainly regulate the targets such as TP53, Akt1, and MYC and PI3K/Akt, p53, and cell cycle signal pathways.	naringenin	45-55	AKT serine/threonine kinase 1	Homo sapiens	137-141
34306252-10	2021	The main compounds of XYS include Quercetin, Naringenin, Isorhamnetin, and Stigmasterol, which mainly regulate the targets such as TP53, Akt1, and MYC and PI3K/Akt, p53, and cell cycle signal pathways.	naringenin	45-55	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	147-150
34306252-10	2021	The main compounds of XYS include Quercetin, Naringenin, Isorhamnetin, and Stigmasterol, which mainly regulate the targets such as TP53, Akt1, and MYC and PI3K/Akt, p53, and cell cycle signal pathways.	naringenin	45-55	AKT serine/threonine kinase 1	Homo sapiens	160-163
34306252-10	2021	The main compounds of XYS include Quercetin, Naringenin, Isorhamnetin, and Stigmasterol, which mainly regulate the targets such as TP53, Akt1, and MYC and PI3K/Akt, p53, and cell cycle signal pathways.	naringenin	45-55	tumor protein p53	Homo sapiens	165-168
34262419-10	2021	Results: The network analysis revealed that the key active components of chenpi (nobiletin, naringenin, hesperetin) regulate five core targets (AKT1, TP53, IL6, VEGFA, MMP9).	naringenin	92-102	thymoma viral proto-oncogene 1	Mus musculus	144-148
34909654-8	2021	In vitro release of naringenin in phosphate buffer saline revealed a sustained release profile up to a maximum of 74.62 +- 4.54% from the formulated nanoemulgel (NG1) within the time-frame of 24 h. Alternatively, the release from the nanoemulsion was much higher (89.17 +- 2.87%), which might be due to lack of polymer coating on the dispersed oil droplets.	naringenin	20-30	interleukin 19	Homo sapiens	162-165
35607381-0	2022	Naringenin upregulates GTPCH1/eNOS to ameliorate high glucose-induced retinal endothelial cell injury.	naringenin	0-10	nitric oxide synthase 3	Homo sapiens	30-34
35607381-9	2022	Compared with the HG-induced group alone, co-treatment with naringenin inhibited HG-induced HREC apoptosis in a dose-dependent manner, increased expression levels of the proliferation-associated proteins Ki67 and PCNA and effectively decreased intracellular ROS levels.	naringenin	60-70	proliferating cell nuclear antigen	Homo sapiens	213-217
35607381-10	2022	Furthermore, naringenin upregulated GTPCH1/eNOS signaling and promoted release of BH4.	naringenin	13-23	GTP cyclohydrolase 1	Homo sapiens	36-42
35607381-10	2022	Furthermore, naringenin upregulated GTPCH1/eNOS signaling and promoted release of BH4.	naringenin	13-23	nitric oxide synthase 3	Homo sapiens	43-47
35607381-11	2022	However, GTPCH1 knockdown partially reversed the ameliorative effect of naringenin on HG-induced HREC injury.	naringenin	72-82	GTP cyclohydrolase 1	Homo sapiens	9-15
35607381-12	2022	In summary, the present study suggested that naringenin effectively inhibited HG-induced HREC apoptosis and intracellular oxidative stress, which may be associated with naringenin-mediated GTPCH1/eNOS upregulation.	naringenin	45-55	GTP cyclohydrolase 1	Homo sapiens	189-195
35607381-12	2022	In summary, the present study suggested that naringenin effectively inhibited HG-induced HREC apoptosis and intracellular oxidative stress, which may be associated with naringenin-mediated GTPCH1/eNOS upregulation.	naringenin	45-55	nitric oxide synthase 3	Homo sapiens	196-200
35607381-12	2022	In summary, the present study suggested that naringenin effectively inhibited HG-induced HREC apoptosis and intracellular oxidative stress, which may be associated with naringenin-mediated GTPCH1/eNOS upregulation.	naringenin	169-179	GTP cyclohydrolase 1	Homo sapiens	189-195
35607381-12	2022	In summary, the present study suggested that naringenin effectively inhibited HG-induced HREC apoptosis and intracellular oxidative stress, which may be associated with naringenin-mediated GTPCH1/eNOS upregulation.	naringenin	169-179	nitric oxide synthase 3	Homo sapiens	196-200
35289026-7	2022	The results revealed that Pb induced a significant (p < 0.05) increase in genetic and oxidative damage as compared with the untreated sample whereas the treatment of cells along with naringenin (10 and 30 microg/ml) and Pb (350 microg/ml) caused a significant reduction in genetic damage and elevation in SOD, GPx, and CAT activities and GSH level, accompanied by a significant reduction in LPO level as compared with Pb alone treated sample.	naringenin	183-193	superoxide dismutase 1	Homo sapiens	305-308
35289026-7	2022	The results revealed that Pb induced a significant (p < 0.05) increase in genetic and oxidative damage as compared with the untreated sample whereas the treatment of cells along with naringenin (10 and 30 microg/ml) and Pb (350 microg/ml) caused a significant reduction in genetic damage and elevation in SOD, GPx, and CAT activities and GSH level, accompanied by a significant reduction in LPO level as compared with Pb alone treated sample.	naringenin	183-193	catalase	Homo sapiens	319-322
35412073-2	2022	Among the prominent polyphenols contained in citrus fruits and primarily in grapefruit, the flavonoid naringenin is known to be a blocker of the human ether-a-go-go related gene (hERG) potassium channel.	naringenin	102-112	ETS transcription factor ERG	Homo sapiens	179-183
34163366-0	2021	Naringenin Attenuates Non-Alcoholic Fatty Liver Disease by Enhancing Energy Expenditure and Regulating Autophagy via AMPK.	naringenin	0-10	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	117-121
34163366-16	2021	NAR increased glucose uptake, decreased the ATP content, activated the CaMKKbeta/AMPK/ACC pathway, and enhanced the mitochondrial biogenesis in 3T3-L1 adipocytes and C2C12 myotubes.	naringenin	0-3	calcium/calmodulin dependent protein kinase kinase 1	Homo sapiens	71-89
34163366-20	2021	Conclusion: NAR alleviates NAFLD by increasing energy expenditure and regulating autophagy via activating AMPK directly and indirectly.	naringenin	12-15	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	106-110
34093630-0	2021	Naringenin Induces Pathogen Resistance Against Pseudomonas syringae Through the Activation of NPR1 in Arabidopsis.	naringenin	0-10	regulatory protein (NPR1)	Arabidopsis thaliana	94-98
34093630-6	2021	Interestingly, we found that naringenin triggers the monomerization and nuclear translocation of non-expressor of pathogenesis-related genes 1 (NPR1) that is a transcriptional coactivator of PR gene expression.	naringenin	29-39	regulatory protein (NPR1)	Arabidopsis thaliana	97-142
34093630-6	2021	Interestingly, we found that naringenin triggers the monomerization and nuclear translocation of non-expressor of pathogenesis-related genes 1 (NPR1) that is a transcriptional coactivator of PR gene expression.	naringenin	29-39	regulatory protein (NPR1)	Arabidopsis thaliana	144-148
34093630-7	2021	Naringenin can induce the accumulation of salicylic acid (SA) that is required for the monomerization of NPR1.	naringenin	0-10	regulatory protein (NPR1)	Arabidopsis thaliana	105-109
34093630-8	2021	Furthermore, naringenin activates MPK6 and MPK3 in ROS-dependent, but SA-independent manners.	naringenin	13-23	MAP kinase 6	Arabidopsis thaliana	34-38
34093630-8	2021	Furthermore, naringenin activates MPK6 and MPK3 in ROS-dependent, but SA-independent manners.	naringenin	13-23	mitogen-activated protein kinase 3	Arabidopsis thaliana	43-47
34093630-9	2021	By using a MEK inhibitor, we showed that the activation of a MAPK cascade by naringenin is also required for the monomerization of NPR1.	naringenin	77-87	regulatory protein (NPR1)	Arabidopsis thaliana	131-135
34093630-10	2021	These results suggest that the pathogen resistance by naringenin is mediated by the MAPK- and SA-dependent activation of NPR1 in Arabidopsis.	naringenin	54-64	regulatory protein (NPR1)	Arabidopsis thaliana	121-125
34262419-10	2021	Results: The network analysis revealed that the key active components of chenpi (nobiletin, naringenin, hesperetin) regulate five core targets (AKT1, TP53, IL6, VEGFA, MMP9).	naringenin	92-102	transformation related protein 53	Mus musculus	150-154
34262419-10	2021	Results: The network analysis revealed that the key active components of chenpi (nobiletin, naringenin, hesperetin) regulate five core targets (AKT1, TP53, IL6, VEGFA, MMP9).	naringenin	92-102	interleukin 6	Mus musculus	156-159
34262419-10	2021	Results: The network analysis revealed that the key active components of chenpi (nobiletin, naringenin, hesperetin) regulate five core targets (AKT1, TP53, IL6, VEGFA, MMP9).	naringenin	92-102	vascular endothelial growth factor A	Mus musculus	161-166
34262419-10	2021	Results: The network analysis revealed that the key active components of chenpi (nobiletin, naringenin, hesperetin) regulate five core targets (AKT1, TP53, IL6, VEGFA, MMP9).	naringenin	92-102	matrix metallopeptidase 9	Mus musculus	168-172
35607381-0	2022	Naringenin upregulates GTPCH1/eNOS to ameliorate high glucose-induced retinal endothelial cell injury.	naringenin	0-10	GTP cyclohydrolase 1	Homo sapiens	23-29
35189328-3	2022	In recent years, multiple studies using various in vitro and rodent models have revealed new mechanisms underlying the hypolipidemic effects of naringin and naringenin, including regulation of lipid digestion, reverse cholesterol transport, and LDL receptor expression.	naringenin	157-167	low density lipoprotein receptor	Homo sapiens	245-257
35606804-0	2022	Naringenin and cryptotanshinone shift the immune response towards Th1 and modulate T regulatory cells via JAK2/STAT3 pathway in breast cancer.	naringenin	0-10	signal transducer and activator of transcription 3	Mus musculus	111-116
35606804-7	2022	RESULTS: We showed higher DTH, increased lymphocyte proliferation, decreased tumor growth and reduced JAK2/STAT3 phosphorylation in mice treated with naringenin and CPT.	naringenin	150-160	Janus kinase 2	Mus musculus	102-106
35606804-7	2022	RESULTS: We showed higher DTH, increased lymphocyte proliferation, decreased tumor growth and reduced JAK2/STAT3 phosphorylation in mice treated with naringenin and CPT.	naringenin	150-160	signal transducer and activator of transcription 3	Mus musculus	107-112
35606804-9	2022	Additionally, the population of intra-tumor CD4+CD25+Foxp3+ T cells was significantly lower in naringenin + CPT treated animals than that in controls.	naringenin	95-105	CD4 antigen	Mus musculus	44-47
35606804-9	2022	Additionally, the population of intra-tumor CD4+CD25+Foxp3+ T cells was significantly lower in naringenin + CPT treated animals than that in controls.	naringenin	95-105	interleukin 2 receptor, alpha chain	Mus musculus	48-52
35606804-9	2022	Additionally, the population of intra-tumor CD4+CD25+Foxp3+ T cells was significantly lower in naringenin + CPT treated animals than that in controls.	naringenin	95-105	forkhead box P3	Mus musculus	53-58
35184257-13	2022	In conclusion, naringenin exerted an anti-tumor effect on OC progression via inactivation of the PI3K/Akt/BCL2L1 pathway.	naringenin	15-25	BCL2 like 1	Homo sapiens	106-112
35586056-6	2022	Naringenin promoted M2 transition and the secretion of osteogenic cytokines including IL-4, IL-10, BMP2, and TGF-beta, while suppressing LPS-induced M1 polarization and the production of proinflammatory factors such as TNF-alpha and IL-1beta.	naringenin	0-10	interleukin 4	Homo sapiens	86-90
35586056-6	2022	Naringenin promoted M2 transition and the secretion of osteogenic cytokines including IL-4, IL-10, BMP2, and TGF-beta, while suppressing LPS-induced M1 polarization and the production of proinflammatory factors such as TNF-alpha and IL-1beta.	naringenin	0-10	interleukin 10	Homo sapiens	92-97
35586056-6	2022	Naringenin promoted M2 transition and the secretion of osteogenic cytokines including IL-4, IL-10, BMP2, and TGF-beta, while suppressing LPS-induced M1 polarization and the production of proinflammatory factors such as TNF-alpha and IL-1beta.	naringenin	0-10	bone morphogenetic protein 2	Homo sapiens	99-103
35586056-6	2022	Naringenin promoted M2 transition and the secretion of osteogenic cytokines including IL-4, IL-10, BMP2, and TGF-beta, while suppressing LPS-induced M1 polarization and the production of proinflammatory factors such as TNF-alpha and IL-1beta.	naringenin	0-10	transforming growth factor alpha	Homo sapiens	109-117
35586056-6	2022	Naringenin promoted M2 transition and the secretion of osteogenic cytokines including IL-4, IL-10, BMP2, and TGF-beta, while suppressing LPS-induced M1 polarization and the production of proinflammatory factors such as TNF-alpha and IL-1beta.	naringenin	0-10	tumor necrosis factor	Homo sapiens	219-228
35586056-6	2022	Naringenin promoted M2 transition and the secretion of osteogenic cytokines including IL-4, IL-10, BMP2, and TGF-beta, while suppressing LPS-induced M1 polarization and the production of proinflammatory factors such as TNF-alpha and IL-1beta.	naringenin	0-10	interleukin 1 alpha	Homo sapiens	233-241
35119637-8	2022	The effective parameters underlying the anticancer effects of naringenin and naringin include GSK3beta inactivation, suppression of the gene and protein activation of NF-kB and COX-2, JAK2/STAT3 downregulation, downregulation of intracellular adhesion molecules-1, upregulation of Notch1 and tyrocite-specific genes, and activation of p38/MAPK and caspase-3.	naringenin	62-72	glycogen synthase kinase 3 alpha	Homo sapiens	94-102
35119637-8	2022	The effective parameters underlying the anticancer effects of naringenin and naringin include GSK3beta inactivation, suppression of the gene and protein activation of NF-kB and COX-2, JAK2/STAT3 downregulation, downregulation of intracellular adhesion molecules-1, upregulation of Notch1 and tyrocite-specific genes, and activation of p38/MAPK and caspase-3.	naringenin	62-72	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	177-182
35119637-8	2022	The effective parameters underlying the anticancer effects of naringenin and naringin include GSK3beta inactivation, suppression of the gene and protein activation of NF-kB and COX-2, JAK2/STAT3 downregulation, downregulation of intracellular adhesion molecules-1, upregulation of Notch1 and tyrocite-specific genes, and activation of p38/MAPK and caspase-3.	naringenin	62-72	Janus kinase 2	Homo sapiens	184-188
35119637-8	2022	The effective parameters underlying the anticancer effects of naringenin and naringin include GSK3beta inactivation, suppression of the gene and protein activation of NF-kB and COX-2, JAK2/STAT3 downregulation, downregulation of intracellular adhesion molecules-1, upregulation of Notch1 and tyrocite-specific genes, and activation of p38/MAPK and caspase-3.	naringenin	62-72	signal transducer and activator of transcription 3	Homo sapiens	189-194
35119637-8	2022	The effective parameters underlying the anticancer effects of naringenin and naringin include GSK3beta inactivation, suppression of the gene and protein activation of NF-kB and COX-2, JAK2/STAT3 downregulation, downregulation of intracellular adhesion molecules-1, upregulation of Notch1 and tyrocite-specific genes, and activation of p38/MAPK and caspase-3.	naringenin	62-72	notch receptor 1	Homo sapiens	281-287
35119637-8	2022	The effective parameters underlying the anticancer effects of naringenin and naringin include GSK3beta inactivation, suppression of the gene and protein activation of NF-kB and COX-2, JAK2/STAT3 downregulation, downregulation of intracellular adhesion molecules-1, upregulation of Notch1 and tyrocite-specific genes, and activation of p38/MAPK and caspase-3.	naringenin	62-72	mitogen-activated protein kinase 14	Homo sapiens	335-343
35119637-8	2022	The effective parameters underlying the anticancer effects of naringenin and naringin include GSK3beta inactivation, suppression of the gene and protein activation of NF-kB and COX-2, JAK2/STAT3 downregulation, downregulation of intracellular adhesion molecules-1, upregulation of Notch1 and tyrocite-specific genes, and activation of p38/MAPK and caspase-3.	naringenin	62-72	caspase 3	Homo sapiens	348-357
35630816-3	2022	Flavanone 3-hydroxylase (F3H) catalyzes the conversion of naringenin into dihydroflavonols and is responsible for the biosynthesis of flavonols and anthocyanidins.	naringenin	58-68	flavanone 3-hydroxylase	Nicotiana tabacum	0-23
35630816-3	2022	Flavanone 3-hydroxylase (F3H) catalyzes the conversion of naringenin into dihydroflavonols and is responsible for the biosynthesis of flavonols and anthocyanidins.	naringenin	58-68	flavanone 3-hydroxylase	Nicotiana tabacum	25-28
35184257-0	2022	BCL2L1 is identified as a target of naringenin in regulating ovarian cancer progression.	naringenin	36-46	BCL2 like 1	Homo sapiens	0-6
35184257-8	2022	Effect of naringenin on the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway was evaluated by Western blot analysis.	naringenin	10-20	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	28-57
35184257-8	2022	Effect of naringenin on the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway was evaluated by Western blot analysis.	naringenin	10-20	AKT serine/threonine kinase 1	Homo sapiens	83-86
35184257-9	2022	BCL2L1 was identified as the candidate target of naringenin against OC.	naringenin	49-59	BCL2 like 1	Homo sapiens	0-6
35184257-11	2022	Naringenin decreased BCL2L1 expression and inactivated the PI3K/Akt pathway in OC cells.	naringenin	0-10	BCL2 like 1	Homo sapiens	21-27
35184257-11	2022	Naringenin decreased BCL2L1 expression and inactivated the PI3K/Akt pathway in OC cells.	naringenin	0-10	AKT serine/threonine kinase 1	Homo sapiens	64-67
35184257-12	2022	Naringenin inhibited cell proliferation and increased the apoptotic rate in OC cells, while these effects were partially abolished by BCL2L1 overexpression and treatment with 740Y-P, a PI3K activator.	naringenin	0-10	BCL2 like 1	Homo sapiens	134-140
35184257-13	2022	In conclusion, naringenin exerted an anti-tumor effect on OC progression via inactivation of the PI3K/Akt/BCL2L1 pathway.	naringenin	15-25	AKT serine/threonine kinase 1	Homo sapiens	102-105
35487926-5	2022	Additionally, inhibition of IL-1beta secretion and TRAP activity were determined for chlorogenic acid, catechin, naringenin and beta-sitosterol.	naringenin	113-123	interleukin 1 alpha	Mus musculus	28-36
35487926-5	2022	Additionally, inhibition of IL-1beta secretion and TRAP activity were determined for chlorogenic acid, catechin, naringenin and beta-sitosterol.	naringenin	113-123	acid phosphatase 5, tartrate resistant	Mus musculus	51-55
35487926-10	2022	IL-6 secretion was significantly inhibited by P. africana methanolic extract (p < 0.0001) and beta-sitosterol (p < 0.0001) and further, chlorogenic acid and naringenin remarkably inhibited IL-1beta production.	naringenin	157-167	interleukin 1 alpha	Mus musculus	189-197
35419072-11	2022	Naringenin treatment significantly reduced MDA, remarkably increased GSH, and meaningfully reduced IL-4 and IL-13 levels in lung tissue.	naringenin	0-10	interleukin 4	Rattus norvegicus	99-103
35502176-7	2022	The network analysis uncovered that naringenin, isorhamnetin, and taxifolin might be the compounds in DO that are mainly in charge of its roles in hyperlipidemia and might play a role by modulating the targets (including PPARG, ADIPOQ, AKT1, TNF, and APOB).	naringenin	36-46	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	221-226
35502176-7	2022	The network analysis uncovered that naringenin, isorhamnetin, and taxifolin might be the compounds in DO that are mainly in charge of its roles in hyperlipidemia and might play a role by modulating the targets (including PPARG, ADIPOQ, AKT1, TNF, and APOB).	naringenin	36-46	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	228-234
35502176-7	2022	The network analysis uncovered that naringenin, isorhamnetin, and taxifolin might be the compounds in DO that are mainly in charge of its roles in hyperlipidemia and might play a role by modulating the targets (including PPARG, ADIPOQ, AKT1, TNF, and APOB).	naringenin	36-46	AKT serine/threonine kinase 1	Rattus norvegicus	236-240
35502176-7	2022	The network analysis uncovered that naringenin, isorhamnetin, and taxifolin might be the compounds in DO that are mainly in charge of its roles in hyperlipidemia and might play a role by modulating the targets (including PPARG, ADIPOQ, AKT1, TNF, and APOB).	naringenin	36-46	tumor necrosis factor	Rattus norvegicus	242-245
35502176-7	2022	The network analysis uncovered that naringenin, isorhamnetin, and taxifolin might be the compounds in DO that are mainly in charge of its roles in hyperlipidemia and might play a role by modulating the targets (including PPARG, ADIPOQ, AKT1, TNF, and APOB).	naringenin	36-46	apolipoprotein B	Rattus norvegicus	251-255
35510223-13	2022	The molecular docking results showed that there was a certain affinity between the main compounds (kaempferol, quercetin, beta-sitosterol, naringenin) and core target genes (PTGS2, CASP3, MAPK1, MAPK3, TP53).	naringenin	139-149	prostaglandin-endoperoxide synthase 2	Homo sapiens	174-179
35510223-13	2022	The molecular docking results showed that there was a certain affinity between the main compounds (kaempferol, quercetin, beta-sitosterol, naringenin) and core target genes (PTGS2, CASP3, MAPK1, MAPK3, TP53).	naringenin	139-149	caspase 3	Homo sapiens	181-186
35510223-13	2022	The molecular docking results showed that there was a certain affinity between the main compounds (kaempferol, quercetin, beta-sitosterol, naringenin) and core target genes (PTGS2, CASP3, MAPK1, MAPK3, TP53).	naringenin	139-149	mitogen-activated protein kinase 1	Homo sapiens	188-193
35510223-13	2022	The molecular docking results showed that there was a certain affinity between the main compounds (kaempferol, quercetin, beta-sitosterol, naringenin) and core target genes (PTGS2, CASP3, MAPK1, MAPK3, TP53).	naringenin	139-149	mitogen-activated protein kinase 3	Homo sapiens	195-200
35510223-13	2022	The molecular docking results showed that there was a certain affinity between the main compounds (kaempferol, quercetin, beta-sitosterol, naringenin) and core target genes (PTGS2, CASP3, MAPK1, MAPK3, TP53).	naringenin	139-149	tumor protein p53	Homo sapiens	202-206
35085994-0	2022	A comparative study of the interaction of naringenin with lysozyme by multi-spectroscopic methods, activity comparisons, and molecular modeling procedures.	naringenin	42-52	lysozyme	Homo sapiens	58-66
35085994-1	2022	The present study applied steady-state fluorescence, UV-Vis spectrophotometry, molecular docking studies, and circular dichroism (CD) to investigate the interaction of naringenin with lysozyme in an aqueous medium.	naringenin	168-178	lysozyme	Homo sapiens	184-192
35085994-2	2022	The UV-Vis measurement indicated the changes in lysozyme secondary and tertiary structure change as a function of the concentration of naringenin.	naringenin	135-145	lysozyme	Homo sapiens	48-56
35085994-3	2022	Naringenin could be used to turn the static quenching mechanism into the intrinsic fluorescence of lysozyme.	naringenin	0-10	lysozyme	Homo sapiens	99-107
35085994-8	2022	Naringenin inhibited lysozyme enzymatic activity, displaying its affinity with the lysozyme active site.	naringenin	0-10	lysozyme	Homo sapiens	21-29
35085994-8	2022	Naringenin inhibited lysozyme enzymatic activity, displaying its affinity with the lysozyme active site.	naringenin	0-10	lysozyme	Homo sapiens	83-91
35419072-11	2022	Naringenin treatment significantly reduced MDA, remarkably increased GSH, and meaningfully reduced IL-4 and IL-13 levels in lung tissue.	naringenin	0-10	interleukin 13	Rattus norvegicus	108-113
35363423-0	2022	Dibutyl phthalate-induced oxidative stress and apoptosis in swine testis cells and therapy of naringenin via PTEN/PI3K/AKT signaling pathway.	naringenin	94-104	phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN	Sus scrofa	109-113
35363423-0	2022	Dibutyl phthalate-induced oxidative stress and apoptosis in swine testis cells and therapy of naringenin via PTEN/PI3K/AKT signaling pathway.	naringenin	94-104	AKT serine/threonine kinase 1	Sus scrofa	119-122
35363423-2	2022	Naringenin (NRG) is a flavanone compound that has shown protection against several environmental chemicals through suppression of oxidative stress and activation of phosphatidylinositol 3-kinase/threonine kinase (PI3K/AKT) signaling pathway.	naringenin	0-10	AKT serine/threonine kinase 1	Sus scrofa	218-221
35363423-2	2022	Naringenin (NRG) is a flavanone compound that has shown protection against several environmental chemicals through suppression of oxidative stress and activation of phosphatidylinositol 3-kinase/threonine kinase (PI3K/AKT) signaling pathway.	naringenin	12-15	AKT serine/threonine kinase 1	Sus scrofa	218-221
35281609-10	2022	The molecular biology experiments demonstrated that naringenin inhibited the mRNA level of NPPA and NPPB induced by Ang II and regulated related targets such as AKT1, MAPK3, PPARA, PPARG, and ESR1.	naringenin	52-62	natriuretic peptide A	Homo sapiens	91-95
35529921-6	2022	As a result, four active components including narirutin, naringenin, hesperidin, and 3,5,6,7,8,3",4"-heptemthoxyflavone were filtered out by variable importance for the projection (VIP) value (VIP > 1.0), which were regarded as chemotaxonomic markers.	naringenin	57-67	vasoactive intestinal peptide	Homo sapiens	181-184
35529921-6	2022	As a result, four active components including narirutin, naringenin, hesperidin, and 3,5,6,7,8,3",4"-heptemthoxyflavone were filtered out by variable importance for the projection (VIP) value (VIP > 1.0), which were regarded as chemotaxonomic markers.	naringenin	57-67	vasoactive intestinal peptide	Homo sapiens	193-196
35240971-4	2022	INTRODUCTION: Naringenin (NGN) is a phytochemical having low oral bioavailability because of poor solubility, and adding to this limitation is enhanced efflux by P-glycoprotein transporters in neuroinflammatory diseases.	naringenin	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	162-176
35240971-10	2022	CONCLUSION: Present studies indicate sustained and targeted brain delivery of Naringenin via the ligand-coated delivery system by inhibition of enhanced P-glycoprotein (P-gp) efflux occurring due to neuroinflammation in Autism Spectrum Disorders.	naringenin	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	153-167
35240971-10	2022	CONCLUSION: Present studies indicate sustained and targeted brain delivery of Naringenin via the ligand-coated delivery system by inhibition of enhanced P-glycoprotein (P-gp) efflux occurring due to neuroinflammation in Autism Spectrum Disorders.	naringenin	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	169-173
35065059-5	2022	Importantly, naringenin potently activated autophagy as evidenced by the increased Beclin-1 expression and LC3 II/LC3 I ratio.	naringenin	13-23	beclin 1, autophagy related	Mus musculus	83-91
35065059-6	2022	Furthermore, results demonstrated that naringenin alleviated oxidative stress by inducing nuclear factor-erythroid 2-related factor 2 (Nrf2) and increasing hepatic SOD activity and GSH level as well as ameliorated endoplasmic reticulum (ER) stress.	naringenin	39-49	nuclear factor, erythroid derived 2, like 2	Mus musculus	90-133
35065059-6	2022	Furthermore, results demonstrated that naringenin alleviated oxidative stress by inducing nuclear factor-erythroid 2-related factor 2 (Nrf2) and increasing hepatic SOD activity and GSH level as well as ameliorated endoplasmic reticulum (ER) stress.	naringenin	39-49	nuclear factor, erythroid derived 2, like 2	Mus musculus	135-139
35065059-7	2022	Likewise, naringenin mitigated LPS/D-Gal-triggered inflammation by suppressing NF-kappaB and NLRP3 pathways.	naringenin	10-20	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	79-88
35065059-7	2022	Likewise, naringenin mitigated LPS/D-Gal-triggered inflammation by suppressing NF-kappaB and NLRP3 pathways.	naringenin	10-20	NLR family, pyrin domain containing 3	Mus musculus	93-98
35065059-8	2022	Accordingly, apoptotic cell death provoked by LPS/D-Gal challenge was markedly attenuated as depicted by the decrease in caspase-3 and p53 in naringenin-treated mice.	naringenin	142-152	caspase 3	Mus musculus	121-130
35065059-8	2022	Accordingly, apoptotic cell death provoked by LPS/D-Gal challenge was markedly attenuated as depicted by the decrease in caspase-3 and p53 in naringenin-treated mice.	naringenin	142-152	transformation related protein 53, pseudogene	Mus musculus	135-138
35281609-10	2022	The molecular biology experiments demonstrated that naringenin inhibited the mRNA level of NPPA and NPPB induced by Ang II and regulated related targets such as AKT1, MAPK3, PPARA, PPARG, and ESR1.	naringenin	52-62	natriuretic peptide B	Homo sapiens	100-104
35281609-10	2022	The molecular biology experiments demonstrated that naringenin inhibited the mRNA level of NPPA and NPPB induced by Ang II and regulated related targets such as AKT1, MAPK3, PPARA, PPARG, and ESR1.	naringenin	52-62	AKT serine/threonine kinase 1	Homo sapiens	161-165
35281609-10	2022	The molecular biology experiments demonstrated that naringenin inhibited the mRNA level of NPPA and NPPB induced by Ang II and regulated related targets such as AKT1, MAPK3, PPARA, PPARG, and ESR1.	naringenin	52-62	mitogen-activated protein kinase 3	Homo sapiens	167-172
35281609-10	2022	The molecular biology experiments demonstrated that naringenin inhibited the mRNA level of NPPA and NPPB induced by Ang II and regulated related targets such as AKT1, MAPK3, PPARA, PPARG, and ESR1.	naringenin	52-62	peroxisome proliferator activated receptor alpha	Homo sapiens	174-179
35281609-10	2022	The molecular biology experiments demonstrated that naringenin inhibited the mRNA level of NPPA and NPPB induced by Ang II and regulated related targets such as AKT1, MAPK3, PPARA, PPARG, and ESR1.	naringenin	52-62	peroxisome proliferator activated receptor gamma	Homo sapiens	181-186
35281609-10	2022	The molecular biology experiments demonstrated that naringenin inhibited the mRNA level of NPPA and NPPB induced by Ang II and regulated related targets such as AKT1, MAPK3, PPARA, PPARG, and ESR1.	naringenin	52-62	estrogen receptor 1	Homo sapiens	192-196
35060921-4	2022	The composition containing vitamin C, N-acetylcysteine, resveratrol, theaflavin, curcumin, quercetin, naringenin, baicalin, and broccoli extract demonstrated a highest efficacy by inhibiting the receptor-binding domain (RBD) binding of SARS-CoV-2 to its cellular ACE2 receptor by 90%.	naringenin	102-112	angiotensin converting enzyme 2	Homo sapiens	263-267
35228523-6	2022	Intriguingly, the protective role of naringenin on AAA was abolished by macrophage-specific TFEB depletion in mice.	naringenin	37-47	transcription factor EB	Mus musculus	92-96
35228523-7	2022	Unbiased interactomics, combined with isothermal titration calorimetry (ITC) and cellular thermal shift assays (CETSAs), further revealed that naringenin is directly bound to 14-3-3 epsilon blocked the TFEB-14-3-3 epsilon interaction, and therefore promoted TFEB nuclear translocation and activation.	naringenin	143-153	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide	Mus musculus	175-189
35228523-7	2022	Unbiased interactomics, combined with isothermal titration calorimetry (ITC) and cellular thermal shift assays (CETSAs), further revealed that naringenin is directly bound to 14-3-3 epsilon blocked the TFEB-14-3-3 epsilon interaction, and therefore promoted TFEB nuclear translocation and activation.	naringenin	143-153	transcription factor EB	Mus musculus	258-262
35228523-8	2022	On one hand, naringenin activated lysosome-dependent inhibition of the NLRP3 inflammasome and repressed aneurysmal inflammation.	naringenin	13-23	NLR family, pyrin domain containing 3	Mus musculus	71-76
35228523-9	2022	On the other hand, naringenin induced TFEB-dependent transcriptional activation of GATA3, IRF4, and STAT6 and therefore promoted reparative M2 macrophage polarization.	naringenin	19-29	transcription factor EB	Mus musculus	38-42
35228523-9	2022	On the other hand, naringenin induced TFEB-dependent transcriptional activation of GATA3, IRF4, and STAT6 and therefore promoted reparative M2 macrophage polarization.	naringenin	19-29	GATA binding protein 3	Mus musculus	83-88
35228523-9	2022	On the other hand, naringenin induced TFEB-dependent transcriptional activation of GATA3, IRF4, and STAT6 and therefore promoted reparative M2 macrophage polarization.	naringenin	19-29	interferon regulatory factor 4	Mus musculus	90-94
35228523-9	2022	On the other hand, naringenin induced TFEB-dependent transcriptional activation of GATA3, IRF4, and STAT6 and therefore promoted reparative M2 macrophage polarization.	naringenin	19-29	signal transducer and activator of transcription 6	Mus musculus	100-105
35068607-3	2022	The aim of this study was to examine the molecular recognition site for naringin and naringenin on the HMGR and TOPOII enzymes of eleven Candida species and one phytopathogen, U. maydis, and evaluate yeast susceptibility to these flavonoids.	naringenin	85-95	high mobility group AT-hook 1	Homo sapiens	103-107
35068607-11	2022	Based on the present findings, naringin and naringenin could possibly be effective for treating diseases caused by pathogenic yeasts of the Candida species and U. maydis, presumably by inhibition of their HMGR and TOPOII enzymes.	naringenin	44-54	high mobility group AT-hook 1	Homo sapiens	205-209
34998792-0	2022	Endoplasmic reticulum stress-dependent activation of TRB3-FoxO1 signaling pathway exacerbates hyperglycemic nephrotoxicity: Protection accorded by naringenin.	naringenin	147-157	tribbles pseudokinase 3	Rattus norvegicus	53-57
34998792-0	2022	Endoplasmic reticulum stress-dependent activation of TRB3-FoxO1 signaling pathway exacerbates hyperglycemic nephrotoxicity: Protection accorded by naringenin.	naringenin	147-157	forkhead box O1	Rattus norvegicus	58-63
34998792-5	2022	Treatment with Naringenin reduced the expression of TRB3, an ER stress-inducible pseudokinase, both in vitro and in vivo.	naringenin	15-25	tribbles pseudokinase 3	Rattus norvegicus	52-56
34998792-8	2022	Prevention of nuclear colocalization of ATF4 and CHOP in Naringenin treated cells was evident.	naringenin	57-67	activating transcription factor 4	Rattus norvegicus	40-44
34998792-8	2022	Prevention of nuclear colocalization of ATF4 and CHOP in Naringenin treated cells was evident.	naringenin	57-67	DNA-damage inducible transcript 3	Rattus norvegicus	49-53
34998792-11	2022	These findings affirm that activation of TRB3-FoxO1 signaling is critical in the pathogenesis of hyperglycemia-induced renal toxicity and protective effect of Naringenin via modulation of ER stress may be exploited as a novel approach for its management.	naringenin	159-169	tribbles pseudokinase 3	Rattus norvegicus	41-45
34998792-11	2022	These findings affirm that activation of TRB3-FoxO1 signaling is critical in the pathogenesis of hyperglycemia-induced renal toxicity and protective effect of Naringenin via modulation of ER stress may be exploited as a novel approach for its management.	naringenin	159-169	forkhead box O1	Rattus norvegicus	46-51
35215494-7	2022	Present results revealed that naringenin could ameliorate the increases in liver enzymes (ALT and AST) induced by CCl4 and attenuate the pathological changes in liver tissue.	naringenin	30-40	C-C motif chemokine ligand 4	Rattus norvegicus	114-118
35215494-9	2022	In addition, naringenin increased the expression of the antiapoptoic cell marker, Bcl-2.	naringenin	13-23	BCL2, apoptosis regulator	Rattus norvegicus	82-87
35215494-10	2022	Significant changes in serum metabolic profiling were noticed in the naringenin-treated group compared to the CCl4 group, exemplified by increases in palmitic acid, stearic acid, myristic acid and lauric acids and decrease levels of alanine, tryptophan, lactic acid, glucosamine and glucose in CCl4 model rats.	naringenin	69-79	C-C motif chemokine ligand 4	Rattus norvegicus	294-298
35215494-12	2022	In conclusion, the current study presents new insights into the hepato- and renoprotective mechanisms of naringenin against CCl4-induced toxicity.	naringenin	105-115	C-C motif chemokine ligand 4	Rattus norvegicus	124-128
35044489-0	2022	Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration.	naringenin	0-10	sialic acid binding Ig-like lectin 1, sialoadhesin	Mus musculus	86-91
35044489-3	2022	Further, we tested the anti-tumor effects of naringenin, which has been previously shown to activate CD169+ macrophages, in a murine OSCC model.	naringenin	45-55	sialic acid binding Ig-like lectin 1, sialoadhesin	Mus musculus	101-106
35044489-8	2022	The mRNA levels of CD169, interleukin (IL)-12, and C-X-C motif chemokine ligand 10 (CXCL10) in lymph nodes and CTL infiltration in tumors significantly increased following naringenin administration in tumor-bearing mice.	naringenin	172-182	sialic acid binding Ig-like lectin 1, sialoadhesin	Mus musculus	19-24
35044489-8	2022	The mRNA levels of CD169, interleukin (IL)-12, and C-X-C motif chemokine ligand 10 (CXCL10) in lymph nodes and CTL infiltration in tumors significantly increased following naringenin administration in tumor-bearing mice.	naringenin	172-182	chemokine (C-X-C motif) ligand 10	Mus musculus	51-82
35044489-8	2022	The mRNA levels of CD169, interleukin (IL)-12, and C-X-C motif chemokine ligand 10 (CXCL10) in lymph nodes and CTL infiltration in tumors significantly increased following naringenin administration in tumor-bearing mice.	naringenin	172-182	chemokine (C-X-C motif) ligand 10	Mus musculus	84-90
35044489-10	2022	Moreover, naringenin is a new potential agent for CD169+ macrophage activation in OSCC treatment.	naringenin	10-20	sialic acid binding Ig like lectin 1	Homo sapiens	50-55
34225639-7	2022	The antioxidant efficacy of NG against MTX was evaluated by quantifying tissue superoxide dismutase (SOD), glutatione peroxidase (GPx), reduced glutathione (GSH) and catalase along with oxidative stress markers (malondialdehyde (MDA) and nitric oxide (NO)).	naringenin	28-30	catalase	Mus musculus	166-174
35087512-7	2021	Therefore, our study found that naringenin could induce inhibition of autophagy and cell proliferation in BC cells and enhance DC differentiation and maturation, at least in part, though regulation of FKBP4/NR3C1/NRF2 signaling pathway.	naringenin	32-42	nuclear receptor subfamily 3 group C member 1	Homo sapiens	207-212
35087512-7	2021	Therefore, our study found that naringenin could induce inhibition of autophagy and cell proliferation in BC cells and enhance DC differentiation and maturation, at least in part, though regulation of FKBP4/NR3C1/NRF2 signaling pathway.	naringenin	32-42	NFE2 like bZIP transcription factor 2	Homo sapiens	213-217
35087512-5	2021	We then reported that naringenin, a flavonoid, widely distributed in citrus and tomato, could suppress autophagy and proliferation of BC cells through FKBP4/NR3C1/NRF2 signaling pathway in vitro and in vivo.	naringenin	22-32	FKBP prolyl isomerase 4	Homo sapiens	151-156
35087512-5	2021	We then reported that naringenin, a flavonoid, widely distributed in citrus and tomato, could suppress autophagy and proliferation of BC cells through FKBP4/NR3C1/NRF2 signaling pathway in vitro and in vivo.	naringenin	22-32	nuclear receptor subfamily 3 group C member 1	Homo sapiens	157-162
35087512-5	2021	We then reported that naringenin, a flavonoid, widely distributed in citrus and tomato, could suppress autophagy and proliferation of BC cells through FKBP4/NR3C1/NRF2 signaling pathway in vitro and in vivo.	naringenin	22-32	NFE2 like bZIP transcription factor 2	Homo sapiens	163-167
35087512-6	2021	Naringenin was also found to promote dendritic cell (DC) differentiation and maturation through FKBP4/NR3C1/NRF2 axis.	naringenin	0-10	FKBP prolyl isomerase 4	Homo sapiens	96-101
35087512-6	2021	Naringenin was also found to promote dendritic cell (DC) differentiation and maturation through FKBP4/NR3C1/NRF2 axis.	naringenin	0-10	nuclear receptor subfamily 3 group C member 1	Homo sapiens	102-107
35087512-6	2021	Naringenin was also found to promote dendritic cell (DC) differentiation and maturation through FKBP4/NR3C1/NRF2 axis.	naringenin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	108-112
35087512-7	2021	Therefore, our study found that naringenin could induce inhibition of autophagy and cell proliferation in BC cells and enhance DC differentiation and maturation, at least in part, though regulation of FKBP4/NR3C1/NRF2 signaling pathway.	naringenin	32-42	FKBP prolyl isomerase 4	Homo sapiens	201-206
35056691-2	2022	DNA fragmentation and the increase in the G2/M phase in HOS and U2OS cells upon treatment with various naringenin concentrations were determined by using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay and Annexin V/propidium iodide double staining, respectively.	naringenin	103-113	annexin A5	Homo sapiens	238-247
35056691-6	2022	In addition, naringenin induced cell cycle arrest in osteosarcoma cells by inhibiting cyclin B1 and cyclin-dependent kinase 1 expression and upregulating p21 expression.	naringenin	13-23	cyclin B1	Homo sapiens	86-95
35056691-6	2022	In addition, naringenin induced cell cycle arrest in osteosarcoma cells by inhibiting cyclin B1 and cyclin-dependent kinase 1 expression and upregulating p21 expression.	naringenin	13-23	cyclin dependent kinase 1	Homo sapiens	100-125
35056691-6	2022	In addition, naringenin induced cell cycle arrest in osteosarcoma cells by inhibiting cyclin B1 and cyclin-dependent kinase 1 expression and upregulating p21 expression.	naringenin	13-23	H3 histone pseudogene 16	Homo sapiens	154-157
35056691-8	2022	Naringenin induced endoplasmic reticulum (ER) stress-mediated apoptosis through the upregulation of ER stress markers, GRP78 and GRP94.	naringenin	0-10	heat shock protein family A (Hsp70) member 5	Homo sapiens	119-124
35056691-8	2022	Naringenin induced endoplasmic reticulum (ER) stress-mediated apoptosis through the upregulation of ER stress markers, GRP78 and GRP94.	naringenin	0-10	heat shock protein 90 beta family member 1	Homo sapiens	129-134
35354142-10	2022	Furthermore, Treatment with Naringenin (50 and 100 mg/kg) regulated adipocytokines and decreased the phosphorylation of STAT3.	naringenin	28-38	signal transducer and activator of transcription 3	Rattus norvegicus	120-125
3955304-10	1986	This 9-PGDH activity was inhibited by naringenin (IC50 10.3 microM).	naringenin	38-48	15-hydroxyprostaglandin dehydrogenase	Rattus norvegicus	7-11